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UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K
(Mark One)

igJ

ANNUAL REPORT PURSUANT TO SECTION 13 OR lS(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 29, 2007
OR

•

TRANSITION REPORT PURSUANT TO SECTION 13 OR lS(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from

to

Commission fiJe number: 0-21116

USANA HEAL TH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
87-0500306
(l.R.S. Employer
Identification No.)

Utah

(State or other jurisdiction of
incorporation or organization)
3838 West Parkway Blvd., Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)
(801) 954-7100
(Registrant's telephone number, including area code)

Securities registered pursuant to Section l2(h) of the Act:
(Title of each class)

(Name of each exchange on which registered)

Common Stock. Par Value S0.00 I Per Share

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:
None
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•

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes D
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes D

No l!l

No l!l

Indicate by check mark whether the registrant (I) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Ycs l!J No D
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Fonn I 0-K. D
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. Sec definition of"large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule l2b-2 of the Exchange Act.
Large accelerated filer D

Accelerated filer l!J

Non-accelerated filer D

Smaller reporting company D

Indicate by check mark whether the registrant is a shcl I company (as defined in Ruic I 2b-2 of the Act). Yes D

No l!J

There were 16,392,384 shares of the registrant's common stock outstanding as of March 3, 2008. The aggregate market value of common stock
held by non-affiliates of the registrant as of June 29, 2007 was approximately $342,758,000.
Documents incorporated by reference. The registrant incorporates information required by Part III (Items 10, 11, 12, 13, and 14) of this report
by reference to the registrant's definitive proxy statement to be filed pursuant to Regulation 14A for the 2008 Annual Shareholders Meeting.
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The statements contained in this report on Form I 0-K that are not purely historical arc considered to be "forward-looking statements" within
the meaning of the Private Securities Litigation Refom1 Act of 1995 and Section 2 IE of the Securities exchange Act of 1934, as amended (the
"Exchange Act"). These statements represent our expectations, beliefs, anticipations, commitments, intentions, and strategics regarding the future,
and include, but arc not limited to, the risks and uncertainties outlined in item l A Risk Factors, and item 7 Management's Discussion and Analysis
of Financial Condition and Results of Operation. Readers arc cautioned that actual results could differ materially from the anticipated results or
other expectations that are expressed in forward-looking statements within this report.
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PARTI
Item I.

Business

General

USANA Health Sciences, Inc. ("We," "USANA" or the "Company") is a Utah corporation, founded in 1992 by Myron W. Wentz, Ph.D., that
develops and manufactures high-quality, science-based nutritional and personal care products, with a commitment to continuous product
innovation and sound scientific research. We distribute and sell our products internationally through a network marketing system, which is a form
of direct selling. Our international markets include Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, and
South Korea, and direct sales from the United States to the United Kingdom and the Netherlands. Our customer base comprises two types of
customers; "Associates" and "Preferred Customers." Associates are independent distributors of our products, who also purchase our products
for personal use. Preferred Customers purchase our products strictly for their personal use and arc not permitted to resell or to distribute the
products. As of December 29, 2007, we had 176,000 active Associates and 78,000 active Preferred Customers worldwide. For purposes of this
report, we only count as "active" those Associates and Preferred Customers who have purchased product from USANA at any time during the
most recent three-month period. Our net sales in fiscal year 2007 were $423. l million, of which 87% was generated by Associates, and 13% by
Preferred Customers.
Associates arc encouraged to build and manage their own sales force by recruiting, managing, and training others to sell our products, and
they are compensated on sales generated by their business group. Associates can also receive compensation by purchasing products at
wholesale prices and selling them at retail prices. We believe that network marketing is an effective way to distribute our products because it
allows person-to-person product education, which is not readily available through traditional distribution channels. This personal touch may
enhance consumers' awareness of the health benefits ofour products, as well as motivate them to Iive and support a healthier Ii festyle.
Additionally, we feel that network marketing appeals to a broad cross-section of people, particularly those seeking to supplement their income,
start a home-based business, or pursue entrepreneurial opportunities other than conventional full-time employment. We consider our high-quality
products, compact product lines, the rewarding USANA Associate compensation plan (the "Compensation Plan"), distributor support and
recognition, and weekly Associate incentive payments to be attractive components of the USANA network marketing system.
We sell products from two primary product lines: USANA® Nutritionals, which includes high-quality supplements and functional foods, and
Sense-beautiful science® (Sense), a unique line of skin and personal care products. We also offer sales and marketing tools that are designed to
assist our Associates in building their businesses and in selling our products, as well as combination packs, which include a variety of products
from each product line. In 2007, the USANA Nutritionals and Sense™ product lines represented approximately 87% and l 0%, respectively, of our
total product sales. Sales from other items, the majority of which include marketing and sales tools, accounted for the remaining 3% of total
product sales. We limit our product lines to include only science-based products that we believe can provide health benefits to a significant
percentage of our customers. Additionally, while not required, our products are designed, manufactured, packaged, and labeled at levels that we
believe arc consistent with the more rigorous pharmaceutical standards.
From July 2003 through August 2007, we also operated a third-party contract manufacturing business at a facility located in Draper, Utah,
which we historically disclosed as a separate reportable business segment. We acquired the contract manufacturing business as part of a vertical
integration strategy to manufacture and package our Sense™ line of skin and beauty care products. On August I 0, 2007, we sold our third-party
contract manufacturing business in order to focus on our direct selling business. We retained the assets that arc associated with manufacturing
and packaging our Sense

3

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

products. We currently lease space from the Draper facility, where we continue to manufacture and package our Sense products. As a result of the
sale of the third-party contract manufacturing business, we now consider our operations to be a single reportable segment: Direct Selling.
Products
Our primary product lines consist of USA NA® Nutritionals and Sensc•M. The USANA® Nutritionals product line is further categorized into
three separate classifications: Essentials, Optimizers, and Macro-Optimizers.

USANA® Nutritionals
The Essentials include core vitamin and mineral supplements that provide a foundation of advanced nutrition for every age group. To help
meet the "essential" nutrient needs of children and teens during the years of development, when good nutrition is especially important, USA NA
offers: Usanimals™, a formulation of vitamins, minerals, and antioxidants, in an easy-to-take, chewable tablet for children who are 13 months to
12 years old; and Body Rox TM, a nutritional supplement containing 31 essential vitamins, minerals, antioxidants, and cofactors for adolescents who
are 12 to 18 years old. USANA® Essentials for adults consists of two products: Mega Antioxidant, a balanced, high-potency blend of 30 vitamins,
antioxidants, and other important nutrients to support cellular metabolism and to counteract free-radical damage; and Chelated Mineral, a complete
spectrum of essential minerals, in balanced, highly absorbablc forms. The USANA® Essentials arc also a part of the HealthPak 10on.1, a convenient
pillow pack that also includes some key Optimizers. During the third quarter of 2007, we introduced a new product concept for our customers called
MyHealthPakTM_ This concept offers a fu11y customizable packaging system for our supplement products that allows customers to create their own
personalized selection ofour full line of nutritional supplements in a pillow pack that is similar to our HealthPak I 00 product.
Optimizers are more targeted supplements that are designed to meet individual health and nutritional needs. Products in this category include
Protlavanol®, Poly C®, Procosa® II, CoQuinone® 30, BiOmega-3TM, E-PrimeTM, BodyRoxTM_Active CalciumTM Chewable, Active Calcium TM,
PhytoEstrinTM, Palmetto Plus™, Ginkgo-PSTM, Garlic ECTM, Visionex®, OptOmega®, Hepasil DTX™, and TenX™ Antioxidant Blast.

~

'1iii,.,

The Macro Optimizers include healthy, low-glycemic functional foods and other related products: NutrimealTM, Fibcrgy®, and SoyaMaxTM
drink mixes, as well as Nutrition and Fibergy Bars™. Our RESET™ weight management program and the accompanying RESET kit are also part of
the Macro-Optimizers. The RESET kit is conveniently packaged in a self-contained box with all of the USA NA products that are needed to
complete a five-day regimen, which is designed to assist adults in losing weight and in beginning a positive, long-term change in their diet.

Sens~-beuutiful sdem.:e®
The Sense product line includes premium, science-based, pers_onal care products that support healthy skin and hair by providing advanced
topical nourishment, moisturization, and protection. These products arc manufactured with our patented self-preserving technology, which uses a
unique blend of botanicals, antioxidants, and active ingredients to keep products fresh, without adding traditional chemical preservatives.
Products in this line include Perfecting Essence, Gentle Daily Cleanser, Hydrating Toner, Daytime Protective Emulsion, Eye Nourisher, Night
Renewal, Serum Intensive, Rice Bran Polisher, Creme Masque, Revitalizing Shampoo, Nourishing Conditioner, Firming Body Nourisher, Energizing
Shower Gel, and Intensive Hand Therapy.

4
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Aii Other
In addition to these principal product lines, we develop and sell materials and online tools that are designed to assist our Associates in
building their businesses and in marketing our products. These resource materials and sales tools include product brochures and business forms
that are designed by us and arc printed by outside publishers. In addition, we occasionally provide reprints of other commercial publications that
feature USANA and may be used as a sales tool. We also periodically contract with authors and publishers to produce or provide books, tapes,
and other items that deal with health topics and personal motivation, which we then sell to our Associates. New Associates are required to
purchase a starter kit, which contains USANA training materials that help them to build their businesses. Associates do not earn commissions on
the sale of starter kits or sales tools.
The following table summarizes the approximate percentages of total product sales that were contributed by our major product lines for the
last three fiscal years:
Year Ended
2006

2005

USANA® Nutritionals
Essentials*
Optimizers
Macro Optimizers
Sense-beautiful science®
All Other

-~

*

38%
34%
10%
15%
3%

2007

36%
38%
13%
10%
3%

37%
34%
13%
11%
5%

The Essentials category (under the USA NA® Nutritionals) includes USANA EssentialsTM, HealthPak l oorn, Body Roxn-1,
and Usanimals™.

Key Products
The following table highlights sales data for our top-selling products as a percentage of total product sales for the last three fiscal years.
Year Ended
2005

2006

2007

,.· :2:21%:.,)·,;2-J%-. '\ 10%

USANA® Essentials
Health Pak l 00™
.. P.roflavanol®

0

13%

14%

JO%

. 9%. ' JO%

13%

Geographic Presence
Our products are distributed and sold in 13 countries throughout the world. We have historically presented information for these countries in
two geographic regions: North America and Asia Pacific. North America included the United States, Canada, Mexico, and direct sales to the United
Kingdom and the Netherlands; and Asia Pacific included Australia-New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, and
Malaysia. As our international presence has continued to grow, we now present this information in four geographic regions:
North America-United States, Canada, Mexico, and direct sales from the United States to the United Kingdom and the
Netherlands
Southeast Asia/Pacific-Australia-New Zealand, Singapore, and Malaysia*

We commenced operations in Malaysia in January 2007.
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East Asia-Hong Kong and Taiwan
North Asia-Japan and South Korea
Currently, a significant portion ofour net sales are concentrated in the North America region, which represented 63.1 % of net sales in 2007.
The United States continues to be our largest market, representing 40.1 % of net sales during 2007. As we continue to expand internationally, our
operatin_g results will likely become more sensitive to economic and political conditions in foreign markets, as well as to foreign currency
fluctuations. Net sales reported for each geographic region are determined by the location from which the product shipment originates and are
reported for the last three fiscal years below. Additional financial information relating to our geographic regions can be found in Note M to the
Consolidated Financial Statements.
Year Ended
Region

North America
Southeast Asia/Paci fie
East Asia
North Asia

2005

$

209,445
58,300
32,349
14,923

$

315,017

2006

66.5%
18.5%
10.3%
4.7%

$

246,489
65,104
37,478
16,095

100.0%

$

365tl6.6

===a

2007

67.5%
17.8%
l0.3%
4.4%

$

267,235
90,690
49,314
15,910

100.0%

$

423,149

-

63.1%
21.4%
11.7%
3.8%
100.0%

---=-===-

Research and Development
We focus our research and development efforts on developing and providing the highest quality, science-based products that reduce the risk
of chronic degenerative disease and promote long-term health. Our research and development activities include developing products that are new
to USANA and new to the industry, updating existing formulas to keep them current with the latest science, and adapting existing formulas to meet
ever-changing regulations in new and existing international markets. Our scientists are continualJy reviewing the latest published research on
nutrition, attending scientific conferences, and working in collaboration with a number of outside research institutions and researchers to identify
possible new products and opportunities to reformulate existing products.
In 2007, we expanded our existing relationship with the Lmus Paulmg Institute ("LPI") at Oregon State University in an effort to better
determine the function and role of micronutrients such as vitamins, minerals, and antioxidants in promoting optimal health and preventing disease.
As part of this relationship, our in-house research team will collaborate with LPI on nutritional and clinical research. Additionally, we plan to
contribute $500,000 annually to LPI to help fund research on the role of nutrition in preventing oxidative stress, glycemic stress, and chronic
inflammation, as well as the development of physiological markers of these conditions.
Our goal is to maintain a sharp focus on nutrition-both inside and outside the body-in the prevention of chronic degenerative diseases,
and on healthy weight management. Because we believe in focusing on key health issues within our society rather than on fads, we do not
introduce a new product unless we believe that it can provide health benefits to a significant percentage of our customers. As a result, we maintain
a focused and compact line of products, which we believe simplifies the selling and buying process for Associates and Preferred Customers.
We follow pharmaceutical standards established by the U.S. Pharmacopeia in the development and reformulation ofour products. Our
ingredients are selected lo meet a number of criteria, including, but not limited to: safety, potency, purity, stability, bio-availability, natural versus
synthetic, and whether the ingredients are readily available. We control the quality of our products beginning at the formulation stage, and we
maintain our quality control through controlled sourcing of raw ingredients, manufacturing, packaging, and labeling. In fiscal years 2005, 2006, and
2007, we expended $2.2 million,
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$3.0 million, and $3.4 million, respectively, on research and development activities. We intend to continue dedicating resources at similar levels for
the research and development of new products and the reformulation of existing products.

·~

Manufacturing and Quality Assurance

Tablet Manufacturing
Tablet manufacturing is conducted at our Salt Lake City, Utah manufacturing facility. Our tablet production process uses automatic and semiautomatic equipment and includes the following: identifying and evaluating suppliers of raw materials, acquiring raw materials, analyzing raw
material quality, weighing or otherwise measuring raw materials, mixing raw materials into batches, forming mixtures into tablets, coating and
sorting the tablets, analyzing tablet quality, packaging finished products, and analyzing finished product quality. We conduct sample testing of
raw materials, in-process materials, and finished products for purity, potency, and composition to determine whether our products conform to our
internal specifications, and we maintain complete documentation for each of these tests.
Our Salt Lake City manufacturing facility is registered with the U.S. Food and Drug Administration ("FDA"), Health Canada, the Australian
Therapeutic Goods Administration ("TGA"), and other governmental agencies, as required. This facility is audited regularly by various
organizations and government agencies to assess, among other things, compliance with Good Manufacturing Practice regulations ("GMPs") and
with labeling claims. Based on these audits, our Salt Lake City manufacturing facility has received and maintains certifications from the Islamic
Foods and Nutrition Counsel of America in compliance with Halal, NSF International in compliance with product testing and GMP, and the TGA in
compliance with the Therapeutic Goods Act of 1989.
For the last several years, the manufacture of nutritional or dietary supplements and related products in the United States has required
compliance with food-model GMPs. On June 22, 2007, however, the FDA published GMPs for dietary supplements, which will become effective
June l, 2008. The dietary supplement GMPs arc based on the food-model GMPs, with additional requirements that are specific to dietary
supplements. We believe that our processes comply with the FDA's more demanding drug-model GMPs and, therefore, do not anticipate making
any significant changes to our current processes to comply with these stricter requirements.

Personal Care Manufacturing
In addition to tablet manufacturing, we manufacture our personal care products at the Draper, Utah manufacturing facility. The production
process for personal care products includes identifying and evaluating suppliers of raw materials, acquiring raw materials, analyzing raw material
quality, weighing or otherwise measuring the raw materials, mixing raw materials into batches, analyzing liquid batch quality, packaging finished
products, and analyzing finished product quality. We conduct sample testing of raw materials, in-process materials, and finished products for
purity, potency, and composition to determine whether our products conform to our internal specifications, and we maintain complete
documentation for each of these tests.
At the Draper facility, we have standard technology for producing batches of personal care items, and we have semi-automatic packaging
equipment for packaging the end product. We employ qualified staff to develop, implement, and maintain a quality system. Although the FDA has
not promulgated GMP requirements for manufacturing personal care products, we voluntarily maintain compliance with the product development
and GMP guidance of the Cosmetic, Toiletry and Fragrance Association.

7
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Third-Party Suppliers a11d Ma11ufacturers

We contract with third-party suppliers and manufacturers for the production of some of our products. These third-party suppliers and
manufacturers produce and, in most cases, package these products according to formulations that have been developed by or in conjunction with
our in-house product development team. These products include gelatin-capsuled supplements, Garlic ECn.t, OptOmega®, certain powdered drink
mixes, and nutrition bars.

•

Quality Control

We conduct quality control processes in two in-house laboratories that are located in Salt Lake City, Utah. In our microbiology laboratory,
scientists test for biological contamination of raw materials and finished goods. In our analytical chemistry laboratory, scientists test for chemical
contamination and accurate levels of active ingredients in both raw materials and finished products. Both laboratories conduct stability tests on
finished products to determine the shelf life of our products. Our laboratory staff also performs chemical assays on vitamin and mineral
constituents, using United States Pharmacopoeia methods and other internally validated methods. In addition to our quality control and clinical
laboratories, our headquarters facility also houses a laboratory designated for research and development.
Most of the raw ingredients that are used in the manufacture of our products arc available from a number of suppliers. We have not generally
experienced difficulty in obtaining necessary quantities of raw ingredients. When supplies of certain raw materials have tightened, we have been
able to find alternative sources of raw materials, as needed, and believe we will be able to do so in the future, if the need arises. Our raw material
suppliers must demonstrate stringent process and product quality control before we use their products in our manufacturing process.

'tw,.

~

Distribution and Marketing
General

We distribute our products internationally through a network marketing system, which is a form of person-to-person direct selling through a
network of vertically organized independent distributors. These distributors purchase products at wholesale prices from the manufacturer and then
make retail sales to consumers. The concept of network marketing is based on the strength of personal recommendations that frequently come
from friends, neighbors, relatives, and close acquaintances. We believe that network marketing is an effective way to distribute our products
because it allows person-to-person product education, which is not as readily available through other distribution channels.
Structure ofNetwork Marketing Program

A person who wishes to sell USANA products must join our independent sales force as an Associate. A person becomes an Associate by
completing an application under the sponsorship of an existing Associate. The new Associate then becomes part of the sponsoring Associatc's
downline sales organization. New Associates sign a written contract and agree to adhere to the USANA policies and procedures. New Associates
arc also required to purchase a starter kit that includes a detailed manual, including our policies and procedures. We sell starter kits at our cost for
a price of approximately U.S. $49. We also offer starter kits in an electronic format at a lower price, which we also sell at our cost. Subject to
payment of a minimal annual renewal fee, Associates may continue to distribute products until they voluntarily withdraw or are terminated for
failing to adhere to our policies and procedures.
We also sell directly to customers who purchase products only for personal consumption. This program is our "Preferred Customer" program.
Preferred Customers may not resell or distribute our
8
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products. We believe this program gives us access to a market that would otherwise be missed, by targeting customers who enjoy USANA
products, but who prefer not to maintain a selling, distribution, or other business relationship with us. Although our policies prohibit Preferred
Customers from engaging in retail sales of products, they may enroll as Associates at any time, if they desire. Preferred Customers are not eligible
to earn commissions, nor to participate in our Compensation Plan.

A.'isociate Training and Motivation
Initial training of Associates about the products, the Compensation Plan, network marketing, and about USANA is provided primarily by an
Associate's sponsor and others in their sales organization. We develop and sell training materials and sales tools to assist Associates in building
their businesses, as well as provide reprints from other commercial publications that feature USA NA and may be used as sales tools. We also
sponsor and conduct regional, national, and international Associate events, as well as intensive leadership training seminars. Attendance at these
sessions is voluntary, and we undertake no generalized effort to provide individualized training to Associates, although experience shows that the
most effective and successful Associates participate in training activities.

Associate Compensation
The Compensation Plan provides several opportunities for Associates to cam compensation, provided they arc willing to consistently work at
building, training, and retaining their downlinc organizations to sell USA NA products to consumers. We believe this Compensation Plan is
distinctive for its weekly payouts, which are designed to create appropriate incentives for the sale of USA NA products. Associates cannot simply
recruit others for the purpose of developing a down line and earn income passively, depending solely on the efforts of their down line. The primary
way in which an Associate can eam compensation is by generating sales volume points through our base Compensation Plan. Sales volume
points arc assigned to each of our products and are generally targeted to represent a certain percent of the price in U.S. dollars. Each Associate is
required to purchase a certain amount of product each month ("Qualifying Purchases"), which they must either resell to consumers or use
personally in order to qualifiy to cam commissions or bonuses under USANA's Compensation Plan. Associates do not earn commissions on these
Qualifying Purchases. The purpose of our Compensation Plan is to reward Associates for actively selling our products and for recruiting and
retaining others to sell our products.
Associates can earn compensation in four ways:
Generating sales volume points, which are based on product sales of their downline sales organization;
Participating in a leadership bonus pool, which is based on certain performance requirements;
Purchasing products at wholesale prices from USA NA and selling them to consumers at higher retail prices; and
Earning prizes or bonuses through Company-sponsored promotions and contests.

VJ

Most Associates sell our products on a part-time basis and consume them personally. The sponsoring of new Associates results in the
creation of multiple levels within our network marketing structure. Sponsored Associates are referred to as the "downline" of the sponsoring
Associate. Downline Associates may also sponsor new Associates, creating additional levels in their network, but also forming a part of the same
downline as the original sponsoring Associate. Associates who arc interested in earning additional income and who successfully expand their
business network or down line can qualify for higher levels of compensation, as well as leadership bonuses, by attaining certain sales volume
levels and by demonstrating leadership abilities. We do not pay commissions based on recruiting or sponsorship activity. Associates may not sell
competitive products to other USANA
9
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Associates or solicit USANA Associates to participate in other network marketing opportunities. Our policies and procedures also restrict
Associates' advertising and representations or claims concerning USANA products or our Compensation Plan.
We endeavor to seamlessly integrate this Compensation Plan across all markets in which USANA products are sold, allowing Associates to
receive commissions for global-not merely local-product sales. This seamless downlinc structure is designed to allow an Associate to build a
global network by establishing down lines in any of the markets where we operate. Associates may expand their down line organizations into new
markets without establishing new downlincs or requalifying for higher levels of compensation in the newly opened markets. We hclicvc this
seamless Compensation Plan significantly enhances our ability to expand internationally, and we intend, where pcnnitted, to continue to integrate
new markets into our Compensation Plan.

Industry Overview
As both a manufacturer and a direct seller of nutritional and personal care products, we compete within two industries: nutrition and direct
selling. The nutrition industry includes many small- and medium-sized companies that manufacture and distribute products that arc generally
intended to maintain the body's health and general well being, including the following:
Nutritional Supplements-products such as vitamins and minerals, specialty supplements, herbs and botanicals, meal replacements,
dietary supplements, and derivative compounds;
Natural and Organic Foods-products such as cereals, milk, non-dairy heveragcs, and frozen entrees;
Functional Foods-products with added ingredients or fortification that are designed specifically for health or performance
purposes; and
Natural Personal Care-products combining nutrition with skin care.
We believe that the following factors drive growth in the nutrition industry:
The general public's heightened awareness and understanding of the connection between diet and health;
The aging population in most ofour markets, particularly the baby-boomer generation in the U.S., who tend to use more nutritional
supplementation as they age;
Rising health care costs and the worldwide trend toward preventative health care; and
Product introductions in response to new scientific findings.
Nutritional products are distributed through six major sales channels. Each channel has changed in recent years, primarily due to advances in
technology and communications that have resulted in improved product distribution and faster dissemination of infonnation. The major sales
channels are as follows:
Mass market retailers, including mass merchandisers, drug stores, supermarkets, and discount stores;
Natural health food retailers;
Network marketing;
Mail order;
Healthcare professionals and practitioners; and
The Internet.
10
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We distribute our products through a network marketing system, which is a common fonn of direct selling. According to the World Federation
of Direct Selling Associations ("WFDSA "), the direct selling industry currently generates approximately$ 110 billion annually in worldwide retail
sales, through approximately 60 million independent distributors.

1.:1)

According to statistics compiled by the Direct Selling Association (the U.S. member of the WFDSA), the United States remains the largest
market for direct selling, with $32 billion in annual retail sales and 15 million independent distributors in 2006. According to the Direct Selling
Association, wellness products, which include nutritional supplements and functional foods, accounted for 20.3% of the U.S. direct retail sales in
2006, and personal care products accounted for 33.7% of such sales.
We believe that we are well positioned to capitalize on growth trends in direct sales, as both a developer and manufacturer of nutritional
supplements and personal care products.
Operating Strengths

vi

Our principal objective is to be a leading developer and manufacturer of science-based nutritional and personal care products and to create a
rewarding opportunity through network marketing for our Associates to distribute our products. Our strategy is to capitalize on our operating
strengths, which include: a strong research and development program; in-house manufacturing capability; science-based products; an attractive
Associate Compensation Plan with strong support; a scalable business model; and an experienced management team.

Emphasis on Research and Development. We have a technical team of approximately 20 individuals who contribute to our research and
development activities. This team includes experienced scientists, including several scientists holding Ph.D. ·degrees, quality engineers, and
regulatory specialists. In our research and development laboratories, our scientists and researchers:
Investigate in vilro and in vivo activity of new natural extracts and fonnulated products;
Identify and research combinations of nutrients that may be candidates for new products;
Develop new nutritional ingredients for use in supplements;
Study the metabolic activity of existing and newly identified nutritional ingredients;
Enhance existing products, as new discoveries in nutrition and skin care are made; and
Formulate products to meet the regulatory requirements in all of our markets.

Our scientists and researchers also perfonn double-blind, placebo-controlled, clinical studies which are intended to further evaluate the
efficacy ofour products. We also collaborate with outside research organizations to further support various aspects of our research and
development efforts. For example, in 2007 we expanded our existing relationship with LPI at Oregon State University. Additionally, we fund clinical
research programs at Boston University and the University of Colorado. It is through our research and development efforts and our partnerships
with outside research organizations that we can provide what we believe to be some of the highest quality health products in the industry.

In-house Manufacluring. We manufacture products that account for approximately 74% of product sales. We believe that our ability to
manufacture our own products is a significant competitive advantage for the following reasons:
We can better control the quality of raw materials and the purity and potency of finished products;
We can more reliably monitor the manufacturing process to reduce the risk of product contamination;
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We can better control production schedules to increase the likelihood of maintaining an uninterrupted supply of products for our
customers;
We arc able to produce most of our own prototypes in the research phase of product development; and
We believe we can better manage the underlying costs associated with manufacturing our products.

Science-based Produc/s. As a result of our emphasis on research and development and our in-house manufacturing capabilities we have
developed a focused and compact line of high-quality health products that we believe provide health benefits to a significant percentage of our
customers. Our products have been developed based on a combination of published research, in vilro and in vivo testing, in-house and thirdparty clinical studies, and sponsored research. Additionally, we design, manufacture, package, and label our products in a manner that we believe
is consistent with pharmaceutical standards.
Allraclive Associate Compensation Plan and Support. We are committed to providing a highly competitive compensation plan to attract
and retain Associates who constitute our sales force. We believe that our Compensation Plan is one of the most financially rewarding in the
network marketing industry. Associate incentives totaled $170.4 million, or 40.3% of net sales in 2007. We pay Associate incentives weekly and
our Compensation Plan is a global-seamless plan, meaning that Associates can be compensated each week for their business success in any
market in which we conduct business.
To support our Associates, we sponsor meetings and events throughout the year, which offer information about our products and our
network marketing system. These meetings arc designed to assist Associates in business development and to provide a forum for interaction with
successful Associates and with the USANA management team. We also provide low-cost sales tools, which we believe arc an integral part of
building and maintaining a successful home-based business for our Associates.
In addition to Company-sponsored meetings and sales tools, we maintain a website exclusively for our Associates, where they can keep up on
the latest USA NA news, obtain training material, manage their personal information, enroll new customers, shop for products, and register for
Company-sponsored events. Additionally, through this website, Associates can access other on line services. For example, we offer an on line
business management service, which includes a tool that helps Associates track and manage their business activity, a personal webpage to which
prospects or retail customers can be directed, c-cards for advertising, and a tax management tool.

Business Model.

We believe our business model provides, among others, the following advantages:

Our business model docs not require a company-employed sales force to sell our products, and we experience a minimal incremental
cost to add a new Associate;
Commissions paid to our Associates arc tied to sales performance;
Because payment is required at the time an Associate or Preferred Customer purchases product, we have virtually no accounts
receivable;
We have a monthly product subscription program known as "Autoship," which provides a stream of recurring revenue, (for the
year ended December 29, 2007, this program represented 51 % of our net sales); and
We can readily expand into new international markets with only moderate investment, because we generally maintain only one
administrative and customer support office and one or two warehouses in each of these markets.
12
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Experienced Managemem Team. Our management team includes individuais with expertise in various scientific and managerial disciplines,
including nutrition, product research and development, international development, marketing, customer network development, information
technology, finance, and operations. The current executive management team has been in place for several years and is responsible for supporting
growth, research and development, international expansion, strengthening our financial condition, and improving our internal controls.
Growth Strategy

We seek to grow our business by pursuing the following strategics:

Attract and Retain Associates and Preferred Customers. We recognize the need to continue to attract and retain Associates. We maintain
emphasis on the partnership between the USANA management team and our Associate leaders. Through this partnership, our Associate leaders
continue to host "Health & Freedom" meetings and onlinc presentations, both aimed at presenting the business opportunity to potential
Associates and providing additional training and resources for existing Associates. In addition to our Annual International Convention and our
Asia Pacific Convention, we hold several regional events in key growth areas to provide support and training to new Associates in these areas.
We intend to continue growing our business by maintaining a focus on our two core values, "True Health" and "True Wealth." We plan to
accomplish this by increasing the number of active Associates and teaching them how to build a strong customer base. By leveraging the growth
we have in our Associate field, we believe we can continue to attract individuals that arc interested in joining a winning team and starting a homebased business with USANA.
We will continue to make it easier for our customers to order product from USANA and to learn about the many products that we offer. This
will be accomplished with an improved onlinc shopping cart and website, a product catalog dedicated to Preferred Customers, product sampling,
and target marketing. We are also working on a Preferred Customer referral system, which will include awards and incentives for bringing in new
customers. We believe we offer the finest web-based business tools in the industry. We will continue to make improvements and enhancements to
these tools, which offer a convenient and simple way for our Associates to manage their business and be more productive.

Enter New Markets. We believe that significant growth opportunities continue to exist in markets where we currently conduct business and
in new international markets. New markets are selected following an assessment of several factors, including market size, anticipated demand for
USANA products, receptiveness to network marketing, and the market entry process, which includes consideration of possible regulatory
restrictions on our products or our network marketing system. We have begun to register certain products with regulatory and government
agencies in preparation for further international expansion. Wherever possible, we expect to seamlessly integrate the Compensation Plan in each
market to allow Associates to receive commissions for global-not merely local-product sales. The seamless downline structure is designed to
allow an Associate to build a global network by creating down lines across national borders. Associates are not required to establish new
down lines or to re-qualify for higher levels of compensation in newly opened markets. We believe this seamless Compensation Plan can
significantly enhance our ability to expand internationally, and we intend, where permitted, to integrate future markets into this plan.
Introduce New and Re-formulate Existing Products. Our research and development team is continually researching the latest scientific
findings related to nutrition, looking at new technology and attending scientific conferences. If, in the process, we see potential for a new product
that provides a true health benefit addressing a particular health issue, and if we believe its benefits can be realized by a significant percentage of
our customers, we will generally pursue development of that product. At our International Convention in August, 2007, we introduced a new
product and technology, called
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MyHcalthPak. This technology allows customers to create their own personalized selection of our line of nutritional supplements in daily AM and
PM pillow packs.
If in the process of our research activities mentioned above, our research and development team identifies a new or existing ingredient that
could possibly be used to enhance one of our existing products, we will generally pursue a product upgrade. Our intention is to ensure that all of
our products, new and existing, incorporate th1; latest science in nutrition. We typically upgrade at least one of our products each year.

Pursue Strategic Acquisitions. We believe that attractive acquisition opportunities may arise in the future. We intend to pursue strategic
acquisition opportunities that would grow our customer base! expand our product lines, enhance our manufacturing and technical expertise, allow
vertical integration, or otherwise complement our business or further our strategic goals.

~

Capital Investment. During 2007 and continuing in 2008, we have significantly added to our capital and human resources in order to support
the growth of our business. In Salt Lake City, we have largely completed an expansion and upgrade of our corporate campus. In addition to the
expansion of the corporate headquarters and manufacturing facilities, in 2007 we purchased a facility in Sydney, Australia and are working on the
remodel and fit-out of this facility, to where our Australian operations will be moved. We also added to our human resources during 2007,
increasing "bench strength" in key functions at our corporate and regional offices. Another significant investment during 2007 was the addition of
a new automated packaging system, which should be fully functioning by the second quarter of2008.

~

Product Returns

Product returns have not been a material factor in our business, totaling approximately 1.6% of net sales during each of the fiscal years 2005
and 2006, and 1.5% of net sales during fiscal year 2007. Because our emphasis on satisfaction is a hallmark of our business model, we pennit
Associates to return any unused product from their first purchase within the first 30 days following their purchase for a I 00% refund of the sales
price. Thereafter, any returned product that is unused and resalable is refunded up to one year from the date of purchase at 100% of the sales price
less a I 0% restocking fee. According to the terms of the Associate agreement, return of product that was not damaged at the time of receipt by the
Associate, where the purchase amount exceeds$ 100, may result in cancellation of the Associate's distributorship. Depending upon the conditions
under which product was returned, Associates and Preferred Customers may receive their refunded amount either based on their original form of
payment or with product or credit on account.

~
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Major Customers

Sales are made to independent Associates and Preferred Customers. No single customer accounted for I 0% or more of net sales in any of the
last three fiscal years. Associates may sell products only in countries where we have approved the sale of our products.

Compliance by Associates
From time to time·some Associates will fail to adhere to the USANA policies and procedures, including those governing the marketing of our
products or the permissible representations regarding the Compensation Plan. We systematically review reports of alleged Associate misbehavior.
Infractions of the policies and procedures are reported to a compliance committee that detennines what disciplinary action may be warranted in
each case. lfwe determine that an Associate has violated any of the USANA policies and procedures, we may lake a number of disciplinary
actions. For example, we may impose sanctions, such as warnings, fines or probation. We also may withdraw or deny awards, suspend privileges,
withhold commissions until specific conditions are satisfied, or take other
14
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appropriate actions in our discretion. More serious infractions may result in termination of the Associate's purchase and distribution rights
completely.

Information Technology
We believe that the ability to efficiently manage distribution, compensation, manufacturing, inventory control, and communications functions
through the use of sophisticated and dependable information processing systems is critical to our success. Our information technology resources
arc maintained primarily by our in-house staff to optimally support our customer base and core business processes. This staff manages an array of
systems and processes which support our global operations 24 hours a day and 365 days a year. Three of our critical applications include the
following:
A web-based application that provides on line services to Associates, such as training sessions and presentations, on line
shopping, enrollment, company and product information, and other tools to help Associates effectively manage their downline
organizations. Our web applications are supported by a clustered environment and a redundant system outside of our home office,
which serves as a disaster recovery site.
A web-enabled order-entry system that handles order entry, customer information, compensation, the hierarchy of Associates,
returns, invoices, and other transactional-based processes.
A fully integrated worldwide Enterprise Resource Planning ("ERP") system that handles accounting, inventory management,
production processes, quality assurance, and reporting requirements in a multinational environment. This ERP system supports
global data integrity and multinational corporate governance and compliance.
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Regulatory Matters

Product Regulation. Numerous governmental agencies in the United States and other countries regulate the manufacturing, packaging,
labeling, advertising, promoting, distributing, and the selling of nutrition, health, beauty, and weight management products. In the United States,
advertisement of our products is regulated by the Federal Trade Commission ("FTC") under the FTC Act and, where such advertising is
considered to be product labeling by the FDA, under the Food, Drug, and Cosmetic Act ("FD&C") and the regulations thereunder. USANA
products are also subject to regulation by, among others, the Consumer Product Safety Commission, the US Department of Agriculture, and the
Environmental Protection Agency. The manufacturing, labeling, and advertising of products are also regulated by various governmental agencies
in each foreign country in which they are distributed. For example, in Australia, we arc subject to the Therapeutic Goods Administration and, in
Japan, to the Ministry of Health, Labor and Welfare.
Our largest selling product group includes products that are regulated as dietary supplements under the FD&C. Dietary supplements are also
regulated in the United States under the Dietary Supplement Health and Education Act of I 994 ("OSHEA"). We believe that the OSHEA provides
a favorable regulatory climate to the dietary supplement industry. Some of our powdered drink, food bar, and other nutrition products are regulated
as foods under the Nutrition Labeling and Education Act of 1990 ("NLEA"). The NLEA establishes requirements for ingredient and nutritional
labeling including labeling claims. Although we believe our product claims comply with the law, we may need to revise some product labeling at a
future date, if these labeling requirements change.
Under these regulations, a dietary supplement that contains a new dietary ingredient (defined as an ingredient not on the market before
October 15, 1994) must have a history of use or other evidence of safety establishing that it is reasonably expected to be safe. The manufacturer
must notify the FDA at least 75 days before marketing products containing new dietary ingredients and must provide the FDA with the
information upon which the manufacturer has based its conclusion that the product has a reasonable expectation of safety.
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For the last several years, the manufacture of dietary supplements and related products in the United States has required compliance with
food-model GMPs. However, on June 22, 2007, the FDA published GMPs for dietary supplements, which will be effective June I, 2008. The dietary
supplement GMPs are based on the food-model GMPs, with additional requirements that arc specific to dietary supplements. We believe that our
processes comply with the FDA's more demanding drug-model GMPs and, therefore, do not anticipate making any significant changes to our
current processes to comply with these more strict requirements.
In general, our personal care products, which arc regulated as cosmetic products by the FDA, arc not subject to pre-market approval by that
agency. Cosmetics, however, are subject to regulation by the FDA under the FD&C adulteration and misbranding provisions. Cosmetics also are
subject to specific labeling regulations, including warning statements, if the safety of a cosmetic is not adequately substantiated or if the product
may be hazardous, as well as ingredient statements and other packaging requirements under the Fair Packaging and Labeling Act. Cosmetics that
meet the definition of a drug (i.e., that are intended to treat or prevent disease or affect the structure or function of the body), such as sunscreens,
are regulated as drugs. OTC drug products may be marketed if they conform to the requirements of the OTC monograph that is applicable to that
drug. Drug products not conforming to monograph requirements require an approved New Drug Application ("NDA") before marketing may
begin. Under these provisions, if the agency were to find that a product or ingredient of one of our OTC drug products is not generally recognized
as safe and effective or is not included in a final monograph that is applicable to one of our OTC drug products, we will have to reformulate or
cease marketing that product until it is the subject of an approved NOA or until the time, if ever, that the monograph is amended to include such
product. If such an agency ruling were to become final, we would be required to stop marketing the product as currently formulated. Whether or
not an OTC drug product conforms to a monograph or is subject to an approved NDA, the drug must comply with other requirements under the
FDCA, including GMP's, labeling, and the FDCA's regulations regarding misbranding and adulteration.
Advertising of products is subject to regulation by the FTC under the FTC Act. Section 5 of the FTC Act prohibits unfair methods of
competition ond unfair or deceptive acts or practices in or affecting commerce. Section I 2 of the FTC Act provides that disseminating any false
advertisement pertaining to drugs or foods, which includes dietary supplements, is an unfair or deceptive act or practice. Under the fTC's
Substantiation Doctrine, an advertiser is required to have a "reasonable basis" for all objective product claims before the claims are made. Failure
to adequately substantiate claims may be considered either deceptive or unfair practices. Pursuant to this FTC requirement, we are required to
have adequate substantiation for all material advertising claims that we make for our products.
In recent years, the FTC has initiated numerous investigations of and actions against companies that sell dietary supplement, weight
management, and cosmetic products. The FTC has issued guidance to assist companies in understanding and complying with its substantiation
requirement. We believe that we have adequate substantiation for all material advertising claims that we make for our products, and we believe that
we have organized the documentation to support our advertising and promotional practices in compliance with these guidelines.
The.: FTC may c.:nfun:e compliance with the law in a variety of ways, both administratively and judicially, using compulsory process, cease and
desist orders, and injunctions. FTC enforcement can result in orders requiring, among other things, limits on advertising, corrective advertising,
consumer redress, divestiture of assets, rescission of contracts, and such other relief as the agency deems necessary to protect the public.
Violation of these orders could result in substantial financial or other penalties. We have not been notified that we were the subject of any action
by the FTC, but any action in the future by the FTC could materially and adversely affect our ability to successfully market our products.
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The Public Health Security and Biotcrrorism Preparedness anJ Response Aci of 2002 ("Uiotcrrnrism Act") includes several provisions that
have resulted in additional regulatory compliance issues for us. For example, one provision in the Bioterrorism Act requires the Secretary of Health
and Human Services to develop regulations that mandate that domestic and foreign facilities, which manufacture, process, pack, or hold food for
human or animal consumption in the United States, register with the FDA. On November 24, 2003, we fulfilled this requirement by registering with
the FDA. Another provision of the Bioterrorisrn Act mandates that the FDA receive prior notification of all food importation. Our TenXTM
Antioxidant Blast is purchased from a manufacturer located in Canada, and therefore, we are required to comply with this notification requirement
upon importation of this product. Although some of our raw materials and other certain manufactured product may originate outside of the United
States, we procure these items from entities in the United States. From time to time, we may bring consumable products that we have sent from our
Salt Lake facility to our international locations back into the United States from one or more of these locations. When bringing these products back
into the United States from any international location, we are also required to comply with this notification requirement.
On December 9, 2006, President Bush signed the Dietary Supplement & Nonprescription Drug Consumer Protection Act into law. The
legislation requires manufacturers of dietary supplement and over-the-counter products to notify the FDA when they receive reports of serious
adverse events. USANA already has an internal adverse event reporting system that has been in place for several years. Based on our
understanding of the new law's requirements, we made some changes to our existing reporting system, and believe that we now comply with these
new regulations.
In markets outside the United States, prior to commencing operations or marketing products, we may be required to obtain approvals, licenses,
or certifications from a country's ministry of health or comparable agency. Approvals or licensing may be conditioned on reformulation ofUSANA
products for the market or may be unavailable with respect to certain products or product ingredients. We must also comply with local product
labeling and packaging regulations that vary from country to country. Foreign regulatory requirements have not placed a significant burden on our
ability to operate in current foreign countries.
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional
governmental regulations or administrative orders, when and if promulgated, would have on our business. Future changes could include
requirements for the refonnulation of certain products to meet new standards, the recall or discontinuation of certain products that cannot be
refonnulated, additional record keeping, expanded documentation of the properties of certain products, expanded or different labeling, and
additional scientific substantiation. Any or all of these requirements could have a material adverse effect on our business, financial condition, and
results of operations.

Network Marketing Regulation. Laws and regulations in each country in which we operate prevent the use of deceptive or fraudulent
practices that have sometimes been inappropriately associated with legitimate direct selling and network marketing activities. These laws include
anti-pyramiding, securities, lottery, referral selling, anti-fraud and business opportunity statutes, regulations, and court cases. Illegal schemes,
typically referred to as "pyramid," "chain distribution," or "endless chain" schemes, compensate participants primarily or solely for the
introduction or enrollment of additional participants into the scheme. Often these schemes are characterized by large up-front entry or sign-up
fees, over-priced products of low value, little or no emphasis on the sale or use of products, high-pressure recruiting tactics, and claims of huge
and quick financial rewards requiring little or no effort. Generally these laws are directed at ensuring that product sales ultimately are made to
consumers and that advancement within sales organizations is based on sales of the enterprise's products, rather than on investments in the
organizations or on other criteria or activity that are not related to·rctail sales. Where required by law, we obtain regulatory approval of our network
marketing system, or, where
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approval is not required or available, the favorable opinion of local counsel as to regulatory compliance.
In addition to federal regulation in the United States, each state has enacted its own "Little FTC Act" to regulate sales and advertising.
Occasionally, we receive requests to supply information regarding our network marketing plan-to regulatory agencies. Although we have, from
time to time, modified our network marketing system to comply with interpretations of various regulatory authorities, we believe that our network
marketing program is in compliance with the laws and regulations relating to network marketing activities in our current markets. Nevertheless, we
remain suhject tQ the risk that, in one or more of our present or future markets, the marketing system or the conduct of certain Associates cou!d be
found not to be in compliance with applicable laws and regulations. Failure by an Associate or by us to comply with these laws and regulations
could have a material adverse effect on our business in a particular market or in general. Any or all of these factors could adversely affect the way
we do business and could affect our ability to attract potential Associates or enter into new markets. In the United States, the FTC has been active
in its enforcement efforts against both pyramid schemes and legitimate network marketing organizations with certain legally problematic
components, having instituted several enforcement actions resulting in signed settlement agreements and the payment of large fines. Although, to
our knowledge, we have not been the target of an FTC investigation, there can be no assurance that the FTC will not investigate us in the future.
On April 5, 2006, the FTC released a proposed New Business Opportunity Ruic. This proposed rule would require pre-sale disclosures for all
business opportunities, which might include network marketing compensation plans. The New Business Opportunity Ruic is currently only a
proposed rule. If implemented at all, the rule ultimately may not be implemented in a form that applies to network marketing compensation plans, or
it may change significantly before it is implemented. If this proposed rule were adopted as it is currently proposed, it would require us to change
some of our current practices regarding pre-sale disclosures.
We cannot predict the nature of any future law, regulation, interpretation, or application, nor can we predict what effect additional
governmental legislation or regulations, judicial decisions, or administrative orders, when and if promulgated, would have on our business. It is
possible that future legal requirements may require that we revise our network marketing program. Such new requirements could have a material
adverse effect on our business, results of operations, and financial condition.

Transfer Pricing Regulation. We have adopted transfer prices, which are supported by a formal transfer pricing study for the sale of
products to our subsidiaries in accordance with applicable transfer pricing laws. In addition, agreements between our subsidiaries and us have
been entered into for services and contractual obligations, sud1 as lht: piJymcnl of AssociiJLt.: incenlivcs Lhat are also supported by the same
formal transfer pricing study. If the United States Internal Revenue Service or the taxing authorities of any other jurisdiction were to successfully
challenge these agreements or require changes in our standard transfer pricing practices for products, we could become subject to higher taxes
and our earnings may be adversely affected. The tax treaties between the United States and most foreign countries provide for competent
authority relief to avoid any double taxation. We believe that we operate in compliance with all applicable transfer pricing regulations. There can be
no assurance, however, that we will continue to be found to be operating in compliance with transfer pricing regulations or that those laws will not
be modified, which may require that we change our operating procedures.
Competition
We compete with other network marketing companies for distributors. We also compete with manufacturers, distributors, and retailers of
nutritional products for consumers. On both fronts, some of our competitors are significantly larger than we are and have greater financial
resources and better
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name recognition than we do. We compete with these entities by emphasizing the underlying science, value, and superior quality of our products,
simplicity in our product offerings, and the convenience and financial benefits afforded by our network marketing system and global seamless
Compensation Plan.
Our business is driven primarily by our distributors, whom we refer to as Associates. Our ability to compete with other network marketing
companies depends, in significant part, on our success in recruiting and retaining Associates. There can be no assurance that our programs for
recruiting and retaining Associates will be successful. The pool of individuals interested in network marketing is limited in each market and is
reduced to the extent other network marketing companies successfully recruit these individuals into their businesses. Although we believe that we
offer an attractive opportunity for our Associates, there can be no assurance that other network marketing companies will not be able to recruit our
existing Associates or deplete the pool of potential Associates in a given market.
We believe that the leading network marketing company in the world, based on total sales, is Amway Corporation and its affiliates, and that
Avon Products, Inc. is the leading direct seller of beauty and related products worldwide. Leading competitors in the nutritional network marketing
and nutritional product industry include Herbalife Ltd., Inc.; Market America, Inc.; Nu Skin Enterprises, Inc.; NBTY, Inc.; Mannatech; and Schiff
Nutrition International, Inc. Based on information that is publicly available, 2006 net sales of the aforementioned companies range from $178 million
to $8. 7 billion. We believe there are other manufacturers of competing product lines that may launch direct selling enterprises, which will compete
with us in certain product lines and in the recruiting of Associates. There can be no assurance that we will be able to successfully meet the
challenges posed by this increased competition.

Intellectual Property
Trademarks. We have developed and we use registered trademarks in our business, particularly relating to our corporate and product
names. We own 13 trademarks that are registered with the United States Patent and Trademark Office. Federal registration of a trademark enables
the registered owner of the mark to bar the unauthorized use of the registered mark in connection with a similar product in the same channels of
trade by any third-party anywhere in the United States, regardless of whether the registered owner has ever used the trademark in the area where
the unauthorized use occurs. We have filed applications and own trademark registrations, and we intend to register additional trademarks in
foreign countries where USANA products are or may be sold in the future. Protection of registered trademarks in some jurisdictions may not be as
extensive as the protection in the United States.

We also claim ownership and protection of certain product names, unregistered trademarks, and service marks under common law. Common
law trademark rights do not provide the same level of protection that is afforded by the registration of a trademark. In addition, common law
trademark rights are limited to the geographic area in which the trademark is actually used. We believe these trademarks, whether registered or
claimed under common law, constitute valuable assets, adding to recognition of USANA and the effective marketing ofUSANA products. We
therefore believe that these proprietary rights have been and will continue to be important in enabling us to compete.
Trade Secrets. We own certain intellectual property, including trade secrets, that we seek to protect, in part, through confidentiality
agreements with employees and other parties, although some employees who are involved in research and development activities have not entered
into these agreements. Even where these agreements exist, there can be no assurance that these agreements will not be breached, that we would
have adequate remedies for any breach, or that our trade secrets will not otherwise become known to or independently developed by competitors.
Our proprietary product
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formulations are generally considered trade secrets, but are not otherwise protected under intellectual property laws.
Patents. We have three U.S. patents. Two of our patents relate to the method of extracting an antioxidant from olives and the byproducts of
olive oil production. These patents were issued in 2002 and will continue in force for 17 years from the date of issue. In 2003, we entered into a
licensing agreement with a supplier to make olive extract using our patented process. Our third patent relates to a method of self preserving our
Sensern line of products. This patent was issued in May 2007 and will continue in force for approximately 11 years from the date of issue.
Currently; it is very difficult to determine the exact future benefit of these patents. We believe, however, that these patents have the potential to
generate additional revenue in the future through new product development and royalties from licensing.

(\&,

We intend to protect our legal rights concerning intellectual property by all appropriate legal action. Consequently, we may become involved
from time to time in litigation to determine the enforceability, scope, and validity of any of the foregoing proprietary rights. Any ·patent litigation
could result in substantial cost and divert the efforts of management and technical personnel.

~

Seasonality
The third quarter is seasonally our softest quarter of each year. In North America, which represents about two thirds of our consolidated net
sales, Associate activity tends to slow down as a result of the summer vacation season. Additionally, we hold our International Convention during
the third quarter each year, when we typically announce new products. Because our Associates anticipate these new products, they tend to order
fewer products in the months preceding this Convention.
·
Backlog

Our products are typically shipped within 72 hours after receipt of an order. As of March 3, 2008 we had no significant backlog of orders.

Working Capital Practices
We maintain sufficit:11l arnuu11ls of invt!nlory in stock in order to provide a high level of service to our Associates and Preferred Customers.
Substantial inventories are required to meet the needs of our dual role as manufacturer and distributor. We also watch seasonal commodity
markets and may buy ahead of normal demand to hedge against cost and supply risks.

Environment
We are not aware of any instance in which we have contravened federal, state, or local laws relating to protection of the environment or in
which we otherwise may be subject to liability for environmental conditions that could materially affect operations.

Employees
As of March 3, 2008, we had 956 employees worldwide, as measured by full-time equivalency. Our employees are not currently represented by
a collective bargaining agreement, and we have not experienced work stoppages as a result oflabor disputes. We believe that we have a good
relationship with our employees.
Additional Availablc Information
We maintain executive offices and principal facilities at 3838 West Parkway Boulevard, Salt Lake City, Utah 84120. Our telephone number is
(801) 954-7100. We maintain a World Wide Web site at
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www.usanahealthscicnces.com. The information on our web site should not be considered part of this report on Form I 0-K.
We make available, free of charge at our corporate web site, copies of our annual reports on SEC Fonn l 0-K, quarterly reports on SEC Form I 0Q, current reports on SEC Form 8-K, proxy statements, and all amendments to these reports, as soon as reasonably practicable after such material
is electronically filed with or furnished to the SEC pursuant to Section 13(a) or l 5(d) of the Exchange Act. This information may also be obtained
from the SEC's on-line database, which is located at www.sec.gov.
Item lA.

Risk Factors

Forward-Looking Statements and Certain Risks

The statements contained in this report that are not purely historical arc "forward-looking statements" within the meaning of Section 21 E of
the Exchange Act. These statements relate to our expectations, hopes, beliefs, commitments, intentions, and strategies regarding the future. They
may be identified by the use of words or phrases, such as "believe," "expect," "anticipate," "should," "plan," "estimate," and "potential," among
others. Forward-looking statements include, but are not limited to, statements contained in "Business" and "Management's Discussion and
Analysis of Financial Condition and Results of Operation" regarding our financial performance, revenue and expense levels in the future, and the
sufficiency of our existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated
results or other expectations expressed in these forward-looking statements or for the reasons discussed below. The fact that some of these risk
factors may be the same or similar to those that we have filed with the Securities and Exchange Commission in past reports means only that the
risks are present in multiple periods. We believe that many of the risks that are described here are part of doing business in the industry in which
we operate and will likely be present in all periods. The fact that certain risks are endemic to the industry does not lessen their significance. The
forward-looking statements in this report are made as of the date of this report, and we assume no obligation to update them or to update the
reasons why our actual results could differ from those that we have projected in these forward-looking statements. Among others, risks and
uncertainties that may affect our business, financial condition, performance, development, and results of operations include the following:
As a network marketing company, we are dependent upon an independent sales force and we do not have direct control over the marketing of
our products. We rely on non-employee, independent Associates to market and sell our products. Associates arc independent contractors who
purchase products directly for their own use or for resale. Associates typically work at the distribution of the products on a part-time basis and
likely will engage in other business activities, some of which may compete with us. We have a large number of Associates and a relatively small
corporate staff to implement our marketing programs and to provide motivational support to our Associates. We undertake minimal effort to
provide individual training to Associates. Our net sales are directly dependent upon the efforts of these non-employee, independent Associates.
Our ability to maintain and increase sales in the future will depend in large part upon our success in increasing the number of new Associates,
retaining our existing Associates, and in improving the productivity of our Associates.

We can provide no assurances that the number of Associates will increase or remain constant or that their productivity will increase. We
experienced a 15 .0% increase in active Associates during 2007 and 2006, and a 16. 7% increase during 2005. The number of active Associates may
not increase and could decline in the future. Associates may terminate their services at any time, and, like most direct selling companies, we
experience a high turnover among new Associates from year to year. We cannot accurately predict any fluctuation in the number and productivity
of Associates because we primarily rely upon existing Associates to sponsor and train new Associates and to motivate new and existing
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Associates. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient
economic incentive or interest to retain existing Associates and to attract new Associates.
The loss of a significant Associate or down line sales organization could adversely affect our business. We rely on the successful efforts of
our Associates that become leaders within our Compensation Plan. Our Compensation Plan is designed to permit Associates to sponsor new
Associates, creating multiple "business centers," or levels in the down line organization. Sponsored Associates are referred to as "downline"
Associates within the sponsoring Associate's "downline network." If these downline Associates in turn sponsor new Associates, additional
business centers are created, with the new down line Associates becoming part of the original sponsor's downline network. As a result of this
network marketing system, Associates develop business relationships with other Associates. The loss of a key Associate or group of Associates,
large turnovers or decreases in the size of the Associate force, seasonal or other decreases in purchase volume, sales volume reduction, the costs
associated with training new Associates, and other related expenses may adversely affect our business, financial condition, or results of
operations. Moreover, our ability to continue to attract and retain Associates can be affected by a number of factors, some of which are beyond
our control, including:

~-

General business and economic conditions;
Public perceptions about network marketing programs;
High-visibility investigations or legal proceeding against network marketing companies by federal or state authorities or private
citizens;
Public perceptions about the value and efficacy of nutritional, personal care, or weight management products generally;
Other competing network marketing organizations entering into the marketplace that may recruit our existing Associates or reduce
the potential pool of new Associates; and

~

Changes to the Compensation Plan required by law or implemented for business reasons that make attracting and retaining
Associates more difficult.
There can be no assurance that we will be able to continue to attract and retain Associates in sufficient numbers to sustain future growth or to
maintain our present growth levels, which could have a material adverse effect on our business, financial condition, or results of operations.
The violation of marketing or advertising laws by Associates in connection with the sale of our products or the promotion of our
Compensation Plan could adversely affect our business. New Associates sign a written contract and agree to adhere to the USANA policies and
procedures. Although these policies and procedures prohibit Associates from making false, misleading and other improper claims regarding
products or income potential from the distribution of the products, Associates may, from time to time, without our knowledge and in violation of
our policies, create promotional materials or otherwise provide information that docs not accurately describe our marketing program. They also
may make statements regarding potential earnings, product claims, or other matters in violation of our policies or applicable laws and regulations
concerning these matters. These violations may result in legal action against us by regulatory agencies, state attorneys general, or private parties.
Legal actions against our Associates or others who are associated with us could lead to increased regulatory scrutiny of our business, including
our network marketing system. We take what we believe to be commercially reasonable steps to monitor the activities of our Associates to guard
against misrepresentation and other illegal or unethical conduct by Associates and to assure that the terms of our policies and procedures and
Compensation Plan are observed. There can be no assurance, however, that our efforts in this regard will be sufficient to accomplish this objective.
Adverse publicity resulting
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~

from such activities could also make it more difficult for us to attract and retain Associates and may have an adverse effect on our business,
financial condition, and results of operations.
Network marketing is subject to intense government scrutiny and regulation, which adds to the expense of doing business and the
possibility that changes in the law might adversely affect our ability to sell some of our products in certain markets. Network marketing systems,
such as ours, arc frequently subject to laws and regulations that are directed at ensuring that product sales are made to consumers of the products
and that compensation, recognition, and advancement within the marketing organization are based on the sale of products rather than on
investment in the sponsoring company. Regulatory authorities, in one or more of our present or future markets, could determine that our network
marketing system docs not comply with these laws and regulations or that it is prohibited. Failure to comply with these laws and regulations or
such a prohibition could have a material adverse effect on our business, financial condition, or results of operations. Further, we may simply be
prohibited from distributing products through a network-marketing channel in some foreign countries, or we may be forced to alter our
Compensation Plan.
We arc also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which
could require us to change or modify the way we conduct our business in certain markets. This could be particularly detrimental to us if we had to
change or modify the way we conduct business in markets that represent a significant percentage of our net sales. For example, the United States
Federal Trade Commission released a proposed New Business Opportunity Ruic on April 5, 2006. The proposed rule would require pre-sale
disclosures for all business opportunities, which might include network marketing compensation plans. The New Business Opportunity Rule is
currently only a proposed rule. If implemented at all, the rule ultimately may not be implemented in a form that applies to network marketing
compensation plans, or it may change significantly before it is implemented. If the proposed rule were adopted as it is currently proposed, it would
require USA NA to change its current practices regarding pre-sale disclosures.
We may have or incur obligations relating to the activities of our distributors. Our distributors are subject to taxation, and, in some
instances, legislation or governmental agencies impose an obligation on us to collect taxes, such as sales taxes or value added taxes, and to
maintain appropriate records of such transactions. In addition, we arc subject to the risk in some jurisdictions of being responsible for social
security and similar taxes with respect to our distributors. In the event that local laws and regulations or the interpretation oflocal laws and
regulations change to require us to treat our independent distributors as employees, or if our distributors are deemed by local regulatory
authorities in one or more of the jurisdictions in which we operate to be our employees rather than independent contractors, under existing laws
and interpretations, we may be held responsible for a variety of obligations that arc imposed upon employers relating to their employees, including
social security and related taxes in those jurisdictions, plus any related assessments and penalties, which could harm our financial condition and
operating results.

Our business is subject to the effects of adverse publicity and negative public perception. Our ability to attract and retain Associates and to
sustain and enhance sales through our Associates can be affected by adverse publicity or negative public perception regarding our industry, our
competition, or our business generally. This negative public perception may include publicity regarding the legality of network marketing, the
quality or efficacy of nutritional supplement products or ingredients in general or our products or ingredients specifically, and regulatory
investigations, regardless of whether those investigations involve us or our Associates or the business practices or products of our competitors
or other network marketing companies. In 2007, we were the victim of false statements made to the press and regulatory agencies, causing us to
incur significant expense in defending and dispelling the allegations. This adverse publicity also adversely impacted the market price of our stock
and caused some insecurity among our Associates. There can be no assurance that we will not be subject to
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adverse publicity or negative public perception in the future or that such adverse publicity will not have a material adverse effect on our business,
financial condition, or results of operations.
The loss of key management personnel could adversely affect our business. Our Founder, Dr. Myron Wentz, is a highly visible spokesman
for our products and our business, and our message is based in large part on his vision and reputation, which helps distinguish us from our
competitors. Any loss or limitation on Dr. Wentz as a lead spokesman for our mission, business, and products could have a material adverse effect
upon our business, financial condition, or results of operations. In addition, our executive officers, including executive vice presidents, are
primarily responsible for our day-to-day operations, and we believe our success depends in part on our ability to retain our executive officers, to
compensate our executive officers at attractive levels, and to continue to attract additional qualified individuals to our management team. We
cannot guarantee continued service by our key executive officers. We do not maintain key man life insurance on any of our executive officers, nor
do we have an employment agreement with any of our executive officers. The loss or limitation of the services of any of our executive officers or
the inability to attract additional qualified management personnel could have a material adverse effect on our business, financial condition, or
results of operations.
The beneficial ownership of a significant percentage of our common stock gives Dr. Wentz effective control and limits the influence of other
shareholders on important policy and management issues. Gull Holdings, Ltd., an entity that is solely owned and controlled by Dr. Wentz, owned
51.3% of our outstanding common stock at December 29, 2007. By virtue of this stock ownership, Dr. Wentz is able to exert significant influence
over the election of the members of our Board of Directors and our business affairs. This concentration of ownership could also have the effect of
delaying, deterring, or preventing a change in control that might otherwise be beneficial to shareholders. In addition, Dr. Wentz also currently
serves as Chairman of our Board of Directors. There can be no assurance that conflicts of interest will not arise with respect to this directorship or
that conflicts will be resolved in a manner favorable to other shareholders of the Company.
Our products and manufacturing activities are subject to extensive government regulation, which could limit or prevent the sale of our
products in some markets. The manufacture, packaging, labeling, advertising, promotion, distribution, and sale of our products are subject to
regulation by numerous national and local governmental agencies in the United States and other countries, including the U.S. Food and Drug
Administration (FDA) and the U.S. Federal Trade Commission (FTC). For example, failure to comply with FDA regulatory requirements may result
in, among other things, injunctions, product withdrawals, recalls, product seizures, fines, and criminal prosecutions. Any action of this type by the
FDA could materially adversely affect our ability to successfuJly market our products. With respect to FTC matters, if the FTC has reason to
believe the law is being violated (e.g., failure to possess adequate substantiation for product claims), it can initiate an enforcement action. The FTC
has a variety of processes and remedies available to it for enforcement, both administratively and judicially, including compulsory process
authority, cease and desist orders, and injunctions. FTC enforcement could result in orders requiring, among other things, limits on advertising,
eon3umcr redress, divestiture of assets, rescission of contracts, or such other relief as may be deemed necessary. Violation of these orders could
result in substantial financial or other penalties. Any action against us by the FTC could materially and adversely affect our ability to successfully
market our products.
The FDA published the final Good Manufacturing Practice (GMP) regulations for dietary supplements in the Federal Register on June 25,
2007. The final rule goes into effect one year from the publication date, or June 25, 2008, for USANA. Until the rule goes into effect, we must
continue to adhere to current good manufacturing practices for food. AJthough not required to do so, we believe that we have always voluntarily
manufactured and continue to manufacture our dietary supplement products in accordance with the standards of the FD A's pharmaceutical model
GMPs, and we do not anticipate making any significant changes to our manufacturing practices to comply with these new regulations.
Nevertheless, manufacturing dietary supplements is a complex process, and there is no
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assurance that we will be able to manufacture our existing or future products in compliance with these GMPs.
On December 9, 2006, President Bush signed the Dietary Supplement & Nonprescription Drug Consumer Protection Act into law. This
legislation came into effect in December 2007 and requires manufacturers of dietary supplement and over-the-counter products to notify the FDA
when they receive reports of serious adverse events involving consumers of their products. Potential FDA responses to any such report could
include injunctions, product withdrawals, recalls, product seizures, fines, or criminal prosecutions. USANA has an internal adverse event reporting
system that has been in place for several years. Based on our current understanding of this legislation and FDA guidance, we do not anticipate the
need to make any significant changes to our existing reporting system. Nevertheless, any action by the FDA in response to a serious adverse
event report that may be filed by us could materially and adversely affect our ability to successfully market our products.
In markets outside the United States, prior to commencing operations or marketing our products, we may be required to obtain approvals,
licenses, or certifications from a country's ministry of health or a comparable agency. For example, our manufacturing facility has been registered
with the FDA and Health Canada and is certified by Australia's Therapeutic Goods Administration. Approvals or licensing may be conditioned on
reformulation of products or may be unavailable with respect to certain products or product ingredients. We must also comply with product
labeling and packaging regulations that vary from country to country. These activities are also subject to regulation by various agencies of the
countries in which our products are sold.
We cannot predict the nature of any future law.s, regulations, interpretations, or applications, nor can we determine what effect additional
governmental regulations or administrative orders, when and if promulgated, could have on our business. These potential effects could include,
however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional
record keeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or
additional scientific substantiation. Any or all of these requirements could have a material adverse effect on our business.
Our net sales are significantly affected by our success in growing existing markets, as wen as opening new markets. As we continue to
expand into international markets, our business becomes increasingly subject to political, economic, legal and other risks. Changes in these
markets could adversely affect our business. We have a history of expanding into new international markets. We commenced operations in
Australia, New Zealand, and the United Kingdom in 1998 and in Hong Kong in 1999. In 2000, we began limited business activity in Japan, where we
launched more formal operations in 2001. In 2002, we began business operations in Taiwan. We commenced operations in South Korea and
Singapore in 2003 and opened operations in Mexico in 2004. In 2007 we began business operations in Malaysia. We believe that our ability to
achieve future growth is dependent in part on our ability to continue our international expansion efforts. There can be no assurance, however, that
we will be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets will be
profitable. We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market. Also, before marketing
commences it is difficult to assess the extent to which our products and sales techniques will be accepted will be or successful in any given
country. In addition to significant regulatory barriers, we may also encounter problems conducting operations in new markets with different
cultures and legal systems from those encountered elsewhere. We may be required to reformulate certain of our products before commencing sales
in a given country. Once we have entered a market, we must adhere to the regulatory and legal requirements of that market. No assurance can be
given that we will be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory
requirements or to attract local customers. Our failure to do so could have a material adverse effect on our business, financial condition, or results
of operations. There can be no assurance that we will be

25

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

able to obtain and retain necessary permits and approvals in new markets or that we will have sufficient capital to finance our expansion efforts in a
timely manner. In many market areas, other network marketing companies already have significant market penetration, the effect of which could be
to desensitize the local Associate population to a new opportunity, such as USANA, or to make it more difficult for us to recruit qualified
Associates. Even if we arc able to commence operations in foreign countries, there may not be a sufficient population of persons who arc
interested in our network marketing system. We believe our future success will depend in part on our ability to seamlessly integrate our
Compensation Plan across all markets in which our products arc sold. There can be no assurance that we will be able to further develop and
maintain a seamless compensation program.
On December l, 2005, China announced the adoption of new regulations governing direct selling. Single-level compensation models arc
permissible under these new regulations, but multi-level compensation models, as practiced by USANA and many other direct selling companies,
arc not. Ifwe were to enter the Chinese market, we would be required to adjust our compensation and selling model to comply with these
regulations. These adjustments could require more time and effort to enter the Chinese market than would otherwise be necessary, if multi-level
compensation models were permissible. Additionally, such adjustments could make it more difficult to be successful there.

An increase in the amount of incentives paid to Associates would reduce profitability. The payment of Associate incentives is our most
significant expense. These incentives include commissions, leadership bonuses, and certain awards and prizes. From time to time, we have
changed our Compensation Plan to better manage these incentives as a percentage of net sales. Management closely monitors the amount of
Associate incentives that arc paid as a percentage of net sales, and they may periodically adjust our Compensation Plan to prevent Associate
incentives from having a significant adverse effect on our earnings. There can be no assurance that changes to the Compensation Plan or product
pricing will be successful in maintaining current levels of Associate incentives as a percentage of net sales. Furthermore, such changes may make
ii difficult lo recruit and retain qualified and motivated Associates. An increase in incentive payments to Associates as a percentage of net sales
would reduce our profitability. Associate incentives as a percent of sales in 2005, 2006, and 2007 were 39.4%, 40.1%, and 40.3%, respectively.
We are subject to risks associated with our reliance upon information technology systems. Our success is dependent on the accuracy,
reliability, and proper use of information processing systems and management information technology. Our information technology systems arc
designed and selected in order to facilitate order entry and customer bilJing, maintain Associate and Preferred Customer records, accurately track
purchases and incentive payments, manage accounting, finance and manufacturing operations, generate reports, and provide customer service
and technical support. Although off-site data back-up is maintained, it is possible that an interruption in these systems could have a material
adverse effect on our business, financial condition, or results of operations.

Our business is subject to the risks associated with intense competition from larger, wealthier, and more established competitors. We face
intense competition in the business of distributing and marketing nutritional supplements, vitamins and minerals, personal care products, and
other nutritional products, as described in greater detail in "Business-Competition." Numerous manufacturers, Associates, and retailers compete
actively for consumers and, in the case of other network marketing companies, for Associates. There can be no assurance that we will be able to
compete in this intensely competitive environment. In addition, nutrition and personal care products can be purchased in a wide variety of
channels of distribution, including retail stores. Our product offerings in each product category are also relatively small, compared to the wide
variety of products offered by many of our competitors.
We are also subject to significant competition from other network marketing organizations for the time, attention, and commitment of new and
existing Associates. Our ability to remain competitive
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depends, in significant part, on our success in recruiting and retaining Associates. There can be no assurance that our programs for recruiting and
retaining Associates will be successful. The pool of individuals who may be interested in network marketing is limited in each market, and it is
reduced to the extent other network marketing companies successfully recruit these individuals into their businesses. Although we believe we
offer an attractive opportunity for Associates, there can be no assurance that other network marketing companies will not be able to recruit our
existing Associates or deplete the pool of potential Associates in a given market.
Taxation and transfer pricing considerations affect our operations. In many countries, including the United States, we are subject to transfer
pricing and other tax regulations that are designed to ensure that appropriate levels of income are reported by our U.S. and foreign entities and are
taxed appropriately. Although we believe that we are in compliance with all material regulations and restrictions in this regard, we are subject to the
risk that taxing authorities could audit our transfer pricing and related practices and assert that additional taxes are owed. We are also subject to
the risk that taxing authorities in any of our markets could change the laws in a manner that may increase our effective tax rate and/or duties on our
products. Under tax treaties, we are eligible to receive foreign tax credits in the United States for foreign taxes actually paid abroad. In the event
any audits or assessments are concluded adversely to us, we may or may not be able to offset the consolidated effect of foreign income tax
assessments through the use of U.S. foreign tax credits. Currently, we are utilizing alJ foreign tax credits in the year in which they arise. Because the
Jaws and regulations governing U.S. foreign tax credits are complex and subject to periodic legislative amendment, we cannot be sure that we
would in fact be able to take advantage of any foreign tax credits in the future. As a result, adverse outcomes in these matters could have a material
impact on our financial condition or operating results.
Exchange rate fluctuations affect our foreign operations and our net sales and earnings. Over the past several years, a significant portion of
our net sales have been generated outside the United States. Such sales for the year ended December 29, 2007 represented 59.9% of our total net
sales. We will likely continue to expand our foreign operations, exposing us to expanding risks of changes in social, political, and economic
conditions in foreign countries, including changes in the laws and policies that govern foreign investment or foreign exchange. Because a
significant portion of our sales is in foreign countries, exchange rate fluctuations may have a significant effect on our sales and earnings. Further,
if exchange rates fluctuate dramatically, it may become uneconomical for us to establish or to continue activities in certain countries. For instance,
changes in currency exchange rates may affect the relative prices at which we and our foreign competitors sell similar products in the same market.
As our business expands outside the United States, an increasing share of our net sales and operating costs will be transacted in currencies other
than the U.S. dollar. Accounting practices require that our non-U.S. financial results be converted to U.S. dollars for reporting purposes.
Consequently, our reported net earnings may be significantly affected by fluctuations in currency exchange rates, with earnings generally
increasing with a weaker U.S. dollar and decreasing with a strengthening U.S. do1lar. Product purchases by our foreign subsidiaries are transacted
in U.S. dollars. As operations expand in countries where foreign currency transactions may be made, our operating results will be increasingly
subject to the risks of exchange rate fluctuations and we may not be able to accurately estimate the impact that these changes might have on our
future business, product pricing, results of operations, or financial condition. In addition, the value of the U.S. dollar in relation to other currencies
may also adversely affect our sales to customers outside the United States. From time-to-time we enter into forward and option foreign exchange
contracts to manage currency fluctuations on certain commitments that are denominated in foreign currency, including intercompany cash
transfers. We do not use derivative instruments for speculative purposes. There can be no assurance that foreign currency contract transactions
will protect our operating results or cash flows from potentially adverse effects of currency exchange fluctuations. Those adverse effects would
also adversely affect our business, financial condition, or results of operations.
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Disruptions to shipping channels that we use to distribute our products to international warehouses may adversely affect our margins and
profitability in those markets. In 2004, the financial press reported congestion at West Coast ports caused by increasing cargo volumes, a lack of
capacity on the railroads, and a shortage of manpower. We felt the effects in our container shipments to Australia, which required additional use of
airfreight to meet demand. Port congestion has since been relieved. Although subsequently there has been no significant port congestion, we
continue to watch for signs of upcoming congestion. Congestion to ports can affect previously negotiated contracts with shipping companies,
resulting in unexpected increases in shipping costs.
The inability to obtain adequate supplies of raw materials for products at favorable prices, or at all, or the inability to obtain certain products
from third-party suppliers, could have a material adverse effect on our business, financial condition, or results of operations. We depend on
outside suppliers for raw materials. We acquire all of our raw materials for the manufacture of our products from third-party suppliers. Materials
used in manufacturing our products are purchased through purchase order, often invoking pre-negotiated annual supply agreements. We have
very fow lung-term agreements for the supply of these materials. We also contract with third-party manufacturers and suppliers for the production
of some ofour products, including gelatin-capsuled supplements, Garlic ECTM, OptOmega®, certain powdered drink mixes, and nutrition bars.
These third-party suppliers and manufacturers produce and, in most cases, package these products according to formulations that have been
developed by or in conjunction with our in-house product development team. There is a risk that any of our suppliers or manufacturers could
discontinue manufacturing our products or selling their products to us. Although we believe that we could establish alternate sources for most of
our products, any delay in locating and establishing relationships with other sources could result in product shortages or back orders for
products, with a resulting loss of net sales. In certain situations, we may be required to alter our products or to substitute different products from
another source. We have, in the past, discontinued or temporarily stopped sales of certain products that were manufactured by third parties while
those products were on back order. There can be no assurance that suppliers will provide the raw materials or manufactured products that are
needed by us in the quantities that we request or at the prices that we are willing to pay. Because we do not control the actual production of
certain raw materials and products, we are also subject to delays caused by any interruption in the production of these materials, hased on
conditions not within our control, including weather, crop conditions, transportation interruptions, strikes by supplier employees, and natural
disasters or other catastrophic events.
Shortages of raw materials may temporarily adversely affect our margins or our profitability related to the sale of those products. In 2003,
the demand for Coenzyme QIO in the nutrition industry began to increase dramatically, which subsequently caused a shortage in supply of this
raw material component. As a result, suppliers began re-tooling their manufacturing facilities to increase production capacity in order to meet the
growing demand. Certain of our nutritional products were affected by this raw material shortage. Although we identified multiple sources to supply
quality raw ingredients, quantities of malerials ac4uire<l <luriug this shortage were purchased at higher prices, which negatively impacted our gross
margins for those products. By mid-2005, some suppliers had re-tooled their manufacturing facilities to increase production capacity of CoQ 10, and
more competitors entered the market to produce it, which has caused supply to increase and purchase prices to decline to pre-2003 levels. There is
no assurance that other raw materials might not be similarly adversely affected in the future.
Nutritional supplement products may be supported by only limited availability of conclusive clinical studies. Our products include nutritional
supplements that are made from vitamins, minerals, herbs, and other substances for which there is a long history of human consumption. Some of
our products contain innovative ingredients or combinations of ingredients. Although we believe that all of our products are safe when taken as
directed, there is little long-term experience with human
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consumption of certain of these product ingredients or combinations of ingredients in concentrated form. We conduct research and test the
formulation and production of our products, but we have perfonncd or sponsored only limited clinical studies. Furthermore, because we are highly
dependent on consumers' perception of the efficacy, safety, and quality of our products, as well as similar products distributed by other
companies, we could be adversely affected in the event that those products prove or be asserted to be ineffective or harmful to consumers or in
the event of adverse publicity associated with any illness or other adverse effects resulting from consumers' use or misuse of our products or
similar products of our competitors.
As a manufacturer, we may be subject to product liability claims. As a manufacturer and a distributor of products for human consumption
and topical application, we could become exposed to product liability claims and litigation. Additionally, the manufacture and sale of these
products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. To date, we have not
been a party to any product liability litigation, although, like any dietary supplement company, we have received reports from individuals who
have asserted that they suffered adverse consequences as a result of using our products. The number of reports we have received to date is
nominal. These matters historically have been settled to our satisfaction and have not resulted in material payments. We are aware of no instance
in which any of our products arc or have been defective in any way that could give rise to material losses or expenditures related to product
liability claims. Although we maintain product liability insurance, which we believe to be adequate for our needs, there can be no assurance that
we will not be subject to such claims in the future or that our insurance coverage will be adequate.

Our business is subject to particular intellectual property risks. Most of our products are not protected by patents. The labeling
regulations governing our nutritional supplements require that the ingredients of such products be precisely and accurately indicated on product
containers. Accordingly, patent protection for nutritional supplements often is impractical given the large number of manufacturers who produce
nutritional supplements having many active ingredients in common. Additionally, the nutritional supplement industry is characterized by rapid
change and frequent reformulations of products, as the body of scientific research and literature refines current understanding of the application
and efficacy of certain substances and the interactions among various substances. In this respect, we maintain an active research and
development program that is devoted to developing better, purer, and more effective formulations of our products. We protect our investment in
research, as well as the techniques we use to improve the purity and effectiveness of our products, by relying on trade secret laws. We have also
entered into confidentiality agreements with certain of our employees involved in research and development activities. Additionally, we endeavor
to seek, to the fullest extent permitted by applicable law, trademark and trade dress protection for our products, which protection has been sought
in the United States, Canada, and in many of the other countries in which we arc either presently operating or plan to commence operations in the
future. Notwithstanding our efforts, as described above, there can be no assurance that these efforts to protect our trade secrets and trademarks
will be successful. Nor can there be any assurance that third-parties will not assert claims against us for infringement of the intellectual proprietary
rights. If an infringement claim is asserted, we may be required to obtain a license of such rights, pay royalties on a retrospective or prospective
basis, or tenninate our manufacturing and marketing of our infringing products. Litigation with respect to such matters could result in substantial
costs and diversion of management and other resources and could have a material adverse effect on our business, financial condition, or operating
results. There can be no assurance that third-party claims will not in the future adversely affect our business, financial condition, or results of
operations.
Our manufacturing activity is subject to certain risks. We manufacture approximately 74% of the products sold to our customers. As a
result, we are dependent upon the uninterrupted and efficient operation of our manufacturing facilities in Salt Lake City, and Draper, Utah. Those
operations are
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subject to power failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment,
natural or other disasters, and the need to comply with the requirements or directives of government agencies, including the FDA. There can be no
assurance that the occurrence of these or any other operational problems at our facility would not have a material adverse effect on our business,
financial condition, or results of operations. We arc subject to a variety of environmental laws relating to the storage, discharge, handling,
emission, generation, manufacture, use and disposal of chemicals, solid and hazardous waste, and other toxic and hazardous materials. Our
manufacturing operations presently do not result in the generation of material amounts of hazardous or toxic substances. Nevertheless, complying
with new or more stringent laws or regulations, or more vigorous enforcement of current or future policies of regulatory agencies, could require
substantial expenditures by us that could have a material adverse effect on our business, financial condition, or results of operations.
Environmental laws and regulations require us to maintain and comply with a number of permits, authorizations, and approvals and to maintain and
update training programs and safety data regarding materials used in our processes. Violations of those requirements could result in financial
penalties and other enforcement actions and could require us to halt one or more portions of our operations until a violation is cured. The
combined costs of curing incidents of non-compliance, resolving enforcement actions that might be initiated by government authorities, or of
satisfying new legal requirements could have a material adverse effect on our business, financial condition, or results of operations.
Our stock price has been volatile and subject to various market conditions. There can be no assurance that an active market in our stock will
be sustained. The trading price of our common stock has been subject to wide fluctuations. The price of our common stock may fluctuate in the
future in response to quarter-to-quarter variations in operating results, material announcements by us or our competitors, governmental regulatory
action, conditions in the nutritional supplement industry, negative publicity, or other events or factors, many of which are beyond our control. In
addition, the stock market has historically experienced significant price and volume 0uctuations, which have particularly affected the market prices
of many dietary and nutritional supplement companies and which have, in certain cases, not had a strong correlation to the operating performance
of these companies. Our operating results in future quarters may be below the expectations of securities analysts and investors. If that were to
occur, the price of our common stock would likely decline, perhaps substantially.
We may incur liability under our "Athlete Guarantee" program, if and to the extent participating athletes make a successful claim against
USANA for testing positive for certain banned substances while taking USANA nutritional supplements. USANA believes that its nutritional
supplement products arc free from substances that have been banned by world-class training and competitive athletic programs. The Company
retains independent testing agencies to conduct periodic checks for banned substances. The Company further believes that, while its products
promote good health, they are not otherwise considered to be "performance enhancing" as that term has been used in defining substances that arc
banned from use in international competition by the World Anti-Doping Agency ("WADA"). For many years, USANA has been a sponsor of
Olympic athletes and professional competitors around the world. These athletes have been tested on many occasions and have never tested
positive for banned substances as a result of taking USA NA nutritional products. To back up its claim that athletes who use the Company's
procluc:ts as part of their trninine reeimr:n will not h~ c.nns11mine hnnn~d substances, the Company has offered to enter into agreements with sdect
athletes, some of whom have high-profiles and are highly compensated, which state that, during the term of the agreement, should the athlete test
positive for a banned substance included in the WADA, and should such positive result be the result of taking USANA nutritional products,
USANA will compensate that athlete two times their current annual earnings up to one million dollars, based on the athlete's personal level of
competition, endorsement, and other income, as well as other factors. To mitigate potential exposure under these agreements, we:
Designate lots identified as dedicated to the program and retain additional samples;
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Store designated lot samples externally with a third-party; and
Establish a chain of custody that requires signatures on behalf of USA NA and the third-party to transfer possession of the product
lots and that restricts access by USANA employees after the transfer.
All applicants to this Athlete Guarantee program arc subject to screening and acceptance by the Company in its sole discretion. Contracts arc
tailored to fit the athlete's individual circumstances and the amount of the Company's exposure is limited based on the level of sponsorship of the
participating athlete. Although the Company believes that the pool of current and potential participants in the program is small, there is no
guarantee that an athlete who is accepted in the program will not successfully make a claim against us. The Company currently has no insurance to
protect it from potential claims under this program.

vP

Item I B.

Unresolved Staff Comments

We received no written comments from the Commission staff that remain unresolved regarding periodic or current reports under the Exchange
Act in the 180 days prior to December 29, 2007.

I tern 2.

Properties

We own and lease administrative, manufacturing and distribution facilities throughout the world to conduct our operations.

Owned and Leased Facilities
In Salt Lake City, Utah, we own a 354,000 square foot facility, which we utilize as our world-wide corporate headquarters. This facility is
located on a company-owned 16-acre parcel of land. In 2006, we began construction of an addition to this facility, which is nearing completion. At
December 29, 2007, approximately 275,000 square feet of this facility was complete and allocated primarily for manufacturing, distribution, research
and development, and administrative purposes. The uncompleted portion of the building will add approximately 79,000 square feet to the facility
and will provide us with flexibility to add additional manufacturing, distribution and administrative space, based on our needs as we experience
future growth. We expect to have the construction of the uncompleted portion of the building completed by the end of2008.
In addition to our corporate headquarters, we own a I 0,000 square-foot production studio and office building in Salt Lake City, Utah, a 31,000
square foot manufacturing facility in Tianjin, China and a 48,000 square foot office/warehouse building in Sydney, Australia. We purchased the
production studio in connection with our acquisition ofFMG Productions, which is now doing business as USA NA Studios. USANA Studios
now operates at our corporate headquarters facility, and the former facility in which they operated is currently held for sale. We purchased our
Australia facility in 2007 to replace the facility that we currently lease there. We are in the process of remodeling and fitting this facility out and
anticipate moving our Australian operations to this facility in mid-2008, at which time we will terminate our existing lease there.
We lease regional offices and distribution warehouses located in Canada, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore,
Mexico, and Malaysia. Although we sold our contract manufacturing business during 2007, we continue to lease a portion of the facility in Draper,
Utah for the manufacture and packaging of our ScnscTM products.

Productive Capacity
Based on equipment capacity and current product mix, the average manufacturing and packaging utilization rate at our corporate headquarters
building is at approximately 90% of capacity. The
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Draper, Utah facility, where our personal care products arc manufactured, is at approximately 70% of manufacturing and packaging capacity.
Current monthly lease commitments for the properties under lease total approximately $330,000.
Item 3.

Leg~I Proceedings

USA NA Health Sciences, Inc. v. Barry Minkow and Fraud Discovery Institute, Inc.
On March 15, 2007, USANA commenced this action against Barry Minkow and his company, the Fraud Discovery Institute, in the United
States District Court, District of Utah, Central Division, claiming that the defendants engaged in activity resulting in defamation, business
disparagement, and other claims for relief. USANA amended the complaint in June 2007 to include claims under federal law and California state law
that defendant's activity resulted in fraudulent stock manipulation and dropped the claim of defamation. On August 2, 2007 the Court approved our
motion for expedited discovery as to the identity of other participants in this alleged manipulation, and we will add them as defendants to the suit,
as appropriate. On September 6, 2007, the defendants filed their response to our initial complaint and petitioned the court to dismiss the case or, in
the alternative, transfer the venue to the State of California. We subsequently filed our response and requested that the case remain in the State of
Utah. In December 2007, the court denied the motion to transfer venue. In March 2008, the Court denied the defendant's motion to dismiss
USANA's federal stock manipulation claim, but dismissed USANA's state law claims. The court's ruling also overturned a previous decision
awarding the defendants expedited discovery against USANA. We will continue to aggressively pursue this litigation.

Consolidated Shareholder Class Action lawsuit: Case No. 2:07cv 177DAK
During 2007, three shareholder class action lawsuits were filed in the United States District Court, District of Utah, Central Division, against
the Company; Myron W. Wentz, our Chief Executive Officer; David A. Wentz, our President; and Gilbert A. Fuller. our Chief Financial Officer.
These lawsuits were prompted by the allegations against the Company by Barry Minkow. By order dated October 17, 2007, the court consolidated
these three lawsuits into one action and appointed the lead plaintiff and counsel for the class. The consolidated amended complaint claims, among
other things, that we violated Sections l O(b) and 20(a) and SEC Rule l 0b-5 under the Exchange Act by knowingly or recklessly failing to make
certain statements that the plaintiffs allege should have been made, including statements regarding the multi-level marketing industry and antipyramid laws, sustainability of our marketing plan, Associate sales to end-user customers, and Associate turnover, income, and profitability.
Plaintiffs assert that because of such alleged omissions, our statements about our future business prospects were lacking in a reasonable basis
and that our reported results and financial statements were misstated. These complaints seek damages, pre-judgment interest, costs, attorney's
fees, and other further relief deemed appropriate by the court. We believe these claims are distorted, ignore the documented history of public
disclosures by the Company on the very subjects allegedly omitted, are not actionable under established interpretations of Sections I O(b) and 20
(a) of the Exchange Act, and are without merit. In December 2007, we filed a motion to dismiss this lawsuit. Plaintiffs filed an opposition to our
motion to dismiss and the court has ordered a hearing on the motion in April 2008. We will continue to vigorously defend the Company and related
defendants in this action. Nevertheless, there can be no assurance that this litigation will not have a material adverse impact on our business,
financial condition, or results of operation.

Larson on behalf ofUSANA Health Sciences, Inc. v. Certain Officers and Directors oJUSANA
On September 4, 2007, a shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah, against
certain of our present and former directors and
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officers. This lawsuit was also prompted by the allegations against the Company by Barry Minkow. The derivative complaint contained allegations
similar to those asserted in the shareholder class action litigation described above and asserted that, as a result of such allegations, the defendant
directors and officers breached their fiduciary duties of good faith and loyalty to the Company and were unjustly enriched. Similar to the
shareholder class action, we believed the claims in the derivative complaint were distorted, not actionable under applicable law, and without merit.
Consequently, we filed a motion to dismiss the lawsuit during the fourth quarter of 2007. In December 2007, the plaintiff offered to withdraw the
lawsuit rather than respond to our motion to dismiss. On December 28, 2007, the court granted the motion to dismiss with prejudice .

.Johnson vs. USANA
In June 2007, two former Associates filed a class action lawsuit against USANA in state court in San Diego, California. The proposed class
consists of distributors who were California residents at any time since 1995. The complaint alleges a number of purported material
misrepresentations to the market in violation of state pyramid, deceptive business practices, and business fraud law based on some of the same
facts alleged in the shareholder class action. This lawsuit was also prompted by the allegations against the Company by Barry Minkow. On
September 4, 2007, we filed our answer to the complaint, which contained a general denial of the allegations in the complaint and set forth our
affirmative defenses. Plaintiffs and USANA have stipulated to an agreement, which entails USANA producing a limited amount of discovery
beginning in February 2008, subject to a confidentiality agreement. Similar to the shareholder class action, we believe the claims in this complaint
arc distorted, not actionable under applicable law, and without merit. Nevertheless, there can be no assurance that this litigation will not have a
material adverse impact on our business, financial condition, or results of operation.

Informal Inquiry by the United States Securities and Exchange Commission

~

During the first quarter of 2007, we received notification from the SEC, Salt Lake District Office, that it had begun an informal inquiry regarding
the Company. This inquiry was also prompted by the allegations against the Company by Barry Minkow. We cooperated fully with the SEC during
the course of this inquiry. In January 2008, we received a letter from the SEC which indicated that the matter had been closed and no enforcement
action would be recommended against the Company.

Item 4.

Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of shareholders during the quarter ended December 29, 2007.
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PART 11
Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information
Our common stock trades on The NASDAQ Global Select Maiket undei the symbol "USNA." The following table coniains ihe reported high
and low sale prices for our common stock as reported on The NASDAQ Global Select Market for the periods indicated:
2006

Low

lligh

First Quarter
Second Quarter
Third Quarter
Fourth Quarter

$
$

$

$

2007

43.42
42.70
47.33
52.84

$
$
$

$

High

First Quarter
Second Quarter
Third Quarter
Fourth Quarter

$
$

$
$

61.80
49.71
51.50
48.50

37.38
35.81
35.06
42.76
Low

$
$

45.27
36.70

$

28.51

$

36.90

On March 3, 2008, the high and low sales prices of our common stock as reported by NASDAQ were $31. !4 and $30.20, respectively.
Shareholders

As of March 3, 2008, we had approximately 511 holders of record of our common stock.

Dividends
We have never declared or paid cash dividends on our common stock. Future cash dividends, if any, will be determined by our Board of
Directors and wi11 be based on earnings, available capital, our financial condition, and other factors that the Board of Directors deems to be
relevant.
Share Repurchases

There were no share repurchases made during the quarter ended December 29, 2007.
Item 6.

Selected Financial Data

Due to the sale of certain assets related to our former third-party contract manufacturing business, we now operate as one reportable business
segment, Direct Se11ing. Our financial results have been adjusted to reflect the reclassification of sales and related expenses in our former Contract
Manufacturing segment to "discontinued operations" for all periods presented. Further information on this can be found in Note B to the
Consolidated Financial Statements herein under-" Discontinued Operations."
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The fulluwing sdecle<l consolidated financial data should be read in conjunction with "Management's Discussion and Analysis of financial
Condition and Results of Operation" and the Consolidated Financial Statements and related notes thereto that are included in this report.
Fiscal Year*

~
2004

2003

2006**

2005

2007

{in thousands, except per share data)

Consolidated Statements of Earnings Data:
Net sales
Cost of sales
~

$

v)

259,040
57,697

315,017
68,703

$

365,166
79,836

$

423,149
87,891

$

201,343

246,314

285,330

335,258

76,486
43,992
1,367

100,960
53,973
1,796

124,045
59,920
2,212

146,251
2,968

170,383
90,811
3,363

Total operating expenses

121,845

156,729

186,177

221,629

264,557

Earnings from continuing operations
Other income (expense), net

31,010
192

44,614
233

60,137
479

63,701
1,408

70,701
471

Earnings from continuing operations before income
taxes
Income taxes

31,202
10,477

44,847
14,243

60,616
20,444

65,109
22,966

71,172
25,243

Income from continuing operations
Income (loss) from discontinued operations, net of tax

20,725
92

30,604
173

40,172
(1~178)

42,143
(877)

45,929
(612)

$

Net earnings

·v:J

$

152,855

Gross profit
Operating expenses:
Associate incentives
SelJing, general, and administrative
Research and development

~

195,980
43,125

20,817

$

30,777

38,994

$

72,410

41,266

$

45,317

$

:·,

Earnings per common share:
Basic
Continuing operatfops
Discontinued operations

1.09

$

Net earnings

$

1.60
0.01

$

·2.~4;_i-$.

2.13 $
(0.06)

$

1.09

$

1.61

$

$

0.98

$

I.SO
0.01

$

$

0.98

$

1.51

$

2.07

,:-2/14
(0.03)

(0.05)

$

2}9·, J:

··:~:\:"<Ttm.

2.25 $
(0.05)

2.67
(0.04)

~

Diluted
Continuing operations
Discontinued operations
Net earnings
~

Weighted average common shares outstanding:
Basic
Diluted
Dividends per share

2.04 $
(0.06)
1.98

19,163
20,415

19,018
21,319

2.20

$

18,873
19,721

2.63

$

18,053
18,724

16,734
17,206

As of
Jan. I,
2005

Jan. 3,
2004

vJ

Dec. 31,
2005

Dec. 30,
2006

Dec. 29,
2007

{in thousands, except other data)

,..;;j

~

Consolidated Balance Sheet Data:
Cash and cash equivalents
Working capital
Current assets
Total assets
Line of credit
Other long-term liabilities
Stockholders' equity
Other Data:
Active Associates
Active Preferred Customers

$
$

s
$

$
$
$

18,965
18,330
38,249
65,127
837
44,371
88,000
51,000

$
$
$
$

$
$
$

15,067
18,073
40,823
71,664
1,017
47,843
114,000
63,000

$
$

$
$

$
$
$

10,579
15,274
41,830
73,708
l,414
45,738

$
$
$
$
$

27,029
20,8IO
60,615
100,002

$

s

133,000
70,000
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$
$

s
$
$
$

60,197
153,000
78,000

$

12,865
5,807
45,992
109,128
28,000
2,305
38,638
176,000
78,000

Total Active Customers

*

139,000

177,000

203,000

231,000

254,000

The Company's fiscal year ends on the Saturday that is closest to December 31. The 2004, 2005, 2006, and 2007 fiscal years were 52•week
years. Fiscal year 2003 was a 53•week year.
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Effective fanuary i, 2006, ihc Company began recognizing equity-based compensation expense in its statements of earnings.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation
The following discussion and analysis of financial condition and results of operations should be read in conjunction with the Consolidated
Financial Statements and notes thereto appearing elsewhere in this report.

Overview
We develop and manufacture high-quality nutritional and personal care products that are distributed internationally through a network
marketing system, which is a form of direct selling. Our customer base comprises two types of customer; "Associates" and "Preferred Customers."
Associates are independent distributors of our products who also purchase our products for their personal use. Preferred Customers purchase our
products strictly for their personal use and are not permitted to resell or to distribute the products.
Our results of operations and financial condition are directly related to the recruitment and retention of Associates and Preferred Customers.
We believe that our high quality products and our financially rewarding Compensation Plan are the key components to attracting and retaining
Associates. AdditionaJiy, we sponsor meetings and events throughout the year, which offer information about our products and our network
marketing system. These meetings are designed to assist Associates in business development and to provide a forum for interaction with
successful Associates and members of the USANA management team. We also provide low cost sales tools, which we believe are an integral part
of building and maintaining a successful home-based business for Associates.
In addition to Company-sponsored meetings and sales tools, we maintain a website exclusively for our Associates where they can keep up on
the latest USANA news, obtain training materials, manage their personal information, enroll new customers, shop, and register for Companysponsored events. Additionally, through this website, Associates can access other on line services to which they may subscribe. For example, we
offer an on line business management service, which includes a tool that helps Associates track and manage their business activity, a personal
webpage to which their prospects or retail customers can be directed, e-cards for advertising, and a tax management tool.
We have ongoing operations in the following markets, which are grouped and presented in four geographic regions:
North America-United States, Canada, Mexico, and direct sales from the United States to the United Kingdom and the
Netherlands
Southeast Asia/Pacific-Australia-New Zealand, Singapore, and Malaysia*

*

Operations in Malaysia commenced in January 2007.
East Asia-Hong Kong and Taiwan
North Asia-Japan and South Korea

The number of active Associates and Preferred Customers are used by management as a key non-financial measure because they are a leading
indicator for net sales. For purposes of this report, we only count as "active" those Associates and Preferred Customers who have purchased
product from USANA at any time during the most recent three-month period. During the years presented, changes in net sales were not
significantly affected by product price changes, rather, they were affected by increased product sales volume resulting from an increasing number
of Associates and Preferred Customers.

36

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

The tables below summarize the changes in our active customer base by geographic region as of the dates indicated.

Active Associates By Region
(rounded to the nearest thousand)
As of
December 30, 2006

North America
Southeast Asia/Paci fie
East Asia
North Asia

94,000
30,000
23,000
6,000
153,000

Change from
Prior Year

As of
December 29, 2007

61.4%
19.6%
15.1%
3.9%

100,000
39,000
30,000
7,000

100.0%

176,000

~

Percent

Change

56.8%
22.2%
17.0%
4.0%

6,000
9,000
7,000
1,000

6.4%
30.0%
30.4%
16.7%

l00.0%

23,000

15.0%

t:::m::zi::==r

Active Preferred Customers By Region
(rounded to the nearest thousand)
As of
December 30, 2006

North America
Southeast Asia/Pacific

70,000
7,000

••

East Asia
North Asia

**

89.7%
9.0%

70,000
6,000

1.3%

1,000

; O.<i¾~~·

1,000
. 78,000-

As of
December 29, 2007

89.8%
7.6%
1.3%.
1.3%

i,opo

-

;JOO,<>%:· ·. 78;QQ.0,

Change from
Prior Year

-

.JQQ.()%.

Percent
Change

(1,000)
l,OQO.

0.0%
(14.3)%
NIA

0.0%

-

0.0%

Active Preferred Customer count was less than 500.

Total Active Customers By Region
(rounded to the nearest thousand}
As of
December 30, 2006

North America
Southeast Asia/Pacific
East Asia
North Asia

164,000'
37,000
23,000
7,000
231,000

Change from
Prior Year

As of
December 29, 2007

?LO%
16.0%
.10.0%
3.0%

170,000'. ''.:
45,000
31,000.8,000

.-66:9% ,.·

100.0%

254,000

100.0%

--===a

17.7%

Ji.2¾'
3.2%

Percent
Change

";'.,6,000 ·
8,000
8,60·0
1,000

3.7%
21.6%
34.8%
14.3%

23,000

10.0%

~

Presentation
Due to the sale of our third-party contract manufacturing business, we now operate as one reportable business segment, Direct Selling. Our
financial results have been adjusted to reflect the reclassification of sales and related expenses in our former Contract Manufacturing segment to
"discontinued operations" for all periods presented. Further information on this sale of assets can be found in Note B to the Consolidated
Firrnncial Statements herein under "Discontinued Operations."
Sales and shipping and handling billed to our customers are recorded as revenue when the product is delivered, title has transferred, and risk
of loss passes to the customer, net of applicable sales discounts. Payments received for undelivered products are recorded as deferred revenue
and are included in other current liabilities. A provision for product returns and allowances is included and is
·
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founded on our historical experience. Additionally, the Company collects an annual renewal fee from Associates that is deferred on receipt and is
recognized as income on a straight-line basis over a twelve-month period.
Cost of sales primarily consists of expenses related to raw materials, labor, quality assurance, and overhead costs that are directly associated
with the production and distribution of our products and sales materials, as well as d·uties and taxes that are associated with the import and export
of products. As our international sales increase as a percentage of net sales, cost of sales are increasingly affected by additional duties, freight,
and other factors, such as changes in foreign currency.
Associate incentive expenses represent our most significant expense at 40.3% of net sales in 2007. Associate incentives include commissions
and leadership bonuses that are paid weekly, based on group sales volume points. Compensation paid to our Associates for promotions and
contests are also reported as a component of Associate incentives. Products are assigned a sales volume point value that is independent of the
product's price. Associates earn commissions based on sales volume points that arc generated in their downline organization. Items such as our
starter kits and sales tools have no sales volume point value, and commissions are not paid on the sale of these items. Although insignificant to
our financial statements, an Associate may earn commissions on sales volume points that are generated from personal purchases that are not
considered to be part of their "Qualifying Purchases." Qualifying Purchases are the amount of product that Associates must purchase each month,
which they must either resell to consumers or personally use in order to qualify to earn commissions or bonuses under USANA's Compensation
Plan. Commissions paid to an Associate on personal purchases are considered a sales discount and are reported as a reduction to our net sales.
Selling, general, and administrative expenses include wages and benefits, depreciation and amortization, rents and utilities, Associate events,
advertising, and professional fees, along with other marketing and administrative expenses. Wages and benefits represent the largest component
of selling, general, and administrative expenses. Significant depreciation and amortization expense is incurred as a result of investments in physical
facilities, computer and telecommunications equipment, and systems to support international expansion. We anticipate that additional capital
investments will be required in future periods to promote and support our anticipated growth in sales and customers.
Research and development expenses include costs incurred in developing new products, enhancing existing products, and in formulating
products for introduction into international markets.

viJ

Sales to customers outside the United States are made in the respective local currencies and are translated to U.S. dollars at weighted-average
currency exchange rates for the period. Most of our raw material purchases from suppliers and our product purchases from third-party
manufacturers are transacted in U.S. dollars. Consequently, our sales and net earnings may be affected by changes in currency exchange rates,
with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar.
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Results of Operations
The following table summarizes our consolidated operating results as a percentage of net sales, respectively, for the periods indicated:
Fiscal Year

2005

Consolidated Statements or Earnings Data:
Net sales
Cost of sales

2006

2007

100.0 %
21.8 %

100.0 %
2i.9 %

100.0%
20.8%

78.2 %

78.1 %

79.2%

39.4 %
19.0 %
0.7 %

40.1 %
19.8 %
0.8 %

40.3%
21.5%
0.8%

59.1 %

60.7 %

62.6%

Earnings from continuing operations
Other income, net

19.1 %
0.2 %

17.4 %
0.4 %

16.6%
0.1%

Earnings from continuing operations before income
taxes
Income taxes

19.3 %
6.5 %

17.8 %

16.7%
6.0%

Income from continuing operations
Loss from discontinued operations, net of tax

12.8 %
(0.4 )%

11.5 %

10.7%

(0.2 )%

. (0.1)%

Gross profit
Operating expenses:
Associate incentives
SelJing, general, and administrative
Research and development
Total operating expenses

Net earnings

12.4 %
ma:m:::m:a:a

6.3 %

11.3 %
iz:::ca=z:a

10.6%
a:iz=a=:z:11

Summary of 2007 Financial Results and Developments
Fiscal 2007 marked the sixth consecutive year of net sales and earnings growth for USANA, with net sales increasing nearly 16% to
$423. l million and with income from continuing operations increasing 9.0% to $45.9 million. Overall sales growth during the year can be attributed
to an increased number of active Associates who purchased our products. Additionally, in January 2007, we began operations in Malaysia, which
contributed $17.1 million to net sales for the year. Also, during 2007, we benefited from changes in foreign currency, which added $10.9 million to
net sales for the full year. The increase in income from continuing operations can be attributed in large part to increased net sales and to improved
gross profit margin, which were offset partially by higher operating costs.
During fiscal 2007, we held our second Asia Pacific Convention in Sydney, Australia, as well as our 15th annual International Convention in
Salt Lake City, Utah. At our International Convention, we introduced MyHealthPakn.1, a new, customizable packaging system for our supplement
products that allows customers to create personalized selections of nutritional supplements in daily AM and PM pillow packs. MyHealthPak is
currently available only to U.S. and Canadian customers. Because MyHealthPak is simply a new packaging system of the bottled products that
many customers currently consume, we expect that sales of this product will increase gradually as customers begin to see the benefits of custom
pillow packs and consume their existing supplies of bottled products.
Also, during the year, we sold our third-party contract manufacturing business, which resulted in operations for the Contract Manufacturing
segment being accounted for as "discontinued operations" in accordance with SFAS No. 144 "Accounting for the Impairment or Disposal of
Long-Lived Assets." We retained the assets that are associated with 1m11rnfocturing and packaging our Sense TM skin and beauty care products
and will continue to manufacture these products.
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Fiscal Year 2007 compared to Fiscal Year 2006

~

The following table summarizes the changes in our net sales by geographic region for the fiscal years ended December 30, 2006 and
December 29, 2007:
Net Sales by Region
(in thousands)
Year Ended
2006

vJ

North America
Southeast Asia/Pacific
East Asia
North Asia

Change from
Prior Year

2007

$

246,489
65,104
37,478
16,095

67.5%
17.8%
10.3%
4.4%

$

267,235
90,690
49,314
15,910

$

365,166

100.0%

$

423,149

Percent
Change

63.1%
21.4%
11.7%
3.8%

$

20,746
25,586
ll,83~
(185)

8.4%
39.3%
31.6%
(l.1)%

100.0%

$

57,983

15.9%

---

~

North America. Net sales in North America, our largest region, increased $20.7 million, or 8.4%, in 2007, compared with 2006. This growth
consisted of modest growth in our most mature market, the United States, of 6.4%, strong growth in Mexico of 23.1 %, and growth in Canada, much
of which came from changes in foreign currency, resulting in a benefit of approximately $4.2 million. Sales growth in this region, however, was
adversely affected by various false aJlegations against the Company that were disseminated in the mass media. We believe these chaJlenges are
now largely behind us. During 2008, we plan to implement several new Associate-related initiatives that arc designed to regain our momentum in
this region.
Southeast Asia/Pacific. Net sales in Southeast Asia/Pacific increased $25.6 million, or 39.3%, in 2007, compared with 2006. This growth was
bolstered by the opening of our Malaysia market in January 2007, which contributed $17. I million in net sales during the year. Also contributing to
growth in this region during 2007 were changes in foreign currency, which resulted in a benefit of approximately $6. 9 million, most of which came
from Australia-New Zealand.
Although Malaysia added significantly to net sales in this region, we believe that a portion of the sales generated in Malaysia would have
otherwise been generated in existing markets within this region, as well as in the North Asia and East Asia regions, due to the seamless nature of
our Compensation Plan.

East Asia. Net sales in East Asia increased $11.8 million, or 31.6%, in 2007, compared with 2006. This growth included strong growth in Hong
Kong of 62.2% to $26.4 million, and modest growth in Taiwan of8.0% to $22.9 million. Sales growth in this region was largely driven by an increase
in the number of active Associates in this region.

-~
North Asia. Net sales in North Asia decreased $185 thousand, or 1.1 %, in 2007, compared with 2006. This decline was due to a 2.0% decrease
in South Korea sales to $6.8 mil1ion. Net sales in this region continue to be soft due to the lack of Associate leadership. A strategic decision was
made during mid-2007 to reorganize our internal reporting structure with our vice president of East Asia now having oversight in this region. We
believe this change will help bolster trust with our Associate leadership and foster growth in this region.

Gross Profit
Gross profit increased to 79.2% of net sales in 2007 from 78.1 % in 2006. This improvement in gross profit margin can be attributed to reduced
inventory scrap of about $1.5 million, and lower relative freight costs on shipments to our customers. Also contributing to the improvement in
gross profit was a reduction of sales of the edition of Success From Home magazine that features the
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Company (which were sold at cost and included free shipping during the third and fourth quarters of2006).
Associate Incentives

Associate incentives were slightly higher during 2007, at 40.3% of net sales, compared with 40.1 % in 2006. This increase is the result of a
higher payout of base Compensation Plan commissions, which was partially offset by reduced amounts spent on contests and promotions relative
lo 2006.
Selling, General, and Administrative Expenses

Selling, general, and administrative expenses increased to 21.5% of net sales in 2007 from 19.8% in 2006. In absolute terms, our selling, general
and administrative expenses increased in 2007 by $18.4 million. This increase, both as a percentage of net sales and in absolute terms, can be
attributed to the following:
Wage-related increases of $9.8 million, which includes a strategic initiative to hire additional employees to add "bench strength,"
and additional wages expense related to Malaysia, and increased equity compensation expense;

A $6. l million increase in spending to support growing sales and an increased number of customers, which includes $1.2 million
spent to support our Malaysia market that commenced operations in January 2007; and
Legal and other professional services of $2.5 million that related to defending false allegations against the Company that were
disseminated in the mass media.
Other Income
Other income decreased from $1.4 mill ion in 2006 to $4 71 thousand in 2007. Th is decrease can largely be attributed to an increase in interest
expense, resulting from our line of credit, of $696 thousand (net of $705 thousand related to funds borrowed for the expansion of our corporate and
Australia facilities, which was capitalized). Additionally, and to a lesser extent, interest income also decreased due to lower cash balances and to
lower foreign currency gains.
Income Taxes
Income taxes totaled 35.5% of earnings before income taxes in 2007, compared with 35.3% in 2006. This change was due to the complete
phase-out of the Extraterritorial Income Exclusion ("EIE"), which provided an effective tax rate reduction of 1.8% in 2006. In 2007, the complete EIE
phase-out was partially offset by tax benefits from a 6.0% deduction for qualified production activities, a favorable adjustment due to the expiration
of statutes of limitations on uncertain tax positions, and favorable 2006 tax return adjustments.
Income from Continuing Operations

Income from continuing operations increased 9.0% to $45.9 million in 2007, which is an increase of$3.8 million from $42.1 million in 2006. This
increase is due primarily to increased net sales and an improved gross profit margin, which were offset partially by higher operating costs.
Diluted earnings per share from continuing operations improved to $2.67 during 2007, which is an increase of$0.42, or 18.7%, from $2.25 in
2006. This improvement resulted from share repurchases and retirements during the first nine months of 2007, which lowered the diluted shares
outstanding by 8.1 %, resulting in an $0.18 benefit per share. Also contributing to the improvement was an increase in income from continuing
operations.
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Fiscal Year 2006 compared to Fiscal Y car 2005
Net Sales

Changes in net sales are primarily associated with the recruitment and retention of Associates and Preferred Customers. The following tables
summarize the changes in our active customer base by geographic region as of the dates indicated:
Active Associates By Region
(rounded to the nearest thousand)
As of
December 31, 2005

North America
Southeast Asia/Pacific

East Asia
North Asia

61.6%
20.3%
12.8%
5.3%

94,000
30,000
23,000
6,000

100.0%

153,000

82,000
27,000
17,000
7,000

m;ooo

Change from
Prior Year

As of
December 30, 2006

=

Percent
Change

61.4%
19.6%
15.1%
3.9%

12,000
3,000
6,000
(1,000)

14.6%
11.1%
35.3%
(14.3)%

100.0%

20,000

15.0%

=

Active Preferred Customers By Region
(rounded to the nearest thousand)
As of
December 31, 2005

North America
Southeast Asia/Pacific
East'Aslif; ;·
North Asia

**

90.0%
8.6%
0.0%
1.4%

70,000
7,000

100;0%

78,000

63,000
6,000

**

1,000
70,000

-

As of
December 30, 2006

**

1,000

Change from
Prior Year

89.7%
9.0%
0.0%
1.3%

7,000
1,000

100:0%

8~000

Percent
Change

11.1%
16.7%

NIA'.·
0.0%

lf:4%

--=a

Active Preferred Customer count was less than 500.

Total Active Customers By Region
(rounded to the nearest thousand)
As of
December 31, 2005

~

North America
Southeast Asia/Pacific
East Asia
North Asia

As of
December 30, 2006

145,000
33,000
17,000
8,000

71.4%
16.2%
8.4%
4.0%

164,000
37,000
23,000
7,000

203,000

100.0%

231.000

Change from
Prior Year

Percent
Change

71.0%
16.0%
10.0%
3.0%

19,000
4,000
6,000
(1,000)

13.1%
12.1%
35.3%
(12.5)%

100.0%

28,000

13.8%

-=,:a
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The following table summarizes the changes in net sales by geographic region for the fiscal years ended December 31, 2005 and December 30,

2006:
Net Sales by Region
(in thousands)
Year F.nded
Change from
Prior Year

2006

2005

North America
Southeast Asia/Pacific
East Asia
North Asia

~
Percent
Change

$

209,445
58,300
32,349
14,923

66.5%
18.5%
10.3%
4.7%

$

246,489
65,104
37,478
16,095

67.5%
17.8%
10.3%
4.4%

$

37,044
6,804
5,129
1,172

17.7%
11.7%
15.9%
7.9%

$

315,017

100.0%

$

365,166

100.0%

$

50,149

15.9%

North America. Net sales in North America, our largest and most mature region, increased $37.0 million, or 17.7%, in 2006, compared with
2005. This growth consisted of strong growth in our most mature market, the United States, of 18. 7%, and strong growth in Mexico of 29.3%.
Canada also had a strong increase in sales of 12. 7%, however much of this increase came from changes in foreign currency, resulting in a benefit of
approximately $4.4 million. This increase was driven by an increase in the number of active Associates and, to a lesser extent, to an increase in the
number of active Preferred Customers. The increase in customers was a result of unique contests and promotions, Company-sponsored events,
and the introduction of new products and sales tools.
Southeast Asia/Pacific. Net sales in Southeast Asia/Pacific increased $6.8 million, or 11.7%, during 2006, compared with 2005. This change
included an 8.1 % increase in sales in Australia-New Zealand to $48.3 million, and a 23.5% increase in sales in Singapore to $16.8 million. This
growth was due to an 11.1 % increase in the number of active Associates and a 16. 7% increase in the number of Preferred Customers.
East Asia. Net sales in East Asia increased $5.1 million, or 15.9%, during 2006, compared with 2005. This increase was driven primarily by
32.8% growth in Hong Kong to $16.3 million. Sales in Taiwan increased a modest 5.5% on a year-over-year basis to $21.2 million. The growth in
this region in 2006 was due to a 35.3% increase in the number of Associates.
North Asia. Net &ales in North Asia increased by $1.2 million, or 7.9%, in 2006, compared with 2005. Although changes in foreign currency
did not significantly affect overall sales growth in this region, it did considerably affect each market within this region. The overall year-over-year
change in this region comprised a I 0.1 % decrease in sales in Japan to $9.2 million, and a 46.1 % increase in sales in South Korea to $6.9 million.
Gross Profit
Gross profit decreased slightly to 78.1 % of net sales in 2006 from 78.2% in 2005. This decrease can be attributed primarily to the following:
Higher freight costs on shipments to customers;
The required inclusion of equity-based compensation expense; and
Additional costs relating to our promotions on the Success from Home magazine, which included selling them to our Associates at
cost and offering free shipping on packs of 56 magazines when such orders were placed on our monthly product subscription
program known as "Autoship."
This increase was partially offset by lower costs on certain key raw materials, such as Coenzyme QI 0.
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Associate incentives

Expenses related to Associate incentives represent our most significant cost as a percentage of net sales. Associate incentives increased to
40. l % of net sales in 2006, compared with 39.4% in 2005. This increase can be primarily attributed to an increase in amounts paid on incentive
promotions, including higher-paying contests and promotions.
Selling, General, and Administrative Expenses

Selling, general, and administrative expenses increased to 19.8% of net sales in 2006 from 19.0% in 2005. This increase, as a percentage of net
sales, can be attributed largely to the recognition of equity-based compensation expense, the selling, general and administrative portion of which
totaled 1.0% of net sales in 2006. This increased cost, as a percentage of sales, was partially offset by modest operating leverage that resulted from
our growing sales base.
In absolute terms, our selling, general and administrative expenses increased by $12.5 million from 2005 to 2006. This absolute increase in
selling, general and administrative expenses can, in great part, be attributed to the following:
increased spending of $8.8 million including that related to supporting growth in our existing markets as well as our international
expansion efforts (mostly in Malaysia, which totaled $210 thousand); and
Expensing of equity-based compensation of $3. 7 million;
Other Income

Other income increased to$ l .4 million in 2006 from $479 thousand in 2005. This improvement can be attributed to foreign currency gains.
Income Taxes

!-@

Income taxes totaled 35.3% of earnings from continuing operations before income taxes in 2006, compared with 33.7% in 2005. This increase
reduced diluted earnings per share from continuing operations in 2006 by approximately $0.05. This increase can be attributed to a 40% phase-out
of the Extraterritorial Income Exclusion in 2006, a tax expense associated with non-deductible value-added taxes, and taxes associated with equitybased compensation under SF AS No. l 23(R). This increase in our 2006 effective tax rate increase was partially offset by an increase in the 2006
Federal Incremental Research Credit.
Income From Continuing Operations

Income from continuing operations increased 4.9% to $42. I million in 2006, an increase of $1.9 million, from $40.2 million in 2005. Income from
continuing operations slowed during 2006 due to the following:
The inclusion of equity-based compensation expense that impacted income from continuing operations by $3.2 million;
Higher relative incentives to our Associates;
Increased expenses that were associated with our international expansion efforts; and
A higher effective tax rate.
Diluted earnings per share from continuing operations improved to $2.25 in 2006, an increase of $0.21, from $2.04 in 2005. Diluted earnings per
share from continuing operations in 2006 included
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equity-based compensation expense that reduced earnings per share by $0.17, whereas the diluted earnings per share from continuing operations
of $2.04 in 2005 did not include equity-based compensation expense. Share repurchases and retirements during 2006 added $0.06 to diluted
earnings per share from continuing operations.

~

Quarterly Financial information (Unaudited)
The following tables set fmth unaudited quarierly operating results for each of the last eight fiscal quarlt:rs, as well as percentages of net
sales for certain data for the periods indicated. This information is consistent with the Consolidated Financial Statements herein and includes
nonnally recurring adjustments that management considers to be necessary for a fair presentation of the. data. Due to the sale of certain assets
related to our fonner third-party contract manufacturing business, we now operate as one reportable business segment, Direct Selling. Our
financial results have been adjusted to reflect the reclassification of sales and related expenses in our former Contract Manufacturing segment to
"discontinued operations" for all periods presented. Further information on this can be found in Note B to the Consolidated Financial Statements
herein under-"Discontinued Operations." Quarterly results are not necessarily indicative offuturc results of operations. This information should
be read in
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~

conjunction with the audited Consolidated Financial Statements and notes thereto that are included elsewhere in this report.
Quarter Ended
April I,
2006

July I,
2006

Sept. 30,
2006

Dec. 30,
2006

March 31,
2007

June 30,
2007

Sept. 29,
2007

Dec. 29,
2007

(in thousands, except per share data)

vJ

Consolidated Statements
of Earnings Data:
Net sales
Cost of sales

$

89,694
19,319

$

91,967
20,274

$

98,121
21,865

$

100,678
20,586

$

107,542
22,443

$

106,181
21,960

$ !08,748

22,902

67,006

70,375

71,693

76,256

80,092

85,099

84,221

85,846

34,006

36,025

36,994

39,226

39,549

43,280

43,021

44,533

administrative

17,489

17,910

17,798

19,213

21.501

22,531

23,053

23,726

Research and
development

674

756

830

708

930

902

864

667

52,169

54,691

55,622

59,147

61,980

66,713

66,938

68,926

14,837

15,684

16,071

17,!09

18,112

18,386

17,283

16,920

295

336

65

712

471

15,132
5,373

16,020
5,462

16,136
5,698

17,821
6,433

18,583
6,783

· ')8~373

9,759

10,558

10,438

11,388

11,800

·11;407

. i,i~663·:;

(249)

(114)

(93)

(405)

Total operating
expenses
Earnings from continuing
operations
Other income (expense),
net

. (270)

(13)

283

Earnings from continuing
operations before

Income faxes
Income taxes

Loss from discontinued
operations

Net earnings

-t:7,013' ·
5,350

6,966

J-7;203
6,144

,, :~.;:>,.' .>..

Income from. c_oritinuing
operations

"

$

Gross profit
Operating expenses:
Associate
incentives
Selling, general, and

vJ

~

85,384
18,378

(199)

(214)

(215)

$

9,560

$

10,344

$

10,223

$

11,139

$

11,686

$

11,314

$

0.53

$

0.58

$

0.59

$

0.64

$

0.66

$

0.68

$.

11,059

ll,258

$

11,059

0.72

$

0.68

Earnings (loss) per
comi:non share*:
~

Basic
Continuing
operations
Discontinued
operations
Net earnings

(0.01)

(0.01)

(0.02)

(0.02)

$

(0.01)

(0.02)

$

0.52

$

0.57

$

0.57

$

0.62

$

0.65

$

0.68

$

0.70

$

0.68

$

0.51

$

0.56

s

0.56

s

0.62

$

0.64

$

0.66

s

0.70

$

0.67

$

0.67

~

Diluted
Continuing
operations
Discontinued
operations

~

Net earnings
Weighted average shares
outstanding:
Basic
Diluted

\JP

(0.01)

s

0.50

18,460
19,228

(0.01)

s

0.55

18,149
18,777

(0.01)

s

0.55

17,780
18,486

(0.01)
$

0.61

17,824
18,405

(0.01)
$

0.63

17,896
18,463

(0.02)
$

0.66

16,709
17,163
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$

0.68

16,173
16,613

16,160
16,586

*

Earnings per common share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly earnings per
share amounts does not necessarily equal the total for the year.
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VJ}

Consolidated Statements of Earnings as a percentage of Net Sa!cs:
Quarter Ended
Aprill,
2006

vJ
Net sales
Cost of sales

~

w)

Gross profit
Operating expenses:
Associate incentives
Selling, general and
administrative
Research and
development
Total operating
expenses
Earnings from continuing
operations
Other income (expense), net

v)

vJ

Earnings from coninuing
operations before
Income taxes
Income twces
Income from continuing
operations
Loss from discontinued
operations
Net earnings

July l,
2006

Sept. 30,
2006

Dec. 30,
2006

March 31,
2007

June 30, ·
2007

100.0%
21.5

100.0%
21.5

100.0%
22.0

100.0%
22.3

100.0%
20.4

78.5

78.5

78.0

77.7

79.6

39.8

40.2

40.2

40.0

20.5

20.0

19.4

0.8

0.8

61.1

17.4

Dec. 29,
2007

100.0%
20.7

100.0%
21.1

79.1

79.3

78.9

39.3

40.2

40.5

41.0

19.6

21.4

21.0

21.7

21.8

0.9

0.7

0.9

0.8

0.8

0.6

61.0

60.5

60.3

61.6

62.0

63.0

63.4

17.5
0.4

17.5
0.1

17.4
0.7

18.0
0.5

17.1
(0.0)

16.3
(0.3)

15.5

OJ

17.7
6.3

17.9
6.1

17.6
6.2

18.1
6.6

18.5
6.7

17.1
6.5

16.0
5.0

15.8
5.6

11.4

11.8

11.4

11.5

11.8

10.6

11.0

10.2

··co.2)

(0.2)

(0.2)

(0.2)

(0.2)

(0.1)

(0.4)

11.6%

11.2%

11.3%

11.6%

10.5%

10.6%

11.2%

100.0%
20.9

Sept. 29,
2007

OJ

10.2%

We may experience variations in the results of operations from quarter to quarter as a result of factors that include the following:
· The recruiting and retention of Associates;
The opening of new markets;
The timing of Company-sponsored events, contests, and promotions;
Fluctuations in currency exchange rates;
New product introductions;
The timing of holidays, which may reduce the amount of time that our Associates spend selling products or recruiting new
Associates;
The negative impact of changes in or interpretations of regulations that may Iimit or restrict the sale of certain products in some
countries;
The adverse effect of a failure by us or an Associate (or allegations of such failure) to comply with applicable governmental
regulations;
The integration and operation of new infonnation technology systems;
The inability to introduce new products or the introduction of new products by competitors;
Entry into one or more of our markets by competitors;
Availability of raw materials;
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General conditions in the nutritional supplement, persona! care, and weight management industries or the network marketing
industry; and
Consumer perceptions of our products and operations.
Because our products arc ingested by consumers or applied to their bodies, we arc highly dependent upon consumers' perception of the
safety, quality, and efficacy of our products. As a result, substantial negative publicity, whether founded or unfounded, concerning one or more of
our products or of other products that arc similar to our products could adversely affect our business, financial condition, or results of operations.
As a result of these and other factors, quarterly revenues, expenses, and results of operations could vary significantly in the future, and
period-to-period comparisons should not be relied upon as indications of future performance. There can be no assurance that we will be able to
increase revenues in future periods or be able to sustain the level of revenue or rate of revenue growth on a quarterly or annual basis that we have
sustained in the past. Due to the foregoing factors, future results of operations could be below the expectations of public market analysts and
investors. If that occurred, the market price ofour common stock would likely decline.

Liquidity and Capital Resources
We have historically met our working capital and capital expenditure requirements, including funding for the expansion of our operations,
through net cash flows that have been provided by our operating activities and have periodically utilized our line of credit in doing so. Our
principal source of liquidity is our operating cash flows, the availability of which is directly affected by variations in the sales of our products.
There are no material restrictions on our ability to transfer and remit funds among our international subsidiaries. In 2007, net cash flows from
operating activities totaled $57.2 million, compared with $60.2 million in 2006. Cash and cash equivalents decreased to $12.9 million at December 29,
2007, from $27.0 million at December 30, 2006. Net working capital decreased to $5.8 million at December 29, 2007, compared with $20.8 million at
December 30, 2006. Most of this decrease resulted from the drop in cash and cash equivalents. During 2007, much of our cash flows from operating
activities and cash and cash equivalents, as well as amounts available under our line of credit, were utilized to purchase shares of our common
stock under the Company's share repurchase plan, totaling $79.6 million. Additionally, $26.3 million was spent on property and equipment,
including costs for the expansion of our corporate headquarters in Salt Lake City, Utah, as well as a portion of the purchase, remodel, and fit-out of
a new facility in Sydney, Australia, both of which arc discussed further below.
We are expanding our corporate headquarters and anticipate that this expansion will involve a total investment of approximately $21 million,
an increase from the $16 million estimate that we provided in our 2006 Form 10-K. This increase is primarily due to a further increase in the scope of
the expansion, as well as to continuing increases in the cost of materials. As of December 29, 2007, billings on this expansion totaled $17.7 million,
of which $16.6 million was paid and of which $1.1 million was accrued for work performed through December 29, 2007.
We have purchased a facility in Sydney, Australia, and we expect to move our Australian operations to this new facility in mid-2008. We
anticipate that the purchase, remodel, and fit-out of this facility will require a total investment of approximately $14 million, an increase from the
$9.6 million estimate that we provided in our 2006 Fonn I 0-K. This increase is due to a further increase in the scope of the remodel and fit-out. As
of December 29, 2007, billings on this facility, including the remodel and fit-out, totaled $9.0 million, of which $8.5 million was paid and of which
$0.5 million was accrued for work perfonned through December 29, 2007.
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During the quarter ended June 30, 2007, our $25 million credit facility was amended, increasing the line of credit to $40 million. As of
December 29, 2007, our outstanding balance on this line of credit was $28.0 million. This balance primarily consists of amounts that we have used
to expand our facilities in Salt Lake City, Utah, and in Sydney, Australia, as well as to fund share repurchases and retirements.
The credit agreement relating to our line of credit contains restrictive covenants that are based on EBITDA and a specified debt coverage
ratio. As of December 29, 2007, we were in compliance with these covenants. This credit agreement also contains other covenants which are
customary for a financing transaction, including a covenant that requires us to comply in all material respects with all laws applicable to us, with
which we believe we were in compliance as of December 29, 2007.
We believe that current cash balances, cash provided by operations, and amounts available under our line of credit will be sufficient to cover
our capital needs in the ordinary course of business for the foreseeable future. lfwe experience an adverse operating environment or unusual
capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required,
would be available on favorable terms. We might also require or seek additional financing for the purpose of expanding new markets, growing our
existing markets, or for other reasons. Such financing may include the sale of additional equity securities. Any financing which involves the sale of
equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing
shareholders.
We believe that the future investments in our corporate headquarters, as well as in the new facility in Australia, will be funded with cash flows
generated from operations, and, to the extent necessary, with our line of credit. Our total investments in property, plant, and equipment in 2008 are
expected to be between $15 and $20 million, including the aforementioned facilities.
During the fiscal year ended December 29, 2007, directors, officers, and employees exercised equity awards, resulting in cash proceeds to the
Company of $3. I million.

Contractual Obligations and Commercial Contingencies
The following table summarizes our expected contractual obligations and commitments subsequent to December 29, 2007:

Payments Due By Period
(in thousands)

[eases:·;

$'

Operating
Capital Commitments

Other Ccimrnittnents".' '.. f:

Less thnn
I year

Total

Contractual Obligations

8,160 · $ .
11,571

5;904·

.::,

Total Contractual Obligations

$

25,635

3;815.'· ·$.
11,571
3,096·

$

18,482

.-4,021

'·:$•,, , ·324

6,267

$

886

-

$::.

.. 562

· .. 2,246 ·
$

More thnn
5 years

3-5 years

1-3 years

.,

•$

-

$

Included in "Capital Commitments" to be paid in less than one year is the estimated remaining of $4.4 million for the expansion to our
corporate headquarters building, and the $5.5 million to complete the remodel and fit-out of the Australia facility.
Additionally, we maintain a line of credit, which had a balance of$28.0 million as of December 29, 2007. We will be required to pay the balance
on our line of credit in full at the time of maturity; May 2011. Also, please refer to Note E to the Consolidated Financial Statements for information
on our potential obligations under FIN No. 48, "Accounting for Uncertainty in Income Taxes-an
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interpretation of FASB Statement No. 109," which clarifies the accounting for uncertainty in income tax positions.

lunation
We do not believe that inflation has had a material impact on our historical operations or profitability.

Critical Accounting Estimates

v;j

Our Consolidated Financial Statements included in this report have been prepared in accordance with accounting principles generally
accepted in the United States of America (US GAAP). Our significant accounting policies are described in Note A to the Consolidated Financial
Statements herein. The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and accompanying footnotes. Those estimates and assumptions are
derived and are continually evaluated based on our historical experiences, current facts and circumstances, and on changes in the business
environment. Actual results, however, may sometimes differ materially from estimates under different conditions. Critical accounting estimates arc
defined as both those that are material to the portrayal of our financial condition and results of operations and those that require management's
most subjective judgments. We believe that our most critical accounting estimates are described in this section.
Revenue Recognition.

In accordance with Staff Accounting Bulletin 104, "Revenue Recognition," revenue is recognized at the estimated point of delivery
of the merchandise, at which point the risks and rewards of ownership have passed to the customer. SAB 104 specifies that revenue
is realizable when the following four criteria are met: persuasive evidence of a sale arrangement exists, delivery of the product has
occurred, the price is fixed or determinable, and payment is reasonably assured. We require cash or credit card payment prior to
shipping and do not extend credit to customers.
Payments received for undelivered products are recorded as deferred revenue and are included in other current liabilities.
A provision for product returns and allowances is established and is founded on our historical experience.
In accordance with Emerging Issues Task Force No 00-10, "Accounting of Shipping and Handling Fees and Costs," amounts billed
to customers for shipping and handling are classified as revenue.
In accordance with the guidelines of Emerging Issues Task Force No 01-09, "Accounting for Consideration Given by a Vendor to a
Customer (Including a Reseller of the Vendor's Products)," commissions paid to an Associate on his or her own orders are captured
and reported as a reduction to net sales in the form of a sales discounts. Management estimates, based on the structure of
USANA's Compensation Plan, that an Associate who places an order with sales volume points in a personal sales position will
eventually be paid commission on that purchase. Such reduction of revenue for Associates outside of the United States is
converted to U.S. Dollars at the average currency exchange rate for the period.
We collect an annual renewal fee from our Associates that is deferred when it is collected and is recognized as income on a straightline basis over the subsequent twelve-month period.
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Allowance for Inventory Valuation. Inventories are stated at the lower of cost or market, using the first-in, first-out method. The components
of inventory cost include raw materials, labor, and overhead. An allowance for inventory valuation is maintained and is based on the difference
between the cost of the inventory and its estimated market value. To estimate the allowance, various assumptions are made in regard to excess or
slow-moving inventories, non-confonning inventories, expiration dates, current and future product demand, production planning, and market
conditions. A change in any of these variables could result in additional reserves.

Valuation of Goodwill and Impairment Analysis. Goodwill represents the excess of purchase price paid over the fair market value of
identifiable net assets of companies acquired. In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill is not
amortized; however it is tested at least annually for impairment or more frequently if events (or changes in circumstances) indicate impairment. We
use a two-step approach to test for impairment. The first step involves testing for impairment of goodwill by estimating the fair values of reporting
units. We determine the fair value of reporting units that we have acquired using widely accepted valuation methods, including both a market
approach and an income approach. The market approach involves judgment when considering the appropriateness ofcomparable entities and the
use of related multiples to determine fair value in tenns of operating activities, size, and scope. The income approach requires the use of estimates
and assumptions in projecting future operating results and related cash flows. If the carrying amount of goodwill exceeds its fair value, the second
step of the impairment test is performed to measure the amount of the impairment loss. In the second step, the implied fair value of the goodwill is
estimated as the fair value of the reporting unit as determined in step one, less fair values of all other net tangible and intangible assets of the
reporting unit. If the carrying amount of the goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that
excess, not to exceed the carrying amount of the goodwill. There were no changes in the carrying amount of goodwill for each of the acquired
subsidiaries for the year ended December 29, 2007.
Accounting for Income Taxes. We calculate income taxes in each of the jurisdictions in which we operate in accordance with SFAS No. 109,
"Accounting for Income Tuxes." This process involves estimating our current tax exposure, together with assessing temporary differences for
items treated differently for tax and financial reporting. Judgment is required in assessing the future tax consequences of events that have been
recognized in our financial statements or tax returns. Additional infonnation is available in Note E to the Consolidated Financial Statements herein.
Variations in the actual outcome of these future tax consequences could materially impact our financial position, results of operations, or cash
flows.
In June 2006, the FASB issued FIN No. 48, "Accounting for Uncertainty in Income Taxes-an interpretation ofFASB Statement No. 109," which
clarifies the required accounting for uncertainty in income tax positions. FIN 48 defines the threshold for recognizing tax return positions in the
financial statements as "more likely than not." FIN 48 also provides guidance on the measurement, classification, and disclosure of tax return
positions in the financial statements. FIN 48 was effective for the Company's first quarterly reporting period in 2007. The impact of adopting FIN 48
was not material.

On an interim basis, we estimate what our effective tax rate will be for the full fiscal year, and we record a quarterly income tax provision in
accordance with this anticipated effective rate. As the fiscal year progresses, we continually refine our estimate based upon actual events and
earnings by jurisdiction during the year. This estimation process periodically results in changes to our expected effective tax rate for the fiscal
year. When this occurs, we adjust the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date
provision equals the expected annual rate.
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Equity-Based Compensation. We calculate equity-based compensation expense using the provisions of Sf AS No. l 23(R), "Share Based
Payment." Under the fair value recognition provisions of this statement, equity-based compensation cost is measured at the grant date based on
the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting
period. For more infonnation regarding the assumptions and estimates used in calculating this equity-based compensation expense, see Note L to
the Consolidated financial Statements herein.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

We conduct business in several countries and intend to continue to expand our foreign operations. Net sales, earnings from operations, and
net earnings are affected by fluctuations in currency exchange rates, interest rates, and other uncertainties that are inherent in doing business and
selling product in more than one currency. In addition, our operations are exposed to risks that are associated with changes in social, political, and
economic conditions in our foreign operations, including changes in the laws and policies that govern foreign investment in countries where we
have operations, as well as, to a lesser extent, to changes in United States laws and regulations relating to foreign trade and investment.

-~

Foreign Currency Risks. Net sales outside the United States represented 57.4%, 56.4%, and 59.9% of our net sales in 2005, 2006, and 2007
respectively. Inventory purchases arc transacted primarily in U.S. dollars from vendors located in the United States. The local currency of each
international subsidiary is considered the functional currency, with all revenue and expenses being translated at weighted-average currency
exchange rates for the applicable periods. In general, our reported sales and earnings are affected positively by a weakening of the U.S. dollar and
negatively by a strengthening of the U.S. dollar. Changes in currency exchange rates affect the relative prices at which we sell our products. Given
the uncertainty of exchange rate fluctuations, we cannot estimate the effect that these fluctuations may have on our future business, product
pricing, results of operations, or financial condition.

We seek to reduce exposure to fluctuations in foreign exchange rates by creating offsetting positions through the use of foreign currency
exchange contracts. We do not use derivative financial instruments for trading or speculative purposes. Our strategy in this regard includes
entering into foreign currency exchange contracts to manage currency fluctuations in our expected net cash flow from certain of our international
markets, which are primarily represented by intercompany cash transfers. More specifically, we purchase put options, which give us the right, but
not the obligation, to sell foreign currency at a specified exchange rate ("strike price"). These contracts provide protection in the event that the
foreign currency weakens beyond the option strike price. The fair value of these contracts is estimated based on period-end quoted market prices,
and the resulting asset and expense, which historically has not been material, is recognized in our Consolidated Financial Statements. At various
periods throughout 2007, we had contracts in place to offset our exposure to the Canadian Dollar, New Zealand Dollar, New Taiwan Dollar, and the
Mexican Peso; none of which, individually or in the aggregate, had a material affect on our results of operations. As of December 29, 2007, we had
no contracts in place to offset exposure to foreign currencies. There can be no assurance that our practices will be successful in eliminating all or
substantially all of the risks that may be encountered in connection with our foreign currency transactions.
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Following are the average exchange rates of foreign currency units to one U.S. dollar for each of our foreign markets for fiscal years 2005, 2006,
and 2007:
Year ended
2005

Canadian Dollar
Australian Dollar
New Zealand Dollar
Hong Kong Dollar
Ji.lpanese Yen
New Taiwan Dollar
Korean Won
Singapore Dollar
Mexican Peso
Chinese Yuan(})
Malaysian Ringitt

2006

2007

1.21
1.31
1.42
7.78
109.95
32.13
1,023.94
1.66
10.89
8.08

1.13
i.33
1.54
7.77
116.27
32.52
954.46
1.59
10.90
7.97

*

*

1.07
i.i 9
1.36
7.80
117.67
32.85
929.03
1.51
10.93
7.61
3.44

(I)

The 2005 Chinese Yuan exchange rate represents the average for the first three months of operations of our Chinese
manufacturing facility, which we acquired in October 2005.

*

USANA operations had not commenced during period indicated.

Interest Rate Risks. As of December 29, 2007, we had a balance of$28.0 million outstanding on our line of credit, with a weighted-average
interest rate of 6.0%. This interest rate is computed at the bank's Prime Rate, or LIBOR, adjusted by features specified in our loan agreements, with
fixed rate term options of up to six months. The annual impact on after-tax expense of a I 00-basis-point increase in the interest rate on the above
balance would not materially affect our earnings.
Item 8.

4:.-

Financial Statements and Supplementary Data

The f-inancial Statements and Supplementary Data required l>y this llt:111 mt: st:l fu1 th al Lht: µagt:s irn.licalt:u al llt:m 15 ut:luw.
Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial DiscJosurc

None.
Item 9A.

Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange
Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such
information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management
recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the
desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible
disclosure controls and procedures.
As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the
design and operation of our disclosure controls and
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procedures (as defined in Ruic 13a- l 5(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that the disclosure controls and procedures were effective to provide reasonable assurance as of December 29, 2007.

'vi

Management's Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, (as defined in Rule l 3a- 15
(f) under the Exchange Act). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with generally
accepted accounting principles. Internal control over financial reporting includes those policies and procedures that:
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of the Company;
Provide reasonable assurance that transactions are recorded, as necessary, to permit preparation of financial statements in
accordance with generally accepted accounting principles and that receipts and expenditures of the Company arc being made only
in accordance with authorizations of management and directors of the Company; and
Provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of
the Company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any
evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions or
that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of the Company's internal control over financial reporting as of December 29, 2007. In making this
assessment, management used the criteria that have been set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in lnlernal Co111rol-/n1egra1ed Framework. Based on its assessment, using those criteria, management concluded that, as of
December 29, 2007, the Company's internal control over financial reporting was effective.

·IJY

The effectiveness of the Company's internal control over financial reporting as of December 29, 2007, has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.

Changes in Internal Control Over Financial Reporting
There were no changes in our internal controls over financial reporting that occurred during the quarter ended December 29, 2007, that have
materially affected, or that arc reasonably likely to materially affect, the Company's internal control over financial reporting.
Item 9B.

Other Information

None.
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PART III
Item 10. Directors, Executive Officers and Corporate Governance

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 11. Executive Compensation

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A uudt!r Lht!
Exchange Act.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 13. Certain Relationships and Related Transactions, and Director Independence

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Hem 14. Principal Accounting Fees and Services

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
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PART IV
Item 15.

Exhibits, Financial Statement Schedules

(a)

The following documents are filed as part of this Form:

l.

Financial Statements

Reports of Independent Registered Public Accounting Firms
Consolidated Balance Sheets
Consolidated Statements of Earnings
Consolidated Statements of Stockholders' Equity and Comprehensive
Income
Consolidated Statements of Cash Flows
Notes to the Consolidated Financial Statements

2.

Financial Statement Schedules.

F-1

F-3
F-4

F-5
F-6

F-7

[Those that are required arc included in the Consolidated Financial Statements or Notes

thereto.]
3.

~

Exhibit
Number

Exhibits.

Description

3.1

Amended and Restated Articles of Incorporation (incorporated by reference to Current Report on
Form 8-K, filed April 25, 2006)

3.2

Bylaws (Incorporated by reference to Current Report on Form 8-K, filed April 25, 2006)

4.1

Specimen Stock Certificate for Common Stock, no par value (incorporated by reference to
Registration Statement on Form IO, File No. 0-21116, effective April 16, 1993)

10.1

2002 USANA Health Sciences, Inc. Stock Option Plan (incorporated by reference to Registration
Statement on Form S-8, filed July 18, 2002)*

I0.2

Form of employee or director non-statutory stock option agreement under the 2002 Stock Option
Plan (incorporated by reference to Report on Form I 0-K, filed March 6, 2006)*

10.3

Form of employee incentive stock option agreement under the 2002 Stock Option Plan (incorporated
by reference to Report on Form 10-K, filed March 6, 2006)*

10.4

Credit Agreement by and between Bank of America, N.A. and USANA Health Sciences, Inc.
(incorporated by reference to Report on Fann 10-Q for the period ended July 3, 2004)

10.5

Amendment, dated May 17, 2006, to Credit Agreement, dated June 16, 2004 (incorporated by
reference to Report on Form I 0-Q for the period ended September 30, 2006)

10.6

Amendment, dated April 24, 2007, to Credit Agreement, dated June 16, 2004 (incorporated by
reference to l~eport on Form I 0-Q for the period ended March 31, 2007)

10.7

USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to
Report on Form 8-K, filed April 25, 2006)*

10.8

Form of Stock Option Agreement for award of non-statutory stock options to employees under the
USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to
Report on Form 8-K. filed April 26, 2006)*

I0.9

Form of Stock Option Agreement for award of non-statutory stock options to directors who arc not
employees under the USANA Health Scienccs, Inc. 2006 Equity Incentive Award Plan (incorporated
by reference to Report on Form 8-K, filed April 26, 2006)*
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10.10

Form of Incentive Stock Option Agreement for award of incentive stock options to employees under
the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to
Report on Form 8-K, filed April 26, 2006)*

10.11

Fonn of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock
appreciation rights to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive
Award Plan (incorporated by reference to Report on Fonn 8-K, filed April 26, 2006)*

10.12

Form of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock
appreciation rights to directors who are not employees under the USA NA Health Sciences, Inc. 2006
Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

10.13

Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who
are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan
(incorporated by reference to Report on form 8-K. filed April 26, 2006)*

11.1

*

Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)

14

Code of Ethics ofUSANA Health Sciences, Inc. (posted on the Company's internet web site at
www.usanahealthsciences.com)

21

Subsidiaries of the Registrant, as of March 3, 2008 (filed herewith)

23.1

Consent oflndependent Registered Public Accounting Firm (Grant Thornton LLP) (filed herewith)

23.2

Consent of Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP) (filed
herewith)

31.1

Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
(filed herewith)

31.2

Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
(filed herewith)

32.1

Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18
U.S.C. Section 1350 (filed herewith)

32.2

Certification ofChiefFinancial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18
U.S.C. Section 1350 (filed herewith)

Denotes a management contract or compensatory plan or arrangement.
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SIGNATURES

Pursuant to the requirements of Section 13 or IS(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.

USANA Health Sciences, Inc.
By:

Isl MYRON W. WENTZ

Myron W. Wentz, PhD,
Chairman and Chief Executive Officer
Date: March I3, 2008
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.
Signature

Isl MYRON W. WENTZ

Myron W. Wentz, PhD

Title

~

Date

Chainnan and Chief Executive Officer
(Principal Executive Officer)

March 13, 2008

President

March 13, 2008

Director

March 13, 2008

Director

March 13, 2008

Director

March 13, 2008

tL

Isl DAVID A. WENTZ

David A. Wentz
~

Isl RONALD S. POELMAN

Ronald S. Poelman
Isl ROBERT ANCIAUX

Robert Anciaux
Isl JERRY G. MCCLAIN

'

Jerry G. McClain
Isl GILBERT A. FULLER

Gilbert A. Fuller

Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting
Officer)
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REPORT OF INDEPENDENT

REGISTERED PUBLIC ACCOUNTING FIRM

(.i,

vJ

vJi

~

vij

To the Board of Directors and Shareholders of USANA Health Sciences, Inc.
In our opinion, the consolidated balance sheet and the related consolidated statements of earnings, stockholders' equity and comprehensive
income and cash flows present fairly, in all material respects, the financial position ofUSANA Health Sciences, Inc. and its subsidiaries at
December 29, 2007, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles
generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control
over financial reporting as of December 29, 2007, based on criteria established in Internal Control-Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial
statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
financial reporting included in, Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is
to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audit. We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement
and whether effective internal control over financial reporting was maintained in all material respects. Our audit of the financial statements included
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used
and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over
financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness
exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinions.
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance
that transactions arc recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors
of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of
the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.

Isl PriccwaterhouseCoopers LLP
Salt Lake City, UT
March 4, 2008
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REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders
USANA Health Sciences, Inc. and Subsidiaries
We have audited the accompanying consolidated balance sheets of USA NA Health Sciences, Inc. and Subsidiaries (the "Company") as of
December 30, 2006, and the related consolidated statements of earnings, stockholders' equity and comprehensive income, and cash flows for each
of the two years in the period ended December 30, 2006. These financial statements arc the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perfonn the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of USANA
Health Sciences, Inc. and Subsidiaries as of December 30, 2006, and the consolidated results of their operations and their consolidated cash flows
for each of the two years in the period ended December 30, 2006 in confonnity with accounting principles generally accepted in the United States
of America.
As discussed in Note A to the consolidated financial statements, the Company adopted Statement I 23R, Share-Based Payment, on a modified
prospective basis as of January I, 2006.
As discussed in Note B to the consolidated financial statements, on June 5, 2007, the Company adopted a plan to discontinue the operations
of its third-party contract manufacturing business. The financial statements referred to above include the effects of the adjustments which have
been retrospectively applied.

Isl GRANT THORNTON LLP
Salt Lake City, Utah
February 19, 2007, except for Note Bas to which the date is March 12, 2008.
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USANA IIEALTII SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
December 30,
2006

December 29,
2007

ASSl.t.:TS
Current assets
Cash and cash equivalents
Inventories
Prepaid expenses and other current assets
Deferred income taxes

$

Total current assets
Property and equipment, net

27.029
22,483
8,908
2,195

$

12,865
19,439
11,639
2,049

60,615

45,992

30,323

52,061
607

Assets held for sale
Goodwill

5,690

5,690

Other assets

3,374

4,778

$

100,002

$

109,128

$

10,241
29,564

$

, ·8;lll
32,074

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable
Other current liabilities

, 39,805

Total current liabilities

40,185
28,000

Line of credit

2,305

Other long-tenn liab1lities
Stockholders' equity
Common stock,' $0.00 I par value;:authorized 5(),000, shares, issued and outstanding 17,859 as of December 30, 2006 and 16,198 as of December 29, 2007
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income
Total stockholders' equity
$

18
15,573
44,251
355

16
7,525
30,108
989

60,197

38,638

100,002

$

The accompanying notes are an integral part of these statements.
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109,128

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS

(in thousands, except per shurc data)
Year ended

2005

Net sales

$

2006

315,017

$

2007

365,166

$

423,149

68,703

79,836

87,891

246,314

285,330

335~258

Operating expenses:
Associate incentives
Selling, general and administrative
Research and development

124,045
59,920
2,212

146,251
72,4!0
2,968

170,383
90,8) I
3,363

Total operating expenses

186,177

221,629

264,557

Earnings from continuing operations

60,137

63,701

70,701

Cost of sales
Gross profit

Other income (expense):
Interest income .. ·
Interest expense
Other, net

654
555
(1 IO)
(806)
_;'~("f~:~ \8.6llh:.'-:::(;i?:"/122:

561
(12)
(70).

47)

479

1,408

Earnings from continuing·operations·before income taxes

60,616

65,109

7U72.

Income taxes

20,444

22,966

25,243

Other income (expense), net

Income.

from coiltiriuirig operatforis

40~172
(1,178)

Loss from discontinued operations, net of tax benefit
.

Net earnings
Earnings (loss) per common share
·
Basic
Continuing operations
Discontinued operations

Diluted
Continuing operations
Discontinued operations
Net earnings
Weighted average common shares outstanding
Basic
Diluted

(612)

$-.

$

Net earnings

(877)

2.13 $
(0.06)

2.34 $
(0.05)

2.74
(0.Q3)

$

2.07

$

2.29

$

2.71

$

2.04
(0.06)

$

2.25
(0.05)

$

2.67
(0.04)

s

1.98

$

2.20

$

2.63

18,873
19,721

18,053
18,724

The accompanying notes arc an integral part of these statements.
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16,734
17,206

~

USANA HEALTH SCIENCES, INC. ANO SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

~

Years ended December 31, 2005; December 30, 2006; and December 29, 2007
(in thousands)
Common Slock

..$)

Value

Sh:1res

Balance at January l, 2005
Comprehensive income
Net earnings for the year
Foreign currency translation adjustment, net of
tax benefit of $420

Addilional
Paid-in
Capil:il

18,953

s

19

s

11,853 $

Accumulaled
Olher
Comprehensive
Income (Loss)

Relained
Earnings

34,496 $

Tolal

1,475

s

38,994

47,843
38,994
(636)

(636)

v;)

Comprehensive,income
Common stock repurchased and retired
Common stock issued under stock option plan,
including tax benefit of$5,775

-,J

,.d

'....r)

..J

Balance at December 31, 2005
Comprehensive income
Net earnings for the year
Foreign currency·translation adjustment, net of
tax benefit of $152 ·
Comprehensive income
Common stock repurehased and retired
Common stock awarded to Associates
Equity~basecfcon.ipinsatfon expense
Common stock issued under stock option and
equity incentive award plans, including tax benefit
of $6,198
Balance at Deceml>~,d,Q,·-2006
Comprehensive income
Net earnings (o(the ·year
Foreign currency translation adjustment, net of
tax expense of $385
Comprehensive:income
Common stock repurchased and retired
Common stock awarded to Associates
Equity-based compensation expense
Common stock issued under equity incentive
award plan, including tax benefit of$2,767
Balance at December 29, 2007

(I)

(1,160)

(11,428)
8,736

550

18,343

38,358
(49,199)

(37,770}

s

18

s

9,161 $

8,736
35,720

s

839

s

41,266

41,266
(484)

(I)

(1,045)
2

(8,222)
100
4,789

I

(32,735}

L

'

..

'

17,859 $

18 $

15,573 $

44,251 ,$

_.

"'

>:~: .~Sf)
·~··

634

(2)

(20,118)
47
6,108

I

16,198

s

16

s

7,525 $

A,789

60,197
. 45,317
634
45,951
(79,580)
47
6,108

(59,460)

5,915

230

40,782
.(40,958)

9,745

45,317

(1,892)

(484)

IOI
-- . ~; :-7:'

9,745

559

45,738

5,915
30,108 $

\.@
The accompanying notes arc an integral part of these statements.
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989 $

38,638

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATIW STATEMENTS OF CASH FLOWS
~

(in thousands)
Year ended
2006

2005

Cash flows from operating activities
Net earnings
Adjustments to reconcile net earnings to net cash provided by operating
activities
Depreciation and amortization
(Gain) loss on sale of property and equipment
Equity-based compensation expense
Excess tax benefit from equity-based payment arrangements
Common stock awarded to Associates
Deferred income taxes
Provision for inventory valuation
Changes in operating assets and liabilities:
Inventories
Prepaid expenses and other assets
Accounts payable
Other liabilities

s

38,994

41,266

$

5,904
10

Total adjustments
Net cash prlJHided by operating activities
Cash flows from investing activities
,Acquisitions, nt!L of cash acquired
Receipts on notes receivable
Increase in notes receivable
Proceeds from sale of property and equipment
Purchases of property and equipment

2007

s

5,562

(631)
1,830

4,789
(5,288)
IOI
(1,304)
2,346

5,333
53
6.108
(2,532)
47
(1,565)
1,323

(6,420)
(1,625)
(107)
10,063

(2,224)
(3,266)
4,374
13,840

2,681
(2,556)
(3,140)
6,150

9,024

18,929

11,902

48,018

60,195

57,219

(I)

-

(1,406)

Net cash used in investing activities
Cash.flows from financing activities
Proceeds from stock options exercised
Excess tax benefits from equity-based payment arrangements
Repurchase of common stock
Borrowings on line of credit
Payments on line of credit

$

19
(4,311)

(660)
18
(11,038)

123
(666)
797
(26,264)

(5,698)

(11,680)

(26,010)

2,961

$

(49,199)

(46,238)

Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year

Supplemental disclosures of cash.flow information
Cash paid during the year for:
Interest, net of amount capitalized
Income taxes

~

45,317

3,547
5,288
(40,958)

$

<t

~

3,148

2,532
(79,580)
104,093
(76,093)

~

(45,900)

(32,123)

(570)

58

(4,488)

16,450

(14,164)

15,067

10,579

27,029

527

$

10,579

$

27,029

$

12,865

$

II
15,156

s

6
19,040

s

659
25,421

~

~

The accompanying notes arc an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFJCANT ACCOUNTING POLICIES

Financial statement presentation
The accounting and reporting policies of USA NA Health Sciences, Inc. and its Subsidiaries (the Company) conform with accounting
principles generally accepted in the United States of America (US GAAP).

Principles of consolidation
The Consolidated Financial Statements include the accounts and operations of USA NA Health Sciences, Inc. and its wholly owned
subsidiaries in four geographic regions: "North America" includes the United States, Canada, Mexico, and direct sales from the United States to
the United Kingdom and the Netherlands; "Southeast Asia/Pacific" includes Australia, New Zealand, Singapore, and Malaysia; "East Asia"
includes Hong Kong, and Taiwan; and "North Asia" includes Japan and South Korea. All significant inter-company accounts and transactions
have been eliminated in this consolidation.

Business activity
The Company operates in one reportable business segment manufacturing high-quality nutritional and personal care products that are
distributed through a network marketing system throughout the United States, Canada, Mexico, the United Kingdom, the Netherlands, Australia,
New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, and South Korea. The Company manages its business primarily by managing its
worldwide Associate base. No Associate accounted for more than l 0% of net sales for the years ended 2005, 2006, or 2007. An immaterial amount
of third-pnrty manufocturing is conducted at the Company's facility located in Tianjin, China.
Prior to the sale of assets that were related to its third-party contract manufacturing business, the Company operated two reportable business
segments: Direct Selling and Contract Manufacturing. The Company's financial results have since been adjusted to reflect the reclassification of
sales and related expenses in the former Contract Manufacturing segment to "discontinued operations" for all periods presented. Further
information on this sale can be found in Note B-Discontinued Operations below.

44.

Fiscal year
The Company operates on a 52-53 week year, ending on the Saturday closest to December 31. Fiscal years 2005, 2006 and 2007 were 52-week
years. Fiscal year 2005 covered the period January 2, 2005 to December 31, 2005 (hereinafter 2005). Fiscal year 2006 covered the period January I,
2006 to December 30, 2006 (hereinafter 2006). Fiscal year 2007 covered the period December 31, 2006 to December 29, 2007 (hereinafter 2007).

Use of estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and the related notes. Significant estimates for the Company include revenue
recognition, obsolescence, goodwill, equity-based compensation, and income taxes. Actual results could differ from
F-7
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USANA HEALTH SCIENCES, INC. AND SUBSIDJARJES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

those estimates. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.

Fair value offi.nancial instn11nents
The Company's financial instruments include: cash and cash equivalents, accounts receivable, accounts payable, and line of credit. The
recorded values of cash and cash equivalents, accounts receivable, and accounts payable approximate their fair values, based on their short-tenn
nature. The recorded value of the line of credit approximates fair value as interest adjusts to market based on LIBOR and prime rates.

Translation offoreign currencies
The Company's foreign subsidiaries' asset and liability accounts, which are originally recorded in the appropriate local currency, are
translated, for consolidated financial reporting purposes, into U.S. dollar amounts at period-end exchange rates. Revenue and expense accounts
arc translated at the weighted-average rates for the period. Equity accounts arc translated at historical rates. Foreign currency translation
adjustments are accumulated as a component of other comprehensive income.

Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. The Company is required to maintain cash deposits with banks in certain subsidiary locations for various operating purposes.

lnven/ories
Inventories consist of raw materials, work in progress and finished goods and are stated at the lower of cost or market, using the first-in, firstout method.

Income taxes
"

~

The Company accounts for income taxes using the asset and liability method as prescribed by SFAS No. 109, "Accounting for Income Taxes."
This method requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the differences between the
financial statement assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates that
arc expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates liabilities is recognized in income in the period that includes the enactment date. Deferred
tax expense or benefit is the result of changes in deferred tax assets and liabilities. The Company evaluates the probability of realizing the future
benefits of its deferred tax assets and provides a valuation allowance for the portion of any deferred tax assets where the likelihood of realizing an
income tax benefit in the future does not meet the "more-likely-than-not" criteria for recognition. The Company adopted the provisions of FIN 48,
"Accounting for Uncertainty in Income Taxes-an interpretation ofFASB Statement No. 109" on December 31, 2006. The Company recognizes
interest and penalties related to unrecognized tax benefits in income taxes.
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USANA HEALTH SCIENCES, INC. AND SUIJSIDJARJES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Interest cost capitalized
In accordance with SF AS No. 34, "Capitalization of Interest Cost," the Company capitalizes interest cost that 1t has incurred on funds that it
has used to construct property, plant, and equipment. This capitalized interest is recorded as part of the asset to which it relates and is amortized
over the asset's estimated useful life once placed in service.

Depreciation and amortization
Property and equipment arc recorded at cost. Maintenance, repairs, and renewals, which neither materially add to the value of the property nor
appreciably prolong its life, arc charged to expense as incurred. Depreciation is provided in amounts sufficient to relate the cost of depreciable
assets to operations over the estimated useful lives of the related assets. The straight-line method of depreciation and amortization is followed for
financial statement purposes. Leasehold improvements are amortized over the shorter of the life of the respective lease or the useful life of the
improvements. When property and equipment arc retired or otherwise disposed of, the cost and accumulated depreciation are removed from the
accounts and any resulting gain or loss is included in the results of operations for the respective period.

~

Goodwill

k..

Goodwill represents the excess of the purchase price over the fair market value of identifiable net assets of acquired companies. In accordance
with SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill is not amortized; however it is tested at least annually for impairment (or
more frequently if events or changes in circumstances indicate impairment). During 2007, the Company's goodwill was tested in July.

Self insurance
The Company is self-insured, up to certain limits, for employee group health claims. The Company has purchased stop-loss insurance on both
an individual and an aggregate basis, which will reimburse the Company for individual claims in excess of$ I 00,000, and aggregate claims that are
greater than 125% of projected claims. The Company reports the cost of claims with an estimate of claims that have been incurred but not reported.
A liability for unpaid claims and the associated claim expenses, including losses that have been incurred but not reported, is estimated and
reflected in the Balance Sheet as an accrued liability. Total expense under this program was approximately $2,497, $3,303 and $3,499 in 2005, 2006
and 2007, respectively.

Common stock and additional paid-in capital
The Company records cash that it received upon the exercise of equity awards by crediting common stock and additional paid-in capital. The
Company received $3,148 in cash proceeds from the exercise of equity awards in 2007. The Company also realizes an income tax benefit from the
exercise of certain equity awards. For equity awards earned prior to January I, 2006, this tax benefit resulted in a decrease in current income taxes
payable and an increase in additional paid-in capital. For equity awards earned after January l, 2006, the tax benefits arc recorded in accordance
with SFAS
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USANA HEALTH SCIENCES, INC. AND SUBS!D!ARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

i..;[j)

No. 123(R), "Share-Based Payment." Under Sf AS No. I 23(R), the Company establishes deferred tax assets for the value of certain equity awards.
Upon exercise, the deferred tax assets are reversed and the difference between the deferred tax assets and the realized tax benefit creates a tax
windfall or shortfall that increases or decreases the additional paid-in capital pool ("APIC Pool") explained further in Note L below. If the APIC
Pool is reduced to zero, additional shortfalls are treated as a current tax expense. The total tax benefit recorded in additional paid-in capital was
$5,775 in 2005, $6,198 in 2006, and $2,767 in 2007.
The Company has a stock repurchase plan in place that has been authorized by the Board of Directors. As of December 29, 2007, $50,261 was
available to repurchase shares under this plan.

Revenue recognition and deferred revenue
The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders. Sales and related fees
billed to customers are recorded as revenue when the product is delivered and when title and the risk of ownership passes to the customer, net of
applicable sales discounts. Payments received for unshipped products are recorded as deferred revenue and are included in other current
liabilities. Certain incentives offered to Associates, including sales discounts, are classified as a reduction ofrevenue. A provision for product
returns and allowances is included and is founded on historical experience. Additionally, the Company collects an annual renewal fee from
Associates that is deferred on receipt and is recognized as income on a straight-line basis over the subsequent twelve-month period.
Taxes that have been assessed by governmental authorities and that are directly imposed on revenue-producing transactions between the
Company and its customers, including sales, use, value-added, and some excise taxes, arc presented on a net basis (excluded from net sales) as
pennitted under EITF 06-3.

Product return policy
All product that is returned within the first 30 days following purchase is refunded at l 00% of the sales price to retail customers and Preferred
Customers. This 30-day return policy is offered to Associates only on their first order. All other returned product that is unused and resalable is
refunded up to one year from the date of purchase at I 00% of the sales price less a l 0% restocking fee. According to the terms of the Associate
agreement, return of product that was not damaged at the time of receipt by the Associate, where the purchase amount exceeds one hundred
dollars, may result in cancellation of the Associate's distributorship. Depending upon the conditions under which product was returned,
Associates and Preferred Customers may receive their refunded amount either based on their original fonn of payment or with product or credit on
account. Product returns totaled approximately 1.6% of net sales during fiscal years 2005 and 2006, and 1.5% of net sales during fiscal year 2007.

Shipping and handling costs
The Company's shipping and handling costs are included in cost of sales for all periods presented.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATl£MENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Equity-based compensation
Effective January 1, 2006, the Company adopted SF AS No. l 23(R) and began recording compensation expense associated with equity awards.
SF AS No. l 23(R) requires companies to recognize in the statement of operations the cost of employee services received in exchange for awards of
equity instruments, based on the grant date fair value of those awards (with limited exceptions). Prior to the adoption of SF AS No. 123(R), the
Company accounted for stock-based employee compensation using the intrinsic value method prescribed by APB Opinion No. 25, "Accounting
for Stock Issued to Employees." Accordingly, compensation expense had only been recorded in the consolidated financial statements for any
equity awards that had been granted below the fair market value of the underlying stock as of the date of grant.

~

The Company adopted the modified prospective transition method provided for under Sf AS No. l 23(R) and, accordingly, prior period results
have not been retroactively adjusted. The modified prospective transition method requires that stock-based compensation expense be recorded for
(i) all new equity awards granted on or after January l, 2006, based on the fair value of the equity award on the date of grant and (ii) all unvcstcd
equity awards granted prior to Janua1y I, 2006, based on the fair value. The fair vulucs uf these awunls are c..letcrmi11ec..l i11 uccurc..lu11ce with SF AS
No. 123(R).
Upon adoption of SF AS No. 123(R) in 2006, the Company presented the cash flows resulting from tax deductions in excess of the cumulative
compensation cost recognized for equity awards exercised ("excess tax benefit") as a financing activity in the Consolidated Statements of Cash
Flows. Prior to the adoption of SF AS No. l 23(R), the Company presented all tax benefits resulting from exercises of equity awards as an operating
activity in the Consolidated Statements of Cash Flows.
Further information regarding equity awards can be found in Note L-Equity-Based Compensation below.

Advertising
Advertising costs arc charged to expense as incurred. Advertising expense totaled $648 in 2005, $656 in 2006, and $1,219 in 2007.

Research and development
Research and development costs are charged to expense as incurred.

Earnings per share
Basic earnings per common share (EPS) are based on the weighted-average number of common shares that were outstanding during each
period. Diluted earnings per common share arc based on shares that were outstanding (computed as under basic EPS) and potentially dilutive
common shares. Potential common shares that are included in the diluted earnings per share calculation include in-the-money, equity-based
awards that have been granted but have not been exercised.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARJES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent accounting pronouncements
In September 2006, the FASH issued SFAS No. 157, "Fair Value Measurements." SFAS No. 157 defines fair value, establishes a framework for
measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value
measurements. SF AS No. 157 is effective for financial assets and liabilities for fiscal years beginning after November 15, 2007. In February 2008, the
FASB issued FSP FAS 157-2, "Effective Date ofFASB Statement No. 157." FSP 157-2 delays the effective date of SFAS No. 157 for all nonfinancial assets and non-financial liabilities that are not re-measured at fair value on a reGurring basis until fiscal years beginning after
November 15, 2008. Any amounts recognized upon adoption of this rule as a cumulative effect adjustment will be recorded to the opening balance
of retained earnings in the year of adoption. The Company has evaluated SF AS No. 157 and has determined that it will not have a material impact
on its Consolidated Financial Statements.
On February 15, 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities-Including an
Amendment off ASB Statement No. 115." SFAS No. 159 permits an entity to choose to measure eligible items at fair value at specified election
dates. An entity will report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent
reporting date. The fair value option: (a) may be applied instrument by instrument, with a few exceptions, such as investments otherwise
accounted for by the equity method; (b) is irrevocable (unless a new election date occurs); and (c) is applied only to entire instruments and not to
portions of instruments. SFAS No. 159 is effective for fiscal years that begin after November 15, 2007. The Company has evaluated SF AS No. 159
and has determined that it will not have a material impact on its Consolidated Financial Statements and the Company has not early adopted.
NOTE B-DISCONTINUED OPERATIONS
Consistent with the Company's long-term objectives of focusing on its Direct Selling Segment, on June 5, 2007, the Company adopted a plan
to discontinue the operations of its third-party contract manufacturing business at its Draper, Utah facility. On August 10, 2007, the Company
completed the sale of certain assets of its third-party contract manufacturing business for total cash proceeds of $3,444. These assets consisted of
accounts receivable, inventories, and property and equipment. The Company retained assets that are associated with manufacturing and
packaging its SenseTM skin and beauty care products and continues to manufacture these products at the Draper, Utah facility. The results of the
third-party contract manufacturing operations have been classified as "discontinued operations" for all periods.
The Company's sales reported in discontinued operations for the years ended December 31, 2005, December 30, 2006, and December 29, 2007
were $8,072, $9,024 and $4,460, respectively.
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USANA HEALTH SCIENCES, INC. AND SUllSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE 8-DISCONTINUED OPERATIONS (Continued)
The following table shows the composition of discontinued operations on the Consolidated Statement of Earnings for the years ended
December 31, 2005, December 30, 2006, and December 29, 2007.
Year ended
2005

2006

Loss from discontinued operations
Income tax benefit
Loss from disposal, included in other income (expense)

$

(1,766 ) $
588

Loss from discontinued operations (net of tax benefit)

$

(1,178 ) $

2007

(1,355 ) $
478

(877)

$

(938)
343
(17)
(612)

The following table is a summary of the assets that were sold:
Inventory
Accounts receivable
Property, plant and equipment, net of $594 of accumulated depreciation
Net assets of discontinued operations

$

1,669
1,086
706

$

3,461

'4;.

~

NOTE C-INVENTORU:S
Inventories consist of the following:
December 30,
2006

Raw materials
Work in progress
Finished goods

December 29,
2007

$

8,073
4,227
10,183

$

5,730
5,825
7,884

$

22,483

$

19,439
(jj_

NOTED-PREPAID EXPENSES AND OTHER CURRENT ASSlffS
Prepaid expenses and other current assets consist of the following:
December 30,
2006

Prepaid insurance
Other prepaid expenses
Federal income taxes receivable
Miscellaneous receivables, net
Deferred commissions
Other current assets

December 29,
2007

$

886
1,264
1,702
3,381
682
993

s

1,300
1.646
2,754
4.109
1,179
651

$

8,908

s

11.639
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE E-INCOME TAXES
Income tax expense (benefit) included in income from continuing operations consists of the following:
Year ended
2006

2005

Current
Federal
State
Foreign

$

17,939
1,881
1,209

$

21,029
Deferred
Federal
State
Foreign

76
5
(666 )
$

20,444

$

2007

s

19,949
2,315
2,033

20,849
2,239
3,416

24,297

26,504

(1,796 )
(127 )
592

(1,064)
(75)
(122)

22,966

$

25,243

lhe income tax provision, as reconciled to the tax computed at the federal statutory rate of 35% for 2005, 2006, and 2007, is as follows:
Year ended

Federal income taxes at statutory rate
State income taxes, net of federal tax benefit
Drffereitce·between U.S. statutory rate and foreign rate
Foreign taxes net of foreign tax credit
Extraterritorial income exclusion
Qualified production activities deduction
R&D tax credit
Equity-based compensation-incentive stock options
Non-deductible VAT Expense
All other, net

$_

21,216
1,623
29,
86
(1,875 )
(343 )
(418 )

-.s\' . _:,-i2,ts·s:'.: .._: s.-- ·:"_.'24~9:10
1,380

20,444

1,762

· , ry ;:_Jj_f\·C:::::,<-: · :(15)
195

:.. {1_,37(f j ..
(332 )
(598 J.
234
406'
249

126

s

2007

2006

2005

$

22,966

~

(991)
(436)
138
133
(258)
$
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USANA IIEALTII SCIENCES, JNC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE E-INCOME TAXES (Continued)
Deferred tax assets and liabilities consist of the following:
December 30,
2006

Current deferred tax assets (liabilities)
Inventory capitalization
lntercompany sales
Prepaid expenses
Vacation accrual
Inventory reserve
Allowance for bad debts
Sales returns and allowances
All other, net

Long-tenn deferred tax assets (liabilities)
Accumulated depreciation/amortization
Accumulated other comprehensive income
Equity based compensation
A II other, net

December 29,
2007

s

$
480
255
(583 )
355
1,015
154
354
165

s

2,195

$

2,049

$

(124 )
(353 )
1,350

$

175
(737)
2,810
34

$

2,282

588
241
(991)
585
970
130
348
178

2
$

875

The Company files income tax returns in the U.S. federal jurisdiction and in various states and foreign jurisdictions. With few exceptions, the
Company is no longer subject to U.S. federal, state, local, or non-U.S. income tax examinations by tax authorities for years before 2003.
The Company adopted the provisions ofFIN 48 on December 31, 2006. The implementation of FIN 48 did not result in a material change to the
Company's previous liability for unrecognized tax benefits. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as
follows:
Balance at December 30, 2006
Additions based on tax positions related to the current year
Additions for tax positions of prior years
Settlements
Lapse of statute
Balance at December 29, 2007

$

1,523
284

319
(9)

(439)
$

1,678

The Company anticipates that it is reasonably possible that unrecognized tax benefits, including interest and penalties, of up to $548 could be
recognized within the next twelve months due to the lapse of the applicable statute of limitations. Recognition of these uncertain tax positions or
any uncertain tax position that is included in the December 29, 2007 balance would result in an adjustment to the Company's effective tax rate.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE E-INCOME TAXES (Continued)
The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income taxes. In 2007, the Company recognized
$121 in interest and penalties, compared to $79 in 2006 and $52 in 2005. The Company has accrued $320 and $352 for the payment of interest and
penalties at the end of 2006 and 2007, respectively.
NOTE F-PROPERTY AND EQUIPMENT

40
5-7
5
3-5
3-5
3-5
3-5
15

Buildings
Laboratory and production equipment
Sound and video library
Computer equipment and software
Furniture and fixtures
Automobiles
Leasehold improvements
Land improvements

December 29,
2007

December JO,
2006

Years

$

10,682
10,863
600
23,365
2,719
242
2,834
931

s

23,466
11,563

600
25,745
3,839
198
3,700
1,579

52,236

70,690

33,330

36,459

18,906

34,231

Land

2,070

1,956

Oeposits and projects in process

9,347

15,874

Less accumulated depreciation and amortization

$

30,323

s

52,061

During 2007, the Company utilized its line of credit to expand its facilities in Salt Lake City, Utah, and in Sydney, Australia. The interest
expense associated with these projects has been capitalized as part of the asset to which it relates and will be amortized over the asset's estimated
useful life. Total interest expense incurred during 2006 and 2007 was $110 and $1,511, respectively, of which $0 was capitalized in 2006, and of
which $705 was capitalized in 2007.
NOTE G-ASSETS HELD FOR SALE
Oue to the completion of the majority of the construction at the Company's corporate headquarters, the Company placed for sale the facility
that had formerly been occupied by its subsidiary, USA NA Studios. The carrying amount of these assets as of December 29, 2007 is $607,
comprising $126 in land and $48 I in building. This amount was dctennined to be less than the fair market value and, as such, the Company has not
recorded an impairment loss on these assets. In accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived
Assets." the Company has stopped depreciating these assets and classified them as available for sale.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE H-GOODWILL
Goodwill represents the excess of the purchase price paid of acquired entities over the fair market value of the net assets acquired. As of
December 29, 2007, goodwill totaled $5,690, comprising $4,267 that was associated with the July I, 2003 acquisition of Wasatch Products
Development and $1,423 that was associated with the February I, 2004 acquisition of FMG. These acquired entities for which the Company has a
goodwill balance both relate to business units within the United States and amounts have not changed since their acquisition.

NOTE I-OTHER CURRENT LIABILITIES
Other current liabilities consist of the following:
December 30,
2006

Associate incentives
Accrued employee compensation
Income taxes
Sales taxes
Associate promotions
Deferred revenue
Provision for returns and allowances
All other

$

$

December 29,
2007

5,793
7,022
3,095
4,031
711
3,092
947
4,873

$

29;564

$

4,733
10,139
2,106
4,111
917
4,302

931
4,835
32,074

NOTE J-LONG-TERM DEBT AND LINE OF CREDIT
The Company has a $40,000 line of credit. At December 29, 2007, there was an outstanding balance of $28,000 associated with the line of
credit, with a weighted-average interest rate of 6.0%. The Company, therefore, had $12,000 available under the line of credit. The interest rate is
computed at the bank's Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement. The collateral for this line of credit is the
pledge of the capital stock of certain subsidiaries of the Company, as set forth in a separate pledge agreement with the bank. The Credit Agreement
contains restrictive covenants based on EBITDA and a debt coverage ratio.

NOTE K-COMMITMENTS AND CONTINGENCIES
I.

i.j

Operating leases

With the exception of the Company's headquarters, facilities are generally leased. Each of the facility lease agreements is a non-cancelable
operating lease and expires prior to or during year 2012.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE K-COMMITMENTS AND CONTINGENCIES (Continued)

The Company utilizes equipment under non-cancelable operating leases, expiring through 2012. The minimum rental commitments under operating
leases at December 29, 2007 are as fo1lows:
Year ending

2008
2009
2010
2011
2012

$

3,815
2,154
1,198
669
324

$

8,160

These leases generally provide that property taxes, insurance, and maintenance expenses are the responsibility of the Company. The total rent
expense for the years ended 2005, 2006, and 2007 was approximately $3,230, $3,412, and $4,530, respectively.

2.

Contingencies

The Company is involved in various lawsuits and disputes arising in the normal course of business. In the opinion of management, based
upon advice of counsel, the probability of an adverse outcome against the Company is remote. As such, management believes that the ul!imate
outcome of these lawsuits will not have a material impact on the Company's financial position or results of operations.

3.

Employee Benefit Plan

The Company sponsors an employee benefit plan under Section 40l(k) of the Internal Revenue Code. This plan covers employees who are at
least 18 years of age and have been employed by the Company longer than three months. The Company makes matching contributions of 50 cents
for each one dollar of contribution up to six percent of the participating employees' compensation, subject to the limits of ERISA. In addition, the
Company may make a discretionary contribution based on earnings. The Company's matching contributions vest at 25% per year. Contributions
made by the Company to the plan in the United States for the years ended 2005, 2006, and 2007 were $363, $503, and $622, respectively. The 40 l (k)
match balances for 2005, 2006, and 2007 were decreased by $36, $25, and $8, respectively, due to the application of prior year forfeitures of the
unvested match balances of terminated employees.

4.

Construction Commitments

As of December 29, 2007, the Company had outstanding commitments for constmction projects of approximately $9.9 million related to the
expansion of the Company's corporate headquarters and another facility in Australia. The Company anticipates completion of both projects during
2008.

NOTE L-EQUITY-BASED COMPENSATION
Effective January I, 2006, the Company adopted the provisions of SF AS No. I 23(R) using the modified prospective application. Under this
method, compensation expense includes the fair value of equity awards earned during the reported periods. Expense for equity awards earned is
determined using the grant date fair value previously calculated for pro fonna disclosures under SF AS No. 148,
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USANA HEAL TH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

NOTE L-EQUITY-BASED COMPENSATION (Continued)

vJJ

"Accounting for Stock-Based Compensation-Transition and Disclosure-An Amendment of FASB Statement No. 123." Prior to adopting SFAS
No. 123(R) the Company accounted for equity-based compensation using the intrinsic value method under the provisions of APB Opinion No. 25,
under which no compensation expense was recognized in the Company's Consolidated Statements of Earnings for the year ended December 31,
2005. In connection with the modified prospective method, disclosures made for periods prior to the adoption of SF AS No. l 23(R) do not reflect
restated amounts.
Equity-based compensation expense for the years ended December 30, 2006 and December 29, 2007 is as follows:
Year Ended
December 30, 2006

Cost of sales
Selling, general and administrative
Research and development

$

Related tax benefit
Net equity-based compensation expense

$

Year Ended
December 29, 2007

3,710
521

650
5,078
380

4,789
1,544

6,108
2,141

558

3,245

$

3,967

$

In 2006 and 2007, earnings per basic and diluted share were reduced $0.17 and $0.23, respectively, from what earnings would have been if the
Company had not been required to accrue equity-based compensation expense. The following table presents the pro forma effects on net earnings
and earnings per share as if the Company had applied the fair value recognition provisions of SFAS No. 123, as amended by SFAS No. 148, to
equity-based compensation for 2005:
Year Ended
2005

As reported

$

38,994

Add: Compensation cost included in reported net income
Deduct: Total compensation expense under the fair value
method for all awards

(7,614)

Net earnings

Proforma

$

31,380

Earnings per share-basic

As reported

$

2.07

Pro fonna

$

1.66

As reported

$

1.98

Proforma

$

1.59

Earnings per share-diluted
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USANA HEALTH SCIENCl~S, INC. ANO SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE L-EQUITY-BASED COMPENSATION (Continued)
The fo11owing table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of equity awards outstanding as
of December 29, 2007. This table does not include an estimate for future grants that may be issued.

~

2008
2009
2010
2011
Thereafter

$

5,807
3,913
3,452
2,015
435

$

15,622

~

The cost above is expected to be recognized over a weighted-average period of 2.2 years.
Prior to the adoption of SF AS No. l 23(R), the Company presented all tax benefits resulting from equity-based compensation as cash flows
from operating activities in the condensed consolidated statements of cash flows. SF AS No. l 23(R) requires cash flows resulting from tax
deductions in excess of the fair value of equity awards on the date of grant to be included in cash flows from financing activities.
The Company has elected to follow the transition guidance indicated in Paragraph 8 I of SFAS No. l 23(R) for purposes of calculating the pool
of excess tax benefits that arc available to absorb possible future tax deficiencies. As such, the Company has calculated its historical APIC Pool of
windfall tax benefits using the long-form method.
The Company's 2006 Equity Incentive Award Plan (the "2006 Plan"), which was approved by the shareholders at the Annual Shareholders'
Meeting held on April 19, 2006, allows for the grant of various equity awards, including stock-settled stock appreciation rights, stock options,
deferred stock units, and other types of equity-based awards, to the Company's officers, key employees, and non-employee directors. Prior to the
approval of the 2006 Plan, the Company maintained the 2002 Stock Option Plan (the "2002 Plan"), which was limited to the granting of incentive
and non-qualified stock options. Options granted under the 2002 Plan generally vest 20% each year on the anniversary of the grant date and expire
five to ten years from the date of grant. The 2006 Plan replaced the 2002 Plan for all future grants, and no new awards have been granted under the
2002 Plan. The 2006 Plan authorized 5,000 shares of common stock for issuance, of which 4,187 shares were available for future issuance as of
December 29, 2007. Of the 813 shares that have been granted under the 2006 Plan, 765 were stock-settled stock appreciation rights, 42 were stock
options, and 6 were deferred stock units. The Company's Compensation Committee has initially determined that awards to be granted to officers
and key employees under the 2006 Plan will generally vest 20% each year on the anniversary of the grant date and expire five to five and one-half
years from the date of grant.
Awards of stock options and stock-settled stock appreciation rights to be granted to non-employee directors will generally vest 25% each
quarter commencing on the last day of the fiscal quarter in which the awards are granted, and will expire five years to five and one-half years from
the date of grant. Awards of deferred stock units are full-value shares at the date of grant, vesting over the periods of service, and do not have
expiration dates.
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USANA HEALTII SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)
NOTE L-EQUITY-BASED COMPENSATION (Continued)

The Company continues to use the Black-Scholes option pricing model to estimate fair value of equity awards, which requires the input of
highly subjective assumptions, including the expected stock price volatility. Prior to the implementation of SFAS No. l 23(R), expected volatility
represented the historical share prices of the Company's common stock over the expected life of the award, and the risk-free interest rate was based
on the U.S. Treasury yield curve on the date of grant with respect to the expected life of the award. Expected life was based on the contractual term
of the award.
Preceding the adoption of SF AS No. l 23(R), the assumptions that were used by the Company in the estimation of fair value of equity awards
were analyzed to determine changes that might be necessary in order to more accurately reflect the equity awards that have been granted by the
Company. Based on this analysis, the Company decided that, effective January 1, 2006, expected volatility would be calculated by averaging the
historical volatility of-the Company and a peer group index in order to incorporate volatility of the industry in which the Company operates. The
risk-free interest rate would continue to be based on the U.S. Treasury yield curve on the date of grant with respect to the expected life of the
award. Also, effective January 1, 2006, due to the "plain vanilla" characteristics of the Company's equity awards, the simplified method, as
permitted by the guidance in Staff Accounting Bulletin No. I 07 was used to dctcnnine expected life for awards granted during 2006 and 2007.
The following table includes weighted-average assumptions that the Company has used to calculate the fair value of equity awards that were
granted during the periods indicated. Deferred stock units arc full-value shares at the date of grant and have been excluded from the table below.
~
Year Ended
2005

v1'

Expected volatility
Risk-free interest rate
Expected life
Expected dividend yield
Weighted-average grant price

70.4%
4.4%

8.6yrs.
0.0%
$39.94

2006

57.0%
4.8%
4.1 yrs.
0.0%

$38.oo·

2007

41.9%
4.6%

4.tyrs.;

0.0%

$42.ii

The weighted-average fair value of stock options and stock-settled stock appreciation rights that were granted in 2005, 2006, and 2007 was
$29.55, $18.77, and $16.81, respectively.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARJES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thous~rnds, except per share data)
NOTE L-EQUITY-BASED COMPENSATION (Continued)

A summary of the Company's stock option and stock-settled stock appreciation right activity is as follows:

Shares

Aggregate
Intrinsic
Value*

Weighted-average
Remaining
Contractual Term

Weighteda,·erage
Exercise Price

7.3

$

9.35
39.94
5.38
1.61

Outstanding at December 31, 2005
Granted
Exc:rcisc:<1
Canceled or expired

1,773 $
518 s
(559) $
(12) $

17.43
38.00
6.35
27.69

7.0

$

37,747

Outstanding at December 30, 2006
Granted
Exercised
Canceled or expired

1,720 $
464 s
(230) $
(90) $

27.15
42.21
13.67
35.06

5.8

$

42,172

1,864

$

32.18

4.9

$

12,606

$

20.28
26J7
24.51

7.7
7.2
5;6

$
$
$

11,950
13,528
10,562

Outstanding at January I, 2005
Granted
Exercised
Canceled or expired

1,932 $
396 $
(551) $
(4)

Outstanding at December 29, 2007

$

~

48,005

~

<ii

====-==a

Exercisable at December 31, 2005
Exercisable at Decembei: JO, 2006
Exercisable at December 29, 2007

*

·

640
535
782

$

$

Aggregate intrinsic value is defined as the difference between the current market value and the exercise price of awards that were in-themoney, and is estimated using the closing price of the Company's common stock on the last trading day of the period.

The total intrinsic value of equity awards that were exercised during 2005, 2006, and 2007, which include stock options and stock-settled stock
appreciation rights, was $21,360, $20,488, and $8,430 respectively.
A summary of the Company's deferred stock unit activity for the year ended December 29, 2007 is as follows:
Weighted-

a,·erngc
Fair Value

Sha.-es

Nonvested at December 30, 2006
Granted
Vested
Canceled or expired

I

3

$

s

(3 ) $

37.60
40.59
39.80

$

s

Nonvestcd at December 29, 2007

=
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USANA HEAL TH SCIENCES, INC. AND SUilSlDIARJES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE L-EQUITY-BASED COMPENSATION (Continued)
The total fair value of equity awards that vested during fiscal years 2005, 2006, and 2007 was $12,180, $3,767, and $5,226 respectively. This
total fair value includes equity-based awards issued in the fonn of stock options, stock-settled stock appreciation rights, and deferred stock units.
NOTE M-SEGMENT INFORMATION

v;_p

USANA operates in one reportable business segment as a direct selling company that develops, manufactures, and distributes high-quality
nutritional and personal care products that arc sold through a global seamless network marketing system of independent Associates. Over the
past three years, the Company's nutritional products have represented between 82% and 87% of net sales, and its personal care products have
represented between l 0% and 15% of net sales. The Company manages its business primarily by managing its worldwide Associate base.
Resources are allocated to markets for the purpose of developing an infrastructure that supports this Associate base and related sales. The
Company does not use profitability reports on a regional or market basis for making business decisions. Performance for a region or market is
primarily evaluated based on sales. No single customer accounted for I 0% or more of net sales in any of the last three fiscal years.

Change in Presentation
Prior to the second quarter of 2007, the Company's operations were reported as two business segments: Direct Selling and Contract
Manufacturing. Due to the sale of assets associated with its third-party contract manufacturing business, which was completed on August I 0,
2007, the Company currently operates in only one reportable segment, Direct Selling. Therefore, the financial results previously disclosed in
segment information for the contract manufacturing business have been reclassified as discontinued operations, and, as such, are excluded from
the presentation below.
Historically, selecte~ financial infonnation for the Direct Selling segment was presented for two geographic regions: North America and Asia
Pacific. North America included the United States, Canada, and Mexico. Asia Pacific included Austra1ia, New Zealand, Hong Kong, Japan, Taiwan,
South Korea, and Singapore. As the Company's international presence has continued to grow, it now presents this information in four geographic
regions: North America, Southeast Asia/Pacific, East Asia, and North Asia. "North America" includes the United States, Canada, and Mexico.
"Southeast Asia/Pacific" includes Australia, New Zealand, Singapore, and Malaysia. "East Asia" includes Hong Kong and Taiwan. "North Asia"
includes Japan and South Korea.
F-23
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE M-SEGMENT INFORMATION (Continued)

Selected Financial Information
Financial information, presented by geographic region for the years ended December 30, 2006 and December 29, 2007, is listed below:
2005

Net Sales to External Customers
North America
Southeast Asia/Pacific
East Asia
North Asia

Long-lived Assets
North.America
Southeas.t Asia/P.acific.
East Asia
NorthAsia
Consolidated Total

Tbtat:A~-~~~s,·

209,445
58,300
32,349
14,923

$

$

315,017

$

267,235
90,690
49,314
15,9IO

246,489
65,104
37,478
16,095

$

$

365,166

$

423,149

27,484
971
1,685
1,738

$

33,347
1,914
1,771
.1,480

$

46,964
10,368
2,030
1,492

$

3!,878

$

38,512

$

60,854

$

56,478

$

79,010
10,2,18 .
6,480
4,294

$

79,697

$

Cuusuli<lulc<l Tutul

2007

2006

~ --·•·

North An1crica

.'.So~t.6.~~~i~~iiUPa'.~ifii'_:/·t:::·:~;.

··1J6I

5,225

East Asia

· · North Xsia · ·

4,044
$

Consolidated Total

73,708

$

100,002

(&;

~

~

i1/J2~
6,911

.·. 4~5,95
$

109,128
~

The following table provides further net sales information on markets that represent ten percent or more of net sales:
2005

Net sales:
United States
Canada
Australia/New Zealand

$
$

s

134,227
61,252
44,711

2007

2006

$

159,377
69,053

$

$

48,316

$

$

$

169,645
75,360
56,471

Due to the centralized structure of the Company's manufacturing operations and its corporate headquarters in the United States, a significant
concentration of assets exists in this market. Long-lived assets in the United States totaled $26,486, $32,998 and $46,620, as of December 31, 2005,
December 30, 2006 and December 29, 2007, respectively. Additionally, due to the purchase, remodel, and fit-out ofa new facility in Sydney,
Australia, during 2007, long-lived assets in this market totaled $9,170. There is no significant concentration of long-I ived assets in any other
market.
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USANA HEA.LTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE N-QUARTERL Y FINANCIAL RES ULTS (Unaudited)
Summarized quarterly financial information for fiscal years 2006 and 2007 is as follows:
First

2006

$
$
$
$

89,694
70,375
10,558
10,344

$
$

0.52
0.50

$
$

0.57
0.55

$

$

2007

First

Net sales
Gross profit
Income from continuing operations
Net earnings
Earnings per share:( I)
Basic
Diluted.

(I)

$

85,384
67,006
9,759
9,560

$

Net sales
Gross profit
Income from continuing operations
Net earnings
Earnings per share:(I)·
Basic
Diluted

$
$
$

0.65
0.63

$

$

$

s

$
$

0.57
0.55

$

s

$

$
$
$

$

11,314

$

0.68
0.66

$

98,121
76,256
11,388
11,139

$
$
$

0.62
0.61

$

Third

107,542
85,099
11,407

$

$

Fourth

91,967
71,693
10,438
10,223

$

$

Second

100,678
80,092
11,800
11,686

$

Third

Second

Fourth

$

106,181
84,221
11,663
11,258

$
$
$

$
$

0.70
0.68

$

$

$

108,748
85,846
11,059
11,059
0.68
0.67

Earnings per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly
earnings per share amounts does not necessarily equal the total for the year.

NOTE 0-EARNINGS PER SHARE

~

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Weighted-average shares that
were redeemed during fiscal years 2005, 2006, and 2007 have been included in the calculation of weighted-average shares that are outstanding for
basic earnings per share. Diluted earnings per common share are based on shares that are outstanding (computed under
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATIW FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE O-EARNINGS PER SHARE (Continued)

basic EPS) and potential dilutive shares. Shares included in the diluted earnings per share calculations include equity awards that are in-the-money
but have not yet been exercised.
Year ended
2005

2007

2006

Earnings from continuing operations available to common shareholders
Loss from discontinued operations available to common shareholders

$

40,172 $·
(1,178)

42,143 $
(877)

45,929
(612)

Net earnings available to common shareholders

$

38,994

41,266

45,317

Basic EPS
Shares
Common shares outstanding entire period
Weighted average common shares:
Issued during period
Canceled during period

$

..

18,953
270
(350)'°.

..}~,343
·•., . . ,
257

17,859

18,053

i6,734

Earningtper. cotnmon sh,ue fr<>m continuing op_eratiQns:-basic
Loss per common share from discontinued operations-basic

$

Earnings per. common share from net earnings-basic

$

:__ tu-: ,L.~: .. -___J!,~1..:J . . . ,
(0.06)

Diluted
EPS
, ..
Shares
Weighted average common shares outstanding during period-basic
Dilutive effect ofin-the-money equity awards

(0.05)

2.74
(0.03)

:,·2.07- $-.

.

" -;-: ~ .

, .. 1 ··•-•·•--,, ' , '

Weighted average common shares outstanding during pcriod--diluted

123
(1,248)

· . -,:··. ~. (547)'.

18,873

Weighted average common shares outstanding during period

$

i'tJ\

.....

{

~..:.

,,,.:.

18,873
848

l~,053
.· 671

16,734
472

19,721

18,724

17,206

Earnings per common share from continuing operations-diluted
Loss per common share from discontinued operations-diluted

$

2.04
(0.06)

$

Earnings per common share from net earnings-diluted

$

1.98

$

2.25 $
(0.05)
2.20

$

2.67
(0.04)
2.63

Equity awards for 17, 163, and 21 shares of stock were not included in the computation of EPS for the years ended 2005, 2006, and 2007,
respectively, due to their exercise prices being greater than the average market price of the shares.
During the years ended December 30, 2006, and December 29, 2007, the Company expended $40,958 and $79,580 to purchase 1,045 and 1,892
shares, respectively, under the Company's share. repurchase plan. The purchase of shares under this plan reduces the number of shares
outstanding in the above calculations.
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EXHIBIT21

SU BS ID IA RIES
Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and
the names under which subsidiaries do business as of March 3, 2008.
Jurisdiction of Incorporation

Name

USANA Canada Co.

Canada

USANA Australia Pty, Ltd.

Australia

USANA Health Sciences (NZ) Corporation

New Zealand

USANA Hong Kong Limited

Hong Kong

USANA Japan, Inc.

Japan

USANA Health Sciences Korea Ltd.

South Korea

USANA Health Sciences Singapore Pte, Ltd.

Singapore

USANA Mexico S.A. de C. V.

Mexico

USANA Health Sciences Tianjin Co. Lid

People's Republic of China

FMG Productions, Inc. (dba USANA Studios)

Utah

UHS Essential Health Malaysia SND BHD

Malaysia

Except as noted above, each subsidiary listed above is doing business under its corporate name.
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Exhibit 23.l

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated Febmary 19, 2007, except for Note Bas to which the date is March 12, 2008, accompanying the consolidated
financial statements in the Annual Report of USA NA Health Sciences, Inc. on Form 10-K for the year ended December 29, 2007. We hereby
consent to the incorporation by reference of said report in the Registration Statements of USA NA Health Sciences, Inc. on Forms S-8 (File Nos.
333-02934, 333-02860, 333-96645, 333-128103, and 333-133385).
Isl GRANT THORNTON LLP

Salt Lake City, Utah
March 12, 2008
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Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File Nos. 333-02934, 333-02860, 333-96645,
333-128103, and 333-133385) ofUSANA Health Sciences, Inc. ofour report dated March 4, 2008 relating to the financial statements and the
effectiveness of internal control over financial reporting, which appears in this Fonn I 0-K.
Isl PricewaterhouseCoopers LLP

Salt Lake City, UT
March 4, 2008

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

. QuickLinks
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

OuickLinks -- Click here to rapidly navigate through this document
EXHIBIT31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION
I, Myron W. Wentz, certify that:
I.

I have reviewed this Annual Report on Form I 0-K of USA NA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this Annual Report docs not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this Annual Report;

3.

Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in
all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods
presented in this Annual Report;

4.

The Registrant's other certifying officer and I arc responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and I 5d-l 5(e)) and internal control over financial reporting (as defined in Exchange Act
Rules I 3a-l 5(f) and I 5d-l 5(t)) for the Registrant and have:

5.

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material infonnation relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this Annual Report is being
prepared;

b)

designed such internal control over financial reponing, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Annual Report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
Annual Report based on such evaluation; and

d)

disclosed in this Annual Report any change in the Registrant's internal control over financial reporting that occurred during
the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the
equivalent functions):
a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which arc reasonably likely to adversely affect the Registrant's ability to record, process, summarize and repon financial
information; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the the
Registrant's internal control over financial reporting.

Date: March 13, 2008

/s/ MYRON W. Wl-:NTZ

Myron W. Wentz, PhD
Chief Executive Officer
(Principal Executive Officer)

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

QuickLinks
CHIEF EXECUTIVE OFFICER CERTIFICATION

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

QuickLinks -- Click here to rapidly navigate through this document
EXIIIBIT 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Gilbert A. Fuller, certify that:
I.

I have reviewed this Annual Report on Form 10-K ofUSANA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this Annual Report does not contain any untrne statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this Annual Report;

3.

Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in
_all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods
presented in this Annual Report;

4.

The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-l5(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules l3a-15(f) and 15d-15(t)) for the Registrant and have:

5.

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material infonnation relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this Annual Report is being
prepared;

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Annual Report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
Annual Report based on such evaluation; and

d)

disclosed in this Annual Report any change in the Registrant's internal control over financial reporting that occurred during
the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the
equivalent functions):
a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial
information; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the the
Registrant's internal control over financial reporting.

l>atc: March D. 7.008

Isl

<ill.BERTA. HJI.LER

Gilbert A. Fuller
Chief Financial Officer
(Principal Accounting and Financial Officer)
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EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies that the Annual Report on Form 10-K of USA NA Health Sciences, Inc. for the year ended December 29, 2007
as filed March 13, 2008 with the Securities and Exchange Commission, fully complies with the requirements of Section I 3(a) or I 5(d) of The
Securities Exchange Act of 1934 ( 15 U.S.C. 78m) and that the information contained in the Annual Report fairly presents, in all material respects, the
financial condition and results ofoperations of USA NA Health Sciences, Inc.
Date: March I 3, 2008

Isl MYRON W. WENTZ
Myron W. Wentz, PhD
Chairman and Chief Executive Officer
(Principal Executive Officer)
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EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
The undersigned hereby certifies that the Annual Report on form I 0-K of USA NA Health Sciences, Inc. for the year ended December 29, 2007
as filed March 13, 2008 with the Securities and Exchange Commission, fully complies with the requirements of Section I 3(a) or 15(d) of The
Securities Exchange Act of 1934 ( 15 U.S.C. 78m) and that the information contained in the Annual Report fairly presents, in all material respects, the
financial condition and results of operations of USA NA Health Sciences, Inc.
Date: March 13, 2008

/s/ GILBERT A. FULLER

Gilbert A. Fuller
Chief Financial Officer
(Principal Accounting and Financial Officer)
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UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K
(Mark One)

.J

IXI

ANNUAL REPORT PURSUANT TO SECTION 13 OR l5(d) OF TIIE SECURITIES EXCHANGE ACT OF 1934

For the fiscal ye:1r ended January 2, 2016
OR

I I

TRANSITION REPORT PURSUANT TO SECTION 13 01{ 15(d) OF TIIE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _ _ _ _ _ lo _ _ _ __
Commission file number: 001-35024

USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specilied in its charier)
87--0500306
(I.R.S. Employer Identification No.)

Utah
(State or other jurisdiction of incorporation or
organization)

3838 West Parkw11y Blvd., Salt Luke City, Utah 84120
(Address of principal executive offices, Zip Code)
(801) 954-7!00
(Registrant's telephone number, including area code)

Securities regislered pursuant 111 Seclion I 2(b) or the Act:
(N:1me of e:ich exchange on which registered)
New York Stock Exchange

(Title of each class)
Common Srock, Par Value S0.001 Per Share

Securities registered pursuant lo Section I 2(g) of the Acl:
None

lnd1ca1e by check mark 1f the registrant 1s a well-known seasoned issuer, as defined

111

Ruic 405 of the• Securities ,\ct Y.:s

I ] :-,!o IX]

Indicate by check mark if the registrant is 1101 required to tile rcpons pursuant to Section 13 or IS(d) of the Act. Y.:s I I No (X}
Indicate by check mark whether 1he rcg1s1ra111 (I) has filed all rcpons required to be filed by Section 13 or I 5(d) of the Securtlics Exchange Act of 1934 durmg the preceding 12 mon1hs (or
for such shoner period that the registrant was required 10 file such rcpons). and (2) has been subject 10 such liltng rcqu1re111en1~ for 1he past 90 days Yes [X] No [ I
Indicate by check mark whether the rcgis1rnn1 has submiued electronically and posted on its corpo1a1e Website, if any. eve1y Interactive Data File required to be submitted and poslcd
pursuan1 to Ruic 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shoncr period 1ha1 1he registrant was required 10 submit and pos1 such
tiles). Yes [X] No [ l
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Indicate by check mark if disclosure of delinquent filers pursuant to llem 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be conrained,
of the registrant's knowledge, in detini1ive proxy or information statements ineorpora1ed by reference in Pan Ill of this Form 10-K or any amendment lo this Fonn 10-K. [ )

lo

lhe hcsl

Indicate by check mark whether 1he registrant is a large accelerated tiler, an accelerated filer, a non-accelerated filer, or a smaller rcponing company. Sec the definitions of "large accelerated
filer," "accelerated filer" and "smaller reporting company" in Ruh: I2h-2 of the Exchange Act.

Large accelerated tiler (X)
Non-accelerated filer [ I

Accelerated filer [ )
Smaller reporting
company [ }

Indicate by check mark wlwthrr the rrgis1n1nt is a shell eompany (;is 1klincd in Rule l2b-2 ofth,_. Act) y,_.s [ J No [X]
The aggregate market value of common stock held by non-alliliatcs of the registrant as of July 2, 2015 was approximately S832,428,673, based on a closing market price of S141.7•1 per
share.
There were 11,944,164 shares of the registrant's common stock ou1s1anding as of February 26, 2016.
Documents incorporated by rererence. The registrant incorporates infonnation required by Pan Ill (hems 10, 11, 12, 13, and 14) of this report by reference to the registrant's dclimll\e
proxy statement 10 be filed pursuant to Regularion I 4A for irs 2016 Annual Shareholders Meeting.
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The statements contained in this report 011 Form 10-K that are not purely historical are considered to be ''forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21 E oft he Securities Exchange Act of 1934, as amended
(the "Exchange Act'~- These forward-looking statements include, but are not limited to: any projections ofnet sales, earnings, or other
financial items; any statements of the strategies, plans and objectives of managementforfuture operations; any statements concerning proposed
new products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any
statements of assumptions underlying any oft he foregoing. Fonvard-looking statements may include the words "may," "will," "estimate,"
"intend," "continue," "believe," "expect'' or "anticipate" and any other similar words. These statements represent our expectations, beliefs,
anticipations, commitments, intentions, and strategies regarding the future and include. but are not limited to, the risks and uncertainties
outlined in Item IA Risk Factors and Item 7 Management's Discussion and Analysis of Financial Condition and Results a/Operations. Readers
are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed infonvardlooking statements within this report. The forward-looking statements included in this report speak only as of the date hereof. and we
undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information.future events or
otherwise, except as required by law.
In this Annual Report on Form 10-K, unless otherwise expressly indicated, references to "dollars" and"$" are to United States dollars.

PARTI
Item 1.

Business

General

~

V,

USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron W. Wentz, Ph.D. We develop and manufacture highquality, science-based nutritional and personal care products with a primary focus on promoting long-term health and reducing the risk of chronic
degenerative disease. In so doing, we are committed to continuous product innovation and sound scientific research. We have operations in 20
markets worldwide, where we distribute and sell our products by way of direct seJling. We have chosen this distribution method as we believe it is
the most conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the
world. Our net sales in fiscal year 2015 were $918.5 million, of which 84.8% were in markets outside of the United States. As a U.S.-based multinational company with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and
political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China,
and the other markets in which we operate with respect to the products that we sell and to our method of distribution.
Our customer base comprises two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by
acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase
our products strictly for personal use and are not permitted to resell or to distribute the products. As of January 2, 2016, we had 421,000 active
Associates and 89,000 active Preferred Customers worldwide.
4
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Current Focus and Recent Developments
We have implemented the following strategics and initiatives to increase the number of Associates and Preferred Customers who use our
products throughout the world and, thereby, further our company vision:

Personalization: Over the last few years, we have focused heavily uu pt:rsunalizing an<l improving uur customers' experience with
USANA.
In August 2015, we introduced our new "MySmart™Foods" line of products, which continues our philosophy and strategy of
personalization. MySmart™Foods arc science-based, healthy nutrition shakes, bars, boosters and navor optimizers. We made
MySmart™Foods available t~ our Associates for a limited time at our 2015 International Convention only, as a pre-launch
opportunity to purchase and try the products. We intend to officially launch MySmartTMFoods during the first halfof 2016.
We will continue to personalize each of our product lines going forward. In this regard, we have new product and technology
launches planned for 2016 and 2017, which we believe will create a new foundation of personalization for USANA to build on as we
go fonvard.
In 2014, we hiuuchcd an aJl-ncw digital marketing suite for our world-wide Associates, which is designed to personalize and simplify
conducting a USANA business. This suite provides our Associates with new tools, consisting of a back office hub, personal
websites, and advanced communication and marketing tools, all of which enhance our Associates' ability to personalize, manage,
promote and build their business in today's demanding e-busincss environment.
In 2013, we implemented several strategic changes to our business ( referred to throughout this report as the "2013 strategic
changes"), which were all aimed at promoting customer loyalty, enjoyment and success with USA NA. These changes included:
(i) simplification of our pricing structure, which included an overall I 0% price reduction, while maintaining a price discount on
products ordered through our monthly Auto Order program (collectively "price discounts"), (ii) a new reward based on the amount
of a customer's initial product order to then be credited on their subsequent two Auto Orders, and (iii) increased payout under and
simplification of our Compensation Plan.
We have experienced growth in several business indicators tied to the strategic changes that we implemented in 2013 and
continued promoting in 2014 and 2015. These indicators include: active customer counts; world-wide unit volume; percent of sales
processed through our Auto Order program; and the number of Associates earning a commission check.

Market-Specific Strategies: We have implemented market-specific strategies to facilitate growth and strengthen our business
around the world.
In 2015, we continued our strategy to increase our brand-recognition to make it easier for our Associates to introduce USANA to
customers. In this regard, we expanded our relationship with Dr. Mchmet Oz and became a Trusted Partner and Sponsor of The
Dr. Oz Show. Under this partnership, USANA products are regularly featured on The Dr. Oz Show. This partnership has helped
drive growth in North America and our other regions around the world by increasing awareness and recognition of the USA NA
brand. Each episode of The Dr. Oz Show that features a USA NA product is translated into the predominant language of a particular
USANA market and made available to Associates in that market via YouTube and other social media outlets for use in promoting
the USA NA brand. Additionally, viewers of The Dr. Oz Show arc able to purchase USA NA products via a direct link on The Dr. Oz
Show website. We plan on continuing this partnership in 2016.

5
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In late 2014, after we passed the anniversary of the 2013 strategic changes, we began offering short-term incentives and promotions
for our Associates around the world to generate excitement and additional customer growth. One particular incentive that we
offered in late 2014 and early 2015 increased compensation to Associates for sales generated by new Associates and accelerated
our sales and customer growth during the fourth quarter of 20 I 4 and the first halfof 2015. We plan to continue offering marketspecific incentives and promotions going forward to generate excitement in our business.
In 2013, we implemented a price reduction in several of our mature markets to make our products and business opportunity more
equitable around the world. Although these price reductions initially had an impact on our net sales on a year-over-year basis, they
have been successful in the past helping grow our active customer counts and net sales in these markets, where growth had been
declining or flat for several years. We followed this pricing initiative with a new worldwide policy to prohibit cross-border
purchasing by our customers. We believe that it is in the best interest of the Company and of our customers to have customers
purchase products that are approved and offered in their home market. While this policy had a short-term negative impact on net
sales in 2013, these policies have strengthened our underlying business and have improved our opportunity for growth going
forward.

Producl bmovalion and Jnformation Technology: Although we originally planned for significant increases in our investment in
product and technology innovation to further our Company vision during 2015, much of this investment was delayed as we
carefully acquired the necessary human resources. In 2016, we plan to continue to pursue these investment strategies as well as
additional investments in our information technology systems and infrastmcture to continue to improve our customers' experience
with us and to prepare to become a much larger company. These investments will be reflected as both additional SG&A expense
and capital expenditures.
Jnternational Development: Given the significant opportunity that exists in China, we plan to continue focusing significant time
and resources on growing this market. Our efforts in this regard include finalizing our new state-of-the-art manufacturing and
production facility in Beijing, which we anticipate will become operational during the first half of 2016. We continue to believe that
significant growth opportunities exist in new international markets. During the fourth quarter of20 I 5 we commenced operations in
Indonesia. Indonesia is our 20th market and we believe it offers a promising growth opportunity for us.

6
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Products
The following table summarizes our product lines.

Prnduct Line/Category
USANA® Nutritionals
Essentials

Optimizers

Description

Percent of
Product Sa!es
by Fiscal Year

Product examples

Includes core vitamin and mineral supplements that provide a foundation
of advanced total body nutrition for every age group beginning with
children I 3 months of age.

2013~-26%
2014 24%
2015-22%

USANA®
Essentials
llcalthPak 10orM

Consists of targeted supplements designed to meet individual health and
nutritional needs. These products suppor1 needs such as cardiovascular
health, skclctaVstnicturnl health, and digestive health and arc intended to
be used in conjunction with the Essentials.

2013-54%
2014-55%
2015-59%

Prollavanol
CoQuinonc® 30
BiOmega-3rn

2013-12%
2014-13%
2015-11%

Nutrimcal
Fibergy
RESEPM weightmanagement
program and
accompanying
RESET kit

2013-6%
2014-7%
2015--7%

Daytime Protective
Emulsion
Night Renewal
Perfecting Essence

2013-2%
2014--1%
2015-1%

Associate Staner Kit
Product Brochures

Foods
Includes low-glyccmic meal replacement shakes, snack bars, and other
related products that provide optimal macro-nutrition (complex
carbohydrates, complete proteins, and beneficial fats) in great tasting and
convenient fonnats. These products can be used along with Essentials
and Optimizers to provide a complete and healthy diet and sustained
energy throughout the day.
Sense-beautiful scienceiID

Includes premium, science-based, personal care products that suppon
healthy skin and hair by providing advanced topical nourishment,
moisturization, and protection. These products arc designed to
complement inner nutrition for the skin provided by the USANA
Nutritionals and arc manufactured with our patented, self-preserving
technology, which uses a unique blend of botanicals, antioxidants, and
active ingredients to keep products fresh, without adding traditional
chemical prcscrv11tivcs.

All Other
Includes materials and online tools that arc designed to assist our
Associates in building their businesses and in marketing our products.

In addition to the products described above, we offer products designed specifically for prenatal, infant, and young-child age groups in
China. As we continue to increase our focus on personalization and innovation, we will look for innovative product opportunities such as our
MyHealthPakTM product, which is a fully customized, supplement regimen that can include any of our Essentials and Optimizers.
The approximate percentage of total product sales represented by our top-selling products for the last three fiscal years is as follows:
Year Ended

..lliL

Key Product

USANA® Essentials
Proflavanol®
BiOmega-)TM

_!ill_

17%
13%

8%

...1Q!L

16%
13%
10%
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Other top-selling products include our HealthPak I OOTM and CoQuinone ® 30.

-:;J

Geographic Presence
Our products are distributed and sold in 20 markets. We have organized our markets into two geographic regions: (i) Asia Pacific, which
includes three sub-regions, and (ii) Americas and Europe, as noted below.

Asia Pacific
Asia Pacific is organized into three sub-regions: Greater China, Southeast Asia Pacific, and North Asia. Markets included in each of these subregions are as follows:
Greater China-Hong Kong, Taiwan, and China< 1l
Southeast Asia Pacific-Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand and Indonesia( 2)
North Asia-Japan and South Korea

~

Asia Pacific has driven our growth the last several years. Our most recent market expansions in this region include our entry into Indonesia in
late 2015, Thailand in 2012 and our entry into China in 2010 through our acquisition ofBabyCarc. Historically, our growth in this region was led by
Hong Kong and the Philippines. Since our acquisition of BabyCarc, however, our strategy in Asia Pacific has been centered on generating growth
in China. Consequently, our growth in Asia Pacific over the last few years has been led by China, and our results in Hong Kong have declined.
Our Hong Kong market has now reached our projected size, in terms of customers and sales, and we anticipate modest organic growth for this
market going forward. We also anticipate that China and the Philippines will continue to drive our growth in this region going forward, but expect
our business to grow in most of our other markets in this region.

Americas and Europe
Americas and Europe is our most mature region. Our most recent market expansions in this region include our entry into Colombia in 2013 and
France and Belgium in 2012. Americas and Europe has grown modestly over the last several years due to sales and customer growth in Canada in
Mexico. Our results in the United States and our newest markets in this region, however, have not paralleled our success in Canada and Mexico.
We remain optimistic about our potential to generate growth in the United States and our newest markets and are confident in the growth
strategies we have in place. We also anticipate that our growth in Canada and Mexico will continue in 2016.

())

(2)

Our business in China is that of BabyCare Holdings, Ltd. ("BabyCare"), our wholly-owned subsidiary.
We commenced operations in Indonesia in the fourth quarter of 2015.

8
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Net Sales by Region

The following table shows net sales by geographic region for our last three fiscal years. We report net sales in a geographic region if a
product shipment originates in that geographic region. Additional financial information relating to our geographic regions can be found in Note K
to the Consolidated Financial Statements included in this report.
2013

2015

2014

(in thousands)

Asia Pacific
Greater China
Southeast Asia Paci fie
North Asia
Asia Pacific Total

$

Americas and Europe
$

271,812
155,362
29,319
456,493

37.9%$ 326,134
177,940
21.6%
32,667
4.1%
63.6% 536,741

41.3%$ 441,284
22.5%
183,828
39,751
4.1%
67.9% 664,863

48.0%
20.0%

261,682
718,175

253,730
36.4%
I00.0%$ 790,471

32.1% 253,636
100.0%$ 918,499

27.6%
I00.0%

4.4%

72.4%

Research and Development

Our research and development efforts are focused on developing and providing high-quality, science-based products that promote long-tenn
health and reduce the risk of chronic degenerative disease. Our research and development activities include developing products that arc new to
USANA and new to the industry, updating existing USANA brand formulas to keep them current with the latest science, and adapting existing
fonnulas to meet ever-changing regulations in new and existing international markets. In addition, we have an active clinical studies program in
place to verify the efficacy of our existing products and our new formulations. Our scientific staff includes experts on human nutrition, cellular
biology, biochemistry, natural product chemistry, and clinical research. These experts continually review the latest published research on nutrition,
attend scientific conferences, and work with a number of third-party research institutions and researchers to identify possible new products and
opportunities and also to reformulate our existing products.
Our in-house research team is working closely with scientists at a number of universities and top research institutes, including the University
of Washington, the University of Texas, the lJniversity of Colorado Health Sciences C:enter in Denver, lJtah Sti-ite lJnivr.rsity, the Linus Pauline
Institute at Oregon State University, The Foods for Health Institute at The University of California, Davis, McGilJ University, in Montreal, Canada,
and The Orthopedic Specialty Hospital ("TOSH"), in Salt Lake City, Utah, to maintain our leadership in clinical research in nutrition, oxidative
stress, glycemic stress, chronic inflammation and health implications of the microbiome.
We follow pharmaceutical standards established by the U.S. Phannacopeia and other pharmacopeias in the development and formulation of
our products. Our ingredients arc selected to meet a number of criteria, including, but not limited to: safety, potency, purity, stability, bioavailability, and efficacy. We control the quality of our products beginning at the formulation stage, and we maintain our quality control through
controlled sourcing of raw ingredients, manufacturing, packaging, and labeling. In fiscal years 2013, 2014, and 2015, we expended $5.1 million,
$5.1 million, and $6.4 million, respectively, on product research and development activities. Going forward, we expect to increase our spending and
resources for research and development in connection with our personalization and product innovation strategies.
9
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Manufacturing and Quality Assurance
We conduct nearly all of the manufacturing, production and quality control operations for our nutritional and personal care products inhouse. We have established and maintain a manufacturing and quality control facility in Salt Lake City, Utah. BabyCare manufactures and
produces nearly all of its products in-house and maintains manufacturing and quality control facilities in Beijing, China and Tianjin, China.
Additional information about our manufacturing, production and quality control operations is set out below.

Tablet Manufacturing

~

Our tablet production process uses automatic and semi-automatic equipment and includes the following activities: auditing and qualifying
suppliers of raw materials, acquiring raw materials, analyzing raw material quality, weighing or otherwise measuring raw materials, mixing raw
materials into batches, forming mixtures into tablets, coating and sorting the tablets, analyzing tablet quality, packaging finished products, and
analyzing finished product quality. We conduct sample testing of raw materials, in-process materials, and finished products for purity, potency,
and composition to determine whether our products conform to our internal specifications, and we maintain complete documentation for each of
these tests. We employ a qualified staff of professionals to develop, implement and maintain a quality system designed to assure that our products
are manufactured to our internal and applicable regulatory agency specifications.

'"'

Our Salt Lake City manufacturing facility is registered with the U.S. Food and Drug Administration ("FDA"), Health Canada Natural Health
Products Directorate, the Australian Therapeutic Goods Administration ("TGA"), and other governmental agencies, as required. This facility is
audited regularly by various organizations and government agencies to assess, among other things, compliance with current Good Manufacturing
Practices ("GMPs") and with labeling claims. Additionally, our Salt Lake City manufacturing facility is also certified, through inspection and audits,
with the Islamic Foods and Nutrition Counsel of America in compliance with Halal, NSF International in compliance with product testing and
GMPs, and the TGA in compliance with the current Therapeutic Goods Act in Australia.
The manufacture of nutritional or dietary supplements and related products in the United States requires compliance with dietary supplement
GMPs, which are based on the food-model GMPs and pharmaceutical GMPs, with additional requirements that are specific to dietary supplements.
We are audited by the FDA, specifically for dietary supplements, and have been found in full compliance with GMPs for dietary supplements.

Personal Care Manufaclllring
The production process for personal care products includes identifying and evaluating suppliers of raw materials, acquiring raw materials,
analyzing raw material quality, weighing or otherwise measuring the raw materials, mixing raw materials into batches, analyzing liquid batch quality,
packaging-finished products, and analyzing finished product quality. We conduct sample testing of raw materials, in-process materials, and
finished products for purity, potency, and composition to determine whether our products conform to our internal specifications, and we maintain
complete documentation for each of these tests.
At our Salt Lake City facility, we have standard technology for producing batches of personal care items, and we have semi-automatic
packaging equipment for packaging end products. We employ qualified staff to develop, implement, and maintain a quality system. Although the
FDA has not promulgated GMPs for personal care items, it has issued guidelines for manufacturing personal care products. We voluntarily
maintain compliance with the guidance established by the FDA and the Personal Care Products Council.
10
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Third-Party Suppliers and Manufacturers
We contract with third-party suppliers and manufacturers for the production of some of our products, which account for approximately 24% of
our product sales. These third-party suppliers and manufacturers produce and, in most cases, package these products according to formulations
that have been developed by or in conjunction with our in-house product development team. These products include most of our gclatincapsulated supplements, Rev3 Energy™ Drink, Probiotic, our powdered drink mixes, nutrition bars, and certain of our personal care products. In
particular, we have entered into a strategic relationship with a third-party manufacturer of our nutrition bars. Under this relationship we have
extended credit to this supplier in the form of a secured loan to allow the supplier to acquire the necessary equipment to manufacture our bars.
This relationship improves our supply chain stability and creates a mutually beneficial relationship between both parties. Products manufactured
by third-party suppliers at their locations must also pass through quality control and assurance procedures to ensure they are manufactured in
conformance with our specifications. We require products manufactured at these facilities to be shipped to USANA, where a quality inspection
and release also takes place.

\i.,

Quality Control/Assurance
We have microbiology and analytical chemistry labs in which we conduct quality control processes. In our microbiology laboratory, scientists
test for biological contamination of raw materials and finished goods. In our analytical chemistry laboratory, scientists test for chemical
contamination and accurate levels of active ingredients in both raw materials and finished products. Both laboratories conduct stability tests on
finished products to determine the shelf life of our products. Our Salt Lake City laboratory staff also performs chemical assays on vitamin and
mineral constituents, using U.S. Pharmacopoeia methods and other internally validated methods. In addition to our quality control and clinical
laboratories, our headquarters and China facilities also house a laboratory designated for research and development.

Raw ,Waterials
Most of the raw ingredients that are used in the manufacture of our products arc available from a number of suppliers. We have not generally
experienced difficulty in obtaining necessary quantities of raw ingredients. When supplies of certain raw materials have tightened, we have been
able to find alternative sources of raw materials. and believe we will be able to do so in the future, if the need arises. Our raw material suppliers
must demonstrate stringent process and quality control before we use their products in our manufacturing process.
Distribution and Marketing

General
We distribute our products internationally through a network marketing system, which is a form of person-to-person direct selling. Under this
system, distributors purchase products at wholesale prices from the manufacturer for resale to consumers and for personal consumption. The
concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and
close acquaintances. We believe that network marketing is an effective way to distribute our products because it allows person-to-person product
education and testimonials, as well as higher levels of customer service, all of which are not as readily available through other distribution
channels.
II
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Structure of Network Marketing Program
Associates. A person who wishes to sell USAN A products must join our independent sales force as an Associate. A person becomes an
Associate by completing an application under the sponsorship of an existing Associate. The new Associate then becomes part of the sponsoring
Associate's sales organization. New Associates sign a written contract and agree 10 adhere to the USANA policies and procedures. Under the
policies and procedures, Associates may not, among other things: (i) use deceptive or unlawful practices to sell USANA products; (ii) make
deceptive or unlawful claims or representations concerning our products or Compensation Plan; or (iii) sell competitive products to other USANA
Associates or solicit USANA Associates to participate in other network marketing opportunities. New Associates are required to purchase a
starter kit that includes a detailed manual describing our business and products, as well as our policies and procedures. We sell these kits at a
nominal cost averaging $30 in each of our markets. No other investment is required to become an Associate.
Once a person becomes an Associate, she or he may purchase products directly from us at wholesale prices for personal use and resale to
customers. Our Associates are also entitled to build sales organizations by attracting and enrolling new Associates and establishing a network of
product users. Associates are not required to recruit or sponsor new Associates and we do not compensate Associates for sponsoring or
recruiting Associates. The sponsoring of new Associates results in the creation of multiple levels within our network marketing structure.
Sponsored Associates are referred to as part of the sales organization of the sponsoring Associate. New Associates may also sponsor new
Associates, creating additional levels in their network, but also forming a part of the same sales organization as the original sponsoring Associate.
As outlined below, Associates who arc interested in earning additional income must successfully sell USA NA products and establish a business
network in order to qualify for commissions, including bonuses. Subject to payment of a minimal annual account renewal fee, Associates may
continue to distribute or consume our products as long as they adhere to our policies and procedures.
Individuals who reside in China and who are interested in being part of USANA's organization in China may do so by joining BabyCare as an
Associate. The process for joining BabyCare is very similar to the process for joining USA NA and requires an initial Associate application and an
agreement by the Associate to adhere to the policies and procedures in China. Much like our operations in other markets, an Associate in China is
provided with opportunities to build a sales organization and receive compensation for sales generated by that organization. Associates in China
arc compensated under a compensation plan created and implemented by BabyCare specifically for China.

Preferred Customers. We also sell directly to customers who purchase products only for personal use. This program is our "Preferred
Customer" program. Preferred Customers may not resell or distribute our products. We believe this program gives us access to a market that would
otherwise be missed, by targeting customers who enjoy USANA products, but who prefer not to maintain a distribution relationship with us.
Although our policies prohibit Preferred Customers from engaging in retail sales of products, they may enroll as Associates at any time, if they
desire. Preferred Customers are not eligible to earn commissions or to participate in our Compensation Plan. Our China operations also utilize a
Preferred Customer program, which is based on USANA's Preferred Customer program in our other markets with modifications that we have made
specifically for our China market.
Associate Training and Motivation
Initial training of Associates about the products, the Compensation Plan, network marketing, and USA NA is provided primarily hy an
Associate's sponsor and others in their sales organization. We develop and sell training materials and sales tools to assist Associates in building
their businesses, as well as provide reprints from other commercial publications that feature USA NA and may be used as

12
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sales tools. We also sponsor and conduct regional, national, and international Associate events, as well as intensive leadership training seminars.
Attendance at these sessions is voluntary, and we undertake no generalized effort to provide individualized training to Associates, although
experience shows that the most effective and successful Associates participate in training activities. Although we provide leadership training and
sales tools, we ultimately rely on our Associates to sell our products, attract new Associates and Preferred Customers to purchase our products,
and to educate and train new Associates regarding our products and Compensation Plan.

1;t,.

Associate Compensation
As outlincct helow, our Compensation Plan provides several opportunities for Associates to earn compensation, provided they are willing to
consistently work at building, training, and retaining their sales organizations to sell USANA products to consumers. The purpose behind each
form of compensation under our Compensation Plan is to reward Associates for generating product sales either directly or indirectly through their
sales organization and network of product consumers. We believe our Compensation Plan is distinctive for its weekly payouts to Associates.

~

Associates can earn compensation in four ways:

Commissions. The primary way an Associate is compensated is through earning commissions. Associates cam commissions
through generating sales volume points, which are a measure of the product sales of their sales organization. Each of our products
has an assigned sales volume point value comprised of a certain percent of the product price in U.S. dollars. To be eligible to earn
commissions, an Associate must sell a certain amount of product each month ("Qualifying Sales"). Qualifying Sales may inclucte
products that the Associates either use personally or that they resell to consumers. Associates do not earn commissions on these
Qualifying Sales. Associates may cam commissions on their sale of products above the Qualifying Sales as well as the sale of
products by Associates in their organization and to Preferred Customers. Additionally, Associates do not earn commissions for
simply recruiting and enrolling others in their organization. Commissions are paid only on the sale of products. We pay Associate
commissions on a weekly basis. As noted elsewhere in this report, our China operations maintain their own compensation plan,
which has been implemented by BabyCare specifically for China.
Bonuses. We offer Associates several bonus opportunities, including our leadership bonus, elite bonus, and lifetime matching
bonus. These bonus opportunities are based on a pay-for-performance philosophy and, therefore, are paid out when the Associate
achieves the required performance measures.
Retail Mark-Ups. As discussed previously, m markets where retail mark-ups are permitted, our Associates purchase products from
us at the Preferred Price and may resell them to consumers at higher retail prices. In this case, the Associate retains the retail markup as another form of compensation.
Contests and Promotions. We periodically sponsor contests and promotions designed to incentivize Associates to generate sales,
grow their sales organization, and increase the number of product users. These promotions are also based on a pay-for-performance
philosophy and, therefore, are only paid upon the achievement of the promotion objectives.
We endeavor to integrate our Compensation Plan seamlessly across all markets where legally permissible, allowing Associates to receive
commissions for global-not merely local-product sales. This seamless sales organization structure is designed to allow Associates to build a
global network by establishing or expanding their sales organization in any of the markets where we operate. We believe
13
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our Compensation Plan significantly enhances our ability to expand internationally, and we intend to continue to integrate new markets, where
permitted, into our Compensation Plan.
Operating Strengths
Our principal objective is to improve the overall health and nutrition of individuals and families around the world. We do this through
(i) developing and manufacturing high-quality, science-based nutritional and personal care products that promote long-term health, and
(ii) providing a rewarding opportunity through network marketing for our Associates who distribute our products. Our strategy is to capitalize on
our operating strengths, which include: a strong research and development program; in-house manufacturing capability; science-based products;
an attractive Associate Compensation Plan; a scalable business model; and an experienced management team.

Emphasis on Research and Development. We have a technical team of experienced scientists, including several holding Ph.D. degrees,
quality engineers, and regulatory specialists who contribute to our research and development activities. In our research and development
laboratories, our scientists and researchers:
Investigate activities of natural extracts and formulated products in laboratory and clinical settings;
Identify and research combinations of nutrients that may be candidates for new products;
Develop new nutritional ingredients for use in supplements;
Study the metabolic activities of existing and newly identified nutritional ingredients;

d

Enhance existing USANA brand products, as new discoveries in nutrition and skin care are made;
Formulate products to meet diverse regulatory requirements across all of our markets; and
Investigate processes for improving the production of our formulated products.

J

Our scientists and researchers also conduct double-blind, placebo-controlled, clinical studies, which are intended to further evaluate the
efficacy of our products. In addition, we work with outside research organizations to further support various aspects of our research and
development efforts. Our in-house research team is working closely with scientists at a number of universities and top research institutes,
including those listed under the caption "Research and Development" above, to maintain our leadership in clinical research in nutrition, oxidative
stress, glycemic stress, chronic inflammation and health implications of the micro-biome. We have also funded clinical research programs at
Boston University, the University of Colorado, the University of Utah, the University of Sydney in Australia, TOSH, and Utah State University.
Our R&D team also works closely with the Medical staff at Sanoviv Medical Institute in Rosarito, Mexico to obtain additional perspectives on the
use of supplements in a clinical setting and to get feedback on formulas in development. Additionally, our Scientific Advisory Council, comprised
of health care professionals and nutritional science experts worldwide, provides us with valuable insights into product applications and efficacy. It
is through our internal research and development efforts, as well as our relationships with outside research organizations and health care
providers, that we can provide what we believe to be some of the highest quality health products in the industry.

In-house Manufacturing. We manufacture products that account for approximately 76% of our product sales. We believe that our ability to
manufacture our own products in-house is a significant competitive advantage for the following reasons:
We can better control the quality of raw materials and finished products;
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We can more reliably monitor the manufacturing process to better guarantee potency and bioavailability and to reduce the risk of
product contamination;
We can better control production schedules to increase the likelihood of maintaining an uninterrupted supply of products for our
customers;
We are able to produce most of our own prototypes in the research phase of product development; and
We are better able to manage the underlying costs associated with manufacturing our products.

Science-based Products. As a result of our emphasis on research and development and our in-house manufacturing capabilities, we have
developed a line of high-quality health products that we believe provides health benefits to our customers. Our products have been developed
based on a combination of published research, in-house laboratory and third-party clinical studies, and sponsored research.
Allractive Associate Compensation Plan and Support. We arc committed to increasing our product sales by providing a highly competitive
compensation plan to attract and retain Associates who constitute our sales force. We motivate our Associates by paying incentives on a weekly
basis. Additionally, our Compensation Plan is, where permissible, a global-seamless plan, meaning that Associates can be compensated each week
for their business success in any market in which they have a sales organization where we conduct business. As noted elsewhere in this report,
our China operations maintain their own compensation plan, which is stmctured differently than USANA's plan in other markets.
To support our Associates, we sponsor meetings and events throughout the year, which offer information about our products and our
network marketing system. These meetings are designed to assist Associates in business development and to provide a forum for interaction with
some of our Associate leaders and with members of the lJSANA management team. We also provide low-cost sales tools and resources, which we
believe are an integral part of building and maintaining a successful home-based business for our Associates. For example, we offer a computerbased, interactive presentation tool, called Health and Freedom Solution, which is designed to help our Associates easily explain and share the
USANA opportunity, including the benefits of our products and our Compensation Plan.
In addition to company-sponsored meetings, sales tools and resources, we maintain a website exclusively for our Associates, where they can
access the latest USANA news, obtain training materials, manage their personal information, enroll new customers, shop for products, and register
for company-sponsored events. Additionally, through this website, Associates can access other online services to which they may subscribe. For
example, we offer an online business management service, which includes a tool that helps Associates track and manage their business activity, a
personal webpage to which prospects or retail customers can be directed, and e-cards for advertising.
We also believe that recognition is an important factor in supporting and retaining our Associates. We understand that being a successful
USANA Associate requires hard work and dedication, and we celebrate key achievements and rank advancements of our Associates. We believe
that our recognition programs greatly contribute to our ability to retain our Associates.

Business Model.

We believe that our business model provides, among others, the following advantages:

No requirement for a company-employed sales force to sell our products, with a relatively low incremental cost to add a new
Associate;

Commissions paid to our Associates arc tied to sales perfonnance;
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Accounts receivable arc minimal because payment is required at the time an Associate or Preferred Customer purchases product;
A stream of recurring revenue from our monthly product subscription program known as" Auto Order," which we utilize in all of our
markets (for the year ended January 2, 2016, this program represented 48% of our product sales volume); and
We can typically expand into new international markets with moderate investment because we generally maintain only warehouse
facilities, customer support, and minimal administrative facilities in those international markets. Larger markets, including China
however, require more significant local investment.

Experienced Management Team. Our management team includes individuals with expertise in various scientific and managerial disciplines,
including nutrition, product research and development, international development, marketing, customer network development, information
technology, manufacturing, finance, legal, regulatory, and operations. This team is responsible for supporting growth, research and development,
international expansion, strengthening our financial condition, and improving our internal controls.
Growth Strategy
We seek to grow our business by pursuing the following strategies:

Allract and Retain Customers. Our customers, and Associates in particular, arc central to the growth and success of our business.
Accordingly, our primary growth strategy focuses on increasing our overall customer counts throughout the world. We will execute this strategy
by applying both world-wide and region-specific initiatives, which include the initiatives set out below. Our management team maintains a close
working relationship with our Associate leaders by interacting with them on a regular basis through in-person meetings and phone calls. Further,
in addition to our Annual International Convention and our Asia Pacific Convention, we hold several regional events in key growth areas to
provide support and training to Associates. We continue to invest in these events and in the marketing of our business to help Associates
improve the productivity of their businesses.

vj
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Personalization. Our personalization initiative has been a key marketing and operating strategy for us over the last few years and will
continue to be a key strategy going forward. This initiative focuses on personalizing and improving our overall business, as well as our customers'
experience with USANA. We have already applied personalization to many aspects of our business and have several additional enhancements
planned going forward, all of which is further discussed under "Current Focus and Recent Developments" above.
New Product Introductions. Our research and development team continually reviews the latest scientific findings related to nutrition,
conducts or manages research and clinical trials, reviews new technologies, and attends scientific conferences. If, in the process, we see potential
for a new product or ingredient that provides a measurable and important health benefit, and if we believe this benefit can be realized by a
significant number of our customers, we will generally pursue development of that product. Our research and development focus has and will
continue to be centered on personalization and innovation. To the extent reasonably possible, we intend to personalize our product offering and
product delivery systems to our customers' individual needs. As discussed above, we have several significant new product introductions and
launches planned for 2016 and 2017, which we believe will create a new foundation for USANA to build on for years to come.
Successfully Grow each of our Regions through Market Specific Strategies and Incentives. In light of the strength of our Asia Pacific
region and our growing Associate base in Asia, we believe that Greater China continues to be the most significant and imminent growth
opportunity for us. Our strategy in this
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region is focused on generating customer growth in each market, with an emphasis on China. Our wholly-owned subsidiary, BabyCare, is our
operating entity in China. BabyCare has been granted licenses to engage in direct selling in the municipalities of Beijing, Jiangsu, Shaanxi and
Tianjin and is working to obtain similar licenses in other provinces. We have spent the last few years registering a portfolio of USANA products
for sale by BabyCare in China, educating our customers on our product offering and business model in China, and improving our information
systems, technology and infrastmcturc in China. In 2016, we will continue to execute these strategies and finalize our new state-of-the-art
manufacturing and production facility, which we anticipate will become operational during the first half of 2016.
We are also confident in our growth potential in our Southeast Asia Pacific region. While the Philippines and Australia-New Zealand have
been key growth markets for us in this region, we generated local currency sales and customer growth in nearly every market in this region in 2015.
We have implemented strategies for each market in this region, which arc intended to continue our customer growth trend in 2016. Additionally,
2016 will be the first full operational year for Indonesia, our newest market in this region. Indonesia is USANA's 20 th market and we believe it offers
a promising growth opportunity for us.
Our Americas and Europe region is also very important to our business and a significant part of our growth strategy. We achieved doubledigit local currency sales and Associate growth in Mexico and Canada through market-specific initiatives in 2015, and expect growth in these
markets to continue in 2016. We also remain focused on customer growth in the United States. Our objective for this region in 2016 is centered on
increasing the overall number of customers who consistently use USANA products. To achieve our objective, we will continue to execute our
personalization and brand-awareness strategics and also utilize market-specific promotions and incentives.

Brand Awareness: To facilitate customer growth, we plan to continue to promote global awareness of the USA NA brand through various
strategics, including professional athlete sponsorships and credible associations with individuals and organizations. Examples of this include our
sponsorship of the U.S. Ski Team and our partnership with the Women's Tennis Association. We continue to serve as the official health
supplement supplier for these teams and organizations and arc also increasing our sponsorship of individual athletes who rely on our products
and brand. We seek to leverage these relationships to build brand credibility and increase product consumption and loyalty. In addition to our
athlete sponsorships, we seek to advertise and collaborate with credible, nationally recognized organizations and individuals to enhance our
global brand. We will also continue our relationship with Dr. Mehmet Oz as a Trusted Partner and Sponsor of The Dr. Oz Show, as discussed
further under "Current Focus and Recent Dcvelopm~nls" abuvc. While branding effurls such as this have a global reach, the primary objective of
this initiative is to grow sales and customers in the Americas and Europe.
Enter New Markets. We believe that significant growth opportunities continue to exist in markets where we currently conduct business and
in new international markets. We commenced operations in Colombia in 2013, and commenced operations in Indonesia during the fourth quarter of
2015. These markets, as well as future markets, are selected following an assessment of several factors, including market size, anticipated demand
for USA NA products, receptiveness to network marketing, and the market entry process, which includes consideration of possible regulatory
restrictions on our products or our network marketing system. We have also begun to register certain products with regulatory and government
agencies in other countries in preparation for further international expansion. Wherever possible, we expect to seamlessly integrate the
Compensation Plan in each market to allow Associates to receive commissions for global-not merely local-product sales. This seamless sales
stmcture is designed to allow an Associate to build a global network by creating a sales organization across national borders. We believe our
seamless Compensation Plan significantly enhances our ability to expand internationally, and we intend, where permitted, to integrate future
markets into this
17
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Compensation Plan. While we deem new market expansion as a key growth strategy, given the significant opportunity that currently exists in
China, we plan to focus the majority of our time and resources on growing that market.

Pursue Strategic Acquisitions. We believe that attractive acquisition opportunities may arise in the future. We intend to pursue strategic
acquisition opportunities that would grow our customer base, expand our product lines, enhance our manufacturing and technical expertise, allow
vertical integration, or otherwise complement our business or further our strategic goals.
Competition
We compete with manufacturers, distributors, and retailers of nutritional products for consumers, and we compete with network marketing
companies for distributors. On both fronts, some of our competitors are significantly larger than we are, have a longer operating history, higher
visibility and name recognition, and have greater financial resources than we do. We compete with these entities by emphasizing the underlying
science, value, and superior quality of our products, the simplicity in our product offerings, and the convenience and financial benefits afforded by
our network marketing system and global seamless Compensation Plan.
Our business is driven primarily by our distributors, whom we refer to as Associates. Our ability to compete with other network marketing
companies depends, in significant part, on our success in attracting and retaining Associates. There can be no assurance that our programs for
attracting and retaining Associates will be successful. The pool of individuals interested in network marketing is limited in each market and is
reduced to the extent other network marketing companies successfully attract these individuals into their businesses. Although we believe that we
offer an attractive opportunity for our Associates, there can be no assurance that other network marketing companies will not be able to recruit our
existing Associates or deplete the pool of potential Associates in a given market.
We believe that the leading network marketing company in the world, based on total sales, is Amway Corporation and its affiliates, and that
Avon Products, Inc. is the leading direct seller of beauty and related products worldwide. Leading competitors in the nutritional network marketing
and nutritional product industry include Herbalife Ltd., Inc.; Nu Skin Enterprises, Inc.; and NBTY, Inc. Based on information that is publicly
available, 2015 net sales of the aforementioned companies ranged from $2.3 billion to $8.6 billion. There arc other manufacturers of competing
product lines that have or may launch direct selling enterprises that compete with us in certain product lines and in the recruiting of Associates.
There can be no assurance that we will be able to successfully meet the challenges posed by increased competition.
Product Returns
Product returns have not been a material factor in our business, totaling approximately 0.9% in 2013, 0.8% in 2014, and 0.6% in 2015. Customer
satisfaction has always been and will continue to be a hallmark of our business. We believe that we have always offered a generous product return
policy. Historically, our standard return policy allowed Associates and Preferred Customers to return any unused product from their first purchase
within the first 30 days for a 100% refund of the sales price. Thereafter, any returned product that was unused and resalable was refunded up to
one year from the date of purchase at I 00% of the sales price, less a I 0% restocking fee. During 2015 we updated our return policy and eliminated
the I 0% restocking fee on product returns. Accordingly, Associates and Preferred Customers now receive a I 00% refund of the sales price of
unused and resalable products that arc returned up to one year from the date of purchase. This standard policy differs slightly in a few ofour
international markets due to the regulatory environment in those markets. To avoid manipulation of our Compensation Plan, return of product
where the purchase amount exceeds $100 and was not damaged at the time of receipt by the Associate may result in cancellation pf an Associate's
distributorship.
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Major Customers

Sales are made to independent Associates and Preferred Customers. No single customer accounted for l 0% or more of net sales.
Notwithstanding the foregoing, the nature of our business model results in a significant amount of sales to several different Associate leaders and
their sales organizations. Although no single Associate accounted for l 0% or more of our net sales, the loss of a key Associate leader or that
Associate's sales organization could ,1dverscly affect om net 5alcs and our overall operating results.
Compliance by Associates

We continually monitor and review our Associates' compliance with our policies and procedures as well as the laws and regulations
applicable to our business around the world. Part of this review entails an assessment of our Associates' sales activities to ensure that Associates
arc actually selling products to consumers. Our policies and procedures require Associates to present our products and the USANA opportunity
ethically and honestly. Associates are not permitted to make claims about our products or Compensation Plan that are not consistent with our
policies and procedures and applicable laws and regulations. The majority of our Associates must use marketing and promotional materials
provided by USANA. Associates who have achieved a certain leadership level arc permitted, however, to produce their own marketing and
promotional materials, but only if such materials arc approved by USANA prior to use.
From time to time, we have Associates who fail to adhere to our policies and procedures. We systematically review reports of alleged
Associate mishchavior. Infractions of the policies and procedures are reported to our compliance group, who determine what disciplinary nction is
warranted in each case. More serious infractions arc reported to our Compliance Committee, which includes USANA executives. If we determine
that an Associate has violated any of our policies and procedures, we may take a number of disciplinary actions, such as warnings, fines or
probation. We may also withdraw or deny awards, suspend privileges, withhold commissions until specific conditions arc satisfied, or take other
appropriate actions in our discretion, including termination of the Associate's purchase and distribution rights.
We believe that Associate compliance is critical to the integrity of our business and, therefore, we are aggressive in ensuring that our
Associates comply with our policies and procedures. As explained above, when an Associate fails to comply with our policies and procedures, we
may terminate their purchase and distribution rights. From time to time, we become involved in litigation with Associates whose purchase and
distribution rights have been terminated. We consider such litigation to be routine and incidental to our business and will continue to be
aggressive in ensuring that our Associates comply with our policies and procedures.
Information Technology
We believe that the ability to efficiently manage distribution, compensation, manufacturing, inventory, and communication functions through
the use of secure, sophisticated, and dependable information processing systems is critical to our success. We continually evaluate changes in
the information technology environment to ensure that we are capitalizing on new technologies, keeping pace with regulatory standards, and
ensuring that our systems and data are secure. Over the next few years we intend to increase our investment in technology systems and
infrastructure as we prepare to become a much larger company.
Our information technology resources are maintained primarily by our in-house staff to optimally support our customer base and core
business processe~. Our IT staff manages an array of systems and
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processes which support our global operations 24 hours a day and 365 days a year. Three of our most critical applications include:
j)

A web-based application that provides onlinc services to Associates, such as training sessions and presentations, online
shopping, enrollment, a real-time reporting engine, Company and product information, web-hosting, email, and other tools to help
Associates effectively manage their business and sales organizations.
A web-based order-entry system that handles order entry, customer information, compensation, Associate business structure,
returns, invoices, and other transactional-based processes.
A fully integrated world-wide Enterprise Resource Planning ("ERP") system that handles accounting, human resources, inventory
management, production processes, quality assurance, and reporting requirements in a multinational environment.
Our web applications are supported by a clustered environment providing high availability. All production systems are fully backed-up and
stored off-site so that our business wi II not suffer significant intermption in the event of a disaster at the locations of our primary servers.

J

Regulatory Matters
General. In the United States and the other countries where we operate, our business is subject to extensive governmental laws and
regulations. These laws and regulations exist at various levels in the United States and other countries and pertain to our products, network
marketing program, and other aspects of our business as described in more detail below.
Product Regulation. Numerous governmental agencies in the United States and other countries regulate the manufacturing, packaging,
labeling, advertising, promoting, importing, distributing, and the selling of nutrition, health, beauty, and weight-management products. In the
United States, advertisement of our products is regulated by the Federal Trade Commission ("FTC") under the FTC Act and, where such
advertising is considered to be product labeling by the FDA, under the Food, Drug, and Cosmetic Act ("FDCA") and the regulations thereunder.
USANA products in the United States arc also subject to regulation by, among others, the Consumer Product Safety Commission, the U.S.
Department of Agriculture, and the Environmental Protection Agency.
Our largest selling product group includes products that are regulated as dietary supplements under the FDCA. Dietary supplements are also
regulated in the United States under the Dietary Supplement Health and Education Act of 1994 ("OSHEA"), which we believe is generally
favorable to the dietary supplement industry. Some of our powdered drink, food bar, and other nutrition products are regulated as foods under the
Nutrition Labeling and Education Act of 1990 ("NLEA"). The NLEA establishes requirements for ingredient and nutritional labeling including
product labeling claims. The manufacture of nutritional or dietary supplements and related products in the United States requires compliance with
dietary supplement GMPs, which are based on the food-model GMPs and Pharmaceutical GMP's, with additional requirements that are specific to
dietary supplements. We are audited annually by the US FDA, specifically for dietary supplements and have been found in full compliance with
GMPs for dietary supplements. The Dietary Supplement & Nonprescription Drug Consumer Protection Act requires manufacturers of dietary
supplement and over-the-counter products to notify the FDA when they receive reports of serious adverse events occurring within the United
States. We have an internal adverse event reporting system that has been in place for several years, and we believe that we arc in compliance with
this law.
In general, our personal care products, which are regulated as cosmetic products by the FDA, are not subject to pre-market approval by that
agency. Cosmetics, however, are subject to regulation by the FDA under the FDCA adulteration and misbranding provisions. Cosmetics also are
subject to specific labeling regulations, including warning statements, if the safety of a cosmetic is not adequately
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substantiated or if the product may be hazardous, as well as ingredient statements and other packaging requirements under the Fair Packaging and
Labeling Act. Cosmetics that meet the definition of a drug, such as sunscreens, are regulated as drugs. Over-the-counter ("OTC") drug products,
including cosmetics, may be marketed if they conform to the requirements of the OTC monograph that is applicable to that drug. Drug products
not conforming to monograph requirements require an approved New Drug Application ("NDA ") before marketing may begin. Under these
provisions, if the agency were to find that a product or ingredient ofone ofour OTC drug products is not generally recognized as safe and
effective or is not included in a final monograph that is applicable to one of our OTC drug products, we would be required to reformulate or cease
marketing that product until it is the subject of an approved NOA or until the time, if ever, that the monograph is amended to include such product.
Advertising of our products in the United States is subject to regulation by the FTC under the FTC Act. Under the FTC's Substantiation
Doctrine, an advertiser is required to have a "reasonable basis" for all objective product claims before the claims are made. Failure to adequately
substantiate claims may be considered either deceptive or unfair practices. Pursuant to this FTC requirement, we are required to have adequate
substantiation for all material advertising claims that we make for our products in the United States. In recent years, the FTC has initiated
numerous investigations of and actions against companies that sell dietary supplement, weight-management, and cosmetic products. The FTC has
issued guidance to assist companies in understanding and complying with its substantiation requirement. We believe that we have adequate
substantiation for all material advertising claims that we make for our products in the United States, and we believe that we have organized the
documentation to support our advertising and promotional practices in compliance with these guidelines. However, no assurance can be given
that the FTC would reach the same conclusion if it were to review or question our substantiation for our advertising claims in the United States.
The FTC may enforce compliance with the law in a variety of ways, both administratively and judicially, using compulsory process, cease and
desist orders, and mjunct1ons. FTC enforcement can result in orders requiring, among other things, limits on advertising, corrective advertising,
consumer redress, divestiture of assets, rescission of contracts, and such other relief as the agency deems necessary to protect the public.
Violation of these orders could result in substantial financial or other penalties. Although, to our knowledge, we have not been the subject of any
action by the FTC, no assurance can be given that the FTC will not question our advertising or other operations in the United States in the future.
Any action in the future by the FTC could materially and adversely affect our ability to successfully market our products in the United States.
The manufacturing, labeling, and advertising of our products are also regulated by various governmental agencies outside the United States
in each country where they arc distributed. For example, in Australia, product registration, labeling and manufacturing is regulated by the TGA
and, in Japan, the Ministry of Health, Labor and Wei fore. In China, the China Food and Drug Administration ("CFDA") regulates product
registration, labeling and manufacturing. In markets outside the ~nited States, prior to commencing operations or marketing products, we may be
required to obtain approvals, licenses, or certifications from a country's Food Administration, Ministry of Health or comparable agency. Approvals
ur lict:nsing may be conditioned on reformulation of USA NA products for the market or may be unavailable with respect to certain products or
product ingredients. We must also comply with local product labeling and packaging regulations that vary from country to country. For example,
China extensively regulates the registration, labeling and marketing of our products. In China, our nutritional products are typically classified as
"health functional foods" and our personal care products arc typically classified as "non-special use cosmetics". The registration process for
health functional foods is complex and generally requires extensive analysis and approval by the CFDA. As a result, it may take several years to
register a product as a health functional food in China. While all products currently sold by BabyCare in China have been registered with the
CFDA, we continue to
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work through the registration process for other health functional food products, which we also hope to begin selling through BabyCare in the
future.
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional
governmental regulations or administrative orders, when and if promulgated, would have on our business. Future changes could include
requirements for the refonnulation of certain products to meet new standards, the recall or discontinuation of certain products that cannot be
refonnulated, additional record keeping, expanded documentation of the properties of certain products, expanded or different labeling, and
additional scientific substantiation. Any or all of these requirements could have a material adverse effect on our business, financial condition, and
operating results.

Network Marketing Regulation Various laws and regulations in the United States and other countries regulate network marketing, or direct
selling. These laws and regulations exist at many levels of government in many different forms, including statutes, rules, regulations, judicial
decisions, and administrative orders. Generally, the regulations arc directed at: (i) ensuring that product sales ultimately arc made to consumers
and that advancement within a sales organization is based on product sales rather than on investments in the organization or on other criteria that
are not related to sales; and (ii) preventing the use of deceptive or fraudulent practices that have sometimes been inappropriately associated with
legitimate direct selling and network marketing activities. Network marketing regulations are inherently fact-based and often do not include "bright
line" rules. Additionally, we are subject to the risk that the regulations, or a regulator's interpretation and enforcement of the regulations, could
change. From time to time, we have received requests to supply information regarding our network marketing plan to regulatory agencies. We have
also modified our network marketing plan in the past to comply with the interpretation of the regulations by authorities. Where required by law, we
obtain regulatory approval of our network marketing plan, or, where approval is not required or available, the favorable opinion of local counsel as
to regulatory compliance. Nevertheless, we remain subject to the risk that, in one or more countries, our network marketing plan, or the conduct of
certain of our Associates, could be found not to be in compliance with applicable laws and regulations. Additionally, we cannot predict the nature
of any future law, regulation, or interpretation, nor can we predict what effect additional governmental regulations, judicial decisions, or
administrative orders, when and if promulgated, would have on our business. failure by us, or our Associates, to comply with these regulations
could have a material adverse effect on our business in a particular market or in general.
Network marketing companies, and the industry in general, continue to experience significant media and public scrutiny in many countries.
Several companies similar to ours have been scrutinized and penalized in several markets where we operate, including the United States, Canada,
China, Japan, and South Korea. This scrutiny, along with the uncertainty of the laws and regulations pertaining to network marketing in many
countries, can affect how a regulator or member of the public perceives our Company. For instance, there has been significant media and shortseller attention regarding the viability and legality of network marketing in the United States and China over the past few years. This attention has
led to intense public scrutiny of the industry, as well as volatility in our stock price and the stock prices of companies similar to our company. We
cannot predict the impact that this scrutiny may have on our business or the industry in general.
The Chinese government has adopted direct selling laws and regulations that are uncertain and evolving. These regulations contain a number
of financial and operational restrictions for direct selling companies, most notably on pyramid selling and multi-level compensation. These
regulations are also subject to discretionary interpretation and enforcement by various municipal and provincial level officials in China. Our
business in China is that of BabyCare, a direct selling company that we indirectly acquired several years ago to facilitate our expansion into China.
BabyCare's business model has been developed specifically for China in light of Chinese direct selling laws and regulations.
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BabyCarc has been granted licenses from the Chinese government to conduct direct selling in four provinces in China and will be required to
obtain licenses from municipalities rind provinces in China where it docs not hold a license. The process for obtaining government approval in
China to conduct direct selling continues to evolve, is time-consuming, and expensive. The complexity of the approval process, as well as the
government's continued cautious approach to direct selling in China, make it difficult to prcchct the timclinc for obtaining additional approvals. If
the process for obtaining approvals is delayed, changed or interpreted differently than currently understood, such events could have a negative
impact on BabyCare's growth prospects in China. Ultimately, there can be no assurance that BabyCare will be successful in obtaining additional
direct-selling licenses or the required approvals to expand into additional locations in China that are important to its business there.
Transfer Pricing Regulation. In the United States and many other countries, we arc subject to transfer pricing and other tax regulations that
arc designed to ensure that appropriate levels of income are reported by our U.S. or international entities and are taxed accordingly. We have
adopted transfer prices, which arc supported by formal transfer pricing studies for the sale of products to our subsidiaries in accordance with
applicable transfer pricing laws. In addition, we have entered into agreements with our subsidiaries for services and other contractual obligations,
such as the payment of Associate incentives that arc also supported by the same formal transfer pricing studies. If the U.S. Internal Revenue
Service or the taxing authorities of any other jurisdiction were to successfully challenge these agreements or require changes in our standard
transfer pricing practices for products, we could become subject to higher taxes and our earnings could be adversely affected. The tax treaties
between the United States and most countries provide competent authority for relief to avoid any double taxation. We believe that we operate in
compliance with all applicable transfer pricing regulations. There can be no assurance, however, that we will continue to be found to be operating
in compliance with transfer pricing regulations or that those laws will not be modified, which may require that we change our operating procedures.

Intellectual Property
Ji-ademarks. We have developed and use registered trademarks in our business, particularly relating to our corporate and product names.
We own 25 trademarks that are registered with the U.S. Patent and Trademark Office. Federal registration of a trademark enables the registered
owner of the mark to bar the unauthorized use of the registered mark in connection with a similar product in the same channels of trade by any
third-party anywhere in the United States, regardless of whether the registered owner has ever used the trademark in the area where the
unauthorized use occurs. We have filed applications and own trademark registrations, and we intend to register additional trademarks in countries
outside the United States where llSANA products are or may be sold in the future. Protection of registered trademarks in some jurisdictions may
not be as extensive as the protection in the United States.
We also claim ownership and protection of certain product names, unregistered trademarks, and service marks under common law. Common
law trademark nghts do not provide the same level of protection that is afforded by the registration of a trademark. In addition, common law
trademark rights are limited to the geographic area in which the trademark is actually used. We believe these trademarks, whether registered or
claimed under common law, constitute valuable assets, adding to recognition of USANA and the effective marketing of USA NA products.
Trademark registration once obtained is essentially perpetual, subject to the payment of a renewal fee. We therefore believe that these proprietary
rights have been and will continue to be important in enabling us to compete.
Trade Secrets. We own certain intellectual property, including trade secrets that we seek to protect, in part, through confidentiality
agreements with employees and other parties. Even where these agreements exist, there can be no assurance that these agreements will not be
breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known to
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or independently developed by competitors. Our proprietary product formulations are generally considered trade secrets, but are not otherwise
protected under intellectual property laws.

Patents. We have three U.S. patents. Two of our patents relate to the method of extracting an antioxidant from olives and the byproducts of
olive oil production. These patents were issued in 2002 and will continue in force until December 20, 2019. Our third patent relates to a method of
self-preserving our SenseTM line of personal care products. This patent was issued in May 2007 and will continue in force until August 5, 2024.
We intend to protect our legal rights concerning intellectual property by all appropriate legal action. Consequently, we may become involved
from time to time in litigation to determine the enforceability, scope, and validity of any of the foregoing proprietary rights. Any patent litigation
could result in substantial cost and divert the efforts of management and technical personnel.

Seasonality
Although we are not significantly affected by seasonality, we do experience variations in the activity of our Associates in many of our
markets in the first and fourth quarters around major cultural events such as Chinese New Year and Christmas.

Backlog
Our products arc typically shipped within 72 hours after receipt of an order. As of February 26, 2016 we had no significant backlog oforders.

Working Capital Practices
We maintain sufficient amounts of inventory in stock in order to provide a high level of service to our Associates and Preferred Customers.
Substantial inventories are required to meet the needs of our dual role as manufacturer and distributor. We also watch seasonal commodity
markets and may buy ahead of normal demand to hedge against cost increases and supply risks.
Environment

'1P

We are not aware of any instance in which we have contravened federal, state, or local laws relating to protection of the environment or in
which we otherwise may be subject to liability for environmental conditions that could materially affect operations.

Employees
As ofFebruary 26, 2016 we had approximately 1,664 employees worldwide, as measured by full-time cquivalency. Our employees are not
currently represented by a collective bargaining agreement, and we have not experienced work stoppages as a result of labor disputes. We believe
that we have a good relationship with our employees.

Additional Available Information

·-.Ji

We maintain executive offices and principal facilities at 3838 West Parkway Boulevard, Salt Lake City, Utah 84120. Our telephone number is
(80 I) 954-7100. We maintain a World Wide Web site at www.usanahealthscicnccs.com. The information on our web site should not be considered
part of this report on Fonn 10-K.
We make available, free of charge at our corporate web site, copies of our annual reports on United States Securities and Exchange
Commission ("SEC") Fom1 10-K, quarterly reports on SEC Fonn I 0-Q, current reports on SEC Form 8-K, proxy statements, and all amendments to
these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC pursuant to Section 13(a) or
I S(d) of the Exchange Act. This information may also be obtained from the SEC's on-line database, which is located at www.sec.gov.
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Item IA.

Risk Factors

Forward-Looking Statements and Certain Risks

We encounter substantial risks in our business, any one of which may adversely affect our business, results of operations or financial
condirion. The fact I hat some of these riskfaclors may be rhe same or similar to those thal we have filed with the Securities and Exchange
Commission in past reports means only that the risks are present in multiple periods. We believe that many of the risks that are described here
are part of doing business in the industry in which we operate and will likely be present in all periods. The fact that certain risks are endemic
Jo Jhe industry dnes nnt lessen their significance. These risk factors should be read together with the other items in this report, including Item I,
"Business," and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations." Among others, risks and
uncertainties that may affect our business.financial condition, performance, development, and results of operations include the following:

<ili,

We are a network marketing company a11d are dependent 11po11 an imlepe11dent sales f"rce of "Associates" to sell our products. If we are
unable to attract and retain Associates, our business may be harmed. We rely on non-employee, independent Associates to market and sell our
products and to generate our sales. Our ability to maintain and increase sales in the future will depend in large part upon our success in increasing
the number of new Associates, retaining and motivating our existing Associates, and in improving the productivity of our Associates. Associates
typically market and sell our products on a part-time basis and likely will engage in other business activities, some of which may compete with us.
We rely primarily upon our Associates to attract, train and motivate new Associates. Our ability to continue to attract and retain Associates can
be affected by a number of factors, some of which arc beyond our control, including:
General business and economic conditions;
Adverse publicity or negative misinformation about our industry, us or our products;
Negative public perceptions about network marketing programs;
High-visibility investigations or legal proceedings against network marketing companies by federal or state authorities or private
citizens;
Public perceptions about the value and efficacy of nutritional or dietary supplement, products generally;
Other competing network marketing organizations entering into the marketplace that may recruit our existing Associates or reduce
the potential pool of new Associates; and
Changes to the Compensation Plan required by law or implemented for business reasons that make attracting and retaining
Associates more difficult.
We can provide no assurance that the number of Associates will increase or remain constant or that their productivity will increase. Our
Associates may terminate their services at any time, and, like most direct selling companies, we experience a high turnover among new Associates
from year to year. While our total number of active Associates has continued to increase during recent years, a few of our markets, including the
United States, have experienced a decline in the number of active Associates. If our strategies and initiatives do not drive growth in our Associate
numbers, particularly in the United States, China and other markets, our operating results could be harmed. We cannot accurately predict any
fluctuation in the number and productivity of Associates because we primarily rely upon existing Associates to sponsor and train new Associates
and to motivate new and existing Associates. Our operating results in other markets could also be adversely affected if we and our existing
Associates do not generate sufficient interest in our business to successfully retain existing Associates and attract new Associates.
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Tlte loss of a sig11ijica11t USA NA Associate or downlitie sales organization coultl atl,1ersely affect our business. We rely on the successful
efforts of our Associates that become leaders within our Compensation Plan. Our Compensation Plan is designed to permit Associates to sponsor
new Associates, creating multiple "business centers," or levels in the downline organization. Sponsored Associates are referred to as "downline"
Associates within the sponsoring Associate's "downlinc network." If these down line Associates in tum sponsor new Associates, additional
business centers are created, with the new downline Associates becoming part of the original sponsoring Associate's down line network. As a
result of this network marketing system, Associates develop business relationships with other Associates. The loss of a key Associate or group
of Associates, large turnover or decreases in the size of the key Associate force, seasonal or other decreases in purchase volume, sales volume
reduction, the costs associated with training new Associates, and other related expenses may adversely affect our business, financial condition, or
results of operations.
Tlte violation of marketing or a1/vertising laws by Associates in connection witlt tlte sale of our products or tile improper promotion of our
Compensation Plan could adversely affect our business. All Associates sign a written contract and agree to adhere to our policies and
procedures. Although these policies and procedures prohibit Associates from making false, misleading and other improper claims regarding
products or income potential from the distribution of the products, Associates may, from time to time, without our knowledge and in violation of
our policies, create promotional materials or otherwise provide information that docs not accurately describe our marketing program. They also
may make statements regarding potential earnings, product claims, or other matters in violation of our policies or applicable laws and regulations
concerning these matters. These violations may result in legal action against us by regulatory agencies, state attorneys general, or private parties.
Legal actions against our Associates or others who arc associated with us could lead to increased regulatory scrutiny of our business, including
our network marketing system. We take what we believe to be commercially reasonable steps to monitor the activities of our Associates to guard
against misrepresentation and other illegal or unethical conduct by Associates and to assure that the terms of our policies and procedures and
Compensation Plan are observed. There can be no assurance, however, that our efforts in this regard will be sufficient to accomplish this objective,
particularly in times/regions where we may experience rapid growth. Adverse publicity resulting from such activities could also make it more
difficult for us to attract and retain Associates and may have an adverse effect on our business, financial condition, and results of operations.

We may have or could itic11r obligations relating t<J the activities of our Associates. Our Associates are subject to taxation, and, in some
instances, legislation or governmental agencies impose an obligation on us to collect taxes, such as sales taxes or value added taxes, and to
maintain appropriate records of such transactions. In addition, we arc subject to the risk in some jurisdictions of being responsible for social
security and similar taxes with respect to our Associates. In the event that local laws and regulations or the interpretation of local laws and
regulations change to require us to treat our independent Associates as employees, or if our Associates are deemed by local regulatory authorities
in one or more of the jurisdictions in which we operate to be our employees rather than independent contractors, under existing laws and
interpretations, we may be held responsible for a variety of obligations that are imposed upon employers relating to their employees, including
social security and related taxes in those jurisdictions, plus any related assessments and penalties, which could harm our financial condition and
operating results.
Network marketing is subject to inte11se government scrutiny, and regulation and cha11ges in tlte law, or the interpretation and
enforcement of the law, might adversely affect our business. Various laws and regulations in the United States and other countries regulate
network marketing, or direct selling. These laws and regulations exist at many levels of government in many different forms, including statutes,
rules, regulations, judicial decisions, and administrative orders. Network marketing regulations arc inherently fact-based and often do not include
"bright line" rules. As a result, regulators and courts
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have broad discretion in their application, interpretation and enforcement of these laws and regulations, and any of the foregoing can change. We
are subject to the risk that, in one or more countries, our network marketing plan, or the conduct of certain of our Associates, could be found not
to be in compliance with applicable laws and regulations. Further, we may simply be prohibited from distributing products through a networkmarketing channel in some countries, or we may be forced to alter our Compensation Plan.
We arc also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, or be
interpreted or enforced differently, which could require us to change or modify the way we conduct our business in certain markets. This could be
particularly detrimental to us if we had to change or modify the way we conduct business in markets that represent a significant percentage of our
net sales.
We arc aware of regulatory challenges, investigations and litigation against other network marketing companies in the industry in the United
States and other countries where we operate. Any adverse ruling in these investigations could harm our business and industry if the laws and
regulations are interpreted in a manner that results in additional burdens or restrictions on network marketing companies. Additionally, we cannot
assure you that we will not be subject to challenges by regulators reg_arding our network marketing plan.

Our prod11cts and manufacturi11g activities are subject to extensive govemment regulation, whic/1 could limit or prevent the sale of our
products in some markets. The manufacture, packaging, labeling, advertising, promotion, distribution, and sale of our products arc subject to
regulation by numerous national and local governmental agencies in the United States and other countries, including the FDA and the FTC. For
example, failure to comply with FDA regulatory requirements may result in, among other things, injunctions, product withdrawals, recalls, product
seizures, fines, and criminal prosecutions. Any action of this type by the FDA could materially adversely affect our ability to successfully market
our products. With respect to FTC matters, if the FTC has reason to believe the law is being violated, it can initiate an enforcement action. The
FTC has a variety of processes and remedies available to it for enforcement, both administratively and judicially. Any action against us by the FTC
could materially and adversely affect our ability lo successfully market our products.
The manufacture of nutritional or dietary supplements and related products in the United States requires compliance with dietary supplement
GMPs, which are based on the food-model GMPs, with additional requirements that arc specific to dietary supplements. We believe our
manufoctu1 ing p1m.:t:sst:s cumply with tht:st: GMPs fur tlietary supplements. Nevt:rthelt:ss, any action by the FDA which determined that our
processes were non-compliant with dietary supplement GMPs, could materially adversely affect our ability to manufacture and market our
products. Additionally, the Dietary Supplement & Nonprescription Dmg Consumer Protection Act requires manufacturers of dietary supplement
and over-the-counter products to notify the FDA when they receive reports of serious adverse events occurring within the United States.
Potential FDA responses to any such report could include injunctions, product withdrawals, recalls, product seizures, fines, or criminal
prosecutions. We have an internal adverse event reporting system that has been in place for several years and believe that we are in compliance
with this new law. Nevertheless, any action by the FDA in response to a serious adverse event report that may be filed by us could materially and
adversely affect our ability to successfully market our products.
In markets outside the United States, prior to commencing operations or marketing our products, we may be required to obtain approvals,
licenses, or certifications from a country's ministry of health or a comparable agency. For example, our manufacturing facility has been registered
with the FDA and Health Canada and is certified by Australia's TGA. Approvals or licensing may be conditioned on reformulation of products or
may be unavailable with respect to certain products or product ingredients. China also extensively regulates the registration, labeling and
marketing of our .products.
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Consequently, the registration process for our products in China is complex and generally requires extensive analysis and approval by the CFDA.
As a result, it may take several years to register a product in China. We must also comply with product labeling and packaging regulations that
vary from country to country. These activities arc also subject to regulation by various agencies of the countries in which our products are sold.
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional
governmental regulations or administrative orders, when and if promulgated, could have on our business. These potential effects could include,
however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional
record keeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or
additional scientific substantiation. Any or all of these requirements could have a material adverse effect on our business, financial condition, or
results of operations.

Our man11facturi11g activity is subject to certain risks. We manufacture approximately 76% of the products sold to our customers. As a
result, we are dependent upon the uninterrupted and efficient operation of our manufacturing facilities. Those operations arc subject to power
failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment, natural or other
disasters, and the need to comply with the requirements or directives of government agencies, including the FDA. There can be no assurance that
the occurrence of these or any other operational problems at our facility would not have a material adverse effect on our business, financial
condition, or results of operations. We are subject to a variety of environmental laws relating to the storage, discharge, handling, emission,
generation, manufacture, use and disposal of chemicals, solid and hazardous waste, and other toxic and hazardous materials. Our manufacturing
operations presently do not result in the generation of material amounts of hazardous or toxic substances. Nevertheless, complying with new or
more stringent laws or regulations, or more vigorous enforcement of current or future policies of regulatory agencies, could require substantial
expenditures by us that could have a material adverse effect on our business, financial condition, or results of operations. Environmental laws and
regulations require us to maintain and comply with a number of permits, authorizations, and approvals and to maintain and update training
programs and safety data regarding materials used in our processes. Violations of those requirements could result in financial penalties and other
enforcement actions and could require us to halt one or more portions of our operations until a violation is cured. The combined costs of curing
incidents of non-compliance, resolving enforcement actions that might be initiated by government authorities, or of satisfying new legal
requirements could have a material adverse effect on our business, financial condition, or results of operations.
We may incur liability with respect lo our products. As a manufacturer and a distributor of products for human consumption and topical
application, we could become exposed to product liability claims and litigation. Additionally, the manufacture and sale of these products involves
the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. To date, we have not been a party to any
product liability litigation, although, like any dietary supplement company, we have received reports from individuals who have asserted that they
suffered adverse consequences as a result of using our products. The number of reports we have received to date is nominal. These matters
historically have been settled to our satisfaction and have not resulted in material payments. We are aware of no instance in which any of our
products are or have been defective in any way that could give rise to material losses or expenditures related to product liability claims. Although
we maintain product liability insurance, which we believe to be adequate for our needs, there can be no assurance that we will not be subject to
such claims in the future or that our insurance coverage will be adequate.

28

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table of Contents

Our Greater Chi11a regio11 acco1111ts for a sig11ijica11t part of our b11si11ess and expecte,I growth. A11y ,lecline i11 sales or customers in this
region would harm our busi11ess,Ji11a11cial co11dition and results of opertJtim1s. Our Greater China region consists of China, Hong Kong and
Taiwan and is currently our largest and most rapidly growing region. Since our acquisition of BabyCare, Ltd. in China in 20 I 0, our international
growth strategy has been centered on growing BabyCare's business in China. As a result of this strategy, China has been our fastest growing
market over the last few years and is now our largest individual market. As we have focused on China, we have also experienced a meaningful
decline in sales and customers in our Hong Kong market and our results in this market may continue to decline in the future. If we arc not
successful in continuing to grow BabyCare's sales and customer base in China, our consolidated growth as a company will be negatively affected
and our business, financial condition and results of operations may be harmed. BabyCarc must comply with significant operational, financial, and
other regulatory requirements to engage in direct selling in China. Although we believe that, in light of our successful Asian Associate base, we
will be successful in growing BabyCare's business in China, it is difficult to assess the extent to which BabyCare's Chinese business model and
Associate compensation plan will be successful in that market or deemed to be compliant with applicable laws and regulations by the Chinese
government. Although we arc required to conduct our operations in China through BabyCare, we believe that our long-term success in China will
depend on our ability to successfully integrate, to the extent possible, our operations with BabyCare's operations. In light of the factors listed
above, and the other risks to our business, there can be no assurance that we will be successful in growing sales and customers in China through
BabyCare.

Our operatio11s in China are subject to sig11ijica11t governme11t regulation and scrutiny, as well as a variety of legal, political, ,md
eco110111ic risks. If the govemment modijies the direct selling regulations, or i11terprets and enforces the regulations in a manner that is adverse
to our business in China. our consolidated business and results of operatio11s may be material(v harme,I. Our business in China is that of
8abyCare, a direct selling company that we indirectly acquired several years ago to facilitate our expansion into China. llabyCare has been granted
licenses from the Chinese government to conduct direct selling operations in four provinces in China and has applied for licenses in additional
municipalities and provinces. BabyCare's business model has been designed specifically for China based on a number of factors, including:
(i) BabyCare's communications with the Chinese government, (ii) BabyCarc's interpretation of the direct selling regulations, as well as their
understanding of how the government interprets and enforces the regulations, and (iii) BabyCare's understanding of how other multinational direct
selling companies operate in China. Notwithstanding the foregoing, BabyCarc has not received confirmation from the Chinese government that its
business model and operations in China comply with applicable laws and regulations, including those pertaining to direct selling.
The Chinese government has adopted direct selling laws and regulations that are uncertain and evolving. These regulations contain a number
of financial and operational restrictions for direct selling companies, most notably on pyramid selling and multi-level compensation. These
regulations are also subject to discretionary interpretation and enforcement by various municipal and provincial level officials in China. We cannot
assure yuu that BabyCare's business motlt:I or the activities of its employees, promoters or c.lircct sellers will be deemed by rt:gulatory authorities
to be compliant with current or future laws and regulations. In the past, the Chinese government has fined, penalized, and, in some cases,
terminated direct selling licenses and shut down companies that it believed were in violation of applicable laws and regulations. As such, there can
be no assurance that the Chinese government's interpretation and enforcement of applicable laws and regulations will not negatively impact
BabyCare's business, result in regulatory investigations or lead to fines or penalties against BabyCare, USA NA or our Associates in China.
The direct selling regulations in China prevent persons who are not Chinese nationals from engaging in direct selling in China. Although we
have implemented internal policies that are designed to promote our Associates' compliance with these regulations, we cannot guarantee that any
of our
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Associates living outside of China or any ofBabyCarc's promoters or Associates in China have not engaged or will not engage in activities that
violate our policies in this market or that violate Chinese law or other applicable laws and regulations and, therefore, might result in regulatory
action and adverse publicity, which would ham1 our business in China.

'...J

BabyCare is required to obtain various licenses and approvals from municipalities and provinces within China to operate its direct selling
business model. Currently, BabyCare holds four such licenses and will be required to obtain licenses from municipalities and provinces within
China where it docs not hold a license. If BabyCare is unable to obtain additional direct selling licenses as quickly as we would like, it would have a
negative impact our ability to expand and grow our business. The process for obtaining the necessary government approvals to conduct direct
selling continues to evolve, is time-consuming and expensive. The complexity of the approval process, as well as the government's continued
cautious approach for direct selling in China, makes it difficult to predict the timelinc for obtaining additional approvals. If the current processes for
obtaining approvals arc delayed for any reason or arc changed or are interpreted differently than currently understood, these events could have a
negative impact on BabyCare's growth prospects in China. Ultimately, there can be no assurance that BabyCare will be successful in obtaining
additional direct-selling licenses or the required approvals to expand into additional locations in China that arc important to its business.
If BabyCare's operations in China are successful, we may experience rapid growth in China, and there can be no assurances that we will be
able to successfully manage rapid expansion of BabyCare's direct selling activities under license in China or the related manufacturing and retail
operations required to support this expansion. If we arc unable to effectively manage BabyCare's growth and expansion, including expansion of
branches, warehouses, and manufacturing operations, BabyCare's government relations may be compromised and our operations in China may be
harmed.

Risks associated with operating in internatim,al markets could restrict our ability to expand globally and harm our business and
prospects, and we could be adversely affected by our failure to comply with the laws applicable to our foreign activities, including the U.S.
Foreign Corrupt Practices Act and other similar worldwide anti-bribery laws. Our international operations arc presently conducted in various
foreign countries, and we expect that the number of countries in which we operate could expand over the next few years. Economic conditions,
including those resulting from wars, civil unrest, acts of terrorism and other conflicts or volatility in the global markets, may adversely affect our
customers, their demand for our products and their ability to pay for our products. In addition, there are numerous risks inherent in conducting our
business internationally, including, but not limited to, potential instability in international markets, changes in regulatory requirements applicable
to international operations, currency fluctuations in foreign countries, political, economic and social conditions in foreign countries and complex
U.S. and foreign laws and treaties, including tax laws, the U.S. Foreign Corrupt Practices Act (FCPA), and the Bribery Act of2010 (U.K. AntiBribery Act). These risks could restrict our ability to sell products, obtain international customers, or to operate our international business
profitably, which would have a negative impact on our overall business and results of operations.
The FCPA prohibits U.S.-based companies and their intermediaries from making improper payments to government officials for the purpose of
obtaining or retaining business. We are also subject to the U.K. Anti-Bribery Act, which prohibits both domestic and international bribery as well
as bribery across both public and private sectors. We pursue opportunities in certain parts of the world that experience government corruption
and, in certain circumstances, compliance with anti-bribery laws may conflict with local customs and practices. Our policies mandate compliance
with all applicable anti-bribery laws. Further, we require our partners, subcontractors, agents and others who work for us or on our behalf to
comply with the FCPA and other anti-bribery laws. Although we have policies and procedures designed to ensure that we, our employees, our
agents and others who work with us in foreign countries comply with the FCPA and other anti-bribery laws, there is no assurance that such
policies or procedures will protect us against liability under the FCPA or other laws for actions taken

30

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table of Contents
by our agents, employees and intermediaries. If wc arc found to be liable for violations of these acts (either due to our own acts or our
inadvertence or due to the acts or inadvertence of others), we could incur severe criminal or civil penalties or other sanctions, which could have a
material adverse effect on our reputation, business, results of operations or cash flows. In addition, detecting, investigating and resolving actual or
alleged violations of these acts is expensive and could consume significant time and attention of our senior management.
We believe that our ability to achieve future growth is dependent in part on our ahility to continue our international expansion efforts. There
can be no assurance, however, that we will be able to grow in our existing international markets, enter new international markets on a timely basis,
or that new markets will be profitable. We must overcome significant regulatory and legal barriers before we can begin marketing in any
international market. Also, before marketing commences in a new country or market, it is difficult to assess the extent to which our products and
sales techniques will be accepted or successful in any given country. In addition to significant regulatory barriers, we may also encounter
problems conducting operations in new markets with different cultures and legal systems from those encountered elsewhere. We may be required
to reformulate certain of our products before commencing sales in a given country. Once we have entered a market, we must adhere to the
regulatory and legal requirements of that market. No assurance can be given that we will be able to successfully reformulate our products in any of
our current or potential international markets to meet local regulatory requirements or to attract local customers. Our failure to do so could have a
material adverse effect on our business, financial condition, or results of operations. There can be no assurance that we will be able to obtain and
retain necessary permits and approvals in new markets or that we will have sufficient capital to finance our expansion efforts in a timely manner.
ln many market areas, other network marketing companies already have significant market penetration, the effect of which could be to
desensitize the local Associate population to a new opportunity, such as USANA, or to make it more difficult for us to attract qualified Associates.
Even if we are able to commence operations in new markets, there may not be a sufficient population of persons who are interested in our network
marketing system. We believe our future success will depend in part on our ability to seamlessly integrate our Compensation Plan across a11
markets where legally permissible. There can be no assurance, however, that we will be able to utilize our Compensation Plan seamlessly in all
existing or future markets. For example, in August 2010, we indirectly acquired BabyCare, a nutritional supplement company that is now licensed
by the government of China to engage in direct selling in the Municipalities of Beijing, Jiangsu, Shaanxi, and Tianjin. ln accordance with Chinese
law, we utilize a compensation plan that has been designed specifically for China and implemented by BabyCarc separately from our Compensation
Plan in our other markets.

Fluctuation in the value of currency excha11ge rates with the U.S. dollar affects Qllr operations a11d our net sales and eamings. Over the
past several years, a majority of our net sales have been generated outside the United States. Such sales for the year ended January 2, 2016
represented 84.8% of our total net sales. We will likely continue to expand our operations into new markets, exposing us to expanding risks of
changes in social, political, and economic conditio11!,, i11duc.li11g d1augcs iu the laws amJ pulicit:s that guvcrn i11vt:stmt:ul ui t:xchaugt! iu lht!st:
markets. Because a significant portion of our sales are generated outside the United States, exchange rate fluctuations will have a significant effect
on our sales and earnings. Further, if exchange rates fluctuate dramatically, it may become uneconomical for us to establish or to continue
activities in certain countries. For instance, changes in currency exchange rates may affect the relative prices at which we and our competitors sell
similar products in the same market. As our business expands outside the United States, an increasing share of our net sales and operating costs
will be transacted in currencies other than the U.S. dollar. Accounting practices require that our non-U.S. financial results be converted to U.S.
dollars for reporting purposes. Consequently, our reported net earnings may be significantly affected by fluctuations in currency exchange rates,
with earnings generally increasing with a weaker U.S. dollar and decreasing with a
31

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Ct.

~

~

4.

~

~

Table of Contents
strengthening U.S. dollar. Product purchases by our subsidiaries are transacted in U.S. dollars. As our operations expand in countries where
transactions may be made in currencies other than the U.S. dollar, our operating results will be increasingly subject to the risks of exchange rate
fluctuations and we may not be able to accurately estimate the impact that these changes might have on our future business, product pricing,
results of operations, or financial condition. In addition, the value of the U.S. dollar in relation to other currencies may also adversely affect our
sales to customers outside the United States. Currently our strategy for reducing our exposure to currency fluctuation includes the timely and
efficient repatriation of earnings from international markets where such earnings arc not considered to be indefinitely reinvested, and settlement of
intercompany transactions. We also from time to time enter into currency exchange contracts to offset foreign currency exposure in various
international markets. We do not use derivative instmments for speculative purposes. There can be no assurance that we will be successful in
protecting our operating results or cash flows from potentially adverse effects of currency exchange fluctuations. Any such adverse effects could
also adversely affect our business, financial condition, or results of operations.

Difficult economic conditions may adversely affect our business. Over the past few years, economic conditions in many of the markets
where we sell our products have resulted in challenges to our business. This is particularly tme in our Americas and Europe region, where,
although we have seen a recent improvement, we continue to experience difficulty generating meaningful growth. We cannot predict whether
world or market-specific economies will improve or deteriorate in the future. If difficult economic conditions continue or worsen, we could
experience declines in net sales, profitability and cash flow due to lower demand for our products or other factors caused by economic challenges
faced by our customers, potential customers or suppliers. Additionally, these conditions may result in a material adverse effect on our liquidity and
capital resources or otherwise negatively impact our operations or overall financial condition.
Our business is subject to the effects of adverse publicity and negative public: perception. Our ability to attract and retain Associates and
to sustain and enhance sales through our Associates can be affected by adverse publicity or negative public perception regarding our industry,
our competition, or our business generally. Our business prospects, financial condition and results of operations could be adversely affected if our
public image or reputation were to be tarnished by negative publicity including dissemination via print, broadcast or social media, or other forms of
Internet-based communications. This negative public perception may include publicity regarding the legality of network marketing, the quality or
efficacy of nutritional supplement products or ingredients in general or our products or ingredients specifically, and regulatory investigations,
regardless of whether those investigations involve us or our Associates or the business practices or products of our competitors or other network
marketing companies.
In 2007, we were the victim of false statements made to the press and regulatory agencies, causing us to incur significant expense in defending
and dispelling the allegations during 2007 and 2008. More recently, in November 2012, we were again the target of false and misleading statements
concerning our business practices, particularly in China and Hong Kong. This adverse publicity also had an adverse impact on the market price of
our stock and caused insecurity among our Associates.
Additionally, there has been significant media and short-seller attention regarding the viability and legality of network marketing in the United
States and internationally over the past few years. This attention has led to intense public scrutiny of the industry, as well as volatility in our stock
price and the stock price of companies similar to ours. There can be no assurance that we will not be subject to adverse publicity or negative
public perception in the future or that such adverse publicity will not have a material adverse effect on our business, financial condition, or results
of operations.
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Our Associate Compe11satio11 Plan, or changes we mllke to it, mlly be viewed negatively by some Associates, could fail to achieve our
desired objectives, am/ co11/t/ have a negative impact 011 our business. Our line of business is highly competitive and sensitive to the
introduction of new competitors, new products and/or new distributor compensation plans. Network marketing companies commonly attempt to
attract new distributors by offering generous distributor compensation plans. From time to time, we modify components of our Compensation Plan
in an effort to (i) keep it competitive and attractive to existing and potential Associates, (ii) cause or address a change in Associate behavior,
(iii) incent Associates to grow our business, (iv) conform to legal and regulatory requirements, and (v) address other business needs. In light of
the size and diversity of our Associate force and the complexity of our Compensation Plan, it is difficult to predict how any changes to the plan will
be viewed by Associates and whether such changes will achieve their desired results. In 2013, we made several changes to our product pricing
structure and Associate Compensation Plan to improve our business, including to increase Associate loyalty and satisfaction and to attract new
Associates. There can be no assurance that the foregoing changes, or any future changes, to our Associate Compensation Plan will allow us to
successfully attract new Associates or retain existing Associates, nor can we assure that any changes we make to our Compensation Plan will
achieve our desired results.
Additionally, the payment of Associate incentives under our Compensation Plan is our most significant expense. These incentives include
commissions, bonuses, and certain awards and prizes. Adjusting or enhancing our Compensation Plan directly affects the incentives we pay as a
percentage of net sales. We may periodically adjust our Compensation Plan to prevent Associate incentives from having a significant adverse
effect on our earnings. There can be no assurance that changes to the Compensation Plan or product pricing will be successful in achieving target
levels of Associate incentives as a percentage of net sales. Furthermore, such changes may make it difficult to attract and retain qualified and
motivated Associates or cause us to lose some of our longer-standing Associates.

legal action by former Associates or third parties against us could harm, our business. We continually monitor and review our
Associates' compliance with our policies and procedures as well the laws and regulations applicable to our business. From time to time, some
Associates fail to adhere to our policies and procedures. If this happens, we may take disciplinary action against the particular Associate. This
disciplinary action is based on the facts and circumstances of the particular case and may include anything from warnings for minor violations to
termination of an Associatc's purchase and distribution rights for more serious violations. From time to time, we become involved in litigation with
an Associate whose purchase and distribution rights have been terminated. We consider this type of litigation to be routine and incidental to our
business. While neither the existence nor the outcome of this type of litigation is typically material to our business, in the past we have been
involved in litigation of this nature that resulted in a large cash award against the Company. Our competitors have also been involved in this type
of litigation, and in some cases class actions, where the result has been a large cash award against the competitor or a large cash settlement by the
competitor. These types of challenges, awards or settlements could provide incentives for similar actions by other former Associates against us in
the future. Any such challenge involving U5 or others in our industry could harm our business by resulting in finc3 or domogcs against us,
creating adverse publicity about us or our industry, or hurting our ability to attract and retain customers. We believe that Associate compliance is
critical to the integrity of our business, and, therefore, we will continue to be aggressive in ensuring that our Associates comply with our policies
and procedures. As such, there can be no assurance that this type of litigation will not occur again in the future or result in an award or settlement
that has a materially adverse effect on our business.
The inability to obtain a1/eq11ate supplies of raw materials for products at favorable prices, or at all, or the inability to obtain certain
products from third-party suppliers, could ha••e a material adverse effect on our b11siness,jinancia/ co11dition, or results of operations. We
acquire all of our raw materials for the manufacture of our products from third-party suppliers. Materials used in manufacturing our products
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arc purchased through purchase order, often invoking pre-negotiated annual supply agreements. We have very few long-term agreements for the
supply of these materials. We also contract with third-party manufacturers and suppliers for the production of some of our products, including
most of our gelatin-capsuled supplements, Probiotic, Rev3 Energy TM Drink, our powdered drink mixes and nutrition bars, and certain of our
personal care products. These third-party suppliers and manufacturers produce and, in most cases, package these products according to
formulations that have been developed by, or in conjunction with, our in-house product development team. There is a risk that any of our
suppliers or manufacturers could discontinue manufacturing our products or selling their products to us. Although we believe that we could
establish alternate sources for most of our products, any delay in locating and establishing relationships with other sources could result in
product shortages or back orders for products, with a resulting loss of net sales. In certain situations, we may be required to alter our products or
to substitute different products from another source. We have, in the past, discontinued or temporarily stopped sales of certain products that were
manufactured by third parties while those products were on back order. There can be no assurance that suppliers will provide the raw materials or
manufactured products that arc needed by us in the quantities that we request or at the prices that we are willing to pay. Because we do not
control the actual production of certain raw materials and products, we are also subject to delays caused by any intermption in the production of
these materials, based on conditions not within our control, including weather, crop conditions, transportation interruptions, strikes by supplier
employees, and natural disasters or other catastrophic events.

Shortages of raw materials may temporarily adversely affect our margins or our profitability related to the sale of those products. In the
past, we have experienced temporary shortages of the raw materials used in certain of our nutritional products. Although we had identified multiple
sources to supply such raw material ingredients, quantities of the materials we purchased during these shortages were at higher prices, which had
a negative impact on our gross margins for those products. While we periodically experience price increases due to unexpected raw material
shortages and other unanticipated events, we have been able to manage this by increasing the price at which we sell our products, therefore, this
has historically not resulted in a material effect on our overall cost of goods sold. However, there is no assurance that our raw materials will not be
significantly adversely affected in the future, causing our profitability to be reduced.
Disruptions to shipping cha1111els that we use to distribute our products to i11ter11atio11al warehouses may adversely affect our margins anti
profitability i11 those markets. In the past, we have felt the impact of disruptions to the shipping channels used to distribute our products.
These disruptions have included increased port congestion, a lack of capacity on the railroads, and a shortage of manpower. Most recently, we
experienced the impact of the West Coast port congestion that started late in 2014 due to worker strikes. In response to this congestion, we
increased lead-times for shipments to our international markets, which caused an increase in our inventory levels. We also pursued alternative
routes of transportation, which increased our shipping costs. Although the west coast ports are now fully functioning, we cannot assure you that
we will not experience port congestion in the future. Congestion to ports can affect previously negotiated contracts with shipping companies,
resulting in unexpected increases in shipping costs and reduction in our net sales.

Nutritional supplement products may be supported by only limited availability of co11clusive clinical studies. Our products include
nutritional supplements that are made from vitamins, minerals, herbs, and other substances for which there is a long history of human
consumption. Some of our products contain innovative ingredients or combinations of ingredients. Although we believe that all of our products
are safe when taken as directed, there is little long-term experience with human consumption of certain of these product ingredients or
combinations of ingredients in concentrated form. We conduct research and test the formulation and production of our products, but we have
performed or sponsored only limited clinical studies. Furthermore, because we are highly dependent on consumers' perception of the efficacy,
safety, and quality of our products, as well as similar products distributed by
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other companies, we could be adversely affected in the event that those products prove or arc asserted to be ineffective or harmful to consumers
or in the event of adverse publicity associated with any illness or other adverse effects resulting from consumers' use or misuse of our products or
similar products of our competitors.

Our business is subject to the risks associated with illte11se co111petitio11Jrom larger, wealthier, am/ more established competit()rs. We
face intense competition in the business of distributing and marketing nutritional supplements, vitamins and minerals, persona! care products, and
other nutritional products, as described in greater detail in "Business-Competition." Numerous manufacturers, distributors, and retailers compete
actively for consumers and, in the case of other network marketing companies, for Associates. There can be no assurance that we will be able to
compete in this intensely competitive environment. In addition, nutrition and personal care products can be purchased in a wide variety of
channels of distribution, including retail stores. Our product offerings in each product category are also relatively small, compared to the wide
variety of products offered by many of our competitors.
We are also subject to significant competition from other network marketing organizations for the time, attention, and commitment of new and
existing Associates. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining Associates. There can
be no assurance that our programs for recruiting and retaining Associates will be successful. The pool of individuals who may be interested in
network marketing is limited in each market, and it is reduced to the extent other network marketing companies successfully recruit these
individuals into their businesses. Although we believe we offer an attractive opportunity for Associates, there can be no assurance that other
network marketing companies will not be able to recruit our existing Associates or deplete the pool of potential Associates in a given market.

Taxation and transfer pricing considerations affect our operations. In many countries, including the United States, we arc subject to
transfer pricing and other tax regulations that are designed to ensure that appropriate levels of income arc reported by our U.S. and foreign entities
and arc taxed appropriately. Although we believe that we are in compliance with all material regulations and restrictions in this regard, we arc
subject to the risk that taxing authorities could audit our transfer pricing and related practices and assert that additional taxes are owed. We arc
also subject to the risk that taxing authorities in any of our markets could change the laws in a manner that may increase our effective tax rate
and/or duties on our products. Under tax treaties, we are eligible to receive foreign tax credits in the United States for foreign taxes paid abroad. In
the event any audits or assessments are concluded adversely to us, we may or may not be able to offset the consolidated effect of foreign income
tax assessments through the use of U.S. foreign tax credits. Currently, we arc utilizing all foreign tax credits in the year in which they arise. Because
the laws and regulations governing U.S. foreign tax credits are complex and subject to periodic legislative amendment, we cannot be sure that we
would in fact be able to take advantage of any foreign tax credits in the future. As a result, adverse outcomes in these matters could have a material
impact on our financial condition or operating results.
Our business is subject to particular intellectual property risks. Most of our products arc not protected by patents. The labeling
regulations governing our nutritional supplements require that the ingredients of such products be precisely and accurately indicated on product
containers. Accordingly, patent protection for nutritional supplements often is impractical given the large number of manufacturers who produce
nutritional supplements having many active ingredients in common. Additionally, the nutritional supplement industry is characterized by rapid
change and frequent reformulations of products, as the body of scientific research and literature refines current understanding of the application
and efficacy of certain substances and the interactions among various substances. In this respect, we maintain an active research and
development program that is devoted to developing better, purer, and more effective formulations of our products. We protect our investment in
research, as well as the techniques we use to improve the purity and effectiveness of our products,
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by relying on trade secret laws. We have also entered into confidentiality agreements with certain of our employees involved in research and
development activities. Additionally, we endeavor to seek, to the fullest extent permitted by applicable law, trademark and trade dress protection
for our products, which protection has been sought in the United States, Canada, and in many of the other countries in which we are either
presently operating or plan to commence operations in the future. Notwithstanding our efforts, there can be no assurance that our efforts to
protect our trade secrets and trademarks will be successful. Nor can there be any assurance that third-parties will not assert claims against us for
infringement of their intellectual proprietary rights. If an infringement claim is asserted, we may be required to obtain a license of such rights, pay
royalties on a retrospective or prospective basis, or terminate our manufacturing and marketing of our infringing products. Litigation with respect
to such matters could result in substantial costs and diversion of management and other resources and could have a material adverse effect on our
business, financial condition, or operating results.

A failure of ()Ur i11formatio11 technology lystems wou/<I harm our business. The global nature of our business and our seamless global
compensation plan requires the development and implementation of robust and efficiently functioning information technology systems. Such
systems are vulnerable to a variety of potential risks, including damage or interruption resulting from natural disasters and telecommunication
failures and human error or intentional acts of sabotage, vandalism, break-ins and similar acts. Although we have adopted and implemented a
business continuity and disaster recovery plan, which includes routine back-up, off-site archiving and storage, and certain redundancies, the
occurrence of any of these events could result in costly interruptions or failures adversely affecting our business and the results of our
operations.
Security breaches and other disruptions could compromise our inf"rmation and expose us lo liability, which would cause our business
and reputation/{) suffer. In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our
proprietary business information and that of our customers, suppliers and business partners, and personally identifiable information of our
customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is
critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable
to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and
the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could
result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our
operations, and damage our reputation, which could adversely affect our business, revenues and competitive position.
We may i11c11r liability under our "Athlete G11ara11tee" program, if and to the extent participating athletes make a successful claim
against USANAfor testing positive for certain banned substances while takilJg USANA nutritional supplements. USANA believes that its
nutritional supplement products are free from substances that have been banned by world-class training and competitive athletic programs. We
retain independent testing agencies to conduct periodic checks for banned substances. We further believe that, while our products promote good
health, they are not otherwise considered to be "performance enhancing" as that term has been used in defining substances that are banned from
use in international competition by the World Anti-Doping Agency ("WADA"). For many years, USANA has been a sponsor of Olympic athletes
and professional competitors around the world. These athletes have been tested on many occa~ions and have never tested positive for banned
substances as a result of taking USA NA nutritional products. To back up our claim that athletes who use USANA products as part of their
training regimen will not be consuming banned substances, we have offered to enter into agreements with select athletes, some of whom have
high-profiles and arc highly compensated, which state that, during the term of the agreement, should the athlete test positive for a banned
substance included in the WADA, and should such positive result be the result of taking USANA nutritional
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products, we will compensate that athlete at an amount equal to two times their current annual earnings up to$ l .O million dollars, based on the
athlete's personal level of competition, endorsement, and other income, as well as other factors. To mitigate potential exposure under these
agreements, we:
Designate lots identified as dedicated to the Athlete Guarantee program and retain additional samples;
Store designated lot samples externally with a third-party; and
Establish a chain of custody that requires signatures on bcha If of USA NA and the third-party to transfer possession of the product
lots and that restricts access by USA NA employees after the transfer.
All applicants to this Athlete Guarantee program arc subject to screening and acceptance by the Company in its sole discretion. Contracts are
tailored to fit the athlete's individual circumstances and the amount of our exposure is limited based on the level of sponsorship of the participating
athlete. Although we believe that the pool of current and potential participants in the program is small, there is no guarantee that an athlete who is
accepted in the program will not successfully make a claim against us. We currently have no insurance to protect us from potential claims under
this program.

The loss ofkey management personnel could adversely affect our business. Our executive officers arc primarily responsible for our day-today operations, and we believe our success depends in part on our ahility to retain our executive officers, to compensate our executive officers at
attractive levels, and to continue to attract additional qualified individuals to our management team. We cannot guarantee continued service by
our key executive officers. We do not maintain key man life insurance on any of our executive officers, nor do we have an employment agreement
with any of our executive officers. The loss or limitation of the services of any of our executive officers or the inability to attract additional qualified
management personnel could have a material adverse effect on our business, financial condition, or results of operations.
Failure to maintain effective internal controls i11 accordance with the Sarbanes-Oxley Act of 2002 could negatively impact our
business. We arc required by federal securities laws to document and test our internal control procedures in order to satisfy the requirements of
the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of internal control over financial reporting.
Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. The SEC, as directed by
Section 404 of the Sarbanes-Oxley Act of 2002, adopted rules requiring public companies to include a report by management on the effectiveness
of our internal control over financial reporting in the companies' Annual Reports on Form I 0-K. In addition, our independent registered public
accounting firm must report on the effectiveness of the internal control over financial reporting. Although we review internal control over financial
reporting in order to ensure compliance with the Section 404 requirements, if we fail to maintain effective internal control over financial reporting,
we could be required to take costly and time-consuming corrective measures, be required to restate the affected historical financial statements, be
subjected to investigations and/or sanctions by federal and state securities regulators, and be subjected to civil lawsuits by security holders. Any
of the foregoing could also cause investors to lose confidence in our reported financial information and in our company and would likely result in a
decline in the market price of our stock and in our ability to raise additional financing if needed in the future.
The beneficial ownership ofa significant percentage of our con111w11 stock gives our founder and parties related to or affiliated with him
effective co11trol, a11d limits the influence of other share/wit/er.\· 011 important policy and management issues. Gull Global, Ltd., an entity that is
solely owned and controlled by our founder Dr. Wentz, owned 51.4% of our outstanding common stock at January 2, 2016. By virtue of this stock
ownership, Dr. Wentz is able to exert significant influence over the election of the members of our Board of Directors and our business affairs. This
concentration of ownership could also have the
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effect of delaying, deterring, or preventing a change in control that might otherwise be beneficial to shareholders. In addition, Dr. Wentz currently
serves as Chairman of our Board of Directors and his son, David Wentz, is our Co-Chief Executive Officer. There can be no assurance that
conflicts of interest will not arise with respect to these relationships or that conflicts will be resolved in a manner favorable to other shareholders of
the Company.

Sales by our shareholders of a substantial 11umber ofshares of our com111011 stock i11 the public market could adversely affect the market
price of our common stock. A large number of outstanding shares of our common stock are held by several of our principal shareholders. If any
of these principal shareholders were to decide to sell large amounts of stock over a short period of time such sales could cause the market price of
our common stock to decline.

Our stock price has bee11 volatile a11d subject to various market co11ditiom. There can be no assurance that an active market in our stock
will be sustained. The trading price of our common stock has been subject to wide fluctuations. We have a relatively small public float compared to
the number of our shares outstanding. Accordingly, we cannot predict the extent to which investors' interest in our common stock will provide an
active and liquid trading market. Due to our limited public float, we are vulnerable to investors taking a "short position" in our common stock,
which is likely to have a depressing effect on the price of our common stock and add increased volatility to our trading market. The price of our
common stock also may fluctuate in the future in response to quarter-to-quarter variations in operating results, material announcements by us or
our competitors, governmental regulatory action, conditions in the nutritional supplement industry, negative publicity, or other events or factors,
many of which are beyond our control. In addition, the stock market has historically experienced significant price and volume fluctuations, which
have particularly affected the market prices of many dietary and nutritional supplement companies and which have, in certain cases, not had a
strong correlation to the operating performance of these companies. Our operating results in future quarters may be below the expectations of
securities analysts and investors. If that were to occur, the price of our common stock would likely decline, perhaps substantially.
Item 1B.

Unresolved Staff Comments

None.

I tern 2.

Properties

Corporate Headquarters
Our world-wide corporate headquarters is a 354,000 square foot company-owned facility located in Salt Lake City, Utah. This facility includes
space for manufacturing and quality control, distribution, administrative functions, and research and development.

Additional Manufacturing
i..;)

We own a 31,000 square foot manufacturing facility in Tianjin, China, which is currently used to manufacture our Sense products that arc sold
in China. The majority of our other China products arc manufactured at leased facilities in this market.
In 2014, we began construction of a state-of-the-art manufacturing facility in China similar in size, potential capacity, and nature to our
headquarters facility located in Salt Lake City, Utah. Construction of this facility is expected to be completed in the first part of 2016. Leases on the
China facilities noted above will be terminated shortly following completion of our new facility, and all manufacturing and production activities in
China will be transferred to our new facility. This new facility has been designed to provide for IO to 20 years of growth in China.
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Other Office and Distribution Warehouse Facilities

We own a 45,000 square foot office/warehouse building in Sydney, Australia. In each of the remainder of our markets, we lease regional
offices and distribution warehouses. Additionally, we lease retail centers for our operations in China and a packaging facility in Singapore, which
fulfills orders for our MyHealthPakTM in our Asia Pacific markets.
We believe that the facilities referenced above arc in good condition and arc adequately utilized. Further, we believe that our current and
planned manufacturing facilities provide for the productive capacity to meet our foreseeable needs.
Item 3.

Legal Proceedings

Rawcliffc on behalf of USA NA Health Sciences. Inc. v. Certain Directors and Officers of USANA
In August 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah
(James Robert Rawcliffc v. Robert Anciaux, et al.,) against certain of our directors and officers. The derivative complaint, which also names
USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and
unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee
of the Company's Board of Directors in February 2014. In October 2014, we filed a motion to dismiss the complaint and, in March 2015, the court
granted that motion and dismissed the complaint without prejudice. On May 6, 2015, the plaintitTs filed an appt.:al with lht.: Utah Supn:mt.: Cuurl.
The Supreme Court remanded our case to the Utah Court of Appeals, which recently issued a briefing schedule for the parties. We believe that the
claims in the complaint arc without merit and will continue to vigorously defend this suit. We continue to believe, based on information currently
available, that the final outcome of this suit will not have a material adverse effect on the Company's business, results ofoperations or
consolidated financial position.
See also our discussion under Note I to the Condensed Consolidated Financial Statements included in Item 8 of Part II of this Annual Report
on Form 10-K, which is incorporated herein by reference.

From time to time we are involved in litigation arising out of our operations. We maintain liability insurance, including product liability
coverage, in amounts our management believes is adequate. We are not currently engaged in any legal proceedings that we expect would
rrmlt.!rially hann our business or financial condition.
Item 4.

Mine Safety Disclosures

None.
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PART II
Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

i..:/J

Our common stock trades on the New York Stock Exchange ("NYSE") under the symbol "USNA." The following table contains the reported
high and low sales prices for our common stock as reported on the NYSE for the periods indicated:
Hinh

2014

First Quarter
Second Quarter
Third Quarter:
Fourth Quarter

$
$
$

$

78.35
80.77
80.86
118.84

Low

High

$

First Quarter
Second Quarter
Third Quarter
Fourth Quarter

$

$
$

114.99 $
145.05 $
176.88 $
140.58 $

1

55.01
66.51
63.22
71.03

$
$
$
$

Low

96.04
112.83
122.54
103.35

The market price of our common shares is subject to fluctuations in response to variations in our quarterly operating results, general trends in
the market for our products and product candidates, economic and currency exchange issues in the markets where we operate, as well as other
factors, many of which are not within our control. In addition, broad market fluctuations, as well as general economic, business and political
conditions may adversely affect the market for our common shares, regardless of our actual or projected performance.
On February 26, 2016, the high and low sales prices ofour common stock as reported by NYSE were $117.99 and $110.90, respectively.

Shareholders
As of February 26, 2016, we had approximately 294 holders of record of our common stock.

vJ

Dividends
We have never declared or paid cash dividends on our common stock. Future cash dividends, if any, will be determined by our Board of
Directors and will be based on earnings, available capital, our financial condition, and other factors that the Board of Directors deems to be
relevant.
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Share Repurchases

Purchases made under our ongoing share repurchase program during the quarter ended January 2, 20 I 6 arc summarized in the following table:

Issuer Purchases of Equity Securities
(amounts in thousands, except per share data)

Total
Number of
Shares
Purchased

Fiscal October
(Oct. 4, 2015 through Nov. 7, 2015)

56

$

129.50

56

$

53,981

Fiscal November
(Nov. 8, 2014 through Dec. 5, 2015)

401

$

134.55

401

$

0

0
457

$

0.00

0
457

$

100,000

Fiscal December
(Dec. 6, 2015 through Jan. 2, 2016)

*

A\lerage
Price Paid
l!er Share

Ap1n·oximatc Dollal'
Value of Shares that
May Yet Be Purchased
Under the Plans or
Pron rams*

Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs

The Company's share repurchase plan has been ongoing since the fourth quarter of 2000, with the Company's Board of
Directors periodically approving additional dollar amounts for share repurchases under the plan. The Company began the
fourth quarter of 2015 with $61,181, remaining under the plan. As announced in a publicly issued press release on
December 8, 2015, the Board of Directors authorized $100,000 for share repurchases under the plan. Subsequent to the year
ended January 2, 2016 and through February 26, 2016, the Company repurchased and retired 553 shares for a total of$64,610
pursuant to a preset trading plan meeting the requirements of Rule I Ob5-l under the Securities Exchange Act of 1934 as
amenrlecl There is no requirement for future share repurchases, and there currently is no expiration date on the approved
repurchase amount.

Stock Performance Graph

The following graph and table compares the performance of our common stock to the S&P 500 Index and to a market-weighted index of four
companies selected in good faith from our industry (the "Peer Group") over the last five years. The data shown assumes an investment on
December 31, 2010, of$100 and reinvestment of all dividends into additional shares of the same class of equity, if applicable to the stock or index.
Each of the companies included in the Peer Group markets or manufactures products similar to USANA's products or markets its products
through a similar marketing channel. The Peer Group includes the following companies: Avon Products, Inc., NuSkin Enterprises, Inc.,
Herbalife Ltd., and Nature's Sunshine.
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Item 6.

Selected Financial Data

The following selected consolidated financial data should be read in conjunction with "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and the Consolidated Financial Statements and related notes thereto that are included in this report.

2011

Consolidated Statements of Earnings Data:
Net sales
Income taxes
Net earnings
Earnings per common share:
Basic
"bfluted

Fiscal Yearp)
2012
2013
2014
(in thousands, except per share data)

2015

&;
581,939 $ 648,726
26,726
31,993
$ 50,752 $
66,433

$

$
$

Weighted-average common shares outstanding:
Basic
Diluted

3.30 $
3.26 $

15,361
15,574

Percentage of Net Sales Data:
Gross profit
A~~oci_ate incentives
S~lling, general and administrative
...,; :-: ,',--~.
tax;rate

4.57
4.45

14,547
14,923

$

718,175
37,557
79,024

$

$
$

5.77
5.56

$

$

13,695
14,204

$

$

790,471 $ 918,499
• 47,917
39,017
76,636 $ 94,672

5.80
5.60

$
$

13,221
13,689

7.44
7.18

~

12,730
13,177

82.5%
45.7%
23.6%

82.1%
43.2%
23.8%

82.3%
42.9%
23.1 %

82.2%
44.2% ..
23.3%

82.6%
44.4%
22.8%

34.5%

32.5%

32.2%

33.7%

33.6%

~

'-;

•·. Effect,~~

Dividends per share

~{6~t%t~:~i~:.~.~iri~t;: ·.
Net cash provided by (used in):
' .' Etls-Oilirnroiiaqti_ylti~i•.:L'. .
Investing activities

'}-•':.' -_:_: Ftiiirncfnif activitie's".:

Purchase of property and equipment
Repurchase· of commori stock

$

70,108 $
(10,609)
(33,372)
(10,643 )
(33,459)

92,805'. l-. 98,893 $_. J 05~:185· ;:: S.<AJI .466>·..
(25,124)
(8,278) ' . (21,589)
(16,266)
(64,542)
(10,165)
(ll3~0f5)
(49;151:)
(8,051 )
(20,421 )
(23,729)
(8,432 )
(18,085)
(61,181)
(68,294)
(138,819)
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As of
Dec. 28,
Jan. 3,
2012
2013
2015
(in thousands, except other data)

Dec. 31,
2011

Consolidated Balance Sheet Data:
Cash and cash equivalents
Working capital
Total assets
Other long-term liabilities
Stockholders' equity
Other Data:
Active Associates
Active Preferred Customers
Total Active Customers

(I)

Item 7.

$

50,353
46,363
244,496
942
173,910

222,000
64,000
286,000

0cc. 29,

$

70,839
61,701
267,355
938
185,572

247,000

64,000
311,000

$

137,343
133,)74
368,470
1,211
260,522

265,000
78,000
343,000

$

111,126
82,222
350,584
l,114
230,164

349,000
81,000
430,000

Jan. 2,
2016

$

143,210
112,852
423,237
1,151
280,852

421,000
89,000
510,000

The Company operates on a 52-53 week year, ending on the Saturday that is closest to December 31. Fiscal years 2011
through 2013, and 2015 were 52-week years. Fiscal year 2014 was a 53-week year.

Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of USANA's financial condition and results of operations is presented in ten sections:
Overview
Customers
Current Focus and Recent Developments
Presentation
Results of Operations
Quarterly Financial Information
Liquidity and Capital Resources
Contractual Obligations and Commercial Contingencies
Inflation
Critical Accounting Estimates
This discussion and analysis should be read in conjunction with the Consolidated Financial Statements and notes thereto appearing
elsewhere in this report.
Overview

We develop and manufacture high-quality, science-based nutritional and personal care products that are distributed internationally through a
network marketing system, which is a form of direct selling. We have chosen this distribution method as we believe it is more conducive to meeting
our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our customer base
includes two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by acting as independent
distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for
their personal use and are not permitted to resell or to distribute the products.
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As of January 2, 2016, we had approximately 421,000 active Associates and approximately 89,000 active Preferred Customers worldwide.
We have ongoing operations in the following markets, which are grouped and presented as follows:
Asia PacificGreater China-Hong Kong, Taiwan, and China(!)
Southeast Asia Pacific-Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indoncsia< 2l
North Asia-Japan and South Korea
Americas and Europe-United States, Canada, Mexico, Colombia<Jl, the United Kingdom, the Netherlands, France, and Belgium
Asia Pacific has largely driven our growth the last several years. Our most recent market expansions in this region include our entry into
Indonesia in late 2015, Thailand in 2012 and our entry into China in 2010 through our acquisition of BabyCare. Since our acquisition ofBabyCarc,
our strategy in Asia Pacific has been centered on generating growth in China. Consequently, our growth in Asia Pacific over the last few years has
been led by China, and our results in Hong Kong, which had previously been our fastest growing market, have declined. Our Hong Kong market
has now reached our projected size, in terms of customers and sales, and we anticipate modest organic growth for this market going forward. We
also anticipate that China will continue to drive our growth in this region going forward, but expect our business to grow in most of our other
markets in this region.
Americas and Europe is our most mature region. Our most recent market expansions in this region include our entry into Colombia in 2013.
Americas and Europe has grown modestiy over the last several years due to sales and customer growth in Canada and Mexico. Our results in the
United States and our newest markets in this region, however, have not paralleled our success in Canada and Mexico. We believe that we have the
appropriate strategics in place to generate growth in the United States and our newest markets and are optimistic about these markets going
forward. We also anticipate that our growth in Canada and Mexico wili continue in 2016.
Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported
U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, our operating results are affected
positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. In 2015, net sales outside of the United States
represented approximately 84.8% of consolidated net sales.
Customers

Because we sell our products exclusively to a customer base of independent Associates and Preferred Customers, in order to increase net
sales, we must either increase the number of, or the productivity of, our Associates and Preferred Customers. Increasing the productivity of our
Associates and Preferred Customers has not been our primary focus. Rather, we seek to increase the number of Associates and Preferred
Customers who use our products. We believe this focus is more consistent with our vision of improving the overall health and nutrition of
individuals and families around the world. Sales to Associates account for the majority of our product sales, representing 92% of product sales
during 2015. The remainder of our sales comes from Preferred Customers. Increases or decreases

(I)

Our business in China is that of BabyCare, our wholly-owned subsidiary.

(2)

We commenced operations in Indonesia in the fourth quarter of 20 I 5.
We commenced operations in Colombia in the third quarter of 2013.
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in product sales are typically the result of variations in the volume of product sold relating to fluctuations in the number of active Associates and
Preferred Customers purchasing our products. The number of active Associates and Preferred Customers is, therefore, used by management as a
key non-financial measure.
The tables below summarize the number of active customers and year-over-year percentage growth by geographic region as of the dates
indicated (quarterly). These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we only
count as active customers those Associates and Preferred Customers who have purchased from us at any time during the most recent three-month
period as of the date indicated.
~

Active Associates bl: Region
July 4,
October 3,
2015
2015

April 4,
2015

Lg;)

Asia Pacific:
Greater China
Southeast Asia Pacific
North Asia
Asia Pacific Total
Americas and Europe

201,000
77,000
12,000
290,000

82.7%
20.3 %
33.3 %
58.5%

216,000
79,000
13,000
308,000

72.8%
17.9%
44.4%
53.2%

218,000
85,000
13,000
316,000

69.0%
21.4 %
30.0%
51.2%

234,000
86,000
13,000
333,000

34.5%
8.9%
18.2%
26.1%

86,000
376,000

4.9%
41.9 %

89,000
397,000

8.5%
40.3%

89,000
405,000

8.5 %
39.2%

88,000
421,000

3.5%
20.6%

Active Preferred Customers bv Rei!ion
July 4,
October 3,
2015
2015

April 4,
2015

Asia Pacific:
Greater China
Southeast Asia Pacific··
North Asia
Asia Pacific Total
Americas and Europe

January 2,
2016

4,000
12,000
7,000
23,000

33.3 %
4,000
·12,ooti:·
20.()'%
75.0%
9,000
35.3% . 25,00.Q;. · -

63,000

86;000

-

.

33.3%

9,000
·26,000

33.3 %
18.2%
50.0%
30.0%

4,000
13,000
9,000
26,000

33.3%
8.3%
50.0%
2~.8%

63,000
66,000
10.0%
3.3 %
IQ;3:o/ci >9:J,0"00',. :···1tf%''•'. 89,000:

10.5 %
is.6·%

63,000
891000

5.0%
9.9%

9.1%
80.0%

3L6%

4,000

January 2,
2016

13~000.

Current Focus and Recent Developments

We have implemented the following strategies and initiatives to increase the number of Associates and Preferred Customers who use our
products throughout the world and, thereby, further our company vision:
Personalization: Over the last few years, we have focused heavily on personalizing and improving our customers' experience with
USANA.

In August 2015, we introduced our new "MySmartTMFoods" line of products, which continues our philosophy and strategy of
personalization. MySmart™Foods arc science-based, healthy nutrition shakes, bars, boosters and navor optimizers. We made
MySmartTMFoods available to our Associates for a limited time at our 2015 International Convention only, as a pre-launch
opportunity to purchase and try the products. We intend to officially launch MySmartTM.Foods during the first half of2016.
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We will continue to personalize each of our product lines going forward. In this regard, we have new product and technology
launches planned for 2016 and 20 I 7, which we believe will create a new foundation of personalization for USA NA to build on as we
go forward.
In 2014, we launched an all-new digital marketing suite for our world-wide Associates, which is designed to personalize and simplify
conducting a US ANA business. This suite provides our Associates with new tools, consisting of a back office hub, personal
websites, and advanced communication and marketing tools, all of which enhance our Associates' ability to personalize, manage,
promote and build their business in today's demanding e-business environment.
In 20 I 3, we implemented several strategic changes to our business ( referred to throughout this report as the "2013 strategic
changes"), which were all aimed at promoting customer loyalty, enjoyment and success with USA NA. These changes included:
(i) simplification of our pricing structure, which included an overall I 0% price reduction, while maintaining a price discount on
products ordered through our monthly Auto Order program ( collectively "price discounts"), (ii) a new reward based on the amount
of a customer's initial product order to then be credited on their subsequent two Auto Orders, and (iii) increased payout under and
simplification of our Compensation Plan.
We have experienced growth in several business indicators tied to the strategic changes that we implemented in 2013 and
continued promoting in 2014 and 2015. These indicators include: active customer counts; world-wide unit volume; percent of sales
processed through our Auto Order program; and the number of Associates earning a commission check.

Market-Specific Strategies: We have implemented market-specific strategics to facilitate growth and strengthen our business
around the world.
In 2015, we continued our strategy to increase our brand-recognition to make it easier for our Associates to introduce USA NA to
customers. In this regard, we expanded our relationship with Dr. Mehmct Oz and became a Trusted Partner and Sponsor of The
Dr. Oz Show. Under this partnership, USANA products are regularly featured on The Dr. Oz Show. This partnership has helped
drive growth in our North America region by (i) increasing awareness and recognition of the USANA brand, and (ii) allowing
viewers of The Dr. Oz Show to purchase USANA products via a direct link on The Dr. Oz Show website. We plan on continuing
this partnership in 2016.
In late 2014, after we passed the anniversary of the 2013 strategic changes, we began offering short-term incentives and promotions
for our Associates around the world to generate excitement and additional customer growth. One particular incentive that we
offered in late 2014 and early 2015 increased compensation to Associates for sales generated by new Associates and accelerated
our sales and customer growth during the fourth quarterof2014 and the first halfof2015. We plan to continue offering marketspecific incentives and promotions going forward to generate excitement in our business.
In 2013, we implemented a price reduction in several of our mature markets to make our products and business opportunity more
equitable around the world. Although these price reductions initially impacted our net sales on a year-over-year basis, they have
been successful in the past helping grow our active customer counts and net sales in these markets, where growth had been
declining or flat for several years. We followed up this pricing initiative with a new worldwide policy to prohibit cross-border
purchasing by our customers. We believe that it is in the best interest of the Company and of our customers to have customers
purchase products that are approved and offered in their home market. While this policy had a short-term negative impact on net
sales in 2013, these policies have strengthened our underlying business and have improved our opportunity for growth going
forward.
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Product Innovation and Information Technology: Although we originally planned for significant increases in our investment in
product and technology innovation to further our Company vision during 20 IS, much of this investment was delayed as we
carefully acquired the necessary human resources. In 2016, we plan to continue to pursue these investment strategies as well as
additional investments in our information technology systems and infrastructure to continue to improve our customers' experience
with us and to prepare to become a much larger company. These investments will be reflected as both additional SG&A expense
and capital expenditures.
International Development: Given the significant opportunity that exists in China, we plan to continue focusing significant time
and resources on growing this market. Our efforts in this regard include finalizing our new state-of-the-art manufacturing and
production facility in Beijing, which we anticipate will become operational during the first half of 2016. We continue to believe that
significant growth opportunities exist in new international markets. During the fourth quarter of 2015 we commenced operations in
Indonesia. Indonesia is our 20th market and we believe it offers a promising growth opportunity for us.
Presentation
Product sales along with the shipping and handling fees billed to our customers arc recorded as revenue net of applicable sales discounts
when the product is delivered, title has transferred, and the risk of loss passes to the customer. Payments received for undelivered products are
recorded as deferred revenue and are included in other current liabilities. Also reflected in net sales is a provision for product returns and
allowances, which is estimated based on our historical experience. Additionally, the Company collects a nominal annual renewal fee from
Associates that is deferred on receipt and is recognized as income on a straight-line basis over a twelve-month period.
Cost of sales primarily consists of expenses related to raw materials, labor, quality assurance, and overhead costs that are all directly
associated with the production and distribution of our products and sales materials, as well as duties and taxes that are associated with the import
and export of our products. As our international sales increase as a percentage of net sales, cost of sales arc increasingly affected by additional
duties, freight, and other factors, such as changes in currency exchange rates.
Associate incentives expense includes all forms of commissions, and other incentives paid to our Associates. Incentives paid to Associates
include bonuses earned, rewards from contests and promotions, and base commissions, which makes up the majority of our Associate incentives
expense. Bonuses are paid out to Associates based on certain business-related criteria, total base commission earnings, and leadership level.
Contests and promotions are offered as an incentive and reward to our Associates and are typically paid out only after an Associate achieves
specific criteria. Base commissions are paid out on the sale of products. Associates earn their commissions based on sales volume points that are
generated in their sales organization. Sales volume points are assigned to each commissionable product and comprise a certain percent of the
product price. Items such as our starter kits and sales tools have no sales volume point value, and commissions are not paid on the sale of these
items. Although insignificant to our financial statements, an Associate may earn commissions on sales volume points that are generated from
personal purchases that arc not considered to be part of their "Qualifying Sales." To be eligible to earn commissions, an Associate must reach a
certain level of Qualifying Sales each month, which may include product that they use personally or that they resell to consumers. Associates do
not earn commissions on their Qualifying Sales. Commissions paid to Associates on personal purchases are considered a sales discount and are
reported as a reduction to our net sales.
Selling, general and administrative expenses include wages and benefits, depreciation and amortization, rents and utilities, Associate event
costs, advertising, professional fees, marketing, and research and development expenses. Wages and benefits represent the largest component of
selling,
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general and administrative expenses. Significant depreciation and amortization expense is incurred as a result of investments in physical facilities,
computer and telecommunications equipment, and systems to support our international operations.

~

Sales to customers outside the United States are transacted in the respective local currencies and arc translated to U.S. dollars at weightedaverage currency exchange rates for each monthly accounting period to which they relate. Most of our raw material purchases from suppliers and
our product purchases from third-party manufacturers arc transacted in U.S. dollars. Consequently, our net sales and earnings are affected by
changes in currency exchange rates. In general, our operating results are affected positively by a weakening U.S. dollar and negatively by a
strengthening U.S. dollar. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating
current year net sales at the average exchange rates in effect during the comparable prior year periods.

~

Results of Operations

The following table summarizes our consolidated operating results as a percent of net sales, respectively, for the years indicated:

Consolidated Statements of Earnings Data:
Net sales
Cost of sales
Gross profit

Operating expenses:
Associate incentives
Selling, general and administrative
Total operating expenses
Earnings from operations
Other income (expense), net
. Earnings betbre income taxes
Income taxes
Net earnings

I 00.0 % l 00.0%
17.7%____}1!%. . fi.4%
82.3 %
82.2 %
82.6%

I00.0 %

42.9%
44.2%
23:3%.
23.1%
66.0%
67.5 %
16.3% ~ % : .
0.0%
-0.l %

44.4%
22:8%
67.2%

'15.4%
0.1 %

~ % ''''14:6.'W''.···.rss¾
5.2%

4.9%

--ri:i°¾ :· -~;?%-'

5.2%

·'.to~3o/o

Summary of 2015 Financial Results

Net sales in 2015 increased 16.2%, or $128.0 million, to $918.5 million, compared with 2014. This increase was driven by higher product sales
volume resulting primarily from strong Associate growth in our Asia Pacific region throughout the year. Our business started the year with strong
momentum, which was reflected by local currency sales and customer growth in most of our markets. During the year, we also utilized marketspecific promotions and incentives to generate growth across our regions. Unfavorable changes in currency exchange rates reduced net sales for
the year by an estimated $53.6 million. Additionally, on a comparative basis, 2014 was a 53-week year and included one additional week of sales,
which contributed approximately $16.0 million to net sales for that year.
Net earnings increased 23.5% to $94.7 million in 2015, when compared with 2014. This increase was driven primarily by higher net sales,
improved gross margins and lower relative selling, general and administrative expense.
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Fiscal Year 2015 compared to Fiscal Year 2014

vP

Net Sales
The following tab]e summarizes the changes in our net sales by geographic region for the fiscal years ended January 3, 2015, and January 2,
2016:
Net Sales by Region
(in thousands)
Year Ended

\J;j
2014

Asia Pacific
Greater China
Southeast Asia
Pacific
North Asia
Asia Pacific
Total

~

$

Americas and
Europe
$

Change
from prior
vear

2015

326,134

41.3%$

441,284

48.0% $

115,150

177,940
32,667

22.5%
4.1%

183,828
39,751

20.0%
4.4%

5,888
7,084

536,741

67.9%

664,863

72.4%

253,730
790,471

32.l %
100.0%$

253,636
918,499

27.6%
100.0% $

Percent

~

Currency
impact on
sales

Percent
change
excluding
currency
imeact

(8,769)

38.0%

3.3%
21.7%

(21,491 )
{3,318)

15.4%
31.8%

128,122

23.9%

(33,578)

30.1%

{94)
128,028 ·

0.0%
16.2%$

{20,053)
{53,631 )

7.9%
23.0%

35.3% $

~

1./d

Asia Pacific: The increase in Greater China continues to be driven by growth in Mainland China, where local currency net sales increased
nearly 75% resulting from strong growth in the number of active Associates throughout the year. Net sales and Associate growth in Mainland
China during 2015 benefited from: (i) momentum created from a short-tenn incentive that we offered during the first quarter of the year, (ii) a more
favorable operating environment for the Company during the first quarter of 2015 when compared with the previous year, and (iii) higher-thananticipated incremental sales of approximately $17 .0 million that occurred following the announcement of our 2015 price adjustments. Net sales
growth in Greater China was partially offset in 2015 by a continued year-over-year decline in Hong Kong sales and Associates, which stabilized
during 2015.
The increase in local currency net sales in Southeast Asia Pacific was driven by double-digit local currency sales growth from nearly every
market, which is reflective of growth in the number of active Associates and Preferred Customers purchasing our products.
The increase in local currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales
increased just over 39% resulting from double-digit increases in the number of active Associates and Preferred Customers during the year.

Americas and Europe: The increase in local currency net sales in this region continues to be driven primarily by growth in Canada and
Mexico, where local currency net sales increased 17.5% and 19.4%, respectively. This growth is reflective of growth in the number of active
Associates and Preferred Customers purchasing our products.
Gross Profit

The 40 basis point relative increase in gross profit from 2014 to 2015 can be attributed to a favorable shift in sales mix by market and by modest
product price adjustments that occurred during 2015. These improvements were partially offset by the negative impact from the strengthening of
the U.S. dollar.
Associate Incentives
The 20 basis point relative increase in Associate incentives can be attributed to higher relative payout under one of our Associate bonus
programs. The increase in Associate incentives expense was partially offset by our annual price adjustment.
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Selling, General and Administrative Expenses

The 50 basis point decrease in selling, general and administrative expense relative to net sales in 2015 was due to leverage gained on increased
sales driven by growth in our Asia Pacific region. In absolute terms, our selling, general and administrative expense increased by $24.5 million. This
increase was primarily driven by costs associated with supporting higher sales and customer base as well as our investment in brand-recognition
initiatives during 2015. In 2016, we plan to make several strategic investments in our business and expect this impact to se11ing, genera! and
administrative expense to decrease our earnings from operations around 100 to 140 basis points.
Income Taxes

Our effective income tax rate was 33.6% in 2015, compared with 33.7% in 2014. This change was primarily due to slightly lower 2015 state tax
expense compared to 2014 state tax expense as a percentage of income.
Diluted Earnings Per Share

Diluted earnings per share in 2015 increased 28.2% to $7 .18, from $5.60 in the prior year. This increase was due to higher net earnings and a
lower number of diluted shares outstanding resulting from share repurchases under our share buyback program during 2015.
Summary of 2014 Financial Results

Net sales in 2014 increased 10. l %, or $72.3 million, to $790.5 million, compared with 2013. Fiscal 2014 was a 53-week year and included,
comparatively, one additional week of sales. We estimate that this extra week contributed approximately$ I 6.0 million to net sales for the year. In
addition to the extra week, the increase was driven by higher product sales volumes resulting from Associate and Preferred Customer growth
throughout the year, primarily in our Asia Pacific region. The increase in active customers was largely the result of (i) the momentum created from
the 2013 strategic changes, which are explained in the business section above, and (ii) a short-term incentive that we announced at our 2014
International Convention in August and offered to our Associates during the fourth quarter of 2014. Net sales in 2014 were also negatively
affected by an estimated $14.9 million from unfavorable changes in currency exchange rates, as well as the price discounts that were implemented
in late 2013 as part of the strategic changes.
Net earnings decreased 3.0% to $76.6 million in 2014, when compared with 2013. This decrease was primarily the result of higher relative
Associate incentives expense related to the 2013 strategic changes and to the short-term incentive we offered to our Associates during the fourth
quarter of 2014.
Fiscal Year 2014 compared to Fiscal Year 2013
The tables below summarize the number of active customers and year-over-year percentage growth by geographic region as of the dates
indicated. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we only count as
active customers those
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Associates and Preferred Customers who have purchased from us at any time during the most recent three-month period as of the date indicated.
Active Associates bv Re 0 ion
June 28,
September 27,
2014
2014

March 29,
·2014

Asia Pacific:
Greater China
Southeast Asia Pacific
North Asia
Asia Pacific Total
Americas and Europe

110,000
64,000
9,000
183,000

26.4 %
14.3 %
12.5 %
21.2%

125,000
67,000
9,000
201,000

21.4 %
11.7 %
0.0%
16.9%

129,000
70,000
10,000
209,000

37.2 %
16.7 %
II.I%
28.2 %

174,000
79,000
11,000
264,000

56.8%
27.4%
10.0%
44.3%

82,000
265,000

5.1 %
15.7 %

82,000
283,000

0.0 %
11.4 %

82,000
291,000

0.0 %
18.8 %

85,000
349,000

3.7%
31.7%

Active Preferred Customers by Re 0 ion
June 28,
September 27,
2014
2014

March 29,
2014

Asia Pacific:
Greater China
Southeast Asia Pacific
North Asia
Asia Pacific Total

3,000
10,000
4,000
17,000

0.0%
42.9%
100.0 %
-4L7%

61,000
78~000

Americas and Europe

January 3,
2015

3,000
11,000
5,000
19,000·

(25.0 )%
57.l %
150.0 %
46.2 %

3,000
11,000
6,000
20,000

10.9 % 60,000
16.4 % . 79,000

5.3 %
12.9%

57,000
77,000

0.0
37.5
200.0
53.8

January 3,
2015

%

3,000
12,000
%~
% 21,000
%

(1.7 )%
8.5 %

60,000
81,000

(40.0 )%
20.0%
100.0 %
16.7%
0.0%
3.8 %

Net Sales

The following table summarizes the changes in our net sales by geographic region for the fiscal years ended December 28, 2013, and
January 3, 2015:
Net Sales by Region
(in thousands)
Year Ended

2013

Asia Pacific
Greater China
Southeast Asia
Pacific
North Asia
Asia Pacific
Total

V,

Americas and
Europe
$

Asia Pacific:

2014
'

$

~

. . . . •• '

271,812

37.9 %

155,362
29,319
456,493
261,682
718,175

Change
from prior
1:ear

,. _;:· •• ·.:.

j

't

·._-!..(: .. '

<

• ,·

- • ,.~ ".

Percent
change

Currency
impact on
sales

Percent
change
excluding
currency
im(!3Cl

: .. _,-_. t:-

326,134

41.3%$

54,322

20.0% $

(1,737)

20.6%

21.6 %
4.1 %

177,940
32,667

22.5%
4.1%

22,578
3,348

14.5%
11.4%

(7,292 )
597

19.2%
9.4%

63.6 %

536,741

67.9%

80,248

17.6%

(8,432 )

19.4%

32.1%
100.0%$

(7,952)
72,296

(3.0)%
IO.I%$

(6,476 )
(14,908)

12.1%

$

36.4 %
253,730
100.0 % $ 790,471

(0.6)%

The increase in net sales in this region was driven by double-digit growth in the number of active Associates throughout the

year.
The increase in net sales in Greater China included a I 03.2% increase in Mainland China resulting from slrong growth in the number of active
Associates in this market. This growth was partially offset by a continued decline in Hong Kong.
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The increase in Southeast Asia Pacific was driven by sales growth from every market despite a $7.3 million reduction from changes in currency
exchange rates. The strongest growth in this region came from the Philippines, where net sales increased 31.1 %. Sales in Australia and New
Zealand increased 5.9% despite a $3.0 million reduction from changes in currency exchange rates.

<ii

The increase in net sales in North Asia resulted from a 24.2% increase in net sales in South Korea, which was driven by an increase in the
number of active Associates and Preferred Customers in this market.

Americas and Europe: The decrease in net sales in this region was due to lower net sales in the United States and to changes in currency
exchange rates, which reduced net sales by $6.S million. Net sales in the United States decreased $13.9 million, or 8.8% due to pressure from price
discounts introduced in the prior year, combined with a decrease in the number of active Associates and Preferred Customers throughout 2014.
The decrease in the United States, however, was partially offset by net sales growth in other markets within the region. Most notably, local
currency sales increased 8. 7% in Canada and 14.4% in Mexico due to continued growth in the number of active Associates and Preferred
Customers in those markets.

1€,J

Gross Profit
The 10 basis point decrease in gross profit from 2013 to 2014 can be attributed to a strengthening of the U.S. dollar, price discounts introduced
in the prior year, and an increase in net freight expense. This decrease was partially offset by annual price changes and favorable changes in
product and market mix.

Associate Incentives
The 130 basis point increase in Associate incentives as a percent of net sales was due to the short-term incentive that we offered to our
Associates during the fourth quarter of 2014, and to the 2013 strategic changes. The increase in Associate incentives expense was partially offset
by annual price changes.
Selling, Generai and Administrative Expenses

The slight increase in selling, general and administrative expense relative to net sales in 2014 was due to higher expenses in China as a result
of our growing sales and customer base in this market. In absolute terms, our selling, general and administrative expense increased by $18.3 million.
This increase was primarily driven by higher wages and benefits expense and other costs associated with supporting a higher sales and customer
base.
Income Taxes

Our effective income tax rate was 33.7% in 2014, compared with 32.2% in 2013. This increase was primarily due to a reduction in tax benefits
from the U.S. manufacturing deduction which declined due to increased sales of China manufactured product. In addition, tax benefits from lower
tax rate jurisdictions and prior year amended returns declined year over year.
Diluted Earnings Per Share

Although net earnings decreased slightly from 2013 to 2014, diluted earnings per share increased to $5.60 in 2014, from $5.56 in 2013. This
increase was due to a lower number of diluted shares outstanding resulting from activity under our share buyback program during 20 I 4.
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Quarterly Financial Information (Unaudited)

®

The following tables set forth unaudited quarterly operating results for each of the last eight fiscal quarters, as well as percentages of net
sales for certain data for the periods indicated. This information is consistent with the Consolidated Financial Statements herein and includes
normally recurring adjustments that management considers to be necessary for a fair presentation of the data. Quarterly results are not necessarily
indicative of future results of operations. T~is information should be read in
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conjunction with the audited Consolidated Financial Statements and notes thereto that arc included elsewhere in this report.
~
Mar. 29,
2014

Consolidated
Statements of
Earnings Data:
Ncl sales
Cost of sales
Gross profit
Operating expenses:
Associate
incentives
Selling, general
and

$

182,401
33,828
148,573

Quarter Ended
Sept. 27,
Jan. 3,
Apr 4,
Jul. 4,
2014
2015
2015
2015
(in thousands, except per share data)

Jun. 28,
2014

s

188,256 $ 191,944
34,585
34,865
153,391
157,359

s 227,870

$ 219,378

$ 233,244

37,516
190,354

38,364
181,014

40,089
193,155

Jan. 2,
2016

Oct.3,
2015

192,244

232,585
40,181
192,404

$ 233,292
41,048

$

78,874

81,098

82,605

106,467

101,353

101,877

101,521

103,409

administrative

44,577

43,206

45,499

51,249

49,875

52,505

521757

53,858

Total operating
expenses

123,451

124,304

128,104

157,716

151,228

154,382

154,278

157,267

25,122

29,087

29,255

32,638

29,786

38,773

37,966

35,137

125

297

441

404

~

~

Earnings from
operations
Other income
(expense), net

(297)

(574)

168

{86)

~

Earnings from
operations before
income taxes

Income taxes

Net :earnfogs

$

25,247
8,710
16~537 $

29,384
10,083
19,301

$

28,958
32,064
9,460
10,764
19,498 $ 21,300 $

.: J8A07. . · J5,S41
29,954
38,687
10,274
11,574
13,271
12,798
19,680 $ . 25;416 .$ 251609 $ "23,967

Earnings per
common share*:

s:asic.
Diluted

~-

$
$

1.19 $
1.15 $

1.40 $
1.36 $

1.51 $
1.47 s

1.72 $
1.65 $

1.56 $
1.50 s

l.99 $
1.92 $

1-.99 $
1.92 $

Weighted.;.~:verag~ ·

,,.

•--~

<sh'rfreS: . .
Basic

,.
,,

ou~tandingr
Diluied·

· 1.89
l.83

13,919
14,395

13,768
14,235

12,873
13,263

12,390
12,920

12,648
13,085

12,740

13,225

12,852
13,317

12,680

Consolidated
Statements of
Earnings as a
percentage of Net
Sales:
Net sales
Cost of sales
Gross profit
Operating expenses:
Associate
incentives
Selling, general
and
administrative
Total operating
expenses
Earnings from
operations
Other income
(expense), net
Earnings from
operations before
income taxes
Income taxes
Net earnin_gs

~-

fJ,082

~

100.0%
18.5
81.5

100.0%
18.5
81.5

100.0%
18.0
82.0

100.0%
16.5
83.5

100.0%
17.5
82.5

100.0%
17.2
82.8

100.0%
17.6
82.4

100.0%
17.3
82.7

43.2

43.1

43.0

46.7

46.2

43.7

43.5

44.5

24.4

23.0

23.7

22.5

22.7

22.5

22.6

23.2

67.6

66.1

66.7

69.2

68.9

66.2

66.1

67.7

13.9

15.4

15.3

14.3

13.6

16.6

I6.3

15.0

0.1

0.2

(0.2)

(0.3)

0.2

0.2

0.1

~0.0)

13.7
16.5
14.0
15.6
15.1
14.0
16.6
4.7
4.8
5.4
4.9
4.7
5.7
5.5
9.3'¼,
9.2%
10.2'½,
10.2%
9.0%
11.0%
10.9%
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Machine-generated OCR, may contain errors.

15.2
5.0
10.2%

~

l

*

Earnings per common share is computed independently for each of the quarters presented. Therefore, the sum of the
quarterly earnings per share amounts does not necessarily equal the total for the year.
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We may experience variations in the results of operations from quarter to quarter as a result of factors that include, but are not limited to the
following:
The number of Associates and Preferred Customers who join our business, purchase and sell our products, and stay with our
business;
The opening of new markets;
The timing of Company-sponsored events, contests, and promotions;
fluctuations in currency exchange rates;
New product introductions;
The timing of holidays, which may reduce the amount of time that our Associates spend selling products or introducing USANA to
potential Associates or Preferred Customers;

~

The negative impact of changes in or interpretations of regulations that may limit or restrict our network marketing model or the sale
of certain products in some countries;
The adverse effect of a failure by us or an Associate (or allegations of such failure) to comply with applicable governmental
regulations;
The integration and operation of new information technology systems;
The inability to introduce new products or the introduction of new products by competitors;
Entry into one or more of our markets by competitors;
Availability of raw materials;
General conditions in the nutritional supplement, personal care, and healthy food industries or the network marketing industry; and
Consumer perceptions of our products and business.
Because our products are consumed by consumers or applied to their bodies, we are highly dependent upon consumers' perception of the
safety, quality, and efficacy of our products and nutritional supplements in general. As a result, substantial negative publicity, whether founded or
unfounded, concerning one or more of our products or of other products that are similar to our products could adversely affect our business,
financial condition, or results of operations.
As a result of these and other factors, quarterly revenues, expenses, and results of operations could vary significantly in the future, and
period-to-period comparisons should not be relied upon as indications of future performance. There can be no assurance that we will be able to
increase revenues in future periods or be able to sustain the level of revenue or rate of revenue growth on a quarterly or annual basis that we have
sustained in the past. Due to the foregoing factors, future results of operations could be below the expectations of public market analysts and
investors. If that occurs, the market price of our common stock would likely decline.
Liquidity and Capital Resources

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and by
drnwing from our line of credit. Our principal source of liquidity is our operating cash now. Although we are required to maintain cash deposits
with banks in certain of our markets, there arc currently no material restrictions on our ability to transfer and remit funds among our international
markets. In Mainland China, however, our compliance with Chinese accounting and tax regulations promulgated by the State Administration of
Foreign Exchange ("SAFE") results in transfer and remittance ofour profits and dividends from Mainland China to the
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United States on a delayed basis. If SAFE or other Chinese regulators introduce new regulations, or change existing regulations which allow
foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from Mainland
China may be limited in the future. Notwithstanding the foregoing, ifwe were to repatriate the $18.2 million of cumulative earnings that have been
indefinitely reinvested in certain ofour markets at January 2, 2016, there would be a tax liability to the Company of approximately $3. l million.
We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled
$111.5 million in 2015, compared with $105.2 million in 2014. Items positively affecting cash flow from operations on a year-over-year basis include:
(i) an increase in net earnings (ii) timing of vendor invoices and payments (iii) increase in deferred revenue. These items were partially offset by a
high level of cash used to increase inventory in 2015 to build up inventory in support of a facility transition in China, and the launch of a new
market.
We generated strong cash flow from operating activities in 2015, cash and cash equivalents increased to $143.2 million at January 2, 2016, from
$111. l million at January 3, 2015. This increase in cash and cash equivalents was primarily due to increased sales and lower share repurchases. Of
the $143.2 million cash and cash equivalents held at January 2, 2016, $16.2 million was held in the United States and $127.0 million was held by
international subsidiaries. Of the $111. l million held at January 3, 2015, $37.8 million was held in the United States and $73.3 million was held by
international subsidiaries. Net working capital increased to $112.9 million at January 2, 2016, from $82.2 million at January 3, 2015.
We are building a state-of-the-art manufacturing and production facility in China, which we anticipate will become operational during the first
halfof2016. This facility has been designed to accommodate 10-20 years of growth in China. We anticipate that this project will require a total
investment of approximately $40 million, of which $25.5 million was incurred through 2015. Leases on our existing manufacturing and production
facilities in China will be tenninated during 2016 following completion of our new facility, and most manufacturing and production activities in
China will be transferred to our new facility. In the near tenn, we will continue to utilize our Tianjin manufacturing facility for our personal care
products in China. With our investments in China and expected capital expenditures to support initiatives discussed under "Current Focus and
Recent Developments,'' our total anticipated capital expenditures in 2016 are expected to be between $35 million and $40 million.
We have extended non-revolving credit to the supplier of our nutrition bars to allow this supplier to modify its facility and acquire the
necessary equipment to manufacture our bars. Notes receivable from this supplier as of January 2, 2016, were $8.3 million and are included as noncurrent other assets on the balance sheet.

:..,J

-.J

Line of credit
We have a long-standing relationship with Bank of America. We currently maintain a $75 million credit facility pursuant to an Amended and
Restated Credit Agreement ("Credit Agreement") with the bank, which expires in April 2016. On February 19, 2016 we entered into a Second
Amendment ("Amendment") to our Credit Agreement, which among other things, extends the term of the Credit Agreement to April 27, 2021. The
Amendment also increases the amount we may borrow under the Credit Agreement from $75 million to up to $125 million through October 31, 2016.
On November I, 20 l 6 the amount we may borrow under the Credit Agreement will revert to $7 5 million for the term of the agreement. The
Amendment also increases our consolidated rolling four-quarter adjusted earnings before interest, taxes, depreciation and amortization ("adjusted
EBJTDA") covenant from $60.0 million to equal to or greater than $100 million.
Bank guarantees are considered a reduction of the overall availability of credit. As of January 2, 2016, such normal course of business bank
guarantees reduced our available borrowing limit by $4.6 million. During 2015, there were no borrowings on this line of credit. As of February 26,
2016, however, we had a balance of$63.0 million on this line of credit.
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The agreement for this credit facility contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter adjusted
earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA") equal to or greater than $60.0 million, and a ratio of
consolidated funded debt lo adjusted EBITDA of 2.0 to 1.0 at the end of each quarter. The adjusted EBITDA under this agreement is modified for
certain non-cash expenses. As of January 2, 2016, we were in compliance with these covenants. Management is not aware of any issues currently
impacting Bank of America's ability to honor their commitment to extend credit under this facility.

Share repurchase
We have a share repurchase plan that has been ongoing since the fourth quarter of 2000. The objective of this plan is to return value to our
shareholders. Our Board of Directors has periodically approved additional dollar amounts for share repurchases under that plan. Share
repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of our
cash balances, general business opportunities, and other factors. During the fourth quarter of 2015, our Board of Directors authorized$ JOO million
for repurchase under this plan. In 20 I 5, we repurchased and retired 457,000 shares of common stock for $61.2 million, at a weighted average market
price of$ 133.94 per share. At January 2, 2016, the remaining approved repurchase amount under the plan was $ JOO million. Subsequent to the year
ended January 2, 2016 and through February, 26, 2016 the Company repurchased and retired 553 shares for $64,610 pursuant to a preset trading
plan meeting the requirements of a Rule 10b5-l under the Securities Exchange act of 1934 as amended. There currently is no expiration date on the
remaining approved repurchase amount and no requirement for future share repurchases.

Summa,y
We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to
cover our operating and capital needs in the ordinary course of business for the foreseeable future. lfwe experience an adverse operating
environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given,
however, that additional financing, if required, would be available at all or on favorable terms. We might also require or seek additional financing
for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may include the use of
additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are
convertible into equity securities could result in immediate and possibly significant dilution to our existing slta1t:ltulllt:rs.
Contractual Obligations and Commercial Contingencies
The following table summarizes our contractual obligations and commitments as of January 2, 2016 and the effect such obligations and
commitments are expected to have on our liquidity and cash flow in future periods:

Payments Due By Period
{in thousands)
Contractual Obligations

Operating Leases
Other Commitments
Line·of Credit
Total Contractual Obligations

Total

$

29,967

10,552

40,565
"i

$

'-840

71,372

I - 3 years

Less than 1 year

$

$

32,439

207· ;. · .•

15,744
6,996

========

·3,671

$

1,130

292

--------$
43,198 $
23,032

More than 5 years

3 - 5 years
$

292
$

5,093

$
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"Operating Leases" generally provide that property taxes, insurance, and maintenance expenses are the responsibility of the Company. Such
expenses are not included in the operating lease amounts that are outlined in the table above.
"Other Commitments" generally include consulting- and IT-related services, investments in brand awareness through corporate and athlete
sponsorships as discussed under "Growth Strategy" within Item I of this report, facility maintenance, and services related to the events that we
hold for our Associates both locally and internationally. Additionally, throughout the year we will enter into various short-term contracts, mostly
for services related to events that we hold for our Associates.
The "Line of Credit" has a maturity date of April 2016. On February 19, 2016 we entered into an Amendment to our Credit Agreement, which
among other things, extends the term of the Credit Agreement to April 2021. During 2015, there were no borrowings on this line of credit. As of
February 26, 2016, however, we had a balance of$63.0 million on this line of credit. Fees on the unused portion of this line are due periodically and
are renected in the table above. If we utilize this line of credit prior to its maturity, we will be required to pay it in full at maturity.
As previously discussed, we are building a state-of-the-art manufacturing and production facility in China, which we anticipate will become
operational during the first ha) f of 2016. We anticipate that this project will require a total investment of approximately $40 million, of which
$25.5 million was incurred as of January 2, 2016. Of the estimated $IO million - $15 million remaining, approximately $5.6 million is currently under
contract and has been included in "Other Commitments" in the table above.
Inflation

We do not believe that inflation has had a material impact on our historical operations or profitability.
Critical Accounting Estimates

Our Consolidated Financial Statements included in this report have been prepared in accordance with accounting principles generally
accepted in the United States of America ("US GAAP"). Our significant accounting policies are described in Note A to the Consolidated Financial
Statements included herein. The preparation of financial statements in accordance with US GAAP requires management to make estimates and
assumptions that affect the amounts reported in the consolidated financial statements and accompanying footnotes. Those estimates and
assumptions are derived and are continually evaluated based on our historical experiences, current facts and circumstances, and on changes in the
business environment. Actual results, however, may sometimes differ materially from estimates under different conditions. Critical accounting
estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and those that require
management's most subjective judgments. We believe that our most critical accounting estimates are described in this section.
Revenue Recognition.

Revenue is recognized at the estimated point of delivery of the merchandise, at which point the risks and rewards of ownership
have passed to the customer. Revenue is recognized when the following four criteria are met: persuasive evidence of a sale
arrangement exists, delivery of the product has occurred, the price is fixed or determinable, and payment is reasonably assured. It is
not practical for us to track the actual delivery date of each shipment as we ship a high volume of orders through several carriers.
Therefore, we use estimates to determine which shipments are delivered and, therefore, recognized as revenue at the end of a
period. Our estimates on delivery date largely relate to orders fulfilled in North America and Australia and arc based on average
shipping transit times, which are calculated using the following factors: (i) the type of shipping
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carrier (as carriers have different in-transit times); (ii) the delivery destination; and (iii) actual transit time experience, which shows
that delivery date is typically one to five business days from the date of shipment. We review and update our estimates on a
quarterly basis based on our actual transit time experience. However, actual shipping times may differ from our estimates. The
estimated total of shipments that are not delivered at the end of a period is not material nor would a change in the average shipping
transit times (I to 2 days) have a material impact on our consolidated financial statements. Additionally, we require cash or credit
card payment prior to shipping and do not extend credit to customers.
Payments received for undelivered products are recorded as deferred revenue and are included in other current liabilities. Deferred
revenue is recognized at the estimated point of delivery of the merchandise. On the occasion that will-call orders arc not picked up
by customers, we periodically assess the likelihood that customers will exercise their contractual right to pick up orders and
recognize revenue when the likelihood is estimated to be remote.

(ii,,

~

A provision for product returns and allowances is established and is based on our historical experience.
Amounts billed to customers for shipping and handling fees are classified as revenue.
Sales discounts earned under USANA's initial order reward program are considered part of a multiple element revenue arrangement
and accordingly are deferred when the first order is placed and recognized as customers place their subsequent two Auto Orders.
Any compensation paid to an Associate on their personal ordc1s arc cuptun::d nm.I reported us o rcductiuu tu net sulcs in the furm
ofa sales discount. Management estimates, based on the structure of USANA's Compensation Plan, that an Associate who places
an order with sales volume points in a personal sales position will eventually be paid commission on that purchase. Such reduction
of revenue for Associates outside of the United States is converted to U.S. Dollars at the average currency exchange rate for the
applicable period.
We collect an annual renewal fee from our Associates that is deferred when it is collected and is recognized as income on a straightline basis over the subsequent twelve-month period.
Inventory Valuation. Inventories are stated at the lower of cost or market. Cost is determined using a standard costing system which
approximates the first-in, first-out method. The components of inventory cost include raw materials, labor, and overhead. Market value is
cl~t~nnim~ci nsine various assumptions with regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current
and future product demand, production planning, and market conditions. A change in any of these variables cou]d affect the valuation of our
inventories.
Impairment of Long-Lived Assets, Goodwill, and Indefinite-Lived Intangible Assets. Long-lived assets, including property and equipment
and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying
amount of the assets may not be recoverable. Events or changes in circumstances that would indicate the need for impairment testing include,
among other factors: operating losses; unused capacity; market value declines; technological developments resulting in obsolescence; changes in
demand for products manufactured; changes in competition and competitive practices; uncertainties associated with the world economies; and
changes in governmental regulations or actions. When indicators of impairment exist, an estimate ofundiscounted net cash flows is used in
measuring whether the. carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is
based upon the difference between the asset group's carrying value and estimated fair value. Fair value is determined through various valuation
techniques, including market and income approaches as considered necessary.
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Goodwill represents the excess of purchase price paid over the fair market value of identifiable net assets of companies acquired. Goodwill is
not amortized, but rather it is tested at the reporting unit level at least annually for impairment (or more frequently if triggering events or changes in
circumstances indicate impainnent). Initially, qualitative factors arc considered to determine whether it is more likely than not that the fair value of a
reporting unit is less than its carrying amount. Some of these qualitative factors may include macroeconomic conditions, industry and market
considerations, a change in financial performance, entity-specific events, a sustained decrease in share price, and consideration of the difference
between the fair value and carrying amount of a reporting unit as determined in the most recent quantitative assessment. If, through this
qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit's fair value is less than its carrying amount, a twostep quantitative impairment analysis is performed to estimate the fair value of goodwill. The first step involves estimating the fair values of a
reporting unit using widely-accepted valuation methodologies including the income and market approaches, which requires the use of estimates
and assumptions. These estimates and assumptions include revenue growth rates, discounts rates, and determination of appropriate market
comparables. If the fair value of the reporting unit is less than its carrying amount, the second step of the impainncnt test is performed to measure
the amount of the impairment loss. In the second step, the implied fair value of the goodwill is estimated as the fair value of the reporting unit as
determined in step one, less fair values of all other net tangible and intangible assets of the reporting unit determined in a manner similar to a
purchase price allocation. If the carrying amount of the goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal
to that excess, not to exceed the carrying amount of the goodwill.

..J

i.j

Indefinite-lived intangible assets arc not amortized; however, they arc tested at least annually for impaim1ent or more frequently if events or
changes in circumstances exist that may indicate impaim1ent. Initially, qualitative factors arc considered to determine whether it is more likely than
not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If, through this qualitative assessment, the conclusion
is made that it is more likely than not that an indefinite-lived intangible asset's fair value is less than its carrying amount, a quantitative impairment
analysis is performed by comparing the indefinite-lived intangible asset's book value to its estimated fair value. The fair value for indefinite-lived
intangible assets is determined through various valuation techniques, including market and income approaches as considered necessary. The
amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset. During 2013, 2014,
and 2015, no impairment of indefinite-lived intangible assets was recorded.
Determining the fair value of our long-lived assets, goodwill, and indefinite-lived intangible assets as part of these impairment analyses
requires significant judgment in estimates and assumptions used under the income and market approaches. A change in any of the estimates or
assumptions used could result in impairment.

Accounting for Income Taxes. Income taxes arc calculated in each of the jurisdictions in which we operate. This process involves estimating
our current tax exposure, together with assessing temporary differences for items treated differently for tax and financial reporting. Tax benefits are
recognized from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing
authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Deferred income tax assets
are reviewed for recoverability, and valuation allowances are provided, when necessary, to reduce deferred income tax assets to the amounts that
are more likely than not to be realized based on our estimate of future taxable income. Should our expectations of taxable income change in future
periods, it may be necessary to establish a valuation allowance, which could affect our results of operations in the period such a determination is
made.
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Judgment is required in assessing the future tax consequences of events that have been recognized in our financial statements or tax returns.
Variations in the actual outcome of these future tax consequences could materially impact our financial position, results of operations, or cash
nows. Additional infonnation regarding income taxes is available in Note D to the Consolidated Financial Statements herein.
On an interim basis, an estimate is made of what our effective tax rate will be for the full fiscal year, and a quarterly income tax provision in
accordance with this anticipated effective rate is recorded. As the fiscal year progresses, we continually refine our estimate based upon actual
events and earnings by jurisdiction during the year. This estimation process periodically results in changes to our expected effective tax rate for
the fiscal year. When this occurs, we adjust the income tax provision during the quarter in which the change in estimate occurs so that the ycar-toclatc provision equals the expected annual rate.

~

Equity-Based Compensation. We record compensation expense in the financial statements for equity-based awards based on the grant date
fair value and an estimate of forfeitures derived from historical experience. We use the Black-Scholes option pricing model to estimate the fair value
of our equity awards, which involves the use of assumptions such as expected volatility, expected term, dividend rate, and risk-free rate. Equitybased compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. For
more information regarding the assumptions and estimates used in calculating this equity-based compensation expense, see Note J to the
Consolidated Financial Statements herein.

~

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Our earnings, cash flows, and financial position arc affected by fluctuations in currency exchange rates, interest rates, and other uncertainties
that are inherent in doing business and selling product in more than one currency. In addition, our operations are exposed to risks that are
associated with changes in social, political, and economic conditions in our international operations. This includes changes in the laws and
policies that govern investment in international countries where we have operations, as well as, to a lesser extent, changes in U.S. laws and
regulations relating to international trade and investment.
Foreign Currency Risks. Net sales outside the United States represented 78.1 %, 81.8%, and 84.8% of our net sales in 2013, 2014, and 2015,
respectively. Because a significant portion of our sales arc generated outside the United States, currency exchange rate fluctuations may have a
significant effect on our sales and earnings. The local currency of each international subsidiary is considered the functional currency, with all
revenue and expenses being translated at weighted-average currency exchange rates for the applicable periods. In general, our reported sales and
gross profit are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar because we manufacture
the majority of our products in the United States and sell them to our international subsidiaries in their respective functional currencies. Currency
nuctuations, however, have the opposite effect on our Associate incentives and selling, general and administrative expenses. We are unable to
reasonably estimate the effect that currency nuctuations may have on our future business, results of operations, or financial condition. This is due
to the uncertainty in, and the varying degrees and type of exposure that we face from, nuctuation of various currencies.
Currently our strategy for reducing our exposure to currency fluctuation includes the timely and efficient repatriation of earnings from
international markets where such earnings are not considered to be indefinitely reinvested, and settlement of intercompany transactions.
Additionally, we may enter into short-term foreign currency credit arrangements in our international markets, primarily as a way to reduce our
exposure to negative effects of changes in foreign currency exchange rates. We also from time to time enter into currency exchange contracts to
offset foreign currency exposure in various
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international markets. We do not use derivative financial instruments for trading or speculative purposes. There can be no assurance that our
practices will be successful in eliminating all or substantially all of the risks that may be encountered in connection with our currency transactions.
Following are the average exchange rates of currency units to one U.S. dollar for each of the international markets in which we operated as of
January 2, 2016 for the quarterly periods indicated:
2015

2014
Second

First

Canadian Dollar
Australian Dollar
New Zealand Dollar
Hong Kong Dollar
Japanese Yen
New Taiwan Dollar
Korean Won
Singapore Dollar
Mexican Peso
Chinese Yuan
Malaysian Ringitt
Philippine Peso
Thailand Baht
Euro
Colombian Peso
Indonesia Rupiah

~

..:/)

...;P

*

Third

Fourth

First

Second

1.10
I.I I
1.20
7.76
l02.8
30.32
1,069.4
1.27
13.23
6.10
3.30
44.84
32.63
0.73
2,006.0

1~09
1.07
1.16
7.75
102.1
30.15
l,Q28.7
1.25
12.99
6.23
3.23
44.12
32.46
0.73
1,912.9

1.09
1.08
1.19
7.75
103.9
30.05
1,025.7
1.25
13.12
6.16
3.19
43.80
32.10
0.75
1,908.4

1.14
1.17
1.28
7.76
114.4
30.86
1,090.4
1.30
13.88
6.15
3.36
44.78
32.72
0.80
2,169.8

1.24
1.28
1.33
7.76
119.2
31.51
l,I04.2
1.36
14.97
6.24
3.63
44.44
32.62
0.89
2,483.7

*

*

*

*

*

Third

Fourth

7.75
121.7
30.83
1,100.2
1.34
15.36
6.20
3.66
44.71
33.36
0.90
2,504.0

1.3 I
1.39
1.54
7.75
121.9
32.13
1,173.7
1.40
16.51
6.32
4.09
46.22
35.40
0.90
2,970.6

*

*

1.34
1.39
1.50
7.75
121.5
32.66
1,158.5
1.41
16.79
6.40
4.28
46.95
35.83
0.92
3,072.5
13,743.19

1.23
1.29
1.38

USANA operations had not commenced during the period indicated.

Interest Rate Risks. As of January 2, 2016, we had no outstanding debt, and therefore, we had no direct exposure to interest rate risk. On
February 26, 2016, we had an outstanding balance of$63.0 million on our line of credit, with a weighted-average interest rate of 1.3%. This interest
rate is computed at the bank's Prime Rate, or LIBOR, adjusted by features specified in our Credit Agreement, with fixed rate term options up to six
months. The annual impact on after-tax expense of a 100-basis-point increase in the interest rate on the above balance would not materially affect
our earnings. If, however, we are unable to meet the covenants in our Credit Agreement, we would be required to renegotiate the term of the credit
under the Credit Agreement, including the interest rate. There can be no assurance that any renegotiated-terms of credit would not materially
impact our earnings.
Item 8.

Financial Statements and Supplementary Data

The Financial Statements and Supplementary Data required by this Item are set forth at the pages indicated at Item 15 below.
Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.
Item 9A.

Controls and Procedures

Disclosure Controls and Procedures

-..tJ

We maintain disclosure controls and procedures that are designed to ensure that infonnation that is required to be disclosed in our Exchange
Act reports is recorded, processed, summarized, and
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reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to
management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding any
required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and
management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and
procedures.
As of the end of the period covered by this report, our Principal Executive Officer and Principal Financial Officer evaluated the effectiveness of
the design and operation of our disclosure controls and procedures (as defined in Rule 13a- 15(e) under the Exchange Act). Based on this
evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the disclosure controls and procedures were effective to
provide reasonable assurance as of January 2, 2016.

~

~

Management's Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financia I reporting, ( as defined in Ru le l 3a- 15
(f) under the Exchange Act). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with generally
accepted accounting principles. Internal control over financial reporting includes those policies and procedures that:
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of the Company;
Provide reasonable assurance that transactions are recorded, as necessary, to permit preparation of financial statements in
accordance with generally accepted accounting principles and that receipts and expenditures of the Company arc being made only
in accordance with authorizations of management and directors of the Company; and
Provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of
the Company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any
evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions or
that the degree of compliance with the policies or procedures may deteriorate.
Our management, including our Principal Executive Officer and our Principal Financial Officer, assessed the effectiveness of the Company's
internal control over financial reporting as of January 2, 2016. In making this assessment, management used the criteria that have been set forth by
the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on its
assessment, using those criteria, management concluded that, as of January 2, 2016, the Company's internal control over financial reporting was
effective.
The effectiveness of the Company's internal control over financial reporting, as of January 2, 2016, has been audited by KPMG LLP, an
independent registered public accounting firm, as stated in their report which appears herein.

Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended January 2, 2016, that have
materially affected or that are reasonably likely to materially affect the Company's internal control over financial reporting.
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Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
USANA Health Sciences, Inc.:
We have audited USA NA Health Sciences, lnc.'s internal control over financial reporting as of January 2, 2016, based on criteria established in

Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
USANA Health Sciences, Inc.'s management is responsible for maintaining effective internal control over financial reporting and for its assessment
of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over
Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the co_mpany; (2) provide reasonable assurance
that transactions are recorded as necessary to pennit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors
of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of
the company's assets that could have a material effect on the financial statements.
·
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
In our opinion, USANA Health Sciences, Inc. maintained, in all material respects, effective internal control over financial reporting as of
January 2, 2016, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO).

~

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of USANA Health Sciences, Inc. and subsidiaries as of January 2, 2016 and January 3, 2015, and the related
consolidated statements of comprehensive income, stockholders' equity, and cash flows for each of the years in the three-year period ended
January 2, 2016, and our report dated March l, 2016 expressed an unqualified opinion on those consolidated financial statements.

Isl KPMG LLP
Salt Lake City, Utah
March I, 2016
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Item 9B.

Other Information

None.

PART Hi
Item 10.

Directors, Executive Officers and Corporate Governance

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 1J.

Executive Compensation

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 13.

Certain Relationships and Related Transactions, and Director Independence

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.
Item 14.

Principal Accounting Fees and Services

The information for this Item is incorporated by reference to the definitive proxy statement to be filed pursuant to Regulation 14A under the
Exchange Act.

PART IV
Item 15.

(a)

Exhibits, Financial Statement Schedules

The following documents are filed as part of this Form:
l.

Financial Statements

Reports of Independent Registered Public Accounting Firms
Consolidated Balance Sheets
Consolidated Statements of Comprehensive Income
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Notes to the Consolidated Financial Statements

2.

Financial Statement Sf'hedules.

For the years ended December 28, 2013, January 3, 2015, and January 2, 2016
Schedule II-Valuation and Qualifying Accounts
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3.

Exhibits.
Exhibit
Number

Descri lion

3.1

Amended and Restated Articles of Incorporation (incorporated by reference to Current Report on
Fann 8-K, filed April 25, 2006)

3.2

Bylaws (incorporated by reference to Current Report on Form 8-K, filed April 25, 2006)

4.1

Specimen Stock Certificate for Common Stock (incorporated by reference to Registration Statement on
Form 10, File No. 0-21116, effective April 16, 1993)

l 0.1

USA NA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current
Report on Fonn 8-K, filed April 25, 2006)*

10.2

Fonn of Stock Option Agreement for award of non-statutory stock options to employees under the
USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current
Report on Form 8-K, filed April 26, 2006)*

10.3

Form of Stock Option Agreement for award of non-statutory stock options to directors who are not
employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by
reference to Current Report on Fonn 8-K, filed April 26, 2006)*

l 0.4

Fonn of Incentive Stock Option Agreement for award of incentive stock options to employees under the
USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current
Report on Fonn 8-K, filed April 26, 2006)*

l 0.5

Fann of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock
appreciation rights to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award
Plan (incorporated by reference to Current Report on Fonn 8-K, filed April 26, 2006)*

l 0.6

Fann of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock
appreciation rights to directors who arc not employees under the USANA Health Sciences, Inc. 2006
Equity Incentive Award Plan (incorporated by reference to Current Report on Fonn 8-K, filed April 26,
2006)*

I 0.7

Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are
not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated
by reference to Current Report on form 8-K, filed April 26, 2006)*

10.8

Fonn of Indemnification Agreement between the Company and its directors (incorporated by reference
to Current Report on Forni 8-K. filed May 24, 2006)*

10.9

Form of Indemnification Agreement between the Company and certain of its officers (Incorporated by
reference to Report on Forni 8-K, filed May 24, 2006)*

10.10

Share Purchase Agreement, dated as of August 16, 20 I 0, among USANA Health Sciences, Inc.,
Petlanc, Inc., Yaolan Ltd., and BabyCare Holdings Ltd. (Incorporated by Reference to Report on Fann 8K, filed August 16, 20 I 0)

10.11

Amended and Restated Credit Agreement, dated as of April 27, 2011 (Incorporated by reference to
Report on Fonn 8-K, filed April 28. 201 I)

10.12

Form of Executive Confidentiality, Non-Disclosure and Non-Solicitation Agreement (incorporated by
reference to Quarterly Report on Form I0-Q for the period ended October I, 2011, filed November 9,
201 I)*

vu

,-4)

,.J
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Exhibit
Number

Descri lion

10.13

Separation and Release of Claims Agreement dated as of December 21, 2012 by and between USANA
Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Fonn 8-K/A, filed
December 26, 2012)*

10.14

Amendment to Confidentiality, Non-Disclosure and Non-Solicitation Agreement dated as of
December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by
reference to Report on Form 8-K/A, filed December 26, 2012)*

I0.15

Amendment to Amended and Restated Credit Agreement, dated as of July 18, 2013 (Incorporated by
reference to Report on Form 8-K, filed July 23, 20 I3)

10.16

USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report
on Fonn 8-K, filed July 31, 2015)

I0.17

Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USA NA
Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Fonn 8K, filed July 31, 2015)*

I0.18

Form of Stock-Settled Stock Appreciation Rights Award Agreement for non-employee directors under
the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to
Report on Fonn 8-K, filed July 31, 2015)*

10.19 Form of Restricted Stock Unit Award Agreement for employees under the USANA Health Sciences, Inc.
20 I 5 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)

*
10.20

Form of Restricted Stock Unit Award Agreement for non-employee directors under the USANA Health
Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed
July31,2015)

10.21

Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to non-employee
director under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by
reference to Report on Fonn 8-K, filed July 31, 2015)

I 0.22

Sec~nd Amendment to the Amended and Restated Credit Agreement and Amendment to loan
documents (incorporated by reference to Report on Form 8-K, filed February 23, 2016)

I I.I

Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)

14

Code of Ethics of USANA Health Sciences, Inc. (posted on the Company's Internet web site at
www. usanahea Ithsciences.com)

21

Subsidiaries of the Registrant, as ofFebruary 26, 20 I 6 (filed herewith)

23.1

Consent of lndeper_1dent Registered Public Accounting Firm (KPMG LLP) (filed herewith)

31.1

Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of2002
(filed herewith)

31.2

Ce1tification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
(filed herewith)

32.1

Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18
U.S.C. Section 1350 (filed herewith)
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Number

32.2

*

Dcscri lion

Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18
U.S.C. Section 1350 (filed herewith)

101.fNS

XBRL Instance Document

IOI.SCH

XBRL Taxonomy Extension Schema Document

IOI.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

IOI.DEF

XBRL Taxonomy Extension Definition Linkbase Document

IOI.LAB

XBRL Taxonomy Extension Label Linkbase Document

IOI.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

Denotes a management contract or compensatory plan or arrangement.
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SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
USANA Health Sciences, Inc.

By:

Isl DAVID A. WENTZ

David A. Wentz
Principal Executive Officer
Date: March I, 2016
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.
Dale

Is! MYRON W. WENTZ

Chairman

March I, 2016

Co-Chief Executive Officer (Principal
Executive Officer)

March I, 2016

Director

March I, 2016

Director

March 1,2016

Director

March 1,2016

Director

March I, 2016

Chief Financial Officer (Principal Financial
and Accounting Officer)

March I. 2016

Myron W. Wentz, PhD

Isl DAVID A. WENTZ
David A. Wentz
Isl RONALD S. POELMAN

Ronald S. Poelman

Isl ROBERT ANCIAUX
Robert Anciaux

Isl JERRY G. MCCLAIN
Jerry G. McClain
Isl GILBERT A. FULLER

Gilbert A. Fuller

Isl PAUL A. JONES
Paul A. Jones
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REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
USANA Health Sciences, Inc.:
We have audited the accompanying consolidated balance sheets of USANA Health Sciences, Inc. and subsidiaries as of January 2, 2016 and
January 3, 2015, and the related consolidated statements of comprehensive income, stockholders' equity, and cash flows for each of the years in
the three-year period ended January 2, 2016. In connection with our audits of the consolidated financial statements, we also have audited financial
statement schedule II. These consolidated financial statements and financial statement schedule are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our
audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of USANA
Health Sciences, Inc. and subsidiaries as of January 2, 2016 and January 3, 2015, and the results of their operations and their cash flows for each of
the years in the three-year period ended January 2, 2016, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the
related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in
all material respects, the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), USANA Health
Sciences, Inc.'s internal control over financial reporting as of January 2, 2016, based on criteria established in Internal Control-Integrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated March I,
2016 expressed an unquali tied opinion on the effectiveness of the Company's internal control over financial reporting.

Isl KPMG LLP
Salt Lake City, Utah
March I, 2016
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USANA HEALTH SCJENCES, INC. AND SUBSJDIARJES
CONSOLJDATED BALANCE SHEETS
(in thousands, except par value)
As of
January 3,

As of
January 2,

2015

2016

ASSETS
Current assets
Cash and cash equivalents
Inventories
Prepaid expenses and other current assets
Total current assets

$

111,126 $ 143,210
45,248
66,119
34;553 ,
34,935
190,927
244,264
-71~]64,

Property and equipment, net

'87,982

17,941
17,432
40,95,2:
. ~8,269.
5,933
9,844
23,667: ,.:. 25,446
$ 350,584 $ 423,237

Goodwill
Intangible assets, net
Deferred tax assets
Other assets

LIABILITIES AND STOCKHOLDERS' EQUITY

;!.

Current liabilities
Acc.ounts payable
OLher current liabililies
Total current liabilities

-;

...:

'

' ~

100,926
121,369
.(.. 108,'1Qf..:)JJr;4tl ·,
10,601
1,114 ·

Stockholders' equity
· Common stock, $0.00 l par value; Authorized-50,000 shares, issued and _outstanding ..
-- ·
12,633 as of January 3, 20 I 5 and 12,488 as of January 2, 2016
·
Additional paid-in capital

Retained earnings

.

$ ' •.•,7,7}9.:'· S.t:o:~l.Q,943.

Deferred tax liabilities
Other long-term ltabilities

Accumulated other comprehensive income
Total stockholders' equity

,,

..

9,822
1,151

. i.13·'·
13
61,613
69,740
· 166,406'
214,875
2,132
(3,776)
.. -230;)64. , .. 280,852
$ 350,584 $ 423,237

The accompanying notes arc an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUllSIDIAR1ES
CONSOLIDATED STATEMENTS OF COMPREHENSI VE INCOME

(in thousands, except per share data)
Year Ended
2014

20 13

s

Net sales
Cost of sales
Gross profit
Operating expenses:
Associate incentives
Selling, general and adm inistrative
Total operating expenses
Earn ings from operations
Other income (expense):
Interest income
Interest expense
Other, net
Other income (expense), net
Earnings before income taxes
Income taxes
Net earnings
Earnings per common share
Basic
Diluted

s

718, 175
127,435
590,740

307,820
166,208
474.028
116,712

464
(I )

$

{594 )
(I 31 )
116,581
37,557
79,024 l,

s
s

5.77
5.56

Weighted average common shares outstanding
'
Basic
Diluted
Comprehensive income:
Net earnings
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment
Tax benefit (expense) related to foreign currency translation adjustment
Other comprehensive income (loss), net of tax
.. Comprehensive income

s
s

79,024

s

(1,458)
316
(1, 142)
77,882

20 15

s

918,499
159,682
758,817

349,044
184,53 1
533,575
11 6,102

408,160
208,995
617,155
141,662

500
(129)
(820)
(449)
115,653
39,017
76,636

1,116
(15 )
{1 74 )
927
142,589
47,917
94,672

5.80
5.60

s
$
$

13,221
13,689

13,695
14,204

s

790,471
140,794
649,677

s

76,636

$

(4,492 )
830
{3,662 _)
72,974

The accompany ing notes arc an integra l part of these statements.
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7.44
7.18

12,730
13,177

s

94,672

$

(9,283 )
3,375
(5,908 )
88,764
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARJES
CONSOLIUATJ.W STATI!:Ml!:NTS OF STOCKHOLUI!:RS' 1!:QUITY
Years ended December 28, 2013; January 3, 2015; and January 2, 2016

(in thousands)
~
Common
Stock

Shares

Balance at December 29,2012
Net earnings
Other comprehensive income (loss), net
oftax
.
Equity-based compensation expense
Common stock repurchased and retired
Common stock issued under equity
award plans
Tax benefit from equity award activity
Balance at December 28, 2013
Net earnings
Other comprehensive income (loss), net
of tax
.. Equity-bascd,compcnsation expense.
Common stock repurchased and retired
. ·~orilmon stock. is5.ued under equity
· award plans .
Tax benefit from equity award activity
:;Balance ~fiariuary 3, 2015
Net earnings
compr€:he,ris1yefocome-(loss); net

Otb~r
•.;

:

.

13,821

Additional
Paid-in
Cal!ital

Value

$

14 $

Accumulated
Other
Comprehensive
Income {Loss}

Retained
Earnings

134,800 ·:$
79,024

43,822 $

Total

185,572
79,024
~

(1,142)
7,624
(4,284)

(414)
479
13,886

454
7,o75
54,691

14

(13,801)

(l·,142)
7,624
c1s:oss >

200,023

454
7;075
260,522

5,794

7MJ6··

76,636
(3.662)

(1,927 )

(2 )

.9,805.: ..
(28,564 )

13

10,969
14,712
61,613

674
12,633

.-

,

.; .: : ,-

::·,-•> i:.;~·;~·j-;:i-... ~~..

(110,253)

,','ti:)970;-'.
··"···

: .. ,·,16.6,406
94,672
• • 0

~

• .'•

>::•:<
.·.··-.'
, ;

'

-.::-• ~; : T

, :~~_.:;.:.:~·:i~·::,:,:;<";·,.

~

14,712

: .·: 2J3'2>. '. /230if6.4:
94,672

,. . '•.: ~;:::

•,'

: (S:908)_·

11,081
(14,978) · .. (46,20fr,::

(457)

(3,662)
. '9~8()5
(138,819 )
..

' .. :ofJax_.'

Equity-based compensation expense
Common s_tock repurchase5} and retired
Common stock issued under equity
award plans
Tax benefit from equity award activity
Balance at January 2, 2016

6,936 $

~· ,;;;>,;:).·.·.':: .

(S,908')
11,081
(6i,t81)

~-

312
12,488

$

=

13

$

12;024
69,740 $

214,875

$

(3,776) $

12.024
280,852
~

The accompanying notes arc an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

~
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Year Ended
2014

2013

~

viP

VJI

~

Cash flows from operating activities
Net earnings
Adjustments to reconcile net earnings to net cash provided by (used in)
operating activities
Depreciation and amortization
(Gain) loss on sale of property and equipment
Equity-based compensation expense
Excess tax benefits from equity-based payment arrangements
Deferred income taxes
Changes in operating assets and liabilities:
Inventories
Prepaid expenses and other assets
Income tax payable related to tax benefit from equity award
activity
Accounts payable
Other liabilities
Net cash provided by (used in) operating activities

$

79,024

$

76,636 $ 94,672

9,044
(I 6 )
7,624
(7,466 )
814

8,810
46
9,805
(14,834)
(1,039)

9,978
3
11,081
(12,024)
(2,572)

(1 I ,783 )

1,102
(3,789)

(23,071 )
(2,047)

(8,465 )

Cash flows from investing activities
Additions to notes receivable
Purchases of investment securities held-to-maturity
.:.. Maturities of investment securities
Proceeds from sale of property and equipment
. Pllrchases of property and equipment
Net cash provide~ by (used in) investing activities

2015

7,Q75
2,790
20,252
98,893

14,712
(1,337 )
15,073
105,185

(4,942)

(4,495)
(3,871 )
12,511
10
{20,42f )·
(16,~66)

(8,643)
47
(8,051)
(21,589)

12,024
2,481
20,941
111,466

(1,580)

185
-(23,729-)
(25,124)

· Cash flows from ·financing activities
~

~

·.JJ

Cash paid during the period for:
Interest
Income taxes
Non-cash investing activities:
Credits on notes receivable
Accrued purchases of property and equipment

I0,970
)4,834

12,024
(61,181 )

(138,819)
30,000

po,ooo)

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosures of cash flow information

vb

454
7,466
(18,085)

Proceeds from equity awards exercised
Excess tax benefits.from equity-based payment arrangements
Repurchase of common stock
Borrowings on line of credit
Payments on line of credit
Net cash provided by (used in) financing activities

$

$

(10,165)

(113,015)

(49,157)

(635)
66,504

(2,121 )
(26,217)

(5,IOI )
32,084

70,839
137,343
I I l,126
137,343 $ 111,126 $ 143,210

I $
26,952

136
26,955

198

720
1,805

The accompanying notes arc an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUBSIDJARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company
USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care products that are sold internationally
through a global network marketing system, which is a form of direct selling. The Consolidated Financial Statements include the accounts and
operations of USANA Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the "Company" or "USANA") in two geographic
regions: Asia Pacific, and Americas and Europe. Asia Pacific is further divided into three sub-regions: Greater China, Southeast Asia Pacific, and
North Asia. Greater China includes Hong Kong, Taiwan and China; Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia,
the Philippines, Thailand, and Indonesia; North Asia includes Japan, and South Korea. Americas and Europe includes the United States, Canada,
Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands.

Principles ofconsolidation and basis ofpresentation
The accompanying Consolidated Financial Statements include the accounts and operations of USANA Health Sciences, Inc. and its whollyowned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The accounting and reporting policies of
the Company conform with accounting principles generally accepted in the United States of America ("US GAAP").

Use of estimates

VO

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates for the Company relate to
revenue recognition, inventory obsolescence, goodwill and other intangible assets, equity-based compensation, and income taxes. Actual results
could differ from those estimates. These estimates may be adjusted as more current information becomes available, and any adjustment could be
significant.

Fiscal year
The Company operates on a 52-53 week year, ending on the Saturday closest to December 31. Fiscal years 2013 and 2015, were 52-week years.
Fiscal year 2014 was a 53-week year. Fiscal year 2013 covered the period December 30, 2012 to December 28, 2013 (hereinafter 2013). Fiscal year
2014 covered the period December 29, 2013 to January 3, 2015 (hereinafter 2014). Fiscal year 2015 covered the period January 4, 2015 to January 2,
2016 (hereinafter 2015 ).

Fair value measurements
The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that
prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to
transfer a liability in an
F-6
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USANA HEAL TH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED flNANCIAL STATEMENTS (Continued)

(in thousands, except pei shaie data)

NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset
or liability. The levels of the fair value hierarchy are:
Level l inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement
date.
Level 2 inputs are from other than quoted market prices included in Level l that are observable for the asset or liability, either
directly or indirectly.
Level 3 inputs un! unobsc, vublc uml urc usc<l tu meusurc fair value in situations where there is little, if any, market activity for the
asset or liability at the measurement date.
As of January 3, 2015 and January 2, 2016, the following financial assets and liabilities were measured at fair value on a recurring basis using
the type of inputs shown:

~

Fair Value Measurements
Using
January 3,
2015

Money market funds includ~d in cash equivalen~s

$

Level 1

Inputs
Level 2

Level 3

--4;~33 .. L:•M_n;.·.,.·L~.,. ,: )$:.,. ,:.::

Fair Value Measurements
Using
January 2,
20 I 6

Moneymarketfundsincluded in cash equivalents.

$-

Inputs
Level I

~

Level 3

14,460.. ,$, l4~460,Ui. ;__.l....!::_ ,$,v.: ,~

There were no transfers of financial assets or liabilities between Level l and Level 2 inputs for the years ended 2014 and 2015.
The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, are not required
to be carried at fair value on a recurring basis. However, if ce11ain triggering events occur (or tested at least annually for goodwill and indefinitelived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impairment charge is recorded to reduce the
carrying value to the fair value, if the carrying value exceeds the fair value. For the years ended 2013, 2014, and 2015, there were no non-financial
assets measured at fair value on a non-recurring basis.

Fair value offinancial ins/rumenls
At January 3, 2015 nnd Jammry 2, 2016, the Company's financial instruments include cash equivalents, accounts receivable, restricted cash,
notes receivable, and accounts payable. The recorded values of cash equivalents, accounts receivable, restricted cash, and accounts payable
approximate their fair values, based on their short-term nature. The carrying value of the notes receivable approximate fair value because the
variable interest rates in the notes renect current market rates.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Translation offoreign currencies

vJ

The functional currency of the Company's foreign subsidiaries is the local currency of their country of domicile. Assets and liabilities of the
foreign subsidiaries are translated into U.S. dollar amounts at month-end exchange rates. Revenue and expense accounts are translated at the
weighted-average rates for the monthly accounting period to which they relate. Equity accounts are translated at historical rates. Foreign currency
translation adjustments are accumulated as a component of other comprehensive income. Gains and losses from foreign currency transactions are
included in the "Other, net" component of Other income (expense) in the Company's consolidated statements of comprehensive income.

Cash and cash equivalents
The Company considers al1 highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents as of January 3, 2015 and January 2, 2016 consisted primarily of money market fund investments, and amounts
receivable from credit card processors.
Amounts receivable from credit card processors are considered cash equivalents because they are both short-term and highly liquid in nature
and are typically converted to cash within three days of the sales transaction. Amounts receivable from credit card processors as of January 3,
2015 and January 2, 2016 totaled $6,209 and $12,516, respectively.

Restricted Cash
The Company is required to maintain cash deposits with banks in certain subsidiary locations for various operating purposes. The most
significant of these cash deposits relates to a deposit held at a bank in China, the balance of which was $3,222 as of January 3, 2015, and $3,080 as
of January 2, 2016. This deposit is required for the application of direct sales licenses by the Ministry of Commerce and the State Administration
for Industry & Commerce of the People's Republic of China, and will continue to be restricted during the periods while the Company holds these
licenses. Restricted cash is included in the "Other assets" line item in the Company's consolidated balance sheets.

inventories
Inventories are stated at the lower of cost or market. Cost is determined using a standard costing system which approximates the first-in, firstout method. The components of inventory cost include raw materials, labor, and overhead. Market value is determined using various assumptions
with regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production
planning, and market conditions. A change in any of these variables could result in an adjustment to inventory.

Accounts Receivable
Accounts receivable arc recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for doubtful
accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical
losses adjusted to
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USANA HEAL TH SCIENCES, INC. AND SUBSIDIARIES

6L,

Qii:iil

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)

NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
take into account current market conditions and our customers' financial condition, the amount of receivables in dispute, and the current
receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts regularly. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Accounts
Receivable is included in "Prepaid expenses and other current assets" line item in the Company's consolidated balance sheets.

<iLJ

Income taxes
The Company accounts for income taxes using the asset and liability method, which requires recognition of deferred tax assets and liabilities
for the expected future tax consequences of the differences between the financial statement assets and liabilities and their respective tax bases.
Deterred tax assets and liabilities are measured using enacted tax rates that arc expected to apply to taxable income in the year in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and
liabilities. The Company evaluates the probability of realizing the future benefits of its deferred tax assets and provides a valuation allowance for
the portion of any deferred tax assets where the likelihood of realizing an income tax benefit in the future does not meet the "more-likely-than-not"
criteria for recognition. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will
be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial
statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon
ultimate resolution. The Company recognizes interest and penalties related to unrecognized tax benefits in income taxes. Deferred taxes are not
provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered indefinitely
reinvested.

~

~

Property and equipment
Property and equipment are recorded at cost. Maintenance, repairs, and renewals, which neither materially add to the value of the property nor
appreciably prolong its life, are charged to expense as incurred. Depreciation is provided in amounts sufficient to relate the cost of depreciable
assets to operations over the estimated useful lives of the related assets. The straight-line method of depreciation and amortization is followed for
financial statement purposes. Leasehold improvements are amortized over the shorter of the life of the respective lease or the useful life of the
improvements. Property and equipment are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying
amount of an asset may not be recoverable. When property and equipment are retired or otherwise disposed of, the cost and accumulated
depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period.

Notes receivable
Notes receivable consists primarily of a secured loan to a third-party supplier of the Company's nutrition bars and are included in the "Other
assets" line item in the Company's consolidated balance
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

~

sheets. The Company has extended non-revolving credit to this supplier to allow them to acquire equipment that is necessary to manufacture the
USANA nutrition bars. This relationship provides improved supply chain stability for USANA and creates a mutually beneficial relationship
between the parties. Notes receivable are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair
value. Interest accrues at an annual interest rate of LIBOR plus 400 basis points. The note has a maturity date of February 1, 2024 and will be repaid
by a combination of cash payments and credits for the manufacture of USANA's nutrition bars. Manufacturing credits applied during 2014 and
2015 were $720 and $966, respectively. There is no prepayment penalty. Notes receivable from this supplier as of January 3, 2015, and January 2,
2016, were $8,519, and $8,339, respectively.
The third-party supplier is considered to be a variable interest entity; however, the Company is not the primary beneficiary due to the inability
to direct the activities that most significantly affect the third-party supplier's economic performance. The Company does not absorb a majority of
the third-party supplier's expected losses or returns. Consequentially, the financial information of the third-party supplier is not consolidated. The
maximum exposure to loss as a result of the Company's involvement with the third-party supplier is limited to the carrying value of the note
receivable due from the third-party supplier.

Goodwill
Goodwill represents the excess of the purchase price over the fair market value of identifiable net assets of acquired companies. Goodwill is
not amortized, but rather is tested at the reporting unit level at least annually for impairment or more frequently if triggering events or changes in
circumstances indicate impairment. Initially, qualitative factors are considered to determine whether it is more likely than not that the fair value of a
reporting unit is less than its carrying amount. Some of these qualitative factors may include macroeconomic conditions, industry and market
considerations, a change in financial performance, entity-specific events, a sustained decrease in share price, and consideration of the difference
between the fair value and carrying amount of a reporting unit as determined in the most recent quantitative assessment. If, through this
qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit's fair value is less than its carrying amount, a twostep quantitative impairment analysis is performed. The first step involves estimating the fair value of a reporting unit using widely-accepted
valuation methodologies including the income and market approaches, which requires the use of estimates and assumptions. These estimates and
assumptions include revenue growth rates, discounts rates, and determi.nation of appropriate market comparables. If the fair value of the reporting
unit is less than its carrying amount, the second step of the impairment test is performed to measure the amount of the impairment loss. In the
second step, the implied fair value of the goodwill is estimated as the fair value of the reporting unit as determined in step one, less fair values of all
other net tangible and intangible assets of the reporting unit determined in a manner similar to a purchase price allocation. If the carrying amount of
the goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that excess, not to exceed the carrying amount of
the goodwill. During 2013, 2014, and 2015, no impairment of goodwill was recorded.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per shai·e data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Intangible assets
Intangible assets represent long-lived and indefinite-lived intangible assets acquired in connection with the purchase of the Company's China
subsidiary in 2010. Long-lived intangible assets are amortized over their related useful lives, using a straight-line or accelerated method consistent
with the underlying expected future cash flows related to the specific intangible asset. Long-lived intangible assets are reviewed for impairment
whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of
impairment exist, an estimate ofundiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group
is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset group's carrying value and
estimated fair value. Fair value is determined through various valuation techniques, including market and income approaches as considered
necessary.
Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or
changes in circumstances exist that may indicate impairment. InitiaJly, qualitative factors are considered to determine whether it is more likely than
not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If, through this qualitative assessment, the conclusion
is made that it is more likely than not that an indefinite-lived intangible asset's fair value is less than its carrying amount, a quantitative impairment
analysis is performed by comparing the indefinite-lived intangible asset's book value to its estimated fair value. The fair value for indefinite-lived
intangible assets is determined through various valuation techniques, including market and income approaches as considered necessary. The
amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset. During 2013, 20 l 4,
and 2015, no impairment of indefinite-Jived intangible assets was recorded.

Self insurance
The Company is self-insured, up to certain limits, for employee group health claims. The Company has purchased stop-loss insurance on both
an individual and an aggregate basis, which will reimburse the Company for individual claims in excess of $125 and aggregate claims that are
greater than 100% of projected claims. A liability is accrued for all unpaid claims. Total expense under this sci f insurance program was $5,281,
$7,019 and $7,287 in 2013, 2014 and 2015, respectively.

Common stock and additional paid-in capital
The Company records cash that it receives upon the exercise of equity awards by crediting common stock and additional paid-in capital. The
Company received $454, and $10,970 in cash proceeds from the exercise of equity awards in 2013 and 2014, respectively. There were no cash
proceeds from the exercise of equity awards in 2015. The Company also realizes an income tax benefit from the exercise of certain equity awards.
Upon exercise, the related deferred tax assets are reversed and the difference between the deferred tax assets and the realized tax benefit
creates a tax windfall or shortfall that increases or decreases the additional paid-in capital pool ("APIC Pool"). If the APIC Pool is reduced to zero,
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
additional shortfalls are treated as a current tax expense. The total tax benefit recorded in additional paid-in capital was $7,075, $14,712, and $12,024,
in 2013, 2014, and 2015, respectively.
The Company has a stock repurchase plan in place that has been authorized by the Board of Directors. As of January 2, 2016, $100,000 was
available to repurchase shares under this plan. The Company expended $18,085, $138,819, and $6 l, 181 to repurchase and retire shares during 2013,
2014, and 20 I 5, respectively. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings
on a pro-rata basis. There currently is no expiration date on the remaining approved repurchase amount and no requirement for future share
repurchases.

Revenue recognition and deferred revenue
Revenue is recognized at the estimated point of delivery of the merchandise, at which point the risks and rewards of ownership have passed
to the customer. Revenue is realizable when the following four criteria are met: persuasive evidence of a sale arrangement exists, delivery of the
product has occurred, the price is fixed or determinable, and payment is reasonably assured.
The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders. Sales and related fees
such as shipping and handling, net of applicable sales discounts, are recorded as revenue when the product is delivered and when title and the
risk of ownership passes to the customer. Payments received for undelivered products are recorded as deferred revenue and are included in other
current liabilities. Deferred revenue is recognized at the estimated point of delivery of the merchandise. On the occasion that will-call orders are not
picked up by customers, we periodically assess the likelihood that customers will exercise their contractual right to pick up orders and recognize
revenue when the likelihood is estimated to be remote. Certain incentives offered on the sale of our products, including sales discounts, are
classified as a reduction of revenue. Sales discounts earned under USANA's initial order reward program are considered part of a multiple element
revenue arrangement and accordingly are deferred when the first order is placed and recognized as customers place their subsequent two Auto
Orders. A provision for product returns and allowances is recorded and is based on historical experience. Additionally, the Company collects an
annual account renewal fee from Associates that is deferred upon receipt and is recognized as income on a straight-line basis over the subsequent
twelve-month period.
Taxes that have been assessed by governmental authorities and that are directly imposed on revenue-producing transactions between the
Company and its customers, including sales, use, value-added, and some excise taxes, are presented on a net basis in the consolidated statements
of comprehensive income (excluded from net sales).

Product return policy
All first-time product orders that arc returned within the first 30 days following purchase are refunded at I 00% of the sales price. After the first
order, all other returned product that is unused and resalable is refunded up to one year from the date of purchase at l00% of the sales price. This
standard policy differs slightly in a few ofour international markets due to the regulatory environment in those markets. According to the terms of
the Associate agreement, return of product where the purchase amount exceeds one hundred dollars and was not damaged at the time of receipt
by the
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NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Associate may result in cancellation of the Associate's distributorship. Depending upon the conditions under which product was returned,
customers may either receive a refund based on their original form of payment, or credit on account for a product exchange. Product returns totaled
approximately 0.9% of net sales in 2013, 0.8% of net sales in 2014, and 0.6% ·ornet sales in 2015.

Shipping and handling costs
The Company's shipping and handling costs are included in cost of sales for all periods presented.

Associate incentives
Associate incentives expenses include all forms of commissions, and other incentives paid to our Associates, less commissions paid to
Associates on personal purchases, which are considered a sales discount and are reported as a reduction to net sales.

Selling. general and administrative
Selling, general and administrative expenses include wages and benefits, depreciation and amortization, rents and utilities, Associate event
costs, advertising and professional fees, marketing, and research and development expenses.

Equity-based compensation
The Company records compensation expense in the financial statements for equity-based awards based on the grant date fair value and an
estimate of forfeitures derived from historical experience. Equity-based compensation expense is recognized under the straight-line method over
the period that service is provided, which is generally the vesting term. Further information regarding equity awards can be found in Note JEquity-Based Compensation.

Advertising
Advertising costs are charged to expense as incurred and are presented as part of selling, general and administrative expense. Advertising
expense totaled $3,650 in 2013, $4,942 in 2014 and $13,766 in 2015.

Research and development
Research and development costs are charged to expense as incurred and are presented as part of selling, general and administrative expense.
Research and development expense totaled $5,083 in 2013, $5,128 in 2014 and $6,420 in 2015.

Earnings per share
Basic earnings per common share (EPS) are based on the weighted-average number of common shares that were outstanding during each
period. Diluted earnings per common share include the effect of potentially dilutive common shores calculated using the treasury stock method,
which include in-the-money, equity-based awards that have been granted but have not been issued.
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NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board ("FASS") issued an Accounting Standard Update ("ASU") No. 2014-09, "Revenue
from Contracts with Customers (Topic 606)." ASU 2014-09 includes a five-step process by which entities will recognize revenue to depict the
transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those
goods or services. The standard also will require enhanced disclosures to enable users of financial statements to understand the nature, amount,
timing, and uncertainty of revenue and cash flows arising from contracts with customers. In July 2015, the FASS announced a decision to defer the
effective date of this ASU. ASU 2014-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early
adoption permitted for annual and interim reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact
ASU 2014-09 will have on its consolidated financial statements.
In February 2015, the FASS issued ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis". This standard
modifies existing consolidation guidance for reporting companies that are required to evaluate whether they should consolidate certain legal
entities. ASU 20 I 5-02 is effective for fiscal years and interim periods within those years beginning after December 15, 20 l 5, and requires either a
retrospective or a modified retrospective approach to adoption. The Company is currently evaluating the impact ASU 2015-02 will have on its
consolidated financial statements.
In April 2015, the FASB issued ASU No. 2015-05, "Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's
Accounting for Fees Paid in a Cloud Computing Arrangement". This ASU provides guidance to customers about whether a cloud computing
arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the
software license element of the arrangement consistent with the acquisition of other software licenses. lfa cloud computing arrangement does not
include a software license, the customer should account for the arrangement as a service contract. The ASU is effective for annual and interim
reporting periods beginning after December 15, 2016. Early adoption is permitted. The standard permits the use of either the retrospective or
cumulative effect transition method. The Company is currently evaluating the impact ASU 2015-05 will have on its consolidated financial
statements.
In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330): Simplifying the Measurement of Inventory". For entities that do not
measure inventory using the last-in, first-out or retail inventory method, ASU 2015-11 changes the measurement principle for inventory from the
lower of cost or market to lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of
business, less reasonably predictable costs of completion, disposal and transportation. The ASU is effective for annual and interim reporting
periods beginning after December 15, 2016. The Company is currently evaluating the impact ASU 2015-11 will have on its consolidated financial
statements.
In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes". The ASU
requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The ASU is effective for annual and
interim periods
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NOTE A-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

in fiscal years beginning after December 15, 2016. Early adoption is permitted at the beginning of an interim or annual period and requires either a
prospective or retrospective approach to adoption. The Company is currently evaluating the impact ASU 20 I 5-17 will have on its consolidated
financial statements.
NOTE B-INVENTORIES

Inventories consist of the following:

Raw materials
Work in progress
.Finished goods

January 3,

January 2,

2015

2016

15,127 $
7,545
22,576:
45,248 $

$

$

22,529
8,701
34,889.
66,119

NOTE C-PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

. ·Prepaid insurance
Other prepaid expenses
Federal income taxes receivable.'.
Miscellaneous receivables, net
Deferred commissions
Deferred tax assets
Other current assets

' • _.

> ::

..

C., '

J:anu:ary J,

January l,

2015

2016

.'$'.',':

'J:~ot.:~:i?}:::n1it::
3,094

3,862

3,656

4,704

9,683

9,674

: ;_•=,·::1IJ10:·_ ::;,:7r:'110.sr:-

- · 3,611 · '. ~-:, ~ tioJ<
· ,,:s,625'. -.' \, · l4;ssf,{
$

34,553

$

34,935
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NOTE D-INCOME TAXES
Income tax expense (benefit) included in income from net earnings consists of the following:
Year ended
2013

Current
Federal
State
Foreign
Total Current

$

Deferred
Federal
State
Foreign
Total Deferred

2014

$ 22,362

26,233
· 94
9,626
35,953

2015

17,492
464
32,198
50,154

$

1,056
16,265
39,683

(1,096) . (5,220)
(43}
(155)
3,138
473
(666)
{2,237)
'$ 37;557 $ 39,017 $, . 47,917
5,507
(5 )
{3,898)
1,604

The income tax provision, as reconciled to the tax computed at the federal statutory rate of35% for 2013, 2014, and 2015, is as follows:
Year ended
2014

2013

· ·... , .. Fe.deral-in'come taxes at statutory rate
State income taxes, net of federal tax benefit
Qu.alified production activities deduction
Foreign rate differential
U.S. research credit
AH other, net

·Si: ':40;803
102

2015

·J ;:,iJQ;f79.hJ:Y4!M.Of.•::
653

670

c1.100 ):.: : ·cs~tt< . ,/{9.52J
(890)

c2p6·J ·
_ _(~55;..._2)

s.

(603 )

(461 )

.c29fr, . :·

'{425 >

(332)

{821 }

37,557. ..--.$;. -39,otr:·>s•.••47~9.t7
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(1n thousands, except per share data)
NOTE D-INCOME TAXES (Continued)
The significant categories of deferred taxes are as follows:
,January 3,
2015

January 2,
2016

Deferred tax assets
Inventory
Acc11£als. not currently deductible
Equity-based compensation expense
,. .. Jil~angi~le.assets
Net operating losses
Accumulated other comprehensive income
Other
deferred tax assets
Valuation allowance
.. ,[. i;'J~ie{d~ferrecftax assets
Deferred tax liabilities

$

i\f~~m~f:.~~-d-~-~~;.~.d~,~~g~~te,~~i~e _income
· - · · ·, · :;;-, rrepa1 ,expen:;es · ·· ·
Intangible assets

.. ·- ::._ i·> ·;;?other _: ·

Gross deferred tax liabilities

,:::,f/::f):'&~t:det~ried'faxei:::;:-·/·i.·; .

3,341
5,892
4,476
9,283

$

I 10

988
4,543
25,449
(526)
24,923

..' Gross

·- .:::rE.tffoic.i~ioiV~riioiiizatfon

3,024
4,427
2,822
10,107
526

3,428
27,518
(607)
26,911

(6,171 )
(6,137)
(1,994)
(1,431 )
(1,566 )
(9,283 )
(10,107)
(5,473)
.(1A§~)
(25,176)
{21,649)
$
5,262
·(253) $

The Components of deferred taxes, net on a jurisdiction basis are as fol lows:
January 3,
2015

. · · Net'curretti'c:ie°ferred tax assets
Net noncurrent deferred tax assets
Nefcurrent defeired)ax liabilities
Net noncurrent deferred tax liabilities
Net deferred-taxes

$

$

9,683
5,933
(5,268)
(10,601 )
(253 )

January 2,
2016

$

$

~-

9,674
9,844
(4,434)
(9,822 )
5;262
I&,

At January 2, 20 I 6, the Company had foreign operating loss carry forwards of approximately $384. If these operating losses are not used, a
portion of them will begin to expire in 2017. A valuation allowance of$1 l0 has been placed on these foreign operating loss carry forwards. The
valuation allowance is detennined using a more likely than not realization criteria and is based upon all available positive and negative evidence,
including future reversals of temporary differences. A future increase or decrease in the current valuation allowance is not expected to impact the
income tax provision due to the Company's ability to fully utilize foreign tax credits associated with taxable income in these jurisdictions.
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NOTE D-JNCOME TAXES (Continued)
The Company has not recognized a deferred tax liability for the undistributed earnings of certain of its foreign operations that arose during
2015 and in prior years as the Company considers these earnings to be indefinitely reinvested. As of January 2, 2016, the undistributed earnings of
these subsidiaries was $18,163. The repatriation of these earnings would result in a tax liability to the Company of approximately $3,071.
The Company recognizes the impact of a tax position in the financial statements if that position is more likely than not of being sustained on
audit, based on the technical merits of the position. As of January 3, 2015 and January 2, 2016, the Company had no significant unrecognized tax
benefits.
From time to time, the Company is subject to federal, state, and foreign tax authority income tax examinations. The Company remains subject to
income tax examinations for each of its open tax years, which extend back to 2012 under most circumstances. Certain taxing jurisdictions may
provide for additional open years depending upon their statutes or if an audit is on-going.
NOTE E-PROPERTY AND EQUIPMENT

Cost of property and equipment and their estimated useful lives is as follows:

Years

Buildings
Lab~~atory and production equipment
.. S.oµrid'a'rfd:videofibrary
Computer equipment and software
)\f'.'. '.:lfumi~re:ana fixtures-' . ·,·
Automobiles
· .:i:easehold:improv~ments i
Land improvements
:-•...

Less accumulated depreciation and amortization
Land
Deposits and projects in process

· · ...39:s

January 3,
2015

38,920
24,864
600
30,842
5J54
3-5
327
J ..:5/f';c .10~857.
2,068
15
... 1:13,832
64,372
. 49,460
6,843
14,861
$
71,164
$

.January 2,
2016

$

5-7
5
3-5
,:·.;•3-5 ·
: , , :.! •' :~ '

$

38,242
27,027
600
34,497
5,214
385

ll;59I
2,052
. 119~608·
71,030
48;578 ·
6,360
33,043
87,982

Depreciation of property and equipment for the years ended 2013, 2014, and 2015 was $8,152, $8,414, and $9,034, respectively.
NOTE F-INTANGIBLE ASSETS

The Company performed its annual goodwill impairment test during the third quarter of 2015. The Company perfonned a qualitative
assessment of each reporting unit and determined that is was not more-likely-than-not that the fair value of any reporting unit was less than its
carrying amount. As a
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NOTE F-INTANGIBLE ASSETS (Continued)
result, the two-step goodwill impairment test was not required and no impairments of goodwill were recognized in 2015.
The Company also performed its annual indefinite-lived intangible asset impainnent test during the third quarter of 2015. The Company
performed a qualitative assessment of the indefinite-lived intangible assets and determined that is was not more-likely-than-not that the fair value
of any indefinite-lived intangible asset was less than the carrying amount. As a result, the quantitative impairment test was not required and no
impairments of indefinite-lived intangible assets were recognized in 2015.
The changes in the carrying amount of goodwill are as follows:

Balance at beginning of year:
Gross goodwill
Accumulated impairment losses
Net goodwill as of beginning,of year
Goodwill acquired during the year
Impairment loss ·
Curfency. translation adjustment
Balance as of end of year
. ... Gros_s good\vill
Accumulated impairment losses
Netgoodwill·as ofend of year

January 3,

January 2,

2015

2016

$

18,243

$

18,243

17,~41
17,941

(302)

.Jt94'j.-_· .

(509)

17,432

Historically, the indefinite-lived intangible assets included the BabyCare direct sales license and BabyCare product formulas. The Company
evaluates the remaining useful life of the indefinite-lived intangible assets each reporting period to determine whether events and circumstances
continue to support an indefinite useful life. During the third quarter of 2015, a process was initiated in China to approve additional USANA
products, which will limit the life of certain of the acquired BabyCare product formulas. As a result, the product formulas intangible asset was
determined to no longer have an indefinite life. Accordingly, the Company began amortization of the product formulas intangible asset on a
straight-line basis over its estimated remaining useful life of 8 years. Upon determining that

F-19

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

~

Table of Contents

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
NOTE F-INTANGIBLE ASSETS (Continued)
the product formulas intangible asset no longer has an indefinite life, it was tested for impainnent and no impairment was noted.
As of January 3, 2015
Gross
carrying
amount

Amortized intangible assets
Trade name and trademarks
Indefinite-lived intangible assets
Product formulas
Direct sales license

$

Net carrying
amount

Accumulated
amortiznfion

4,274

$

(1,898) $

2,376

$

9,425
29,151
38,576
40,952

9,425
29,151
38,576
$ 42,850

Weighted-average
amortization
l!eriod (Years)

10

As of Januarv 21 2016

Gross
carrying
amount

... ,Arri9rtize!ffotangi~I~ asseJs
Trade name and trademarks
. -, Product formulas.

$

4,086

·9,cfrn

Accumulated
amortization

$

(2,205 )
(489)

Net carrying
amount

$

Weighted-average
amortization
l!eriod ~years)

1,881
8,521

10

8

Indefinite-lived intangible assets

.' · ·,:bire'c::rsaies"license ·. ·

$

27,867
40,963

$

1,535
1,535
1,535
1,535
1,378
2,884
10,402

Estimated Amortization Expense:
2016
2017
2018
2019
2020
Thereafter

$

27,867
38,269

Aggregate amortization of intangible assets for the years ended 20 I 3, 2014, and 2015 was $897, $431, and $900, respectively.
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(in thousands, except per share data)
NOTE G-OTHER CURRENT LIABILITIES
Other current liabilities consist of the following:
January 3,
2015

Associate incentives
Accrued employee compensation
Income taxes
Sales taxes
Deferred tax liabilities
Associate promotions
Defem:d revenue
Provision for returns and allowances
Accrued purchases of property and equipment
All other

$

34,297

January 2,
2016

$

18,360
4,110

9,643
5,268
1,982

38,852
24,489
5,561
10,109
4,434
2,712
17,637
521

15,717

718

6,863
10,191

1,805

9,026
$

100,926

$

121,369

NOTE H-LINE OF CREDIT
The Company has a $75,000 line of credit with Bank of America. Interest is computed at the bank's Prime Rate or LIBOR, adjusted by features
specified in the Credit Agreement. The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, set
fo1th i11 a !>epaiale plcugt: ag1ce111c11l with tlu: l,auk. Pail uftl11: c1t:uil ag1t:t:111t:11l is lhal auy t:xisliug l,auk guaiault:es a1e cu11sidt:1t:d a 11::uucliuu uf
the overalJ availability of credit and part of the covenant calculation. This resulted in a $4,575, and $4,153 reduction in the available borrowing limit
as of January 3, 2015 and January 2, 20 I 6, respectively, due to existing normal course of business guarantees in certain markets. The Credit
Agreement contains restrictive covenants based on adjusted EBITDA and a debt coverage ratio.
There was no outstanding balance on this line of credit at January 3, 2015 or at January 2, 2016. The Company will be required to pay any
balance on this line of credit in full at the time of maturity in April 2016 unless the line of credit is replaced or terms are renegotiated.
NOTE I-COMMITMENTS AND CONTINGENCIES
I.

Operating leases

With the exception of the Company's Salt Lake City headquarters, Australian facility, Beijing, China and Tianjin, China facility, facilities arc
generally leased. Each of the facility lease agreements is a non-cancclablc operating lease generally structured with renewal options and expires
prior to or
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NOTE I-COMMITMENTS AND CONTINGENCIES (Continued)
during 2020. The Company utilizes equipment under non-cancelable operating leases, expiring through 2019. The minimum commitments under
operating leases at January 2, 2016 are as follows:
Year ending
2016
2017
2018
2019
2020
Thereafter

vP

$

10,552
. 9,263
6,481

2,684
987
$ 29,967

These leases generally provide that property taxes, insurance, and maintenance expenses are the responsibility of the Company. Such
expenses are not included in the operating lease amounts outlined in the table above or in the rent expense amounts that follow. The total rent
expense for the years ended 2013, 2014, and 2015 was approximately $9,254, $11,129, and $10,503, respectively.
The Company has other unconditional purchase obligations relating to capital projects and advertising agreements of $14,758 that will be paid
in the next year.
~

2.

Contingencies

The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting
business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees
and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company has not accrued for any
contingency at January 2, 2016 as the Company does not consider any contingency to be probable nor estimable. The Company faces
contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given to
the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a
material adverse effect on the Company's financial condition, liquidity or results of operations.
In August 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah
(James Robert Rawc1iffe v. Robert Anciaux, et al.,) against certain of our directors and officers. The derivative complaint, which also names
USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and
unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee
of the Company's Board of Directors in February 2014. ln October 2014, The Company filed a motion to dismiss the complaint and, in March 2015,
the court granted that motion and dismissed the complaint without prejudice. In May 20 l 5, the plaintiffs filed an appeal with the Utah Supreme
Court. The Supreme Court remanded The Company's case to the Utah Court of Appeals, which recently issued a briefing schedule for the parties.
The Company believes that the claims in the complaint are without merit and will continue to vigorously defend this suit. The Company continues
to believe, based on information currently available, that the
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NOTE I-COMMITMENTS AND CONTINGENCIES (Continued)
final outcome of this suit will not have a material adverse effect on the Company's business, results of operations or consolidated financial
position.

3.

Employee Benefit Plan

The Company sponsors an employee benefit plan under Section 401 (k) of the Internal Revenue Code. This plan covers employees who arc at
least 18 years of age and have met a one-month service requirement. The Company makes a matching contribution equal to I 00 percent of the first
one percent of a participant's compensation that is contributed by the participant, and 50 percent of that deferral that exceeds one percent of the
participant's compensation, not to exceed six percent of the participant's compensation, subject to the limits of ERISA. In addition, the Company
may make a discretionary contribution based on earnings. The Company's matching contributions cliff vest at two years of service. Contributions
made by the Company to the plan in the United States for the years ended 2013, 2014, and 2015 were$ I, 149, $1,324, and $1,458, respectively.

NOTE J-EQUITY-BASED COMPENSATION
Equity-based compensation expense for fiscal years 2013, 2014, and 2015 was $7,624, $9,805, and $11,081 respectively. The related tax benefit
for these periods was $2,575, $3,308, and $3,766, respectively.
The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of unvested equity awards
outstanding as of January 2, 2016. This table does not include an estimate for future grants that may be issued.

2016
::·.,..._.,
:i ~~".. 1 ~r.;

..

I

17,856

$

2017

16,744

2018·

14,024·
8,889

2019
•• ; ,-r ~- .•

•,·

2020+
$

943
58,456

~

The cost above is expected to be recognized over a weighted-average period of 3.4 years.
Following Company shareholder approval in May of 2015, the Company adopted its 2015 Equity Incentive Award Plan (the "2015 Plan") to
replace its 2006 Equity Incentive Award Plan (the "2006 Plan"), which is set to expire in April of 2016. Similar to the 2006 Plan, the 2015 Plan allows
for the grant of various equity awards including stock-settled stock appreciation rights, stock options, deferred stock units, and other types of
equity-based awards to the Company's officers, key employees, and non-employee directors. Since its inception 10,000 shares had been authorized
under the 2006 Plan. As of January 2, 2016, a total of 6,920 awards had been granted under the 2006 Plan, of which 6,798 were stock-settled stock
appreciation rights, 8 were stock options, and 114 were deferred stock units. Also, as of January 2, 2016, a total of I, 166 awards ha<l been forfeited
and added back to the number of shares available for issuance under the 2006 Plan. No further awards will be issued under the 2006 Plan. Under
the 2015 Plan, 5,000 shares have been authorized. As of January 2, 2016, a total of 1,005 awards

F-23

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

~

Table of Contents

USANA HEALTH SCIENCES, INC. AND SUBSIDIARJES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
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NOTE J-EQUITY-BASED COMPENSATION (Continued)
had been issued under the 2015 Plan, all of which have been in the fonn of stock-settled stock appreciation rights. Of the 1,005 awards issued
under the 2015 Plan, 50 awards have been forfeited and added back to the number of shares available for issuance under the 2015 Plan.
General terms of awards issued under the 2015 Plan are similar in nature to those issued under the 2006 Plan. The Company's Compensation
Committee utilizes two types of vesting methods when granting awards to officers and key employees based upon the nature of the grant. Awards
granted to officers and key employees upon hire or promotion to such a position will generally vest 20% each year on the anniversary of the grant
date and expire five and one-half years from the date of grant. Awards granted as a supplement to existing equity awards held by officers and key
employees vest each year beginning on the first grant date anniversary following the final vesting of previous grants. The expiration of these
supplemental awards is generally within 12 months following the last vest date of such award. Awards of stock options and stock-settled stock
appreciation rights to be granted lo non-employee directors generally vest 25% each quarter, commencing on the first vest date anniversary
following the final vesting oft he previous award. The expiration of these awards is generally within 12 months following the last vest date of the
previous award. Awards of deferred stock units are full-value shares at the date of grant, vesting over the periods of service, and do not have
expiration dates. Beginning in 2015, new grants of stock-settled stock appreciation rights became subject to a mandatory post-vesting holding
requirement of l 0% of the shares derived upon exercise for the sooner of five years following the exercise or at such time the grantee no longer
qualifies as a participant under the Plan. As a result of this requirement, the Company has included an illiquidity discount in the fair value
calculation of these awards.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awards. The weighted-average fair value, net
of illiquidity discount, of stock-settled stock appreciation rights that were granted in 2013, 2014, and 2015 was $17.59, $18.91, and $46.99,
respectively.
Following is a table that includes the weighted-average assumptions that the Company used to calculate fair value of equity awards that were
granted during the periods indicated. Deferred stock units arc full-value shares at the date of grant and have been excluded from the table below.
Year ended
2013

Expected.volatility( 1)
Risk-free interest rate(2)
Expected life(3)
Expected dividend yield(4)
Weighted~average exercise price(5)

0.7 %
3.9 yrs.
0.0 %

$ 53.83

2014

2015

,-40;2 %
l.2 %
3.6 yrs.
$ .

0.0 %
60.61

44.0%
1.3%
3.8 yrs.
0.0%
$
135.41

(I)

The Company utilizes historical volatility of the trading price of its common stock.

(2)

Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
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NOTE .J-EQUITY-BASED COMPENSATION (Continued)
(3)

Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company's equity awards and a hypothetical
holding period, or (ii) the simplified method.

(4)

The Company historically has not paid and currently has no plan to pay dividends.

(5)

Exercise price is the closing price of the Company's common stock on the date of grant.

A summary of the Company's stock option and stock-settled stock appreciation right activity is as follows:

Weightedaverage
exercise !!rice

Shares

Outstanding at January 3, 2015
Granted
Ex_er~is_ed
Forfeited
Expired
Outstanding at January 2, 2016

1,555
1,135
(73 )
2,175

-121

49.20

Aggregate
inlrinsic
value*

2.9

$

82,564

JJ
1.8

$

83,475

$

.9,998 ·

135.41
37.93
l02.12

. (442 ):

Exercisable ~Panuary 2, 2016-

*

$

Weighledaverage
remaining
conlracrual lerm

$

94.68

$,

45.26

Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing
price of the Company's common stock on the last trading day of the period) and the exercise price of awards that were in-themoney. The closing price of the Company's common stock at January 3, 2015, and January 2, 2016, was $102.28 and $127.75,
respectively.

The total intrinsic value of stock options and stock-settled stock appreciation rights exercised was $32,837 in 2013, $51,795 in 2014, and
$41,548 in 2015. The Company currently has no deferred stock units that are non vested.
The total fair value of equity awards that vested during fiscal years 2013, 2014, and 2015 was $8,096, $7,568, and $7,184, respectively. This total
fair value includes equity-based awards issued in the form of stock-settled stock appreciation rights.

~
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NOTE K-SEGMENT INFORMATION
USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products
that are sold through a global network marketing system of independent distributors ("Associates"). As such, management aggregates its
operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial
performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate
accounted for I 0% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue
that has been contributed by the Company's nutritional and personal care products for the periods indicated.
Year Ended

USANA® Nutritionals
USANA Foods
Sense~beautiful science®
~

-1Q.!L ..1.!!!.!.. ~
80%
79%
81%
11%
13%
11%
6%
7%
7%

Selected financial information for the Company is presented for two geographic regions: Asia Pacific, with three sub-regions under Asia
Pacific, and Americas and Europe. Individual markets are categorized into these regions as follows:
Asia PacificGreater China-Hong Kong, Taiwan and ChinaCl)
Southeast Asia Pacific-Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia< 2)
North Asia-Japan and South Korea
Americas and Europe-United States, Canada, Mexico, Colombia<3), the United Kingdom, France, Belgium, and the Netherlands.

(I)

The Company's business in China is that of BabyCare, its wholly-owned subsidiary.

(2)

The Company commenced operations in Indonesia in the fourth quarter of 20 l S.

(3)

The Company commenced operations in Colombia at the beginning of the third quarter of 2013.
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NOTE K-SEGMENT INFORMATION (Continued)

Selected Financial Information
Financial information, presented by geographic region is listed below:
Year Ended
2014

2013

Net Sales to External Customers
Asia Pacific
Greater China
Southeast Asia Pacific
North Asia
Asia Pacific Total

$

Americas and Europe
Consolidated Total

$

271,812
155,362
29;319
456,493

326,134 $ 441,284
177,940
183,828
32;667.
39,751
536,741
664,863

$

: 261,6s2. :. , . 2sji1ao_,;; r,:. •2-53~636
718,175 $ 790,471 $ 918,499

January 3,
2015

Long.Jived:Assets:. __ ·
Asia Pacific
Greater China
Southeast Asia Pacific
• North Asia . •·
Asia Pacific Total

2015

.

.January 2,
2016

,;,; '.: .. ::i:.:~L(~3l4:7t::J:J;.i-.. 9.thZ~i ..·
14,175

13,463

·- . ::·::, ;;'·,C6if'f:~·::?;.;:;i1{938,'.
99,267

110,193

- .', -." :. ··. •.·, ..... ·•1·,·:.:: •,'

;:1t~~;;::=:\::. _~ssi~3'6'··

Americas and Europe
Consolidated Total
Total Assets
Asia Pacific
Greater China
Southeast Asia Pacific
North Asia
Asia Pacific Total
Americas and Europe
Consolidated Total

$

153,724

.$ ::

J54~.l~~'. :-$.- iJt\Ol~

_

38,404
____;_;5~:..;,.;62=2 ..
198,179

$

152,405
350,584

$

169,129

40,038
6,695
277,751

$

145,486
423,237
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The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets,
respectively:

2013

Net sales:
China
United States
Hong Kong
Long-lived Assets:
China
United States

vi)

Year Ended
2014

2015

$

106,710 $ 216,842
157,543 $ 143,669
$ 132,285
NIA

"$

$

$

81,704
53,322

$

$
$

371,737
141,758
NIA

$

92,835
57,797

NOTE L-QUARTERLY FINANCIAL RESULTS (Unaudited)

The following table summarizes quarterly financial information for fiscal years 2014 and 2015.
First

2014

$

182,401

$

188,256

l· 191;944

Gross profit

$

148,573

$

153,3~1

$

Net earnings

$

16,537

$

Earnings per share:

l

Fourth

Third

Second

Net sales

$

227,870

15J,359 $ 190,354

9;~~i\::}·: i: .1!>;498'.IA<ty:s:,:t ' L5f

.•.•

$ . iI,3O0

Basic

$

1.19

$

Diluted

$

1.15

$

Net sales

$

219,378

$

233,244

$

233,292 $ 232,585

Gross profit

s

181,014

$

193,155

$

192,244 $ 192,404

Net earnings

$

19,680 $

25,416

$

Earnings per share:
Basic
Diluted

$

~

First

$

1.56
1.50

1.36 $

Second

$
$

1.47

Third

1.99 $
1.92 $

Fourth

25,609 $

1.99
1.92

1.75
1.65

$
$

23,967

$
$

1.89
1.83

NOTE M-EARNINGS PER SHARE

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been
repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that
are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per
common share are based on shares that arc outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in
the diluted earnings per share calculations
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NOTE M-EARNJNGS PER SHARE (Continued)
under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.
The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share
for the periods indicated:

2013

Net earnings available to common shareholders

"$

Weighted average common shares outstanding-basic

2015

79,024· $ ·'76:636 "$ 94,672
13,221
13,695
12,730
509
14,204

Dilutive effect of in-the-money equity awards
Weighted average common shares outstanding-diluted

Year Ended
2014

Earnings per common share from net earnings-basic

$

., · 5.77

Earnings per common share from net earnings-diluted

$

5.56

468
13,689
$
5.80 ·$
$
5.60 $

447
13,177
7.44
7.18

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be antidilutive:
Year Ended

During the years ended 2013, 2014, and 2015, the Company repurchased and retired 414 shares for $18,085, 1,927 shares for $138,819, and 457
shares for $61,181, respectively, under the Company's share repurchase plan. The excess of the repurchase price over par value is allocated
between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares
outstanding in the above calculations.

NOTE N-RELATED-PARTY TRANSACTIONS

.vJ

The Company's Founder and Chairman of the Board, Myron W. Wentz, PhD is the sole beneficial owner of the largest shareholder of the
Company, Gull Global, Ltd. As of January 2, 2016, Gull Global, Ltd. owned 51.39% of the Company's issued and outstanding shares. Dr. Wentz
devotes much of his personal time, expertise, and resources to a number of business and professional activities outside of USANA. The most
significant of these is the Sanoviv Medical Institute, which is a unique, fully integrated health and wellness center located near Rosarito, Mexico
that Dr. Wentz founded in 1998. Dr. Wentz's private entity, Sanoviv S.A. de C.V. ("Sanoviv"), contracts with Medicis, S.C. ("Medicis"), an entity
that is owned and operated independently of Dr. Wentz, to conduct the operations of the Sanoviv Medical Institute. Sanoviv leases the medical
building to Medicis and Medicis carries out all of the operations of the medical institute, which include employing all of the medical and healthcare
professionals who provide services at the medical institute. The Medicis medical and
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NOTE N-RELATED-PARTY TRANSACTIONS (Continued)
healthcare professionals possess expertise in the fields of human health, digestive health, nutritional medicine, lifestyle medicine and other medical
fields that are important to USANA.
Medicis performs research and development of novel product formulations for future development and production by USANA, and they also
perform research and development of improvements in existing USANA product formulations. In addition to providing contract research services,
Medicis provides physicians and other medical staff to speak at USANA Associate events. Finally, Medicis performs health assessments and
physical examinations for the Company's Executives. In consideration for these services, USANA paid Medicis $381 in 2013, $239 in 2014, and $383
in 2015. The Company's agreements with Medicis were approved by the Audit Committee in advance of the Company's entry into the agreements.
USANA's collaboration with Medicis is terminable at will by USANA at any time, without any continuing commitment by USANA.
NOTE O-SUBSEQUENT EVENTS

Subsequent to January 2, 2016, and through February 26, 2016, the Company repurchased and retired 553 shares of common stock for $64,610,
at an average market price of $116.82 per share.
On February 19, 2016, the Company entered into an Amended and Restated Credit Agreement ("Credit Agreement"), which among other
things, extends the term of the Credit Agreement to April 27, 2021. The Credit Agreement also increases the amount the Company may borrow
under the credit facility from $75,000 to up to $125,000, through October 31, 2016. On November 1, 2016, the amount the Company may borrow
under the Credit Agreement will revert to $75,000 for the term of the agreement. The only other modification to Credit Agreement was an increase in
the Company's consolidated rolling four-quarter adjusted EBITDA covenant from $60,000 to equal to or greater than $100,000.
Subsequent to January 2, 2016, the Company made draws on its line of credit, and on February 26, 2016, the Company had an outstanding
balance of$63,000 on this line of credit, with a weighted average rate of 1.27%. The Company will be required to pay any balance on this line of
credit in full at the time of maturity in April 2021 unless the line of credit is replaced or terms are renegotiated.
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SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
(in thousands)
Balance at
beginning or
period

Description

December 28, 2013
Allowance for sales returns
Allowance for doubtful accounts
Valuation allowance-deferred tax
assets

Charged to costs
and expenses

44

717
1,808

98

1,598

January 3, 2015
Allowance for sales returns
Allowance for doubtful accounts
Valuation allowance-deferred tax
assets

591

194

1,880

26

January 2, 2016
Allowance for sales returns
Allowance for doubtful accounts
Valuation allowance-deferred tax
assets

1,788

49
162

526

81

530

718

Charged to
other accounts

Deductions

Balance at
end or period

170
26

1,880

1,068

530

67
118

718
1,788

4

526

246
14

521
1,936
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EXHIBIT 21
SUBSIDIARIES
Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and
the names under which subsidiaries do business as of March I, 2016.
Jurisdiction of Incorporation

USANA Canada Holding, Inc.

Delaware

USANA Health Sciences, China, Inc.

Delaware

USANA Health Sciences New Zealand, Inc.

Delaware

International Holdings, Inc.

Delaware

FMG Productions, Inc. (dba USANA Studios)

Utah

UHS Essential Health Philippines, Inc.

Utah

USANA Sense Company, Inc.

Utah

Pet Lane Inc.

Delaware

USANA Acquisition Corporation

Utah

USANA Canada Co.

Canada

USANA Australia Pty, Ltd.

:Australia, ·

USANA Health Sciences (NZ) Corporation

New Zealand

USANA Hong Kong Limited

Horig Kong

USANA Health Sciences Japan, LLC.

Japan

USANA Health Sciences Korea Ltd.

South Korea

USANA Health Sciences Singapore Pte, Ltd.

Singapore

USANA Mexico S.A. de C.V.

Mexico

Mercadotecnia Nutricional S de R.L. de C. V.

Mexico

UHS Essential Health Malaysia SND BHD

Malaysia

BabyCare Holding Ltd.

Utah/ Cayman Islands

BabyCarc Ltd.

People's Republic of China

Tianjin BabyCare Biological Science and Technology Ltd

People's Republic of China

Tianjin Health Resources Sales Co., Ltd

People's Republic of China

USANA Health Sciences (Thailand) Ltd

Thailand

USANA Health Sciences (France) SAS

France
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Singapore

USANA Asia Holding Ltd.

: :.. :(;:;, '(~!./~:~~·;_~;)!·!J~f~.~rf.}~~:jlr•..: ...
USANA Health Sciences (Colombia) SAS

Colo~nbia

PT. USANA Health Sciences Indonesia

Indonesia

Except as noted above, each subsidiary listed above is doing business under its corporate name.
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EXHIBIT 23.1
Consent oflndependent Registered Public Accounting Firm

The Board of Directors
USANA Health Sciences, Inc.:
We consent to the incorporation by reference in the registration statements on fonn S-8 (Nos. 333-96645, 333-128103, 333-133385, 333-174695,
and 333-206070) and Fonn S-3 (No. 333-169946) ofUSANA Health Sciences, Inc. ofour reports dated March I, 2016, with respect to the
consolidated balance sheets of USA NA Health Sciences, Inc. as of January 2, 2016 and January 3, 2015, and the related consolidated statements of
comprehensive income, stockholders' equity, and cash flows for each of the years in the three-year period ended January 2, 2016, and the related
financial statement schedule, and the effectiveness of internal control over financial reporting as of January 2, 2016, which reports appear in the
January 2, 2016 annual report on Fonn IO-K ofUSANA Health Sciences, Inc.
Isl KPMG LLP

Salt Lake City, Utah
Marchi, 2016
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EXHIBIT 31.1
CHIEF EXECUTIVE OFFICER CERTIFICATION

I, David A. Wentz, certify that:
I.

I have reviewed this Annual Report on Form 10-K ofUSANA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.

The Registrant's other certifying officer and I arc responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules l 3a-l 5(e) and I 5d-l 5(e)) and internal control over financial reporting (as defined in Exchange Act Rules l 3a15(f) and 15d-15(0) for the Registrant and have:

5.

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and

d)

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent
functions):
a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's
internal control over financial reporting.

Date: March I, 2016

Isl DAVID A. WENTZ

David A. Wentz
Principal Executfre Officer
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EXHIBIT 31.2
CHIEF FINANCIAL OFFICER CERTIFICATION
I, Paul A. Jones, certify that:
I.

I have reviewed this Annual Report on Form 10-K ofUSANA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.

The Registrant's other certifying officer and I arc responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-l 5(e) and ISd-1 S(e)) and internal control over financial reporting (as defined in Exchange Act Rules l Ja15( t) and 1Sd-15( t)) for the Registrant and have:
·

5.

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and

d)

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors ( or persons perfonning the equivalent
functions):
a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's
internal control over financial reporting.

Date: March l, 2016

Isl PAUL A. JONES
Paul A. Jones
Principal Financial and Accounting Officer
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EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
The undersigned hereby certifies that the Annual Report on Fonn 10-K of USA NA Health Sciences, Inc. for the period ended January 2, 2016
as filed March I, 2016 with the Securities and Exchange Commission, fully complies with the requirements of Section l 3(a) or l S(d) of The
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the
financial condition and results ofoperations of USA NA Health Sciences, Inc.
Date: March I, 2016

Isl DAVID A. WENTZ
David A. Wentz

Principal Executive Officer
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EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SAR.BANES-OXLEY ACT OF 2002

The undersigned hereby certifies that the Annual Report on Fonn I0-K of USA NA Health Sciences, Inc. for the period ended January 2.2016
as filed March 1, 2016 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The
Securities Exchange Act of 1934 ( 15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations ofUSANA Health Sciences, Inc.
Date: March I, 2016

Isl PAUL A. JONES

Paul A. Jones
Principal Financial and Accounting Officer
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Document And Entity
Information - USD ($)

12 Months Ended
Jan. 02, 2016

Fcb.26,2016 Jul.02,2015

Document And Entity Information (Abstract}
Document Type
I 0-K
Amendment Flag
false
Document Period End Date
Jan. 02, 2016
Document Fiscal Period Focus
FY
Entity Central Index Key
0000896264
Entity Registrant Name
USANA HEAL TH SCIENCES INC
Current Fiscal Year End Date
--01-02
Document Fiscal Year Focus
2015
Entity Filer Category
Large Accelerated Filer
Entity Current Reporting Status
Yes
Entity Well-known Seasoned Issuer
No
No
Entity Voluntary Filers
Entity Common Stock. Shares Outstanding
11,944,164
Entity Public Float
Trading Symbol
usna
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$ 832,428,673

Consolidated Balance Sheets
- USD ($)
$

in Thousands

.Jan. 02,
2016

Jan. 03,
2015

Current assets

~

Cash and cash equivalents
Inventories
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Goodwill
Intangible assets, net
Deferred tax assets
Other assets
Total assets

$ 143,210
66, l I 9
34,935
244,264
87,982
17,432
38,269
9,844
25,446
423,237

$ 111,126
45,248
34,553
190,927
71,164
17,941
40,952
5,933
23,667
350,584

10,043
121,369
131,412
9,822
I, 151

7,779
100,926
108,705
10,601
1,114

Current liabilities

Accounts payable
Other current liabilities
Total current liabilities
Deferred tax liabilities
Other long-tenn liabilities
Stockholders' equity

v,

Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 12,633 as of
13
January 3, 2015 and 12,488 as of January 2, 20 l 6
Additional paid-in capital
69,740
214,875
Retained earnings
(3,776)
Accumulated other comprehensive income
280,852
Total stockholders' equity
$423,237
Total liabilities and stockholder's equity
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13
61,613
166,496
2,132
230,164
$350,584

Consolidated Balance Sheets
(Parenthetical) - $/shares
shares in Thousands

Jan. 02, 2016 Jan. 03, 2015

Consolidated Balance Sheets [Abstract]

Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding

$ 0.001

$ 0.001

50,000

50,000

12,488

12,633
· 12,633

12,488
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Consolidated Statements Of
Comprehensive Income USD ($)
shares in Thousands, $ in
Thousands

I 2 Months Ended

.Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

Consolidated Statements Of Comprehensive Income (Abstract]

~

vP

Net sales
Cost of sales
Gross profit

$918,499

$790,471

$718,175

159,682

140,794

127,435

758,817

649,677

590,740

408,160

349,044

307,820

208,995

184,531

166,208

617,155

533,575

474,028

141,662

116,102

116,712

1,116

464

(15)

500
(129)

( 174)

(820)

(594)

927

(449)

( I 31)

142,589

115,653

47,917

39,0 I 7

$ 94,672

$76,636

l 16,581
37,557
$79,024

$ 7.44

$ 5.80

$ 5.77

$ 7.18

$ 5.60

$ 5.56

12,730

13,22 l

13,695

13,177

13,689

14,204

$94,672

$76,636

$79,024

(9,283)

(4,492)

(1,458)

3,375

830

316

(5,908)

(3,662)

(1,142)

$ 88,764

$72,974

$77,882

Operating expenses:

Associate incentives
Selling, general and administrative
Total operating expenses
Earnings from operations
Other income (expense):

~

\JP

Interest income
Interest expense
Other, net
Other income (expense), net
Earnings before income taxes
Income taxes
Net earnings

(I)

Earnings per common share

Basic
Diluted
Weighted average common shares outstanding

~

Basic
Diluted
Comprehensive income:

Net earnings
Other comprehensive income (loss}~ net of tax:
vj

Foreign currency translation adjustment
Tax benefit (ex12ense) related to foreign currency translation adjustment
Other comprehensive income (loss), net of tax
Com12rehensive income

~
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Consolidated Statement Of
Stockholders' Equity - USD
($)

Common
Stock
[Member]

shares in Thousands, $ in
Thousands
13,821
Balance. shares at Dec. 29: 2012
$ 14
Balance, value at Dec. 29, 20 I 2
Net earnings
Other comgrehensive income (loss),
net of tax
Eguity-based com12ensation ex12ense
Common stock re12urchased and
(414)
retired: shares
Common stock re12urchased and
retired, value
Common stock issued under eguity
479
award Qlans. shares
Common stock issued under eguity
award plans, value
Tax benefit from eguity award activity
Balance, shares at Dec. 28, 2013
13,886
$ 14
Balance, value at Dec. 28, 2013
Net earnings
Other com:grehensive income (loss),
net of tax
Eguity-based compensation expense
Common stock repurchased and
(1,927)
retired, shares
Common stock re12urchased and
$ (2)
retired, value
Common stock issued under eguity
674
award 12lans, shares
Common stock issued under eguity
$ 1
award 12Ians, value
Tax benefit from eguity award activity
12,633
Balance, shares at Jan. 03: 2015
$ 13
Balance, value at Jan. 03: 2015
Net earnings
Other com12rehensive income (loss.}.
net of tax
Egui!Y-based com12ensation ex12cnse
Common stock re12urchascd and
(457)
retired, shares
Common stock re12urchascd and
retired: value
Common stock issued under eguity
312
award Qlans 1 shares
Tax benefit from eguity award activity

Additional
Paid-in Capital
[Member]

$43,822

Retained
Earnings
[Member]

$ 134,800

Accumulated Other
Comprehensive Income
(Loss) [Member]

$6,936

79,024

Tota)
~

$ 185,572

79,024
(1,142)

7,624

(1,142)

•

$7,624
(414)

(4,284)

$
(18,085)

(13,801)

454

454

7,075

7,075

54,691

200,023

5,794

76,636

ti;;

~

260,522
76,636
~

(J,662)
9,805

(J,662)
$9,805
(1,927)

(28,564)

$

(110,253)

<i;I

(138,819)

10,969

10,970

14,712

$14,712

(si

12,633
61,613

166,406

2,132

94,672

$230,164
94,672

(5,908)
11,081

(i;,

(5,908)
$11,081
(457)

(14,978)

(46,203)

12,024
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$

(6 I, 181)

$12,024

~

Balance, shares at Jan. 02, 2016
Balance, value at Jan. 02; 2016

12,488
$ 13

$69,740

$214,875

$ (3,776)

@

@

@
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12,488
$280,852

•
12 Months Ended

Consolidated Statements Of
Cash Flows - USD ($)
$ in Thousands

Jan. 02,
2016

Jan. 03,
2015

Dec. 28,
2013
~

Cash flows from operating activities

Net earnings

$94,672

$ 76,636

$79,024

9,978

8,810

9,044

3

46

(16)

11,081

9,805

7,624

(12,024)

(14,834)

(7,466)

(2,572)

(1,039)

814

(23,071)

1,102

(11,783)

(2,047)

(3,789)

(8,465)

12,024

14,712

7,075

2,481

(1,337)

2,790

20,941

15,073

20,252

111,466

l 05, l 85

98,893

(1,580)

(4,495)

(4,942)

(3,871)

(8,643)

Adjustments to reconcile net earnings to net cash ~rovided b:y {used in}
o~erating activities

Depreciation and amortization
(Gain) loss on sale of 12ro12erty and egui12ment
Equity-based compensation expense
Excess tax benefits from egui!Y-based payment arrangements
Deferred income taxes
Changes in o~erating assets and liabilities:

Inventories
Prepaid expenses and other assets
Income tax Qayable related to tax benefit from eguity award activity
Accounts payable
Other liabilities
Net cash 12rovided b~ (used in) 012erating activities

~

(I;

(ii)

Cash flows from investing activities

Additions to notes receivable
Purchases of investment securities held-to-maturi!Y
Matllfities of investment securities
Proceeds from sale of proper!Y and egui:oment
Purchases of pro12erty and equipment
Net cash 12rovided by (used in) investing activities

12,511
185

10

47

(23,729)

(20,421)

(8,051)

(25,124)

(I 6,266)

(21,589)

Cash flows from financing activities

Proceeds from equi!Y awards exercised
Excess tax benefits from equi!Y-based payment arrangements
Repurchase of common stock
Borrowings on line of credit
Payments on line of credit
Net cash 12rovided by (used in) financing activities
Effect of exchange rate changes on cash and cash egui valents
Net increase (decrease} in cash and cash equivalents
Cash and cash equivalents 2 beginning of 12eriod
Cash an<l cash eyuivalents 2 end of period

(i.;

o·

10,970

454

12,024

14,834

7,466

(61,181)

(138,819)

(18,085)

30,000
~

(30,000)
(49,157)

(113,015)

(10,165)

(5,101)

(2,121)

(635)

32,084

(26,217)

66,504

111,126

137,343

70,839

143,210

111,126

137,343

15

136

I

35,782

26,955

26,952

966
$6,863

720

$ 198

~

Cash paid during the period for:

Interest
Income taxes

~

Non-cash investing activities:

Credits on notes receivable
Accrued Qurchases of QfOQer!Y and eguiQment

$ 1,805
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12 Months Ended
Jan.02,2016

Summary Of Significant
Accounting Policies
~

Summary Of Significant
Accounting Policies [Abstract)
Summary Of Significant
Accounting Policies

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Comparw
USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care
products that arc sold internationally through a global network marketing system, which is a form of direct
selling. The Consolidated Jo'inancial Statements include the accounts and operations of USt\NJ\ I Iealth Sciences,
Inc. and its wholly-owned subsidiaries (collectively, the "Company" or "USJ\NN') in two geographic regions:
t\sia Pacific, and :\mericas and Europe. 1\sia Pacific is further divided into three sub-regions: Greater China,
Southeast 1\sia Pacific, and North Asia. Greater China includes Hong Kong, Taiwan and China; Southeast Asia
Pacific includes Australia, New Zealand, Sin!,r.ipore, t-.,fa)aysia, the Philippines, Thailand, and Indonesia; Nonh
:\sia includes Japan, and South Korea. Americas and Europe includes the United States, Canada, Mexico,
Colombia, the United Kingdom, France, Belgium, and the Netherlands.
Principles of consolidation and basis of presentation
The accompanying Consolidated Financial Statements include the accounts and operations of US,\N,\
Health Sciences, Inc. and its wholly-owned subsidiaries. All inter-company accounts and transactions have been
eliminated in consolidation. The accounting and reporting policies of the Company conform with accounting
principles generally accepted in the United States of America ("US GJ\J\P").
Use of estimates
The preparation of consolidated financial statements in conformity with US GJ\1\P requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and fo1bilities at the date of the consolidated financial statements and the reported
amounts of revenues and expenses during the reporting period. Significant estimates for the Company relate to
revenue recognition, inventory obsolescence, goodwill and other intangible assets, equity-based compensation,
and income taxes. 1\ctual results could differ from those estimates. These estimates may be adjusted as more
current information becomes available, and any adjustment could be significant.
Fiscal vear
The Company operates on a 52-53 week year, ending on the Saturday closest to December 31. Fiscal
years 2013 and 2015, were 52-week years. Fiscal year 2014 was a 53-week year. Fiscal year 2013 covered the period
December 30, 2012 to December 28, 2013 (hereinafter 2013). Fiscal year 2014 covered the period December 29,
2013 to January 3, 2015 (hereinafter 2014). Fiscal year 2015 covered the period January 4, 2015 to January 2, 2016
(hereinafter 2015).
Fair value measurements
The Company measures at fair value certain of its financial and non-financial assets and liabilities by
using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date, essentially an exit price, based on the highest and best use
of the asset or liability. The levels of the fair value hierarchy arc:
•

Level l inputs arc quoted market prices in active markets for identical assets or liabilities that arc
accessible at the measurement dare.

•

I ,evel 2 inputs arc from other than l)UOtcd market prices included in Level I that arc observable for
the asset or liability, either directly or indirectly.

•

Level 3 inputs arc unobservable and arc used to measure fair value in situations where there is
li11lc, if any, market activity for the asset or liability at the measurement date .

.\s of.January 3, 2015 and Januat)' 2, 2016, the following financial assets and liabilities were measured at
fair value on a recurring basis using the type of inputs shown:

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED

Fair Value Measurements Using
Inputs
lamrarv 3, 2015
t\loncy marker fumls included in cash e9uivalcnts

S

4,833 S

I.eve! I

Level 3

Level 2

-s

4,833 S

Fair Value Measurements Using
Inputs
lanuan· 2. 2016

l.t"vd I
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l,cvcl 2

Lt"vcl 3

i\loney market funds included in cash el1uivalents

S

14,460 S

14,460 S

-s

There were no transfers of financial assets or liabiliric:- between I ..eve! 1 and Level 2 inputs for the years
ended 2014 and 2015.
The majority of the Company's non-financial asset:., which include goodwill, intangible asset~, and
property and el1uipment, are not required to he carried at fair value on a recurring basis. However, if certain
triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a nonfinancial asset is rc'luired to be evaluated for impairment, an impairment charge is recorded to reduce the carrying
value to the fair value, if the carrying value exceeds the fair value. For the years ended 2013, 2014, and 2015, there
were no non-financial assets measured at fair value on a non-recurring basis.
Fair value of financial instruments

M January 3, 2015 and January 2, 2016, the Company's financial instruments include cash equivalents,
accounts receivable, restricted cash, notes receivable, and accounts payable. The recorded values of cash
equivalents, accounts receivable, restricted cash, and accounts payable approximate their fair values, based on their
short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest
rates in the notes reflect current market rates.
Translation of foreign currencies
The functional currency of the Company's foreibl'fl subsidiaries is the local currency of their country of
domicile. Assets and liabilities of the foreign subsidiaries arc translated into U.S. dollar amounts at month-end
cxc.:hangc rares. Revenue and expense accounts arc translated at the weighted-average rates for the monthly
accounting period to which they relate. Eguity accounts arc translated at historical rates. Foreign currency
translation adjustments arc accumulated as a component of other comprehensive income. Gains and losses
from foreign currency transactions arc included in the "Other, net" component of Other income (expense) in the
Company's consolidated statements of comprehensive income.
Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less
from the date of purchase to be cash e,1uivalents. Cash equivalents as of January 3, ;2015 and January 2, 2016
consisted primarily of money market fund investments, and amounts receivable from credit card processors.
1\mounts receivable from credit card processors arc considered cash equivalents because they arc both
:shu1 Hcuu aml liiglily liyui<l i11 nature a11d arc typit:ally t:onverred ro cash wirhin rhree days of rhc sales
transaction. Amounts receivable from credit card processors as of January 3, 2015 and January 2, 2016 totaled
$6,209 and $12,516, respectively.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
Restricted Cash
The Company is required to maintain cash deposits with banks in certain subsidiary locations for
various operating purposes. The most significant of these cash deposits relates to a deposit held at a bank in
China, the balance of which was S3,222 as of January 3, 2015, and $3,080 as of January 2, 2016. This deposit is
required for the application of direct sales licenses by the l\linistry of Commerce and the State Administration for
Industry & Commerce of the People's Republic of China, and will continue to be restricted during the periods
while the Company holds these licenses. Restricted cash is included in the "Other assets" line item in the
Company's consolidated balance sheets.
Inventories
Inventories arc stated at the lower of cost or market. Cost is determined u:;ing a standard costing
system which approximates the first-in, first-out method. The components of inventory cost include raw
mate1ials, labor, and overhead. f'vlarket value is determined using various assumptions with regard to excess or
slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand,
production pl:lnning, and market conditions. ;\ change in any of these variables could result in an adjustment to
inventory.
,\ccounts Rcceivabh:
;\ccouni:,; receivable arc recorded at the invoiced amount and do not bear interest. The Company
maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio.
In establishing the rn1uired allowance, management considers historical losses adjusted to take into account
current market conditions and our customers' fin.1ncial condition, the amoum of receivables in dispute, and the
current n:ccivablcs aging and current payment paltcrns. The Company reviews its allowance for doubtful
accoums regularly. ,\ccount balances arc charged off against the allowance ;1ftcr all means of collection have been
exhausted and the potential for recovery 1s considered remote. 1\ccounts Receivable is included in "Prepaid
expenses and other current assets" line item 1n the Company's consolidated balance sheets.
1ncome taxes
The Company accounts for income taxes us1r1g the asset and liability method, which rel1uu-es
rcCO!--,'llit1on of ddcrred tax assets and liabil11ies for the expected future tax consel1ucnces of the differences
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between the financial statement assets and liabilities and their respective tax bases. Deferred tax assets and
liabilities arc measured using cnactec.l tax rates that arc expected to apply to taxable income in the year in which
those temporary differences arc expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred
tax expeme or benefit is the result of changes 111 c.lcfcrrcd tax assets and liabilities. The Company evaluates the
probability of realizing the future benefits oi its deferred tax assets and provides a valuation allowance for the
portion of any deterred tax assets where the likelihood of realizing an income tax benefit in the future docs not
meet the "more-likely-than-not" criteria for recognition. The Company recognizes tax benefits from uncertain
tax
positions only if it is more likely than not that the tax position will be sustained on examination by the taxing
aurhorities, based on the technical merits of the position. The tax benefits recognized in the financial statements
from such a position arc measured based on the largest benefit that has a greater than fifty percent likelihood of
being realized upon ultimate resolution. The Company recognizes interest and penalties related to unrecognized
tax benefits in income taxes. Deferred taxes arc not provided on the portion of undistributed earnings of
subsidiaries outside of the United States when these earnings arc considered indefinitely reinvested.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
Property and equipment
Property and equipment arc recorded at cost. 1\laintcnancc, repairs, and renewals, which neither
materially add to the value of the property nor appreciably prolong its life, arc charged to expense as
incurred. Depreciation is provided in amounts sufficient to relate the cost of depreciable assets to operations
over the estimated useful lives of the related assets. The straight-line method of depreciation and amortization
is followed for financial statement purposes. I .casehold improvements arc amortized over the shorter of the life
of the respective lease or the useful life of the improvements. Property and C()Uipmcnt arc reviewed for
impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may
not be recoverable. \Vhen property and cl1uipmcnt arc retired or otherwise disposed of, the cost and
accumulated depreciation arc removc<l from the accounts and any resulting !-,Y.!in or loss is included in the results
of operations for the respective pcrio<l.
Notes receivable
Notes receivable consists primarily of a secured loan to a thir<l-party supplier of the Company's
nutrition bars and are included in the "Other assets" line item in the Company's consolidated balance sheets.
The Company has extended non-revolving credit to this supplier to allow them to aCl1uirc equipment that is
necessary to manufacture the USANJ\ nutrition bars. This relationship provides improved supply chain stability
for USANA and creates a mutually beneficial relationship between the parties. Notes receivable arc valued at their
unpaid principal balance plus any accrncc.l but unpaid interest, which approximates fair value. Interest accrues at
an annual interest rate of LI BOR plus 400 basis points. The note has a maturity date of February 1, 2024 and
will be repaid by a combination of cash payments and credits for the manufacture of USANA's nutrition
bars. Manufacturing credits applied during 2014 and 2015 were $720 and $966, respectively. There is no
prepayment penalty. Notes receivable from this supplier as of January 3, 2015, and January 2, 2016, were $8,519,
and $8,339, respectively. '.
The third-party supplier is considered to be a variable interest entity; however, the Company is not the
primary beneficiary due to the inability to direct the activities that most significantly affect the third-party
supplier's economic performance. The Company docs not absorb a majority of the third-party supplier's
expected losses or returns. Consequentially, the financial information of the third-party supplier is not
consolidated. The maximum exposure to loss as a result of the Company's involvement with the third-party
supplier is limited to the carrying value of the note receivable due from the third-party supplier.
Goodwill
Goodwill represents the excess of the purchase price over the fair market value of identifiable net assets
of acquired companies. Goo<lwill is not amortized, but rather is tested at the reporting unit level at least
annually for impairment or more frequently if triggering events or changes in circumstances indicate impairment.
Initially, qualitative factors arc considered to determine whether it is more likely than not that the fair value of a
reporting unit is less than its carrying amount. Some of these 9ualitativc factors may include macroeconomic
conditions, industry and market considerations, a change in financial performance, entity-specific events, a
sustained decrease in share price, and consideration of the difference between the fair value and carrying amount
of a reporting unit as determined in the most recent tJUantitativc assessment. If, through this qualitative
assessment, the conclusion is made that it is more likely than not that a reporting unit's foir value is less than its
carrying amount, a two-step quantitative impairment analysis 1s performed. The first step involves estimating
the fair value of a reporting unit using w1dcly-acceptcd valuation methodologies including the income and
market approaches, which rcl1uires the use of estimates and assumptions. These estimates and assumptions
include revenue growth rates, discounts rates, and determination of appropriate market comparablcs. If the fair
value of the reporting unit is less than it:; carrying amount, the second :acp of the impairment test is performed
to measure the amount of the impairment loss. In the Sl'cond step, the unplinl fair value of the goodwill is
estimated as the fair value of the reportmg umt as dctc:nnmcd 111 :;tcp one, less fair values of all other net tangible
and intangible assets of the rqmrting umt lktennincd Ill a manner :-imibr to a purchase price allocation. If the
c1rrying amount of the goodwill exceeds its implied fair Yalue, an impairnwnt loss is recognized in an amount
ClJUal to that excess, not to l'Xcecd the carrying amount of rhe goodwill. I)uring 2013, 2014, and 2015, no
impairment of goodwill was recorded.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
I ntangiblc assets
lnrnngiblc assets represent long-lived and i11dc:li1111e-lt\'ed 1nta11g1ble a::::ct:,; an1urred in connection with
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the purchase of the ( :ompany's China subsidiary in 20 I 0. I .ong-livcd intangible assets arc amortized over their
related useful lives, using a straight-line or accelerated method consistent with the underlying expected future
cash flows related to the specific intangible asset. I .ong-lived intangible assets arc reviewed for impairment
whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be
recoverable. When indicators of impairment exist, an estimate of undiscountec.l nc1 cash flows is used in
measuring whether the carrying amount of the asset or related asset group is recoverable. l\kasuremcnt of the
amount of impairment, if any, is based upon the difference between the asset group's carrying value and
estimated foir value. Fair value is determined through various valuation tcchnil1ucs, including market and income
approaches as considered ncC'essary.
I ndefinite-livcd intangible assets arc not amortized; however, they arc tested at least annually for
impairment or more frequently if cvc1Hs 01 changes i11 circuinsranccs exist llral may iuJicatc impain11c11I.
Initially, qualitative factors arc considered to determine whether it is more likely than not that the fair value of an
indefinite-lived intangible asset is less than its carrying amount. If, through this tiualirativc assessment, the
conclusion is made that it is more likely than not that an indefinite-lived intangible asset's fair value is less than
its carrying amount, a ,1uan11tat1ve tmpatrmcnt analysts ts performed by companng the indctinitc-livcd intangible
asset's book value to its estimated fair value. The fair value for indefinite-lived intangible assets is determined
through various valuation technigucs, including market and income approaches as considered necessary. The
amount of any impairment is measured as the difference between the carrying amount and the fair value of the
impaired asset. During 2013, 2014, and 2015, no impairment of indefinite-lived intangible assets was recorded.
Self insurance
The Company is self-insured, up to certain limits, for employee group health claims. The Company
has purchased stop-loss insurance on both an individual and an aggregate basis, which will reimburse the
Company for individual claims in excess of$125 and aggregate claims that arc greater than 100% of projected
claims. i\ liability is accrued for all unpaid claims. Total expense under this self insurance program was S5,281,
$7,019 and S7,287 m 2013, 2014 and 2015, respectively.
Common stock and additional paid-in capital
The Company records cash that it receives upon the exercise of c,1uity awards by cre<liring common
stock and additional paid-in capital. The Company received $454, and $10,970 in cash proceeds from the exercise
of equity awards in 2013 and 2014, respectively. There were no cash proceeds from the exercise of ctp1ity awards
in 2015. The Company also realizes an income tax benefit from the exercise of certain eguity awards.

Upon cxcn.:isc, die 1 dated dcfcnnl lax a:,;:,;ets ate 1evcrscu ·,mu Ilse differe11Le lu.:twceu tlic dcfcncd t·,1x
assets and the realized tax benefit creates a tax windfall or shortfall that increases or decreases the additional paidin capital pool ("APIC Pool"). If the APIC Pool is reduced to zero, additional shortfalls arc treated as a current
tax expense. The total tax benefit recorded in additional paid-in capital was $7,075, S14,712, and S12,024, in
?01 \ ?014, :md ?015, rcspr:r.tivdy
The Company has a stock repurchase plan in place that has been authorized by the Board of Directors.
1\s of January 2, 2016, $100,000 was available to repurchase shares under this plan. The Company expended

$18,085, $138,819, and S61, 181 to repurchase and retire shares during 2013, 2014, and 2015, respectively. The
excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnin!-,,s
on a pro-rata basis. There currently is no expiration date on the remaining approved repurchase amount and no
requirement for future share repurchases.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
Revenue recognition and deferred revenue
Revenue is recognized at the estimated point of delive1y of the merchandise, at which point the risks
and rewards of ownership have passed to the customer. Revenue is realizable when the following four criteria
arc met: persuasive evidence of a sale arrangement exists, delivery of the product has occurred, the price is fixed or
determinable, and payment is reasonably assured.
The Company receives payment, primarily via credit card, for the sale of products at rhc time customers
place orders. Sales and related fees such as shipping and handling, net of applicable sales discounts, arc recorded
as revenue when the product is delivered and when title and the risk of ownership passes to the
customer. Payments received for undelivered products arc recorded as <lcfcrrcd rcwnuc and arc included in other
current liabilities. Deferred revenue is recognized at the estimated point of delivery of the merchandise. ( )n the
occasion rhar will-call orders arc nor picked up by cusromcrs, we periodically assess the likelihood that customers
will exercise their contractual right to pick up orders and recognize revenue when the likelihood is estimated to be
remote. ( :errain incentives offered on the sale of our products, including sales discounts, arc classiticd as a
reduction of revenue. Sales discounts earned under US:\N1\'s initial order reward program arc considered pan
of a multiple clement revenue arrangement and accordingly arc deferred when the first ord(."r is placed and
recognized as custonwrs place their subsctiuent two ,\uto Orders. r\ provision for product returns and
allowances is recorded and is base<l on historical (."Xpcricncc. ,\dditionally, the Company collects an annual
account renewal frc from :\ssociatcs that is deferred upon receipt and is recognized as income on a straight-line
·
basis over the suhsCl(llCnt rwclvc-month period.
T:1xcs that have been assessed by governmental authorities and that arc dircctly impo:-ed on 1Tve1111cprn<lucing transac11ons between the Company and its customers, including sales, use, valuc-addcd, and some
excise taxes, arc presented on a net basis in the consolidated statements of compn:hcnsive income (excluded
from net sales).
Product return polin·
.\II first-tim(." product orders that arc returned within the first 30 days f11llow1ng purchas(." arc refunded
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at 100% of rhc sales price. After the first order, all other returned product that is unused and resalable is
refunded up to one year from the date of purchase at 100% of the sales price. This standard policy differs
slightly in a few of our international markets due to the regulato111 envi.romnent in those markets. i\ccording to
the terms of the Associate agreement, return of product where the purchase amount exceeds one hundred
dollars and was nor damaged at the time of receipt by the Associate may result in cancellation of the ,\ssociatc's
distributorship. Depending upon the conditions un<lcr which product was returned, customers may either
receive a refund based on their original form of payment, or credit on account for a product exchange. Product
returns totaled approximately 0.9% of net sales in 2013, 0.8% of net sales in 2014, and 0.6% of net sales in 2015.

Shipping and handling costs
The Company's shipping and handling costs arc included in cost of sales for all periods presented.
,\ssociate incentives
1\ssociate incentives expenses include all forms of commissions, and other incentives paid to our
Associates, less commissions paid to Associates on personal purchases, which arc considered a sales discount
anti arc reported as a reduction to net sales.
Sclling 1 general and administrative
Selling, general and administrative expenses include wages and benefits, depreciation and amortization,
rents and utilities, Associate event costs, advertising and professional fees, marketing, and research and
development expenses.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
Equitv-bascd compensation
The Company records compensation expense in the financial statements for C(JUity-bascd awards based on the
grant date fair value and an estimate of forfeitures derived from historical experience. Equity-based
compensation expense is recognized under the straight-line method over the period that service is provided,
which is generally the vesting term. Further information regarding equity awards can be found in Note J Equity-Based Compcnsa tion.
1\dvcrtising
Advertising costs arc charged to expense as incurred and are presented as part of scUing, general and
administrative expense. Advertising expense totaled S3,650 in 2013, $4,942 in 2014 and $13,766 in 2015.
Research and development
Research and development costs are charged to expense as incurred and arc presented as part of selling,
general
and administrative expense. Research and development expense totaled $5,083 in 2013, $5,128 in 2014 and
$6,420 in 2015.
Earnings per share
Basic earnings per common share (EPS) arc based on the weighted-average number of common shares
that were outstanding during each period. Diluted earnings per common share include the effect of potentially
dilutive common shares calculated using the treasury stock method, which include in-the-money, equity-based
awards that have been granted but have not been issued.
Recent Accounting Pronouncements
In !\fay 2014, the Financial Accounting Standards Board ("F1\SB") issued an 1\ccouming Standard
Update ("t\SU") No. 2014-09, "Revenue from Contracts with Customers (fopic 606)." ,\SU 2014-09 includes a
five-step process by which entities will recognize revenue to depict the transfer of goods or services to customers
in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those goods or
services. The standard also will require enhanced disclosures to enable users of financial statements to
understan<l the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. In July 2015, the F1\SB announced a decision to defer the cffecrive date of this t\SU. 1\SU 2014-09 is
effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption
permitted for annual and interim reporting periods beginning after December I 5, 2016. The Company is
currently evaluating the imp;1c1 :\SU 2014-09 will have on its consolidated financial statements.
In February 2015, rhc h\SB issued ,\SU No. 2015-02, "Consolidation (l'opic 810): 1\mendmcnts to
the Consolidation .\11alys1s". This standard modifies existing consolidation guidance for reporting companies
that arc reyuin:d 10 evaluate whether they should consoli<late certain legal entities. ,\SU 2015-02 is effective for
fiscal years and interim periods within those years beginning after December 15, 2015, and re9uircs either a
retrospective or a modified retrospective approach to adoption. The Company is currently evaluating the impact
:\SU 20 I 5-02 will have on its consolidated financial statements.
In ,\pnl 201 S, 1he 1:,\SH issued :\SU No. 2015-05, "Intangibles- .(;oodwill and Other-Internal-Use
Software (Subtopic 350-40): Customer's 1\ccounting for Fees Paid in a Cloud Computing. \rrangement". This
.-\SU provides guidance to customers about whether a cloud computing arrangemenl includes a software license.
If a cloud compu1i11g arrangement includes a software license, then the customer should account for the software
license clement of 1he arrangement consistent with the an1uisition of other software licenses. If a cloud
computing arrangement docs 1101 include a sofrw.ue license, the customer should account for the arrangement as
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a service contract. The i\SU is effective for annual and interim reporting periods bq.,,inning after December 15,
2016. Early adoption is permitted. The standard permits the use of either the retrospective or cumulative effect
transition method. The Company is currently evaluating the impact ASU 2015-05 will have on its consolidated
financial statements.

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
In.July 2015, the F:\SB issued J\SU No. 2015 11, "Inventory (l'opic 330): Simplifying the
Measurement of Inventory". For entities that do not measure inventory using the last-in, first-out or retail
inventory method, :\SU 2015- t l changes the measurement principle for inventory from the lower of cost or
market to lower of cost anrl net rt:alizablc value, where net realizable value is the estimated selling prices in th1.·
ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The
J\SU is effective for annual and interim reporting periods beginning after December t 5, 2016. The Company is
currently evaluating the impact ASU 2015-11 will have on its consoli(latcd financial statements.
In November 2015, the F1\SB issued J\SU No. 2015-17, "Income Taxes (fopic 740): Balance Sheet
Classification of Deferred Taxes". The ,-\SU requires entities with a classified balance sheet to present all deferred
tax assets anJ liabilities as noncurrent. The :\SU is effective for annual and interim periods in fiscal years
beginning after December 15, 2016. Early adoption is permitted at the beginning of an interim or annual period
and re9uircs either a prospective or retrospective approach to adoption. The Company is currently evaluating the
impact ASU 2015-17 will have on its consolidated financial statements.
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12 Months Ended
Jan.02,2016

Inventories
Inventories [Abstract]
Inventories

NOTE B - INVENTORIES
Inventories consist of the
following:

Raw materials

January 3,

January 2,

2015

2016

s

15,127$
7,545
22,576

22,529
8,701
34,889

s

45,248$

66,119

Work in progress
Finished goods

@
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Prepaid Expenses And Other

12 Months Ended

Current Assets

Jan.02,2016

Other Assets [Abstract)
Prepaid Expenses And Other Current Assets NOTE C - PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consist of
the following:

Prepaid insurance

Janua.ry 3,

janua.ry 2,

2015

2016

s

Other prepaid expenses
f<ederal income taxes receivable
Miscellaneous receivables, net
Deferred commissions
Deferred tax assets
Other current assets
$

i)
1,507
3,094
7,370
3,656
3,618
9,683
5,625

$

34,553

s
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1,727
3,862
7,080
4,704
3,305
9,674
4,583
34,935

i)

12 Months Ended
Jan.02,2016

Income Taxes
Income Taxes (Abstract)

Income Taxes

NOTED-INCOME TAXES

Income tax expense (benefit) included in income from net earnings consists of the following:

Year ended

2014

2013

2015

Current
Federal

s

s

26,233

22,362

94

Foreign
Total Current

s

17,492
464

9,626

1,056
16,265

32,198

35,953

39,683

50,154

5,507

(1,096)

(5,220)

(5)

(43)

(t 55)

(3,898)

473

3,138

1,604

(666)

(2,237)

State

Deferred
Federal
State
Foreign
Total Deferred

s

s

37,557

39,017

s

47,917

The income tax provision, as reconciled to the tax computed at the federal statutory rate of 35% for 2013, 2014,
and

2015, is as follows:

Year ended

2014

2013
Federal income taxes at statutory rate

$

s

40,803

40,479

102
(1,700)
(890)
(206)

State income taxes, net of federal tax benefit
Qualified production activities deduction
Foreign rate differential
U.S. research credit

(552)

All other, net

s

s

37,557

2015

$

49,906

653

670

(887)

(952)

(603)

(461)

(293)

(425)

(332)

(821)

39,017

s

47,917

NOTED- INCOME TAXES- CONTINUED
The significant categories of deferred taxes arc as follows:

Deferred tax assets
Inventory

January 3,

January 2,

2015

2016

s

3,024
4,427

,\ccruals not currently deductible

2,822

4,476
9,283

526

Net operating losses

4,543

3,428

25,449

27,518
(607)

Other

(526)

Valuation allowance
Net deferred tax assets

I IO
988

Accumulated other c1,mprchcnsivc incc ,nw

Gross deferred tax assets

3,341
5,892

10,107

Equity-based compensation expense
Intangible ;1sscts

s

24,923
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26,911

~
Deferred tax liabilities
Depreciation/ amortizati1m

(6,171)

(6,137)

(1,994)
(1,431)

(1,566)

(10,107)

(9,283)

(5,473)

(4,663)

(25,176)

(21,649)

1\ccumulated other comprehensive income
Prepaid expenses
Intangible assets
Other
Gross deferred tax liabilities
Net deferred taxe~

s

(253)

s

5.262

~

The Cumponenrs of deferred taxes, ner on a jurisdiction basis arc as follows:

Net currenr deferred tax assets

January 3,

January 2,

2015

2016

s

9,683

s

(4,434)
(9,822)

(10,601)

Net noncurrent deferred tax liabilities

s

(253)

9,674
9,844

5,933
(5,268)

Net noncurrent deferred tax assets
Net current deferred tax liabilities

Net deferred raxes

~

s

5,2(,2

At January 2, 2016, the Company had foreign operating loss carry forwards of approximately $384. If
these operating losses arc not used, a portion of them will begin to expire in 2017. ,\ valuation allowance of
$110 has been placed on these foreign operating loss carry forwards. The valuation allowance is determined using
a more likely than not realization criteria and is based upon all available positive and negative evidence, including
future reversals of temporary differences. J\ future increase or decrease in the current valuation allowance is not
expected to impact the income tax provision due to the Company's ability to fully utilize foreign rax credits
associated with taxable income 111 these junsdict1ons.

NOTED - INCOME TAXES- CONTINUED
The Company has not recognized a deferred tax liability for the undistributed earnings of certain of its
foreign operations that arose during 2015 and in prior years as the Company considers these earnings to be
indefinitely reinvested. J\s ofJanuary 2, 2016, the undistributed earnings of these subsidiaries was Sl 8,163. The
repatriation of these earnings would result in a tax liability to the Company of approximately $3,071.
The Company recognizes the impact of a tax position in the financial statements if that position is more
likely than not of being sustained on audit, based on the technical merits of the position. As of January 3, 2015
and January 2, 2016, the Company had no significant unrecognized tax benefits.
From time to time, the Company is subject to federal, state, and foreign tax authority income tax
examinations. The Company remains subject to income tax examinations for each of its open tax years, which
extend back to 2012 under most circumstances. Certain taxing jurisdictions may provide for additional open
years depending upon their stanues or if an audit is on-going.
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12 Months Ended

Property And Equipment
Property And Equipment
IAbstract!
Property And Equipment

Jan.02,2016

NOTE E- PROPERTY AND EQUIPMENT
Cost of property and equipment and their estimated useful lives is as follows:

January 3,

January 2,

2015

2016

Years

Buildings

39.5

Laboratory and production equipment

5-7

s

38,920

s

38,242
27,027

24,864
600

600

Computer equipmenr and software

3-5

30,842

34,497

Furniture and fixtures

3-5

5,354

5,214

Automobiles

3-5

327

385

Leasehold improvements

3-5

10,857

11,591

Land improvements

15

Sound and video library

5

Less a~c111!mla1ed depreciation and
amorttzatton

Land
Deposits and projects in process

s

2,068

2,052

113,832

119,608

64,372

71,030

49,460

48,578

6,843

6,360

14,861

33,043

71,164

s

87,982

Depreciation of property and equipment for the years ended 2013, 2014, and 2015 was $8,152, $8,414, and
$9,034, respectively.
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12 Months Ended

Intangible Assets

.Jan. 02, 2016

Intangible Assets !Abstract)

Intangible Assets

NOTE F - INTANGIBLE ASSETS
The Company performed its annual goodwill impairment test during the third quarter of 2015. The
Company performed a <.1ualitativc assessment of each reporting unit and determined that ts was not more-likclythan-not that the fair value of any reporting unit was less than its carrying amount. i\s a result, the two-step
goodwill impairment test was not required and no impairments of goodwill were recognized in 2015.
The Company also performed its annual indefinite-lived intangible asset impairment test during the
rhirrl 'l11arrrr nf ~01 S. Thr Cnmpany p<•rform<'d a ri11alitativr assrssm,·nt nf rhr indf'finit<'-liv<'rl inrnngihlc asscrs
and determined that is was not more-likely-than-not that the fair value of any indefmitc-lived intangible asset was
less than the carrying amount. As a result, the quantitative impairment test was not re<.1uired and no impairments
of indefinite-lived intangible assets were recognized in 2015.

~

The changes in the carrying amount of goodwill arc as follows:

Balance at beginning of year:
Gross goodwill

January 3,
2015

January 2,
2016

s

s

18,243

17,941

:\ccumulated impairment losses
Net goodwill as of bq.,>inning of year

17,941

18,243

Goodwill acquired during the year
Impairment loss
(509)

(302)

Currency translation adjustment
Balance as of end of year
Gross goodwill

17,941

17,432

1\ccumulated impairment losses

s

Net goodwill as of end of year

$

17,941

~

17,432

Historically, the indefinite-lived intangible assets included the BabyCare direct sales license and BabyCare
product formulas. The Company evaluates the remaining useful life of the indefinite-lived intangible assets each
reporting period to determine whether events and circumstances continue to support an indefinite useful life.
During the third quarter of 2015, a process was initiated in China to approve additional USAN1\ products, which
will limit the life of certain of the acquired BabyCare product formulas. 1\s a result, the product formulas
intangible asset was determined to no longer have an indefinite life. Accordingly, the Company began
amortization of the product formulas intangible asset on a straight-line basis over its estimated remaining useful
life of 8 years. Upon determining that the product formulas intangible asset no longer has an indefinite life, it
was tested for impairment and no impairment was noted.

NOTE F- INTANGIBLE ASSETS-CONTINUED
As of January 3, 2015
Gross carrying Accumulated
amortization
amount

Net carrying
amount

Weighted-aver
amortizatirn
period (vcar:

:\morll:t.L·d 1111a11gihk assets
Trade nanw and trademarks

s

4,274S

(1,898)

s

2,376

10

I rH.kfinirt·-livcd intangible assets
Product formulas

9,425

9,425

Direct sail's lirrnse

29,151

29,151

38,57(>

38,576

s

42,850

s
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~

40,952

~

@
As of January 2, 2016

Amortized intangible assets
Trade name and
trademarks
Product formulas

s

Gross carrying

Accumulated

amount

amortization

4,086$

9,010

Indefinite-lived intangible
assets
Direct sales license

Weightedaverage
Net carrying amortization
period
amount
(years)

(2,205)$
(489}

27,867

s

40,963

1,881
8,521

10
8

27,867

s

38,269

Estimated Amortization
Expense:

2016
2017
2018
2019
2020
Thereafter

1,535
1,535
1,535
1,535
1,378
2884

s

10,402

Aggregate amortization ofintangiblc assets for the years ended 2013, 2014, and 2015 was $897, $431, and $900,
respectively.

@

@
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12 Months Ended

Other Current Liabilities

Jan.02,2016

Other Current Liabilities (Abstract)

Other Current Liabilities

NOTE G - OTHER CURRENT LIABILITIES
Other currcnr liabilities consist of the
following:

january 3,

2015
Associate incentives

s

Accrued employee compensation

34,297

January 2,
2016

s

38,852
24,489

18,360

Income taxes

4,110

5,561

Sales taxes

9,643

10,109

Deferred tax liabilities

5,268

4,434

Associate promotions

1,982

2,712

15,717

17,637

Deferred revenue
Provision for returns and allowances
t\cc~·ue<l purchases of property and
equipment

718

521

1,805

,\II other

9,026

6,863
10,191

s

100,926

s

121,369
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12 Months Ended
Jan.02,2016

Line Of Credit
Line Of Credit [Abstract]
Line Of Credit

NOTE 1-1- LINE OF CREDIT
The Company has a $75,000 line of credit with Bank of America. Interest is computed at the bank's
Prime Rate or LIBOR, adjusted by features specified in the Credit 1\greement. The collateral for this line of credit
is the pledge of the capital stock of certain subsidiaries of the Company, set forth in a separate pledge agreement
with the bank. Part of the credit agreement is that any existing bank guarantees arc considered a reduction-of the
overall availability of credit and part of the covenant calculation. This resulted in a $4,575, and S4, 153 reduction in
the available borrowing limit as of January 3, 2015 and January 2, 2016, respectively, due to existing normal
course of business guarantees in certain markets. The Credit J\grecmcm contains restrictive covenants based on
adjusted EBITDJ\ and a debt coverage ratio.
There was no outstanding balance on this line of credit at January 3, 2015 or at January 2, 2016. The Company
will be required to pay any balance on this line of credit in full at the time of maturity in April 2016 unless the line
of credit is replaced or terms arc renegotiated.
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12 Months Ended
Jan.02,2016

Commitments And
Contingencies

Commitments And
Contingencies [Abstract]
Commitments And Contingencies NOTE I - COMMITMENTS AND CONTINGENCIES
I.

Operating leases

With the exception of the Company's Salt Lake City headquarters, 1\usrrnlian facility, Beijing, China
and Tianjin, China facility, facilities arc generally leased. Each of the facility lease agreements is a non-cancclable
operating lease generally structured with renewal options and expires prior to or during 2020. The Company
utilizes equipment umlcr non-cancclable operating leases, expiring through 2019. The minimum commitments
under operating leases at Ianuary 2, 2016 arc as follows:
Year ending
2016

s

/4,,

~

10,552

2017

9,263

2018

6,481

2019

2,684

2020

987

~

Thereafter

s

29,967

NOTE I - COMMITMENTS AND CONTINGENCIES - CONTINUED
~
These leases generally provide that property taxes, insurance, and maintenance expenses are the
responsibility of the Company. Such expenses are not included in the operating lease amounts outlined in the
table above or in the rent expense amounts that follow. The total rent expense for the years ended 2013, 2014,
and 2015 was approximately $9,254, Sl 1,129, and $10,503, respectively.
The Company has other unconditional purchase obligations relating to capital projects and advertising
agreements of $14,758 that will be paid in the next year.

2.

Contingencies

The Company is involved in various lawsuits, claims, and other legal matters from time to time that
arise in the ordinary course of conducting business, including matters involving our products, intellectual
property, supplier relationships, distributors, competitor relationships, employees and other matters. The
Company records a liability when a particular contingency is probable and estimable. The Company has not
accrued for any contingency ar January 2, 2016 as the Company docs not consider any contingency to be probable
nor estimable. The Company faces contingencies that arc reasonably possible to occur; however, they cannot
currently be estimated. While complete assurance cannot be given to the outcome of these proceedings,
management docs not currently believe that any of these matters, individually or in the aggregate, will have a
material adverse effect on the Company's financial condition, liquidity or results of operations.
In August 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District
Court of Salt Lake Counry, State of Utah Oamcs Robert Rawcliffe v. Robert Anciaux, ct al.,) against certain of
our directors and officers. The derivative complaint, which also names US,\NJ\ as a nominal defendant but is
asserted on USANJ\'s behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust
enrichment against the defendant directors and officers in connection with cerrain equity awards granted by the
Compensation Committee of the Company's Board of Directors in February 2014. In October 2014, The
Company filed a motion to d1sm1ss the complaint and, in March 2015, the court grnnte<l that motion and
dismissed the complaint without prejudice. In May 2015, the plaintiffs filed an appeal with the Utah Supreme
Court. The Supreme Court reman<le<l The Company's case to the Utah Court of Appeals, which recently issued
a briefing schedule for the parties. The Company believes that the claims in the complaint arc without merit and
will continue to vieorously defend this suit. The Company c:ontimws to hclit•vr, hasrd on informMinn currently
available, that the final outcome of this suit will not have a material adverse effect on the Company's business,
results of operations or consolidated financial position.

3.

1:,,;,

•

~

~

l :mplovcc Benefit Plan
•

'I "he Company sponsors an employee benefit plan under Seer ion 40 I (k) of the I nrernal Revenue
Code. This plan covers employees who arc at least 18 years of age and have met a one-month service
requirement. The Company makes a matching contribution eLJUal ro I 00 percent of rhe first one percent of a
participant's compensation that is contributed by the participant, and 50 percent of that deferral that exceeds one
percent of the participant's compensation, not to exceed six percent of the p,wicipant's compensation, subject to
the limits of ERIS,\. In addition, the Company may make a discrctionarv contribution based on
earnmgs. The Company's matching contributions cliff vest at two yl';1rs ot' service. Contributions made by the
Company to the plan in the United States for the years ended 2013, '.Wl-t, and 2015 were St ,149, S1 ,324, and
Sl ,458, respectively.
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Equity Based Compensation
[Abstract)

Equity Based Compensation

NOTEJ- EQUITY-BASED COMPENSATION
E9uity-base<l compensation expense for fiscal years 2013, 2014, and 2015 was $7,624, $9,805, and
$11,081 respectively. The related tax benefit for these periods was $2,575, $3,308, and $3,766, respectively.
The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all
types of unvestc<l cl1uity awards outstanding as of J:tnuary 2, 2016. This table docs not include an estimate for
future grants that may be issued.

s

2016

17,856

2017

16,744

2018

14,024

2019

8,889

943

2020+

s

58,456

The cost .tt)ove is expected to be recognized over a weighted-average period of 3.4
years.

Following Company shareholder approval in May of 2015, the Company adopted its 2015 Equity
Incentive Award Plan (the "2015 Plan") to replace its 2006 Equity Incentive Award Plan (the "2006 Plan"), which
is set to expire in J\ pril of 2016. Similar to the 2006 Plan, the 2015 Plan allows for the grant of various equity
awards including stock-settled stock appreciation rights, stock options, deferred stock units, and other types of
equity-based awards to the Company's officers, key employees, and non-employee directors. Since its inception
10,000 shares had been authorized under the 2006 Plan. As of January 2, 2016, a total of 6,920 awards had been
granted under the 2006 Plan, of which 6,798 were stock-settled stock appreciation rights, 8 were stock options,
and 114 were deform.I stock units. Also, as of January 2, 2016, a to ta.I of 1,166 awards had been forfeited and
added back to the number of shares available for issuance under the 2006 Plan. No further awards will be issued
under the 2006 Plan. Under the 2015 Plan, 5,000 shares have been authorized. As of January 2, 2016, a total of
1,005 awards had been issued under the 2015 Plan, all of which have been in the form of stock-settJed stock
appreciation rights. Of the 1,005 awards issued under the 2015 Plan, 50 awards have been forfeited and added
back to the number of shares available for issuance under the 2015 Plan.
General terms of awards issued under the 2015 Plan are similar in nature to those issued under the
2006 Plan. The Company's Compensation Committee utilizes two types of vesting methods when granting
awards to officers and key employees based upon the nature of the grant. Awards granted to officers and key
employees upon hire or promotion to such a position will generally vest 20% each yc.-ar on the anniversary of the
grant date and expire five and one-half years from the date of grant. Awards granted as a supplement to existing
equity awards held by officers and key employees vest each year beginning on the first grant date anniversary
following the final vesting of previous grants. The expiration of these supplemental awards is generally within
12 months following the last vest date of such award. Awards of stock options and stock-settJed stock
appreciation rights IO be granted to non-employee directors generally vest 25% each quarter, commencing on the
first vest date anniversary following the final vesting of the previous award. The expiration of these awards is
generally within 12 months following the last vest date of the previous award. Awards of deferred stock units
are fu.11-valuc shares at the date of grant, vesting over the periods of service, and do not have expiration dates.
Beginning in 2015, new grants of stock-settled stock appreciation rights became subject to a mandatory postvesting holding rel1uirement of l 0% of the shares derived upon exercise for the sooner of five years following
the exercise or at such time the grantee no longer lJllalifics as a participant under the Plan. As a result of this
rc9uircment, the Company has included an illit1uidity discount in the fair value calculation of these awards.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awanh
The weighted-average fair value, net of illi911idity discount, of stock-settled stuck appreciation rights that were
granred in 2013, 2014, anJ 2015 was S17.59, S18.91, and S46.99, respectively.

NOTEJ- EQUITY-BASED COMPENSATION -CONTINUED
Following is a ta hie that includes the weighted-average assumptions that the Company used to calculate fair value
ClJllity awards that were gr.inrcd during the periods indicated. Deferred stock units arc full-value shares at the date
grant and have been exclu<lcd from the table below.

Year ended
2013

Expected volattlny (I)

2015

2014

-l 1.9°/o

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

40.2~'o

44.0%

~
0.7°/c,

1.2%

1..1%

3.9 yr:-.

3.6 yrs.

3.8 yrs.

Risk-free interest rate (2)
Expecred life (3)
Expecred dividend yield (4)
Weighted-average exercise price (5)

0.0%

0.0%

0.0%

S53.83

S60.61

S135.41

(1) The Company utilizes hisrorical volatility of the trading p1ice of its common srock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average rhat includes historical settlement data of the Company's e4uiry awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid and currently has no plan to pay dividends.
(5) J•:xcrcise price is the closing price of the Company's common stock on the date of grant.
:\ summary of the Company's stock option and stock-settled stock appreciation right activity is as
follows:

Shares
Outstanding at January 3, 2015

1,555

Weightedaverage
exercise erice
g
49.20

Weightedavera~e
remammg
contractual
term
2.9

Aggregate
intrinsic
value*

s

82,564

135.41

Cranted

1,135

Exercised

(442)

37.93

1:orfcited

(73)

102.12

~

Expired
Outstanding at January 2, 2016
Exercisable at J:muary 2, 2016

~

2,175

s

94.68

3.3

s

83,475

121

s

45.26

1.8

s

9,998

* 1\ggregare intrinsic value is defined as the difference between the current market value at the reporting date (the
closmg pnce ot the Company's common stock on the last trading day ot the period) and the exercise price of
awards that were in-the-money. The closing price of the Company's common stock at January 3, 2015, and
January 2, 2016, was $102.28 and $127.75, respectively.
The total intrinsic value of stock options and stock-settled stock appreciation rights exercised was
$32,837 in 2013, SSl,795 in 2014, and $41,548 in 2015. The Company currently has no deferred stock units that
arc nonvcsted.
The total fair value of equity awards that vested during fiscal years 2013, 2014, and 2015 was $8,096,
$7,568, and S7, 184, respectively. This total fair value includes equity-based awards issued in the form of stocksettled stock appreciation rights.
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12 Months Ended

Segment Information
Segment Information
[Abstract)
Segment Infonnation

Jan.02,2016

NOTE K-SEGMENT INFORMATION
USAN1\ operates as a direct selling company that develops, manufactures, and distributes high-<1uality
nutritional and personal care products that arc sold through a global network marketing system of independent
distributors ("Associates"). 1\s such, management aggregates its operating segments into one reportable
se&>mcnt as management believes that the Company's segments exhibit similar long-term financial perfo1mance
and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No
single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes
the approximate percentage of total product revenue that has been contributed by the Company's nutritional and
personal care products for the periods indicated.

Year Ended

2013
USi\NA& Nutritionals
US1\N1\ Foods
Sense - beautiful science"

2015

2014
80%
11%

79%
13%

81%
11%

6%

7%

7%

Selected financial information for the Company is presented for two geographic regions: Asia Pacific,
with three sub-regions under 1\sia Pacific, and Americas and Europe. Individual markets arc catego1ized into
these regions as follows:
•

~

Asia Pacific •

Greater China- Hong Kong, Taiwan and China(I'

•

Southeast Asia Pacific - Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand,
and Indoncsia<2>

•

North Asia - Japan and South Korea

•
(I)
(Z)

~

(l)

Americas and Europe- United States, Canada, Mexico, Colombia(ll, the United Kingdom,
France, Belgium, and the Netherlands.
The Company's business in China is that of BabyCare, its wholly-owned subsidiary.
The Company commenced operations in Indonesia in the fourth quarter of 2015.
The Company commenced operations in Colombia at the beginning of the third quarter of 2013.

NOTE K- SEGMENT INFORMATION - CONTINUED
Selected Fi11a11tial lllfimnolio11
Financial information, presented by geographic region is listed below:
Year Ended

2013

2015

2014

Net Sales to External Customers
Asia Pacific
Greater China
Southeast i\sia Pacific

s

North ,\sia
Asia Pacific Total
.\mcricas anJ Europe
ConsoliJatcd 'J'oral

s

s

271,81·2
155,362
29,319

326,134
177,940
32,667

s

441,284
183,828
39,751

456,493

536,741

664,863

261,682

253,730

253,636

s

718,175

790,471

s

918,499

January 3,

January 2,

2015

2016

Long-lived 1\ssets
Asia Pacific
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s

Greater China
Southeast Asia Pacific

s

83,471
14,175
1,621

North Asia

94,792
13,463
1,938

Asia Pacific Total

99,267

110,193

Americas anc.l Europe

54,457

58,936

Consolidated Total

s

153,724

s

169,129

s

154,153
38,404
5,622

s

231,018
40,038
6,695

®

Tota! 1\sscts
Asia Pacific
Greater China
Southeast Asia Pacific
North 1\sia
Asia Pacific Total
Americas and Europe

198,179

277,751

152,405

145,486

s

Consolic.latcc.l Total

s

350,584

423,237

i)

ti;

NOTE K- SEGMENT INFORMATION - CONTINUED
The following table provides further information on markets representing ten percent or more of
consolidated net sales and long-lived assets, respectively:

Year Ended

2014

2013

2015

Net sales:
China
United States

$
$

Hong Kong

s

106,710
157,543
132,285

$

$

216,842
143,669

$

$

N/A

371,737
141,758

N/A

Long-lived Assets:
China
United States

$
$
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81,704
53,322

$

$

92,835
57,797

(ii

~

12 Months Ended

Quarterly Financial Results

~

Jan.02,2016

Quarterly Financial Results
[Abstract)

Quarterly Financial Results

NOTE L-QUAR.TERLYFINANCIAL RESULTS (Unaudited)
The following table summarizes c1uartcrly financial information for fiscal years 2014 and
2015.

2014
~

s
s
s

Net sales
Gross profit
Net earnings

~

First

s
s
s

188,256

1.19

s

1.40

1.15

s

1.36

182,401
148,573
16,537

153,391
19,301

Third

s
s
s

191,944

s
s

Fourth

157,359

s
s

190,354

19,498

s

21,300

1.51

s
s

1.65

227,870

Earnings per share:

s
s

Basic
Diluted

2015

(.j)

Second

First

Second

1.47

Third

Net sales

s

219,378

s

233,244

s

233,292

Gross profit

$

181,014 $

193,155

$

Net earnings

s

19,680

s

25,416

s
s

1.75

Fourth
232,585

192,244

s
s

$

25,609

s

23,967

1.99

s

1.99

$

1.89

1.92

$

1.92

s

1.83

192,404

Earnings per share:

~

Basic

s

1.56

Diluted

s

I.SO
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Earnings Per Share
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Earnings Per Share (Abstract]

Earnings Per Share

NOTE M - EARNINGS PER SHARE
Basic earnings per share are based on the weighted-average number of shares outs randing for each
period. Shares that have been repurchased and retired during the periods specified below have been included in
the calculation of the number of weighted-average shares that arc outstanding for the calculation of basic earnings
per share based on the time they were outstanding in any period. Diluted earnings per common share are based
on shares that arc outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that arc
included in the diluted earnings per share calculations under the treasury stock method include equity awards that
;ire in-the-money but have not yet been exercised.
The following is a reconciliation of the numerator and denominator used
share and diluted earnings per share for the periods indicatc<l:

to

calculate basic earnings per

Year Ended

2014

2013
Net earnings available to common shareholders
\Vciglitcd avcrngc

<:uu1111011

s

shares uutstamli11g - basic.:

79,024 $

76,636 S

94,672

13,695

13,221

12,730

509

468

447

14,204

13,689

13,177

Dilutive effect of in-the-money equity awards
Weighted average common shares outstanding - diluted

2015

Earnings per common share from net earnings - basic

s

5.77

s

5.80

Earnings per common share from net earnings - diluted

s

5.56

s

5.60

s
s

7.44
7.18

Equity uwurdr. for the following nhurcn were not included in the computntion of diluted EPS due to the fnct
that
their effect would be anti-dilutive:

Year Ended

2013

2014
344

2015
287

393

During the years ended 2013, 2014, and 2015, the Company repurchased and retired 414 shares for
$18,085, 1,927 shares for $138,819, and 457 shares for $61,181, respectively, under the Company's share
repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital
and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares
outstanding in the above calculations.
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12 Months Ended
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Related Party Transactions
[Abstract)

Related Party Transactions

NOTE N - RELATED-PARTY TRANSACTIONS
The Company's Founder and Chairman of the Board, Myron W. Wentz, PhD is the sole beneficial
owner of the largest shareholder of the Company, Gull Global, Ltd. As of January 2, 2016, Gull Global, Ltd.
owne<l 51.39% of the Company's issued and outstanding shares. Dr. Wentz devotes much of his personal
time, expertise, and resources to a number of business and professional activities outside of USJ\NA. The most
significant of these is the Sanoviv Medical Institute, which is a unique, fully inte&rrated health and wellness center
located near Rosariro, Mexico that Dr. Wentz founded in 1998. Dr. Wentz's private entity, Sanoviv S.A. de C.V.
("Sanoviv"), contracts with Medicis, S.C. ("Medicis"), an entity that is owned and operated independently of Dr.
Wentz, to conduct the operations of the Sanoviv Medical Institute. Sanoviv leases the medical building to
Medicis and Medicis carries our all of the operations of the medical institute, which include employing all of the
medical and healthcare professionals who provide se1vices at the medical institute. The Medicis medical and
healthcare professionals possess expertise in the fields of human health, digestive health, nutritional medicine,
lifestyle medicine and other medical fields that arc important to USJ\NA.
Medicis performs research and development of novel product formulations for future development
and production by USA NA, and they also perform research and development of improvements in existing
USANA product formulations. In addition to providing contract research services, Medicis provides physicians
and other medical staff to speak at USAN,\ 1\ssociate events. Finally, Medicis performs health assessments and
physical examinations for the Company's Executives. In consideration for these services, USANA paid Medicis
$381 in 2013, $239 in 2014, and S383 in 2015. The Company's agreements with Medicis were approved by the
Audit Committee in advance of the Company's entry into the agreements. USANA's collaboration with
Medicis is terminable at will by US,\NAat any time, without any continuing commitment by USANA.
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Subsequent Events
Subsequent Events (Abstract)

Subsequent Events

NOTE 0- SUBSEQUENT EVENTS
Subsequent to January 2, 2016, and through February 26, 2016, the Company repurchased and retired
553 shares of common stock for $64,610, at an average market price of $116.82 per share.
On February 19, 2016, the Company entered into an Amended and Restated Credit 1\grccmcnr ("Credit
Agreement"), which among other things, extends the term of the Credit Agreement to i\pril 27, 2021. The
Credit .Agreement also increases the amount the Company may borrow under the credit facility from $75,000 to
up to $125,000, through October 31, 2016. On November 1, 2016, the amount the Company may borrow
under the Credit 1\greement will revert to $75,000 for the term of the agreement. The only other modification to
Credit Agreement was an increase in the Company's consolidated rolling four-quarter adjusted EBITDJ\
covenant from S60,000 to equal to or greater than S100,000.
Subsequent to January 2, 2016, the Company made draws on its line of credit, and on February 26,
2016, the Company had an outstanding balance of $63,000 on this line of credit, with a weigh red average rare of
1.27%. The Company will be required to pay any balance on this line of credit in full at the time of maturity in
April 2021 unless the line of credit is replaced or terms arc renegotiated.
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Valuation And Qualifying
Accounts
Valuation and Qualifying Accounts
[Abstract]
Schedule II - Valuation And Qualifying

Balance
at
beginning
of

Accounts

Description
December 28, 2013
Allowance for sales returns
Allowance for doubtful
accounts
Valuation allowance deferred tax assets
January 3, 2015
Allowance for sales returns
Allowance for doubtful
accounts
Valuation allowance deferred tax assets
January 2, 2016
Allowance for sales returns
1\Uowance for doubtful
accounts
Valuation allowance deferred tax assets

period

Charged to
costs
and
expenses

Charged
to
other
accounts

Balance at
end of
Deductions
period

717

44

170

591

1,808

98

26

1,880

1,068

530

1,598

591

194

67

718

1,880

26

118

1,788

4

526

530

718

49

246

521

1,788

162

14

1,936

526

81
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12 Months Ended
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Summary Of Significant
Accounting Policies (Policy)
Summary Of Significant
Accounting Policies [Abstract]
Principles Of Consolidation And
Basis Of Presentation

Principles of consolidation and basis of presentation
The accompanying Consolidated Financial Statements include the accounts and operations of USANJ\
Healrh Sciences, inc. and its wholly-owned subsic.liarie:,;. All inrer-cornpany accounts and transaction:,; have been
eliminated in consolidation. The accounting and reporting policies of the Company conform with accounting
principles generally accepted in the United States of America ("US GAAP").
Use of estimates

Use Of Estimates

The preparation of consolidated financial statements in conformity with US GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported
amounts of revenues and expenses during the reporting period. Significant estimates for the Company relate to
revenue recognition, inventory obsolescence, goodwill and other intangible assets, equity-based compensation,
and income taxes. 1\ctual results could differ from those estimates. These estimates may be adjusted as more
current information becomes available, and any adjustment could be significant.

~

Fiscal vcar

Fiscal Year

The Company operates on a 52-53 week year, ending on the Saturday closest to December 31. Fiscal
years 2013 and 2015, were 52-week years. Fiscal year 2014 was a 53-wcck year. Fiscal year 2013 covered the period
December 30, 2012 to December 28, 2013 (hereinafter 2013). Fiscal year 2014 covered the period December 29,
2013 to January 3, 2015 (hereinafter 2014). Fiscal year 2015 covered the period January 4, 2015 to January 2, 2016
(hereinafter 2015).

Fair Value Measurements

Iii)

Fair value measurements
The Cumpauy measures at fair valut: ccrtai.t, of il:i financial aml nun-finaucial assets and liabilities by
using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date, essentially an exit price 1 based on the highest and best use
of the asset or liability. The levels of the fair value hierarchy arc:
•

Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are
accessible at the measurement date.

•

Level 2 inputs arc from other than quoted market prices included in Level 1 that arc observable for
the asset or liability, either directly or indirectly.

•

Level 3 inputs are unobservable and are used to measure fair value in situations where there is
little, if any, market activity for the asset or liability at the measurement date.

As of January 3, 2015 and January 2, 2016, the following financial assets and liabilities were measured at
fair value on a recurring basis using the type of inputs shown:

NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED

Fair Value Measurements Using
lanuarv 3, 2o-t 5
ivloney market funds incluc.lcc.l in cash equivalents

S

4,833 S

Level 1

Inputs
Level 2

Lcvel3

-s

4,833 S

Fair Value Measurements Using
Januarv 2, 2016
i\loney market funds incluc.led in cash equivalents

S

14,460 S

Level I
14,460 S

Inputs
Level 2

Level 3

-s

There were no transfers of financial assets or liabilities between I ,evcl 1 and Level 2 inputs for the years
ended 2014 and 201 5.
'I 'he majority of the Company's non-financial assets, which include goodwill, intangible as:,;cts, and
property and etJuipment, arc not required to be carried at fair value on a recurring basi:,;. However, if certain
triggering events occur (or tested at least annually for goodwill and indefinite-liveJ intangibles) such that a non-

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

4j;

financial asset is reyuireJ to be evaluated for impairment, an impairment charge is recorded to reduce the carrying
value to the fair value, if the carrying value exceeJs the fair value. For the years ended 2013, 2014, and 2015, there
\Vere no non-financial a:;:;cts 1nea:1uret! ~t f«ir value on a non-recurring basis.
Fair value of financial instruments

Fair Value Of Financial
Instruments

1\ t January 3, 2015 and January 2, 2016, the Company's financial instruments incluc.le cash equivalents,
accounts receivable, restricted cash, notes receivable, and accounts payable. The recorded values of cash
equivalents, accounts receivable, restricted cash, and accounts payable approximate their fair values, based on their
short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest
rates in the notes reflect current market rates.

Translation Of Foreign
Currencies

Translation of foreign currencies

Cash And Cash Equivalents

Cash and cash eguivalents

The functional currency of the Company's foreign subsidiaries is the local currency of their country of
domicile. Assets and liabilities of the foreign subsidiaries arc translated into U.S. dollar amounts at month-end
exchange rates. Revenue and expense accounts arc translated at the weighted-average rates for the monthly
accounting pc1iod to which they relate. Eyuity accounrs are translated at historical rates. Foreign currency
translation ac.ljustments arc accumulatec.l as a component of other comprehensive income. Gains and losses
from foreign currency transactions arc included in the "Other, net" component of Other income (expense) in the
Company's consolidated statements of comprehensive income.

The Company considers all highly liyuid investments with an original maturity of three months or less
from the date of purchase to be cash equivalents. Cash eyuivalents as ofJanuary 3, 2015 and January 2, 2016
consisted primarily of money market fund investments, and amounts receivable from credit card processors.
Amounts receivable from credit card processors arc considered cash eyuivalents because they are both
short-term and highly liyuid in nature and arc typically converted to cash within three days of the sales
transaction. Amounts receivable from credit care.I processors as of January 3, 2015 and January 2, 2016 totaled
$6,209 and S12,516, respectively.

Restricted Cash

Restricted Cash
The Company is required to maintain cash deposits with banks in certain subsidiary locations for
various operating purposes. The most significant of these cash deposits relates to a deposit held at a bank in
China, the balance of which was $3,222 as of January 3, 2015, and $3,080 as of January 2, 2016. This deposit is
required for the application of direct sales licenses by the Ministry of Commerce anc.l the State Administration for
Industry & Commerce of the People's Republic of China, and will continue to be restricted during the periods
while the Company holds these licenses. Restricted cash is included in the "Other assets" line item in the
Company's consolidated balance sheets.

Inventories

Inventories
Inventories are statec.l at the lower of cost or market. Cost is determined using a standard costing system which
approximates the first-in, first-out method. The components of inventory cost include raw materials, labor, and
overhead. Market value is determined using various assumptions with regard to excess or slow-moving
inventories, non-conforming inventories, expiration dates, current and future product demand, production
planning, and market conditions. J\ change in any of these variables could result in an adjustment to
inventory.

Accounts Receivable

Accounts Receivable
1\ccounts receivable are recordec.l at the invoiced amount and do not bear interest. The Company
maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio.
In establishing the required allowance, management considers historical losses adjusted to take into account
current market conditions and our customers' financial conc.lition, the amount of receivables in dispute, and the
current receivables aging and current payment patterns. The Company reviews its allowance for doubtful
accounts regularly. Account balances arc charged off ab1<1inst the allowance after all means of collection have been
exhausted and the potential fur recovery is considered remote. Accounts Receivable is included in "Prepaid
expenses and other current assets" line item in the Company's consolidated balance sheets.

Income Taxes

Income taxes
The Company accounts for income taxes using the asset and liability method, which requires
recognition of deferred tax assets and liabilities for the expected future tax consc9uences of the differences
between the financial statement assets and liabilities and their respective t~tx bases. Deferred tax assets and
liabilities are measured using enacted tax rates that arc expected to apply to taxable income in the year in which
those temporary differences arc expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred
tax expense or benefit is the result of changes in deferred tax assets anc.l liabilities. The Company evaluates the
probability of realizing the future benefits of its deferred tax assets and provides a valuation allowance for the
portion of any deferred tax assets where the likelihood of realizing an income tax benefit in the future docs nor
meet the "more-likely-than-not" criteria for n:cognition. The Company recognizes tax benefits from uncertain
tax
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positions only if iris more likely than nor that the tax position will be sustained on examination by the taxing
authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements
from such a position arc measured based on the largest benefit that has a greater than fifty percent likelihood of
being realized upon ultimate resolution. The Company recognizes interest and penalties related to unrecognized
rax benefits in income taxes. Deferred taxes arc not provided on the portion of undistributed earnings of
subsidiaries outside of the United States when these earnings arc considered indefinitely reinvested.

Prope1ty And Equipment

Propertv and equipment
Property and ec.1uipment arc reconled at cost. Maintenance, repairs, and renewals, which neither
materially add to the value of the property nor appreciably prolong its life, arc charged to expense as
incurred. Depreciation is provided in amounts sufficient to relate the cost of depreciable assets to operations
over the estimated useful lives of the related assets. The straight-line method of depreciation and amortization
is followed for financial statement purposes. I ,case hold improvements arc amortized over the shorter of the life
of the respective lease or the useful life of the improvements. Property and c<.1uipment arc reviewed for
impairment whenever events or changes in circumstances exist that indirntc the carrying amount of an asset may
not be recoverable. When property and c9uipmcm arc retired or otherwise disposed of, the cost and
accumulated depreciation arc removed from the accounts and any resulting g.1in or loss is included in rhc results
of operations for the respective period.

Notes Receivable

Notes receivable
Norcs receivable consists primarily of a secured loan to a third-party supplier of the Company's
nutrition bars and arc included in the "Other assets" line item in the Company's consolidated balance sheets.
The Company has extended non-revolving credit to this supplier to allow them to aClJUire equipment that is
necessary to manufacture the US1\N1\ nutrition bars. This relationship provides improved supply chain stability
for US:\NA ,ltld creates a mutually beneficial 1ch11io11:;hip between the pa1ties. Notes rcceivuble are valued at thei1
unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. Interest accrues at
an annual interest rate of LIBOR plus 400 basis points. The note has a maturity date of February 1, 2024 and
will be repaid by a combination of cash payments and credits fr>r the manufacture of USJ\NA's nutrition
bars. l\lanufacturinp, credits applied during 2014 and 2015 were $720 and $966, respectively. There is no
prepayment penalty. Notes receivable from this supplier as of January 3, 2015, and January 2, 2016, were SS,519,
and $8,339, respectively.
The third-parry supplier is considered to be a variable interest entity; however, the Company is not the
primary beneficiary due to the inability to direct the activities that most significantly affect the third-party
supplier's c1.:u110111i1.: performam.:c. The Compa11y docs not absorb a majority of the third-party supplier's
expected losses or returns. Consequentially, the financial information of the third-party supplier is not
consolidated. The maximum exposure to loss as a result of the Company's involvement with the third-party
:mpplier i:i limited to the carrying value of the note receivable due from the third party :mpplicr.

Goodwill

Goodwill
Goodwill represents the excess of the purchase price over the fair market value of identifiable net assets of
acquired companies. Goodwill is not amortized, but rather is tested at the reporting unit level at least annually
for impairment or more frequently if triggering events or changes in circumstances indicate impairment. Initially,
qualitative factors arc considered to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. Some of these qualitative factors may include macroeconomic conditions,
indusll)' and market considerations, a change in financial performance, entity-specific events, a sustained decrease
in share price, and consideration of the difference between the fair value and carrying amount of a reporting unit
as determined in the most recent quantitative assessment. l f, through this qualitative assessment, the
conclusion is made that it is more likely than not that a reporting unit's fair value is less than its carrying amount,
a two-step quantitative impairment analysis is performed. The first step involves estimating the fait· value of a
reporting unit using widely-accepted valuation methodologies including the income and market approaches,
which requires the use of estimates and assumptions. These estimates and assumptions include revenue growth
rates, discounts rates, and determination of appropriate market comparablcs. If the fair value of the reporting
unit is less than its carrying amount, the second step of the impairment test is performed to measure the
amount of the impairment loss. Jn tlw second step, the implied fotr value of the goodwill is estimated as the
fair value of the reporting unit as determined in step one, less fair values of all other net tangible and intangible
assets of the reporting u11it determined in a manner similar to a purchase price allocation. If the carrying amount
of the goodwill exceeds its implied fair value, :111 impairment loss is recognized in an amount equal to that
excess, not to exceed the carrying amount of the i~oodwill. Durini~ 2013, 2014, and 2015, no impairment of
goodwill was recorded.

Intangible Assets

~

Intangible assets
Intangible assets represent long-lived and indefinite-lived mtangible assets acquired in connection with
the purchase of rhc Company's China subsidiary 1112010. I ,ong-livcd mtangiblc assets arc amortized over their
related useful lives, using a straight-line or accelerated method consiste1it with the underlying expected future
cash flows rehlted to the specific intangible asset. I .ong-livcd intangible assets are reviewed for impairment
whenever events or changes in circumstances exist that indicate the carr\'ing amount of an asset mav not be
recoverable. \X1hen indicators of impairment cxi:-1, an estimate of unJi~co~mted net cash flows is ~scd in
measuring whether the carrying amount of the a:;sl"t or rdated asset group is recoverable. I\.lcasurcmcnt of the
amount of impairment, if any, is based upon the difference between the a:-:-el group's carrying value :tml
estimated fair value. Fair value is Jctenrnncd through various valuation techllllJlll'S, including market and income
approaches as considered necessary.
I nddinitc-livcd intangible asset~ arc 1101 amortized; however, they arc tested at least annually for
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impairment or more ft"ClJUently if events or changes in circumstances exist that may indicate impairment.
Initially, qualitative factors arc considered to determine whether it is more likely than not char the fair value of an
indefinite-lived intangible asset is !css than its carrying amount. If, through this qualitative assessment, the
conclusion is made that it is more likely than not char an indefinite-lived intangible asset's fair value is less than
its carrying amount, a quantitative impairment analysis is performed by comparing the indefinite-lived intangible
asset's book value to its estimated fair value. The fair value for indefinite-lived intangible assets is determined
through various valuation technil1ues, including market and income approaches as considered necessary. The
amount of any impairment is measured as the difference between the carrying amount and the fair value of the
impaired asset. During 2013, 2014, and 2015, no impairment of indcfinite-liv~d intangible assets was recorded.
Self insurance

Self Insurance

The Company is self-insured, up to certain limits, for employee group health claims. The Company
has purchased stop-loss insurance on both an individual and an aggregate basis, which will reimburse the
Company for individual claims in excess of $125 and aggregate claims that are greater than 100% of projected
claims. A liability is accrued for all unpaid claims. Total expense under this self insurance program was $5,281,
$7,019 and $7,287 in 2013, 2014 and 2015, respectively.

Common Stock And Additional
Paid-In Capital

Common stock and additional paid-in capital
The Company records cash that it receives upon the exercise of equity awards by crediting common
stock and additional paid-in capital. The Company received S454, and $10,970 in cash proceeds from the exercise
of equity awards in 2013 and 2014, respectively. 'rhcrc were no cash proceeds from the exercise of equity awards
in 2015. The Company also realizes an income tax benefit from the exercise of certain equity awards.
Upon exercise, the related deferred tax assets are reversed and the-difference between the deferred tax
assets and the realized tax benefit creates a tax windfall or shortfall that increases or decreases the additional paidin capital pool ("APIC Pool"). If the t\PIC Pool is reduced to zero, additional shortfalls are treated as a current
tax expense. The total tax benefit recorded in additional paid-in capital was $7,075, $14,712, and $12,024, in
2013, 2014, and 2015, respectively.
The Company has a stock repurchase plan in place that has been authorized by the Board of Directors.
i\s ofJanuary 2, 2016, $100,000 was available to repurchase shares under this plan. The Company expended
$18,085, $138,819, and S61,181 to repurchase and retire shares during 2013, 2014, and 2015, respectively. The
excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings
on a pro-rata basis. There currently is no expiration date on the remaining approved repurchase amount and no
requirement for future share repurchases.

Revenue Recognition And
Deferred Revenue

Revenue recognition and deferred revenue
Revenue is recognized at the estimated point of delivery of the merchandise, at which point the risks
and rewards of ownership have passed to the customer. Revenue is realizable when the following four criteria
arc met: persuasive evidence of a sale arrangement exists, delivery of the product has occurred, the price is fixed or
determinable, and payment is reasonably assured.
The Company receives payment, primarily via credit card, for the sale of products at the time customers
place orders. Sales and related fees such as shipping and handling, net of applicable sales discounts, arc recorded
as revenue when the product is delivered and when title and the risk of ownership passes to the
customer. Payments received for undelivered products arc recorded as deferred revenue and are included in other
current liabilities. Deferred revenue is recognized at the estimated point of delivery of the merchandise. On the
occasion that will-call orders arc not picked up by customers, we periodically assess the likelihood that customers
will exercise their contractual right to pick up orders and recognize revenue when the likelihood is estimated to be
remote. Certain incentives offered on the sale of our products, including sales discounts, arc classified as a
reduction of revenue. Sales discounts earned under USANA's initial order reward program are considered part
of a multiple clement revenue arrangement and accordingly are deferred when the first order is placed and
recognized as customers place their subsequent two 1\uto Orders. A provision for product returns and
allowances is recorded and is based on historical experience. Additionally, the Company collects an annual
account renewal fee from Associates that is deferred upon receipt and is recognized as income on a straight-line
basis over the subsequent twelve-month period.
Taxes that have been assessed by governmental authorities and that arc directly imposed on revenueproducing transactions between the Company and its customers, including sales, use, value-added, and some
excise taxes, arc presented on a net basis in the consolidated statements of comprehensive income (excluded
from net sales).

Product Return Policy

Product return policv
All first-time product orders that arc returned within the first 30 days following purchase arc refunded
at l 00% of the sales price. 1\ fter the first order, all other re tu med product that is unused and resalable is
refunded up to one year from the date of purchase at I 00% of the sales price. This standard policy differs
slightly in a few of our international markets due to the regulatory environment in those markets. ,\ccording to
the terms of the 1\ssociatc agreement, return of product where the purchase amount exceeds one hundred
dollars and was not damaged at the time of receipt by the ,\ssociare may result in cancellation of the /\ssociate's
distributorship. Depending upon the conditions under which product was returned, customers may either
receive a refund based on their original form of payment, or credit on account for a product exchange. Product
returns totaled approximately 0.9% of net salcs in 2013, 0.8% of net sales in 2014, and 0.6% of net sales in 2015.
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Shipping And Handling Costs

Shipping and handling costs
The Company's shipping and handling costs arc included in cost of sales for all periods presented.

1\ssociatc incentives

Associate Incentives

Associate incentives expenses include all forms of commissions, ,me.I other incentives paid to our
:\ssociates, less commissions paid to ,\ssociates on personal purchases, which arc considered a sales discount
and arc reported as a reduction to net sales.
Selling, general and administrative

Selling, General And
Administrative

Selling, general and administrative expenses include wages and benefits, depreciation anc.l amorti:,rntion,
rents and utilities, 1\ssociate event costs, advertising and professional fees, marketing, and research and
development expenses.

Equity-based Compensation

Eguitv-based compensation
The Company records compensation expense in the financial statements for equity-based awards based on the
grant date fair value and an estimate of forfeitures derived from historical experience. Equity-based
compensation expense is recobrnized under the straight-line method over the period that service is provided,
which is generally the vesting term. Further information regarding equity awards can be found in Note J Equity-Based Compensation.
1\dvcrtising

Advertising

Advertising costs are charged to expense as incurred and are presented as part of selling, general and
administrative expense. Advertising expense totaled $3,650 in 2013, S4,942 in 2014 and Sl 3,766 in 2015.

Research And Development

Research and development
Research and development costs are charged to expense as incurred and arc presented as part of selling,
general
and administrative expense. Research and development expense totaled $5,083 in 2013, S5, 128 in 2014 and
$6,120 in 2015.

Earnings Per Share

Earnings per share
Basic earnings per common share (EPS) are based on the weighted-average number of common shares
that were outstanding during each period. Diluted earnings per common share include the effect of potentially
dilutive common shares calculated using the treasury stock method, which include in-the-money, equity-based
awards that have been granted but have not been issued.

Recent Accounting
Pronouncements

Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board ("FASB") issued an Accounting Standard
Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (fopic 606)." i\SU 2014-09 includes a
five-step process by which entities will recognize revenue to depict the transfer of goods or services to customers
in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those goods or
services. The standard also will require enhanced disclosures to enable users of financial statements to
understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. In July 2015, the F1\SB announced a decision to defer the effective date of this 1\SU. i\SU 2014-09 is
effective for annual and interim reporting pe1iods beginning after December 15, 2017, with early adoption
permitted for annual and interim reporting periods beginning after December 15, 2016. The Company is
currently evaluating the impact ASU 2014-09 will have on its consolidated fmancial statements.
In February 2015, the F1\SB issued 1\SU No. 2015-02, "Consolidation (J'opic 810): Amendments to
the Consolidation 1\nalysis". This standard modifies existing consolidation guidance for reporting companies
that arc 1-cl1uired to evaluate whether they should consolidate certain legal entities. 1\SU 2015-02 is effective for
fiscal years and interim periods within those years beginning after December 15, 2015, and reyuires either a
retrospective or a modified retrospective approach to adoption. The Company is currently evaluating the impact
:\SU 2015-02 will have on its consolidated fmancial statements.
In April 2015, the FJ\SB issued J\SU No. 2015-05, "Inrangibles-Coodwill and Other-Internal-Use
Software (Subtopic 350-40): Customer's 1\ccounting for 1:ees Paid in a Cloud Computing :\rrangement". This
,\SU provides guidance to customers about whether a cloud computing arrangement includes a software license.
If a cloud computing :1rrnngement includes a software license, then the customer shoulc.l account for the software:
liccnse element of the arrangement consistent with thc acyuisition of othcr software licenses. If a cloud
computing arrangement c.loes not include a software license, the customer should account for the arrangement as
a service contract. The t\SU is effective for annual and interim reporting periods beginning a frer December 15,
2016. Early adoption is permitted. The standard permits the use of either the rctmspecrive or cumulative effect
transition method. The Company is currently evaluating the impact :\SU 2015-05 will have on its consolidated
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NOTE A- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES- CONTINUED
In July 2015, the Ft\SB issued ,\SU No. 2015-11, "Inventory (fopic 330): Simplifying the
Measurement of Inventory". For entities that do not measure inventory using the last-in, first-out or retail
inventory method, :\SU 2015-11 changes the measurement principle for inventory from the lower of cost or
market to lower of cost and net realizable value, where net realizable value is the estimated selJing prices in the
ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The
:\SU is effective for annual and interim reporting periods beginning after December 15, 2016. The Company is
currently evaluating the impact ASU 2015-11 will have on its consolidated financial statements.
In November 2015, the FASB issued 1\SU No. 2015-17, "Income Taxes (l'opic 740): Balance Sheet
Classification of Deferred Taxes". The t\SU requires entities with a classified balance sheet to present alJ deferred
tax assets and liabilities as noncurrent. The ASU is effective for annual and interim periods in fiscal years
beginning after December 15, 2016. Eady adoption is permitted at the beginning of an interim or annual period
and requires either a prospective or retrospective approach to adoption. The Company is currently evaluating the
impact ,\SU 20 I 5-17 will have on its consolidated financial statements.
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12 Months Ended
Jan.02,2016

Summary Of Significant
Accounting Policies (Tables)
Summary Of Significant Accounting Policies
[Abstract)
Schedule Of Assets And Liabilities Measured At
Fair Value

Fair Value Measurements Using
Inputs
lanuary 3,2015
Money market funds included in
cash equivalents

$

Level 1

4,833$

Level 2

4,833$

Level 3

-$

Fair Value Measurements Using
Inputs
lanuary 2, 2016
Money market funds included in
cash equivalents

S

Level 1

14,460$
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14,460$

Level 2

Level 3

@

12 Months Ended
Jan.02,2016

Inventori~s (Tables)

@

Inventories {Abstract]
Schedule Of Inventories

Inventories consist of the
following: .

January 3,
2015
Raw materials
Work in progress

@)

January 2,
2016

s

15,127$
7,545
22,576

22,529
8,701
34,889

s

45,248$

66,119

Finished goods

@

@

@

@

@
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12 Months Ended
Jan.02,2016

Prepaid Expenses And Other
Current Assets (Tables)
Other Assets [Abstract)

Schedule Of Prepaid Expenses And Other Current
Assets

Prepaid expenses and other current assets consist
of the following:

Prepaid insurance
Other prepaid expenses
Federal income taxes receivable
Miscellaneous receivables, net
Deferred commissions
Deferred tax assets

January 3,
2015

January 2,
2016

s

$.

s

34,553

1,727
3,862
7,080
4,704
3,305
9,674
4,583

9,683
5,625

Other current assets
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1,507
3,094
7,370
3,656
3,618

$

34,935

12 Months Ended

Income Taxes (Tables)

Jan.02,2016

Income Taxes (Abstract)

Schedule Of Income Tax Expense
(Benefit)

Income tax expense (benefit) included in income from net earnings consists of the following:

Year ended

2013
Current
Federal

s

2015

2014

s

16,265

35,953

39,683

50,154

Federal
State

5,507

(1,096)

(5,220)

(5)

1:oreign

{3,898}

(43)
473

(155)
3,138

1,604

(666)

(2,237)

Foreign
Total Current

26,233
94
9,626

22,362
1,056

s

17,492
464
32,198

State

Deferred

~

Total Deferred

s
Reconciliation Of Income Tax Provision

s

37,557

47,917

$

The income tax provision, as reconciled to the tax computed at the federal statutory rate of 35% for
2013,2014,and
2015, is as follows:

Year ended
2014

2013
Federal income taxes at statutory rate
State income taxes, net of federal tax benefit
Qualified production activities deduction

$

Foreign rate diffen:ntial
U.S. research credit

40,803
102
(1,700)
(890)
(206)

40,479
653
(887)

$

{552}

All other, net

$

Schedule Of Deferred Taxes

39,017

s

37,557

2015

(603)
(293)

49,906
670
(952)
(461)
(425)

{332}

{821}

39,017

$

47,917

$

The significant categories of deferred taxes arc as follows:
January 3,

January 2,

2015

2016

Deferred tax assets
Inventory
:\ccruals no, currently deductible
1•:tiuity-based compensation expense
Intangible assets
Net operating losses
:\ccumulated other comprchens1n· income

s

( )ther
Gross deterred tax assets
\'aluarion allowance
Net deferred tax a:-:scts
Dl'forrcd tax liabilities
l)epreciari,m/am,irtization
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3,024
4,427
2,822
10,107
526

s

3,341
5,892
4,476
9,283
110

988
4,543

3,428

25,449

27,518

(526)

(607)

24,923

26,911

(6,171)

(6,137)

(!)
Accumulated other comprehensive income
Prepaid expenses
Intangible assets
Other
Gross deferred tax liabilities
Net deferred taxes

(1,994)
(1,431)
(10,107)
(5,473)

(1,566)
(9,283)
(4,663)

{25,176)

{21,649)

s

(253)

s

5,262

The Components of deferred taxes, net on a jurisdiction basis arc as follows:

Januacy 3,
2015

January 2,
2016

Net current deferred tax assets
Net noncurrcnt deferred tax assets
Net current deferred tax liabilities
Net noncurrent deferred tax liabilities

s

s

Net cJefcrrcd taxes

$

9,683
5,933
(5,268)
(10,601)
{253)

9,674
9,844
(4,434)
(9,822)

(i)

5,262

,-

-

@

@
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12 Months Ended

Property And Equipment
(Tables)
Property And Equipment IAbstract)
Schedule Of Property And Equipment

(a

(a

Jan.02,2016

Cost oi property an<l eyuipmcnt and their estimated useful lives is as follows:
January 3,
January 2,
Years
2015
2016

Buildings
Laboratory and production
equipment
Sound and video library
Computer e{1uipment and
software
Furniture and fixtures
,\utomobilcs
Leasehold improvements
Land improvements

I,css accumulated depreciation
and amortization

~
Land
Deposits and projects in process

39.5

$

38,920S

38,242

5-7
5

24,864
600

27,027
600

3-5

30,842

3-5
3-5
3-5

5,354
327
10,857

34,497
5,214
385
11,591

15

2,068

2,052

113,832

119,608

64,372

71,030

49,460

48,578

6,843
14,861

6,360
33,043

71,164$
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87,982

12 Months Ended

Intangible Assets (Tables)

Jan.02,2016

Intangible Assets [Abstract)

®

Schedule Of Goodwill
January 3,

January 2,

2015

2016

Balance at beginning of year:

s

Gross goodwill

18,243

s

17,941

®

t\ccumulatcd impairmt>nt losses
Net goodwill as of beginning of year

18,243

17,941

Goodwill acquired <luring the year
Impairment loss
Currency translation ac.ljustmcnt

{302}

{509}

~

Balance as of enc.I of year
Gross goodwill

17,941

17,432

Accumulated impairment losses

$

Net goodwill as of end of year

17 941

s

17,432

~

Schedule Of Finite And Indefinite Lived
Intangible Assets

As of January 3, 2015
Weightedaverage
Gross
carrying
amount

Accumulated Net carrying
amortization
amount

amortizatio
period (year

Amorrizcd intangible assets

s

Trade name and trademarks

4,274$

(1,898) $

2,376

10

Indefinite-lived intangible assets
Product formulas

9,425

9,425

Direct sales license

29,151

29,151

38,576

38,576

$

s

42,850

40,952

As of January 2, 2016

Amorti%cd intangible
assets
Trade name and
trademarks
S
Product formulas

Gross carrying

Accumulated

amount

amortization

4,0865
9,010

Weightedaverage
Net carrying amortization
period
amount
(years)

(2,20S)S
(489)

1,881
8,521

I ndefinite-livcc.l
intangible assets
27,867

Direct sales license

s
Schedule Of Estimated Amortization
Expense

40,963

Estimated Amortization
Expense:
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27,867

s

38,269

10
8

@
2016

1,535
1,535
1,535
1,535

2017
2018
2019
2020

@

1,378
2,884

Thereafter

s

10,402

@
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12 Months Ended

Other Current Liabilities
(Tables)

Jan.02,2016

Other Current Liabilities [Abstract]

Schedule Of Other Current Liabilities

Other current liabilities consist of the
foUowing:

Associate incentives

January 3,

January 2,

2015

2016

s

,\r.rnwd c>mployc-c rnmp,·nsarion

34,297

s

18,160

38,852
24,489

Income taxes

4,110

5,561

Sales taxes

9,643

10,109

Deferred tax liabilities

5,268

4,434

1\ssociate promotions

1,982

2,712

15,717

17,637

718

521

Deferred revenue
Provision for returns anc.l allowances
1\cc!ued purchases of property and
equipment

1,805

6,863

All other

9,026

10,191

s

100,926

s

121,369
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@

Commitments And
Contingencies (Tables)
@

@

12 Months Ended
Jan.02,2016

Commitments And Contingencies [Abstract]
Schedule Of Minimum Rental Payments For Operating Leases
Year ending
2016
2017
2018
2019
2020
Thereafter

s

10,552
9,263
6,481
2,684
987

s

29,967

@

@

@

@
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12 Months Ended
Jan.02,2016

Equity-Based Compensation
(Tables)
Eguitv Based Compensation [Abstractf
Schedule Of Remaining Unrecognized Compensation
Expense For Unveste<l Awards

s

20"16
2017
2018
2019
2020+

17.856
16,744
14,0'.M

8,889
943
58,,)5(1

s
The cost above is expecte<l to be recognize<l over a weightedaverage perio<l of 3.4 years.

Schedule Of Fair Value Assumptions
Year ended

2013

Risk-free interest rate (2)

41.9%
0.7%

40.2%
1.2%

Expected life (3)

3.9 yrs.

Expected dividend yield (4)

0.0%
$53.83

3.6 yrs.
0.0%

Expected volatility (l)

Wcip,htcd-avcragc exercise price (5)

2015

2014

44.0%
1.3%
3.8 yrs.
0.0%

$60.61

$135.41

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the
expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to
calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company's
equity awards and a
hypothetical holding period, or (ii) the simplified method.

(4) The Company historically has not paid and currently has no plan to pay
dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of
grant.

Schedule Of Stock Option Activity

Shares
Outstanding at January 3, 2015
Granted

1,555

Weightedaverage
Weightedremaining
average
contractual
term
exercise cnce

s

1,135

49.20

1\ggregate
intrinsic
value·•

2.9

s

82,SM

135.41

Exercised

(442)

37.93

Forfeited

(73)

102.12

Expired
( )utsranding at january 2, 2016
Exercisable at January 2, 2016

2,175

s

94.68

3.3

s

83,475

121

s

45.26

1.8

s

9, 1)98
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12 Months Ended

Segment Information (Tables)

.Jan. 02, 2016

Segment Information (Abstract!

Schedule Of Revenue Percentage By Product

Year Ended

2014

2013
US1\N 1\ ~ N utritionals
USAN,\ Foods
Sense - beautiful science"

2015

80%

79%

81%

11%

13%

11%

6%

7%

7%

Schedule Of Revenues From External Customers By Geographical Areas

Year Ended

2013

2014

2015

Net Sales to External
Customers

Asia Pacific
Greater China

s

Southeast Asia Pacific

271,812S

326,134S

441,284

155,362

177,940

183,828

29,319

32,667

39,751

456,493

536,741

664,863

261,682

253,730

253,636

718,175$

790,471 S 918,499

North Asia

Asia Pacific Total
Americas and Europe
Consolidated 'I'otal

s

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in
Individual Foreign Countries by Country [Table Text Block)

January 3,

January 2,

2015

2016

Long-lived Assets
Asia Pacific

s

Greater China

83,471$
14,175

Southeast Asia Pacific

94,792
13,463

1,621

1,938

Asia Pacific Total

99,267

110,193

Americas and Europe

54,457

58,936

s

153,724$

169,129

s

154,153S

231,018

38,104

40,038

North Asia

Consolidated Total

Total Assets
Asia Pacific
(; reater China

Southeast Asia Pacific
North Asia
Asia Pacific Total
,\mericas and Europe

Consolidated Total

S

5,622

6,695

198,179

277,751

152,105

145,486

350,584S

423,237

=======:=======

Consolidated Net Sales And Long Lived Assets

Year Ended
2013

Net sales:
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2014

2015

China
s
United
States
Hong Kong$

s

106,710S

216,842S

371,737

157,543$
132,285

143,669$

141,758
N/1\

Long-lived
Assets:
China
United
States

N/A

@)
$

81,704$

92,835

$

53,322$

57,797

@
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12 Months Ended
Jan.02,2016

Quarterly Financial Results
(Tables)
~

Quarterly Financial Results [Abstract!
Summary Of Quarterly Financial Information

Third

Fourth

s

182,401 S

188,256$

191,944$

227,870

Gross profit

s
s

148,573S

153,391 S

157,359$

190,354

16,537$

19,301$

19,498$

21,300

1.19S

1.40$

1.5 IS

1.75

1.15S

1.36S

1.47$

1.65

Earnings per share:
Basic
Diluted

s
s

2015

w

Second

Net sales

Net earnings
~

First

2014

First

Second

Third

Fourth

Net sales

s

219,3785

233,244$

233,292$

232,585

Cross profit

s
s

181,014S

193,155$

192,244$

192,404

19,680S

25,416$

25,609S

23,967

Net earnin!,ri;
l·'.arnings per share:

~

Basic

s

1.56S

1.99$

1.99S

1.89

Diluted

s

I.SOS

1.92S

1.92S

1.83
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12 Months Ended

Earnings Per Share (Tables)

.Jan. 02, 2016

Earnings Per Share [Abstract)
Schedule Of Earnings Per Share

Year Ended

2013

s

Net earnings available to common shareholders
Weighted average common shares outstanding - h:1sic

79,024 S

2015

76,636 $
13,221

12,730

509

468

447

14,204

13,689

13,177

Earninh}!; per common share from net earnings - basic

s

5.77

s

5.80

Earnings per common share from net earnings - dilured

~

5.56

s

5.60

Equity awards for the following shares wen:
rhar
their effect would be anti-dilutive:

11111

94,672

13,695

Dilutive effect of in-the-money equity awards
\VeighteJ average common shares outstanding - diluteJ

2014

s
s

7.44
7.18

included iu the cu111pulalio11 uf JilutcJ EPS Jue lu Ilic faLI

Year Ended

2013

2014

344
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2015
287

393

Summary Of Significant
Accounting Policies
(Narrative) (Details)

12 Months Ended
Dec. 28,

Jan.02,2016 Jan.03,2015
USD ($)
item

2013

USD ($)

USD ($)

Summary Of Significant Accounting Policies (Line Items)

Geographical regions I item
Sub-geographical regions I item
Transfers of financial assets or liabilities
Non-financial assets
Receivable from credit card processors
Restricted cash
Maturity date
Credits on notes receivable
Notes receivable
Goodwill impainnent
lmpainnent of indefinite-lived intangible assets
Amount of individual claims before reimbursement
Minimum percentage of projected aggregate claims before insurance
reimbursement
Self insurance program expense
Proceeds from Stock Options Exercised
Tax benefit from equity award activity
Amount available to repurchase under the stock repurchase plan
Repurchase of common stock
Account renewal fee period
Duration of product return for first order
Percentage of sale refunded
Duration of product return
Amount of returned product which could result in cancellation of distributorship
Product return percentage of net sales
Advertising expense
Research and development expense
Manufacturing Credits [Member]
Summary Of Significant Accounting Policies (Line Items)
Credits on notes receivable
LIBOR (Member]
Summary Of Significant Accounting Policies !Line Items)
Basis point

2
3
$0
$0
0
0
12,516,000 6,209,000
$3,080,000 3,222,000
Feb.01,2024
$ 966,000
720,000
8,519,000
8,339,000

$0

198,000

0

0

0

0

0

0

7,019,000
I 0,970,000
14,712,000

5,281,000
454,000
7,075,000

$125,000
100.00%
$7,287,000
0
12,024,000
I 00,000,000
$ 61,181,000
12 months
30 days
100.00%
I year
$ 100
0.60%
$ 13,766,000
6,420,000

$966,000

$ 138,819,000 $ 18,085,000

0.80%
$ 4,942,000
5,128,000

$720,000

4.00%
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0.90%
$ 3,650,000
$5,083,000

Summary Of Significant
Accounting Policies (Schedule
Of Assets And Liabilities
Measured At Fair Value)
(Details) - Fair Value,
Measurements, Recurring
[Member] - USD ($)
$ in Thousands
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line
Items)
Money market funds included in cash equivalents
Fair Value. Inputs. Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis (Line
Items)
Money market funds included in cash equivalents

Jan. 02,
2016

Jan. 03,
2015

$ 14,460

$4,833

$ 14,460

$4,833
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Inventories (Details) - USD
($)
Jan. 02, 2016 Jan. 03, 2015
$ in Thousands
Inventories [Abstract]

Raw materials
Work in progress
Finished goods
Inventories

$22,529
8,701
34,889
$ 66,119

$ 15,127

7,545
22,576
$45,248

®
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Prepaid Expenses And Other
Current Assets (Details) USO($)
$ in Thousands
Other Assets [Abstract)
Prepaid insurance
Other prepaid expenses

Jan.02,2016Jan.03,2015

$ 1,727

$ 1,507

3,862

3,094
7,370
3,656
3,618
9,683
5,625
$ 34,553

7,080
Federal income taxes receivable
Miscdlaneuus receivables. nel
4,704
Deferred commissions
3,305
Deferred tax assets
9,674
Other current assets
4,583
Prepaid expenses and other current assets$ 34,935
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Income Taxes (Narrative)
(Details) - USO ($)
$

in Thousands

12 Months Ended
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

Income Taxes (Abstract)

Federal statutory rate
35.00%
Foreign operating loss carryforward
$ 384
Operating loss carryforward valuation allowance
110
Accumulated undistributed earnings of subsidiaries
18, 163
Deferred tax liability not recognized from undistributed earnings 3,071
Significant unrecognized tax benefits
$0

35.00%

35.00%

$0
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Income Taxes (Schedule Of
Income Tax Expense

12 Months Ended

(Bcnef~)! <~:tails) ~USD ($) Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013
m
ousan s

iJ

Income Taxes [Abstract)

Current, Federal
Current, State
Current, Foreign
Total Current
Deferred, Federal
Deferred. State
Deferred. Foreign
Total Deferred
Income taxes

$17,492

$22,362

$ 26,233

464

1,056

94

32,198

16,265

9,626

50,154

39,683

35,953

(5,220)

(1,096)

5,507

(155)

(43)

(5)

3,138

473

(3,898)

(2,237)

(666)

1,604

$47,917

$39,017

$ 37,557
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~

•

Income Taxes (Reconciliation
Of Income Tax Provision)
(Details) - USO($)
$ in Thousands

12 r,.fonths Ended
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

Income Taxes (Abstract]

$49,906
Federal income taxes at statutoa rate
State income taxes 2 net of federal tax benefit 670
(952)
Qualified Qroduction activities deduction
(461)
Foreign rate differential
(425)
U.S research credit
(821)
All other2 net
$47,917
Income taxes

$40,479
653
(887)
(603)
(293)
(332)
$39,017

$40,803
102
( l ~700)
(890)
(206)
(552)
$ 37,557

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

•
Income Taxes (Schedule Of
Deferred Taxes By
Significant Categories)
(Details) - USD ($)
$ in Thousands

Jan. 02, 2016 Jan. 03, 2015

ii

Income Taxes (Abstract]

Inventory

$3,341

Accruals not currently deductible
5,892
F.guity-based compensation expense
4,476
Intangible assets
9,283
Net operating losses
110
Accumulated other comprehensive income 988
Other
3,428
Gross deferred tax assets
27,518
Valuation allowance
(607)
Net deferred tax assets
26,911
Depreciation/amortization
(6,137)
Accumulated other comprehensive income
Prepaid expenses
(1,566)
Intangible assets
(9,283)
(4,663)
Other
(21,649)
Gross deferred tax liabilities
Net current deferred tax assets
9,674
9,844
Net noncurrent deferred tax assets
(4,434)
Net current deferred tax liabilities
(9,822)
Net noncurrent deferred tax liabilities
$5,262
Net deferred taxes
Net deferred taxes

$3,024
4,427

2,822

~

I 0, I 07
526
4,543
25,449

~

(526)
24,923
(6,171)
(1,994)

~

(1,431)
(10,107)
(5,473)
(25,176)
9,683

~

5,933
(5,268)
(l 0,60 I)
$ (253)
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Property And Equipment
(Details) - USD ($)
$ in Thousands

12 Months Ended

Jan.02,2016 Jan.03,2015Dcc.28,2013

Property, Plant and Equipment [Line Items)

Property and equipment, gross
Less accumulated depreciation and amortization
Property and equipment, net
Property and equipment, net

$119,608
71,030
48,578
87,982
$9,034

Depreciation
Buildings [Member]
Property, Plant and Equipment [Line Items)
39 years 6 months
Useful life
$ 38,242
Property and equipment. gross
Laboratory And Production Equipment [Member)
Property, Plant and Equipment (Line Items)
$27,027
Property and equipment, gross
Sound And Video Library [Member]
Property, Plant and Equipment (Line Items)
5 years
Useful life
$ 600
Property and equipment, gross
Computer Equipment And Software [Member]
Property, Plant and Equipment [Linc Items)
34,497
Property and equipment, gross
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items)
5,214
Property and equipment, gross
Automobiles (Member]
Property, Plant and Equipment [Line Items)
385
Property and equipment, gross
Leasehold Improvements (Member]
Property, Plant and Equipment [Line Items)
$ 11,591
Property and equipment, gross
Land Improvements [Member)
Property, Plant and Equipment [Linc Items)
15 years
Useful life
Property and equipment, gross
$ 2,052
Land [Member]
Property, Plant and Equipment [Linc Items)
Property and equipment, net
6,360
Deposits And Projects In Process [Member]
Propertv, Plant and E(Juipmcnt [Line Items)
Property and equipment, net
$ 33,043
Minimum [Member] I Laboratory And Production Equipment [Member]
Property, Plant and Equipment [Line Items)
5 years
Useful life

$ 113,832
64,372
49,460
71,164
8,414

38,920

24,864

600

30,842

5,354

327

10,857

2,068

6,843

$14,861
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$8,152

Minimum [Member)! Computer Equipment And Software [Member]
Property, Plant and Equipment [Linc Items)
Useful life

3 years

Minimum [Member] I Furniture And Fixtures [Member]
Propertv, Plant and Equipment [Line Items)
Useful life

3 years

Minimum [Member] I Automobiles fMemberl
Property, Plant and Equipment [Line Items)
Useful life
3 years
Minimum [Member] I Leasehold Improvements [Member]
Propertv, Plant and Equipment [Line Items)
Useful life
3 years
Maximum [Member] I Laboratory And Production Equipment [Member]
Propertv, Plant and Equipment [Line Items)
Useful life
7 years
Maximum [Member] I Computer Equipment And Software [Member]
Property, Plant and Equipment [Linc Items]
Useful life
5 years
Maximum [Member] I Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
.5 years
Useful life
Maximum (Member] I Automobiles (Member]
Property, Plant and Equipment [Line Items)
5 years
Useful life
Maximum [Member11 Leasehold Improvements (Member]
Property, Plant and Equipment [Line Items]
5 years
Useful life
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Intangible Assets (Narrative)
· (Details) - USD ($)
$ in Thousands

12 Months Ended
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

Intangible Assets [Abstract)

$0
Goodwill impainnent
Impairment of indefinite-lived intangible assets 0
Aggregate amortization of intangible assets · $ 900
Estimated remaining useful life
8 years

$0

$0

0

0

$ 431

$ 897
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Intangible Assets (Schedule
Of Goodwill) (Details) - USD
($)
$ in Thousands

12 Months Ended
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

Intangible Assets (Abstract!

Gross goodwill, Beginning
$ 17,941
Accumulated impainnent losses, Beginning 0
Net goodwill, Beginning Balance
17,941
Goodwill acyuired during the year
0
Impainnent loss
0
Currency translation adjustments
(509)
Gross goodwill, Ending
17,432
Accumulated impainncnt losses, Ending 0
$ 17,432
Net goodwill, Ending Balance

$ I 8,243
0

18,243
0
0
(302)
17,941
0
$ 17,94 I

$0

18,243
0
$ 18,243
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Intangible Assets (Schedule
Of Finite And Indefinite Lived
Intangible Assets) (Details) USD ($)
$ in Thousands

12 Months Ended
Jan. 02, 2016 Jan. 03, 2015

Schedule Of Finite and Indefinite Intangible Assets !Linc Items]

Amortized intangible assets, Net carrying amount
Weighted-average amortization period (years)
Unamortized intangible assets
Total, Gross carrying amount
Total, Net carrying amount
Trade Name And Trademarks [Member]

$ I 0,402
8 years
$40,963
38,269

$38,576
42,850
40,952

4,086
(2,205)
$ 1,881
IO years

4,274
(1,898)
$2,376
IO years

(489)
$ 8,521
8 years
$9,010

$9,425

Schedule Of Finite and Indefinite Intangible Assets !Linc Items]

Amortized intangible assets, Gross carrying amount
Accumulated amortization
Amortized intangible assets, Net carrying amount
Weighted-average amortization period (years)
Product Fonnulas [Member]
Schedule Of Finite and Indefinite Intangible Assets !Line Items]

Accumulated amortization
Amortized intangible assets, Net carrying amount
Weighted-average amortization period (years)
Unamortized intangible assets
Direct Sales License [Member]

$

Schedule Of Finite and Indefinite Intangible Assets !Line Items l

Unamortized intangible assets

$

27,867

$29,151
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Intangible Assets (Schedule
Of Estimated Amortization
Expense) (Details)
$ in Thousands
Intangible Assets [Abstract]
2016
2017
2018

Jan.02,2016
USD ($)

$ 1,535

1,535
1,535
2019
1,535
2020
1,378
Thereafter
2,884
Total estimated amortization expense $ I 0,402
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Other Current Liabilities
(Details) - USD ($)
$ in Thousands
Other Current Liabilities (Abstract)

Jan. 02, 2016 Jan. 03, 2015

$ 38,852
Associate incentives
24,489
Accrued employee compensation
5,561
Income taxes
Sales taxes
10, l 09
4,434
Deferred tax liabilities
2,712
Associate promotions
17,637
Deferred revenue
Provision for returns and allowances
521
Accrued purchases of property and equipment 6,863
All other
l 0, 19 l
Other current liabilities
$ 121,369

$34,297
18,360
4,110
9,643
5,268
l,982
15,717
718
1,805
9,026
$100,926
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Line Of Credit (Details) 12 Months Ended
USD ($)
Jan. 02, 2016 Jan. 03, 2015
$ in Thousands
Line Of Credit (Abstract]
$75,000
Credit facility
Reduction in available borrowing limit 4,153
$4,575
Outstanding debt
$0
$0
Line of credit facility. maturity date 2016;..04
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Commitments And
Contingencies (Narrative)
(Details) - USD ($)
$ in Thousands
Commitments And Contingencies [Linc Items)
Total rent expense
Unconditional purchase obligations due in one year
Minimum employee age to partake in 40 l (k)
Requisite service period to partake in 40 l (k)
Employers' percentage match of employee's contribution percentage
Percentage of employee's gross pay that is matched by the employer
Employers' percentage match of employee's contribution percentage over one
percent
Employers' maximum contribution of employee's compensation
Requisite service in order to cliff vest
Contributions made by the Company
Buildings [Member]
Commitments And Contingencies (Linc ltemsl
Lease expiration date
Equipment [Member]
Commitments And Contingencies [Line Items I
Lease expiration date

12 Months Ended
Dec. 28,
2013

Jan. 02,

Jan. 03,

2016

2015

$ 10,503
$ 14,758
18 years
l month
100.00%
1.00%

$11,129

$9,254

$ 1,324

$1,149

50.00%
6.00%
2 years
$ 1,458

2020

2019
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Commitments _And
Contingencies (Schedule Of
Minimum Rental Payments
For Operating Leases)

Jan.02,2016
USD ($)

(Details)
$ in Thousands

Commitments And Contingencies [Abstract)
$10,552
2017
2018
2019

9,263
6,481
2,684

2020

$ 987

Thereafter
Total

$29,967
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Equity-Based Compensation
(Narrative) (Details) - USD

12 Months Ended

($)

v,j

~

$/shares in Units, shares in
Thousands, $ in Thousands
Share-based Compensation Arrangement by Share-based Payment Award
(Line Items]
Equity-based compensation expense
Equity-based compensation related tax benefit
Weighted-average grant date fair value
Total intrinsic value of stock options and stock-settled stock am~reciation rights
exercised
Closing Price Of Common Stock
Total fair value of equity awards vested
2006 Incentive Stock Plan (Member]
Share-based Compensation Arrangement by Share-based Pavment Award
(Line Items]
Total shares authorized under the plan
Additional shares authorized
Total awards granted
Awards canceled
2015 Incentive Stock Plan (Member]
Share-based Compensation Arrangement by Share-based Payment Award
(Line Items 1
Total shares authorized under the plan
Awards canceled
Stock Appreciation Rights {SARs) [Member] I 2006 Incentive Stock Plan (Member]
Share-based Compensation Arrangement by Share-based Payment Award
(Line Items]
Total awards granted
Stock Appreciation Rights (SARs) [Member] I 2015 Incentive Stock Plan [Member"!
Share-based Compensation Arrangement by Share-based Pavment Award
[Line Items]
Total awards granted
Stock Options [Member) I 2006 Incentive Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
(Linc Items]
Total awards granted
Deferred Stock Units [Member] I 2006 Incentive Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
JLine Items]
Total awards granted
Officers Upon Hire Or Promotion [Member] I 2015 Incentive Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Pavment Award
(Linc Items]
Vesting percentage
Expiration from grant date

.Jan. 02,
2016

Jan. 03,
2015

Dec. 28,
2013

·$ 7,624

$ 11,08 I

$ 9,805

$3,766

$ 3,308

$2,575

$ 46.99

$ 18.91

$ 17.59

$41,548

$51,795

$ 32,837

$ 127.75

$ 102.28

$ 7,184

$ 7,568

I 0,000
0

6,920
1,166

5,000
50

6,798

1,005

8

114

20.00%
5 years
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$8,096

Officers [Member] I 2015 Incentive Stock Plan [Member)
Share-based Compensation Arrangement by Share-based Payment Award
(Line Items}
Post-vesting percentage
Directors [Member] I 2015 Incentive Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
(Line Items}
Vesting percentage

10.00%

25.00%
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Equity-Based Compensation
(Schedule Of Remaining
Unrecognized Compensation
Expense For Unvestcd
Awards) (Details)
$ in Thousands
Equity Based Compensation [Abstract]
2016
2017
2018
2019
2020+
Total
Unrecognized compensation expense weighted average period of recognition

i 2 Months Ended
Jan.02,2016
USO($)

$ 17,856

16,744
14,024
8,889
943
$ 58,456

3 years 4 months 24 days
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Equity-Based Compensation
12 Months Ended
(Schedule Of Fair Value
Assumptions) (Details) - $ I
Jan.02,2016
Jan.03,2015
shares
Equity Based Compensation [Abstract)
Expected volatility
44.00%
40.20%
i .30%
1.20%
Risk-frt:e i11lcn:st rate
Expected life
3 years 9 months 18 days 3 years 7 months 6 days
0.00%
0.00%
Expected dividend yield
$ 135.41
$ 60.61
Weighted-average exercise price

Dec. 28, 2013

41.90%
0. 70%
3 years IO months 24 days
0.00%
$ 53.83
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Equity-Based Compensation
12 Months Ended
(Schedule Of Stock Option
Activity) (Details) - USD ($)
$ I shares in Units, shares in
.Jan.03,2015
.Jan. 02, 2016
Thousands, $ in Thousands
Equity Based Compensation (Abstract]
1,555
Shares, Outstanding
1,135
Shares, Granted
(442)
Shares. Exercised
(73)
Shares, Forfeited
2,175
1,555
Shares, Outstanding
121
Shares, Exercisable
$ 49.20
Weighted-average exercise price, Outstanding
Weighted-average exercise price, Granted
135.41
Weighted-average exercise price, Exercised
37.93
Weighted-average exercise price, Forfeited
102.12
Weighted-average exercise price, Outstanding
94.68
$ 49.20
Weighted-average exercise price, Exercisable
$ 45.26
Weighted-average remaining contractual term, Outstanding 3 years 3 months I 8 days 2 years IO months 24 days
Weighted-average remaining contractual term, Exercisable I year 9 months 18 days
Aggregate intrinsic value, Outstanding
$ 82,564
Aggregate intrinsic value, Outstanding
83,475
$ 82,564
Aggregate intrinsic value, Exercisable
$ 9,998
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12 Months Ended
Segment Information
(Narrative) (Details)

Jan.02,2016
item
segment

Segment Information [Abstract]
Number of reportable segments I segment 1
Sub-geographical regions I item
3
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Segment Information
(Percentage Of Total Product
Revenue Contributed By
Company's Nutritional And
Care Products) (Details)

12 Months Ended
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013

USANA Nutritionals [Member]

Revenue from External Customer [Line Items]
Percentage of product revenue

81.00%

79.00%

80.00%

11.00%

13.00%

11.00%

7.00%

7.00%

6.00% .

USANA Foods (Member]

Revenue from External Customer [Line Items!
Percentage of product revenue
Sense - Beautiful Science [Member]

Revenue from External Customer [Line Items]
Percentage of product revenue
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Segment Information
3 Months Ended
12 Months Ended
(Schedule Of Revenues From
External Customers And
,Jan. 02, Oct. 03, Jul. 04, ~~r. Jan. 03, Sep. Jun. 28, Mar. Jan. 02, Jan. 03, Dec.
Assets By Geographic
Region) (Details) - USD ($)
2016
2015
2015
2015
2015
2~~4
2014
2~~4
2016
2015
2~~3
$ in Thousands
Revenues from External
Customers and Long-Lived
Assets [Line Itemsl
Net Sales to External Customers $
$
$
$
$
$
$
$
$
$
$
232,585 233,292 233,244 219,378 227,870 191,944188,256182,401918,499790,471 718,175

Greater China (Member]
Revenues from External
Customers and Long-Lived
Assets [Line Items]
Net Sales to External Customers
Southeast Asia Pacific [Membcrj
Revenues from External
Customers and Long-Lived
Assets [Line I terns I
Net Sales to External Customers
North Asia [Member]
Revenues from External
Customers and Long-Lived
Assets [Line Items)
Net Sales to External Customers
Asia Pacific [Member]
Revenues from External
Customers and Long-Lived
Assets [Line I terns)
Net Sales to External Customers
Americas And Europe
[Member]
Revenues from External
Customers and Long-Lived
Assets [Line Items)
Net Sales to External Customers

441,284 326, 134 271,812

183,828 177,940 155,362

39,751 32,667 29,319

664,863 536,741 456,493

$

$

$

253,636 253,730 261,682
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Segment Information
(Schedule Of Long-Lived
Assets By Geographic
Region) (Details) - USD ($)
$ in Thousands

Jan. 02, 2016 Jan. 03, 2015

Revenues from External Customers and Long-Lived Assets (Line Items)

Long-lived Assets

$ 169,129

$153,724

Assets

423,237

350,584

Long-lived Assets

94,792

83,471

Assets

231,018

154,153

Long-lived Assets

13,463

14,175

Assets

40,038

38,404

Long-lived Assets

1,938

1,621

Assets

6,695

5,622

Long-lived Assets

110, I 93

99,267

Assets

277,751

I 98,179

58,936

54,457

$ 145,486

$ 152,405

Greater China [Member]
Revenues from External Customers and Long-Lived Assets I Line Items]

Southeast Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets !Line Items)

North Asia [Member]
Revenues from External Customers and Long-Lived Assets (Line Items)

Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets !Line Items]

Americas And Europe [Member]
Revenues from External Customers and Long-Lived Assets {Line Items]

Long-lived Assets
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Segment Information
3 Months Ended
12 Months Ended
(Consolidated Net Sales And
Long Lived Assets) (Details) Jan. 02, Oct. 03, Jul. 04, Apr. Jan. 03, Sep. Jun. 28, Mar. Jan. 02, Jan. 03, Dec.
4
27
'
- USO($)
2016
2015
2015
2015
'
2014
2~~'4
2016
2015
2~~'3
2
0
1
5
20 14
$ in Thousands
Revenues from External
Customers and Long-Lived
Assets (Line Items!
Net.sales
$
$
$
$
$
$
$
$
$
$
$
232,585 233,292 233,244 219,378 227,870 191,944 188,256 182,401918,499790,471 718,175
Long-lived Assets
169,129
153,724
169,129 153,724
China (Member}
Revenues from External
Customers and Long-Lived
Assets (Linc Items!

°

Net sales
Long-lived Assets
United States [Member]
Revenues from External
Customers and Long-Lived
Assets (Line Items)
Net sales
Long-lived Assets

371,737 216,842 106,710
92,835

81,704

92,835 81,704

141,758 143,669 157,543
$

$

57,797

53,322

Hong Kong [Member}
Revenues from External
Customers and Long-Lived
Assets (Line Items)
Net sales
Americas And Europe
[Member]
Revenues from External
Customers and Long-Lived
Assets [Linc Items)
Net sales
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57,797 53,322

132,285

$
$
$
253,636 253,730 261,682

12 Months Ended
3 Months Ended
Quarterly Financial Results
(Details) - USD ($)
Sep.
Mar.
Dec.
Apr.
Jun. 28,
.Jan. 02, .Jan. 03,
Jan. 03,
.Jan. 02, Oct. 03, Jul. 04,
$/shares in Units,$ in
27,
04,
29,
28,
2014
2016
2015
2015
2016
2015
2015
Thousands
2015
2014
2014
2013
Quarterly Financial Results
(Abstract!
Net sales

Gross profit
Net income (loss)
Basic
Diluted

$
$
$
$
$
$
$
$
$
$
$
232,585 233,292 233,244 219,378 227,870 191,944 188,256 182,401918,499790,471 718,175

192,404 192,244 193,155 181,014 190,354 157,359 153,391 148,573 758,817 649,677 590,740
$
$
$
$
$
$
$
$
$
$
$
23,967 25,609 25,416 19,680 21,300 19,498 19,301 16,537 94,672 76,636 79,024

$ 1.89

$ 1.99

$ 1.99

$ 1.56

$ 1.75

$ 1.51

$ 1.40

$ 1.19

$ 7.44

$ 5.80

$ 5.77

$ 1.83

$ 1.92

$ 1.92

$ 1.50

$ 1.65

$

1.47

$ 1.36

$ 1.15

$ 7. 18

$ 5.60

$ 5.56
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Earnings Per Share
(Narrative) (Details).- USD

12 Months Ended

($)

shares in Thousands,$ in
Jan. 02, 2016 Ja11:. 03, 2015 Dec. 28, 2013
Thousands
Earnings Per Share [Abstract)
Shares repurchased and retired
457
1,927
414
Value of shares repurchased and retired $ 61, 181
$138,819
$ 18,085
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~

~

Earnings Per Share (Schedule
Of Earnings Per Share)
(Details) - USD ($)
$/shares in Units, shares in
Thousands, $ in Thousands
Earnings Per Share [Abstract)
Net earnings available to common
shareholders
Weighted average common shares
outstanding - basic
Dilutive effect of in-the-money eguity
awards
Weighted average common shares
outstanding - diluted
Earnings 12er common share from net
earnings - basic
Earnings 12er common share from net
earnings - diluted
Eguity awards of stock excluded in
com12utation of diluted EPS

12 Months Ended

3 Months Ended
Jan. Oct. Jul. Apr. Jan.
04,
03,
02,
03,
04,
2016 2015 2015 2015 2015

Dec.
Sep. Jun. Mar.
Jan. 02, Jan. 03,
28,
27,
28,
29,
2016
2015
2013
2014 2014 2014
$
$
$
94,672 76,636 79,024
12,730 13,221

13,695

447

509

468

13,177 13,689 14,204
$1.89 $1.99 $1.99 $1.56 $1.75 $1.51 $1.40 $ l.19 $7.44

$ 5.80

$ 5.77

$ 1.83 $ l.92 $ 1.92 $ 1.50 $ l.65 $ I .47 $ 1.36 $ 1.15 $ 7.18

$ 5.60

$ 5.56

287

344

393
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Related.Party Transactions.
12 Months Ended
(Details) - USD ($)
Jan. 02, 2016 Jan. 03, 2015 Dec. 28, 2013
$Jn Thousands
Related Party Transactions [Abstract}
Principal owner beneficial ownership percentage 51.39%
Amount paid to Medicis
$ 383
$ 239
$ 381
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Subsequent Events (Details) USD ($)

~

,4i

~

~

~

$/shares in Units, shares in
Thousands, $ in Thousands
Subseguent Event (Linc Items I
Shares re2urchased and retired
Value of shares re12urchased and retired
Amount available
Credit facility
Outstanding debt
Subseguent Event [Member]
Subseguent Event (Linc Items]
Shares re12urchased and retired
Value of shares re12urchased and retired
Average market 12rice
Adjusted EBITDA covenant
Outstanding debt
Weighted average interest rate
Amended And Restated Credit Agreement
[Member] I Subseguent Event [Member]
Subseguent Event (Line Items]
Credit facility
Adjusted EBITDA covenant
Amended And Restated Credit Agreement
[Member] I Scenario 2 Forecast [Member]
Subseguent Event (Line Items]
Credit facility

2 Months
i 2 Months Ended
Ended
Feb. 26, Jan. 02, .Jan. 03, Dec. 28, Nov. 01, Feb. 19, Feb. 18,
2016
2015
2013
2016
2016
2016
2016
457

1,927

414

$61,181 $ 138,819 $ 18,085
100,000
75,000
$0

$0

553
$64,610
$116.82
$60,000
$63,000
1.27%

$ 125,000
$ 100,000

$75,000

~

..,;;;

.
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Valuation And Qualifying
12 Months Ended
Accounts (Details) - USD ($)
Jan. 02, 2016.Jan.03, 2015 Dec. 28, 2013
$ in Thousands
Allowance For Sales Returns [Member!
Valuation and Qualifying Accounts Disclosure [Linc Hems)
Balance at beginning of period
$ 718
$ 591
$ 717
Charged to costs and expenses
$ 44
$49
$ 194
Charged to other accounts
Deductions
Balance at end of period
Allowance For Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Linc Items)
Balance at beginning of period
Charged to costs and expenses
Charged to other accounts
Deductions
Balance at end of period
Valuation Allowance - Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items)
Balance at beginning of period
Charged to costs and expenses
Charged to other accounts
Deductions
Balance at end of period

$ 246

$ 67

$ 170

521

718

591

1,788

1,880

1,808

$ 162

$ 26

$ 98

$14

$ 118

$ 26

1,936

1,788

1,880

~

~

526

$ 530

$1,598

$4

$1,068

$ 526

$ 530

$ 81

$ 607
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Exhibit 10.5

USANA HEALTH SCIENCES, INC.
2006 EQUITY INCENTIVE AWARD PLAJ\i

STOCK-SETTLED STOCK APPRECIATION RIGIIT AWARD
AGREEMENT FOR INDEPENDENT DIRECTORS
Recipient Name:
Grant Date:
Number of SSARs:
Per Share Grant Price: S
Expiration Date: Fifth Anniversary of the Grant Date
I.
Award. USA NA Health Sciences, Inc. (the .. Company") has awarded you the number of Stock-Settled Stock Appreciation Rights
("SSARs") indicated above, subject to the terms and conditions set forth in the Company's 2006 Equity Incentive Award Plan (the "Plan") and this
A ward Agreement.
2.
Term and Vesting. The term of the SSARs commences on the Grant Date and ends on the Expiration Date, provided that you
remain an Independent Director of the Company. In no event may the SSARs be exercised later than the Expiration Date. The SSA Rs shall become
vested and exercisable in four equal quarterly installments of twenty five percent (25%) of the SSA Rs, so as to be 100% vested and exercisable on
the first anniversary of the Grant Date, subject to your continued service as an Independent Director of the Company on each vesting date. If your
service as an Independent Director of the Company terminates, the SSARs may be exercised only as described in paragraph 4 below.
3.

Exercise of SSAR.

a.
Upon exercise of the SSARs, you shall be entitled to receive a number of shares of Common Stock of the Company (the
"Stock") for each share with respect to which the SSA Rs are exercised equal to the quotient of (i) the excess of the Fair Market Value of one share
of Stock on the date of exercise over the Per Share Grant Price, divided by (ii) the Fair Market Value of one share of Stock on the date of exercise.
To exercise all or part of the SSARs you must deliver to the Company a "Notice of Exercise," in such form as the
b.
Company authorizes. You shall not have any rights as a shareholder of the Company with respect to the shares of Stock subject to the SSA Rs
until you have exercised the SSARs for such shares. While you are alive, the SSA Rs may be exercised only by you or your legal representative.
Upon exercise, the number of shares of Stock issued will be reduced to satisfy the minimum statutorily required tax
c.
withholding obligations. The remaining shares of Stock will be issued to you or, in case of your death, your beneficiary designated in accordance
with the procedures specified by the Committee. If at the time of your death, there is not an effective beneficiary designation on file or you are not
survived by your designated beneficiary, the shares will be issued to the legal representative of your estate. Upon any exercise of the SSA Rs, you
must furnish to the Company before the closing of such exercise such other

documents or representations as the Company may require to comply with applicable laws and regulations.
4.
Termination. If you cease to be an Independent Director for any reason, all then unvestcd SSA Rs awarded hereunder shall
immediately terminate without notice to you and shall be forfeited. Vested SSARs will be exercisable according to the following provisions:
a.
If you cease to be an Independent Director for any reason other than retirement or Disability (which are governed by
paragraph b. below), removal for Cause (which is governed by paragraph c. below) or death (which is governed by paragraph d. below), all SSARs
awarded hereunder that are vested at such time shall be exercisable at any time prior to the Expiration Date.
b.
If you cease to be an Independent Director on account of your retirement or Disability, all SSA Rs awarded hereunder
that arc vested at such time shall be exercisable at any time prior to the Expiration Date.
c.
If you arc removed as an Independent Director prior to expiration of your term for Cause (as defined below), all
outstanding SSA Rs awarded hereunder which arc not exercisable immediately prior to removal, and all outstanding SSA Rs awarded hereunder
which arc exercisable immediately prior to removal, shall terminate as of the date of removal for Cause and may not be exercised. For purposes of
this Award Agreement, "Cause" shall mean (i) any act of personal dishonesty in connection with your responsibilities to the Company and
intended to result in substantial personal enrichment to you, (ii) your conviction of a felony or (iii) your willful act which constinlles gross
misconduct and which is injurious to the Company.
d.
If your service as an Independent Director of the Company terminates by reason of your death. or if you die within the
ninety day period after the date you cease to be an Independent Director of the Company for any reason other than Cause. any of your vested
SSA Rs hereunder may be exercised by your estate, personal representative or beneficiary who has acquired the SSARs by will or by the laws of
descent and distribution, at any time prior to the Expiration Date.
5.

Tax Withholding. The Company will withhold from the number of shares of Stock otherwise issuable hereunder a number of
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shares necessary to satisfy the minimum statutorily required tax withholding obligations. Such shares will be valued at their Fair Market Value
when the taxable event occurs.
6.
Transfcrabilitv. The SSARs may not be transferred, pledged, assigned, hypothecated or otherwise disposed of in any way,
except by will or by the laws of descent and distribution. In the event that you become legally incapacitated, the SSA Rs shall be exercisable by
your legal guardian, committee or legal representative. If you die, the SSA Rs shall thereafter be exercisable by your beneficiary as designated by
you in the manner prescribed by the Committee or, in the absence of an authorized beneficiary designation, by the legatee of such SSA Rs under
your will, or by your estate in accordance with your will or the laws of descent and distribution, in each case in the same manner and to the same
extent that the SSA Rs were exercisable by you on the date of your death. The SSA Rs shall not be subject to execution,

2

attachment or similar process. Any attempted assignment, transfer, pledge, hypothecation or other disposition of the SSA Rs contrary to the
provisions hereof, and the levy of any execution, attachment or similar process upon the SSA Rs, shall be null and void and without effect.
7.
Other Restrictions. The issuance of shares of Stock hereunder is subject to compliance by the Company and you with all
applicable legal requirements applicable thereto, including tax withholding obligations, and with all applicable regulations of any stock exchange
on which the Stock may be listed at the time of issuance. The Company may delay the issuance of shares of Stock hereunder to ensure at the time
of issuance there is a registration statement for the shares in effect under the Securities Act of 1933.
8.
No Employment or Continued Service. Neither the award to you of the SSA Rs nor the delivery to you of this Award Agreement
or any other document relating to the SSA Rs will confer on you the right to employment with the Company or to continued service as an
lmkpcn<lcnt Director.
9.
No Shareholder Rights. Neither the award to you of the SSARs nor the delivery to you of this Award Agreement or any other
document relating to the SSA Rs will entitle you to any rights of a shareholder of the Company with respect to the shares of Stock subject to this
Award Agreement prior to the exercise of the SSA Rs and the receipt of shares of Stock in accordance with this Award Agreement.
I0.
No Fractional Shares. The SSA Rs granted hereunder may be exercised only with respect to whole shares of Stock, and no
fractional share of Stock shall be issued.
11.
Mergers. Reorganizations. and Certain Other Changes. In the event of the Company's liquidation, reorganization, separation,
merger or consolidation into, or acquisition of property or stock by another corporation, or sale of substantially all assets to another corporation,
your rights with respect to the SSAR.s awarded hereunder shall be governed by the Committee, as provided in the Plan.
12.

Additional Provisions.

This Award Agreement is subject to the provisions of the Plan. A copy of the Plan is available upon request.
a.
Capitalized terms not defined in this Award Agreement arc used as defined in the Plan. If the Plan and this Award Agreement are inconsistent, the
provisions of the Plan will govern.
The Plan and this Award Agreement represent the entire agreement of you and the Company with respect to the SSARs
b.
granted pursuant to this Award Agreement and supersedes in their entirety all prior undertakings and agreements of the Company and you with
respect to the subject of this Award Agreement and may not be modified except by means of a written agreement between the Company and you.
c.

Interpretations of the Plan and this Award Agreement by the Committee arc binding on you and the Company.

3

d.
Neither the Plan nor this Award Agreement shall create or be construed to create a trust or separate fund of any kind or
a fiduciary relationship between the Company and any other person. To the extent that any person acquires a right to receive payments form the
Company pursuant to an Award Agreement, such right shall be no greater than the right of any unsecured creditor of the Company.
e.
Any notice hereunder by you to the Company shall be given in writing and such notice shall be deemed duly given
only upon receipt thereof by the Secretary of the Company. Any notice hereunder by the Company to you shall be given in writing and such
notice shall be deemed duly given only upon receipt thereof at such address as is reflected on the then-current records of the Company.

f.
This Award Agreement shall be construed and enforced in accordance with the laws of the State of Utah, without
giving effect to the choice of law principles thereof.
IN WITNESS WHEREOF, the Company and the recipient of the SSARs hereunder have executed this Award Agreement effective as
of the date first above v.:ritten.
USA NA HEALTH SCIENCES, INC.

By: - - - - - - - - - - - - - - - - -
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Name:
Title:

RECIPIENT

Signature of Participant

Print Name

@

Social Security Number
4

@
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